To	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
and	O
the	O
effect	O
on	O
aqueous	O
humor	O
dynamics	O
of	O
0.005%	O
latanoprost	O
applied	O
topically	O
once	O
daily	O
with	O
0.5%	O
timolol	O
given	O
twice	O
daily	O
for	O
12	O
months	O
to	O
patients	O
with	O
pigmentary	O
glaucoma.	O

Prospective,	O
randomized,	O
double-masked,	O
clinical	O
study.	O

Thirty-six	O
patients	O
affected	O
with	O
bilateral	O
pigmentary	O
glaucoma	O
controlled	O
with	O
no	O
more	O
than	O
a	O
single	O
hypotensive	O
medication	O
were	O
enrolled	O
in	O
the	O
study.	O

The	O
sample	O
population	O
was	O
randomly	O
divided	O
into	O
2	O
age-	O
and	O
gender-matched	O
groups	O
each	O
of	O
18	O
patients.	O

Group	O
1	O
received	O
0.005%	O
latanoprost	O
eyedrops	O
once	O
daily	O
and	O
the	O
vehicle	O
(placebo)	O
once	O
daily;	O
group	O
2	O
was	O
assigned	O
to	O
timolol	O
0.5%	O
eyedrops	O
twice	O
daily.	O

Diurnal	O
curves	O
of	O
intraocular	O
pressure	O
(IOP)	O
were	O
performed	O
on	O
the	O
baseline	O
day	O
and	O
after	O
0.5,	O
3,	O
6,	O
and	O
12	O
months	O
of	O
treatment.	O

The	O
IOP	O
measurements	O
were	O
performed	O
at	O
8:00	O
AM,	O
12:00	O
noon,	O
4:00	O
PM,	O
and	O
8:00	O
PM.	O

Outflow	O
facility	O
(C)	O
was	O
measured	O
on	O
the	O
baseline	O
day	O
and	O
on	O
the	O
last	O
day	O
of	O
the	O
study	O
with	O
a	O
Schiotz	O
electronic	O
tonometer.	O

A	O
two-tailed	O
Student's	O
t	O
test	O
for	O
paired	O
or	O
unpaired	O
data	O
was	O
used	O
for	O
statistical	O
evaluation	O
of	O
differences	O
between	O
treatment	O
and	O
baseline	O
values	O
or	O
between	O
the	O
latanoprost	O
and	O
timolol	O
group.	O

Diurnal	O
IOP	O
measurements	O
were	O
compared	O
hour	O
by	O
hour.	O

Mean	O
values	O
of	O
the	O
two	O
eyes	O
IOP	O
and	O
C	O
were	O
used	O
for	O
analysis.	O

Compared	B-Premise
with	I-Premise
baseline	I-Premise
measurements,	I-Premise
both	I-Premise
latanoprost	I-Premise
and	I-Premise
timolol	I-Premise
caused	I-Premise
a	I-Premise
significant	I-Premise
(P	I-Premise
<	I-Premise
0.001)	I-Premise
reduction	I-Premise
of	I-Premise
IOP	I-Premise
at	I-Premise
each	I-Premise
hour	I-Premise
of	I-Premise
diurnal	I-Premise
curve	I-Premise
throughout	I-Premise
the	I-Premise
duration	I-Premise
of	I-Premise
therapy.	I-Premise

Reduction	B-Premise
of	I-Premise
IOP	I-Premise
was	I-Premise
6.0	I-Premise
+/-	I-Premise
4.5	I-Premise
and	I-Premise
5.9	I-Premise
+/-	I-Premise
4.6	I-Premise
with	I-Premise
latanoprost	I-Premise
and	I-Premise
4.8	I-Premise
+/-	I-Premise
3.0	I-Premise
and	I-Premise
4.6	I-Premise
+/-	I-Premise
3.1	I-Premise
with	I-Premise
timolol	I-Premise
after	I-Premise
6	I-Premise
and	I-Premise
12	I-Premise
months,	I-Premise
respectively.	I-Premise

Comparison	B-Premise
of	I-Premise
mean	I-Premise
diurnal	I-Premise
measurements	I-Premise
with	I-Premise
latanoprost	I-Premise
and	I-Premise
timolol	I-Premise
showed	I-Premise
a	I-Premise
statistical	I-Premise
significant	I-Premise
(P	I-Premise
<	I-Premise
0.001)	I-Premise
difference	I-Premise
at	I-Premise
3,	I-Premise
6,	I-Premise
and	I-Premise
12	I-Premise
months.	I-Premise

Mean	B-Premise
C	I-Premise
was	I-Premise
found	I-Premise
to	I-Premise
be	I-Premise
significantly	I-Premise
enhanced	I-Premise
(+30%)	I-Premise
only	I-Premise
in	I-Premise
the	I-Premise
latanoprost-treated	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
baseline	I-Premise
(P	I-Premise
=	I-Premise
0.017).	I-Premise

Mean	B-Premise
conjunctival	I-Premise
hyperemia	I-Premise
was	I-Premise
graded	I-Premise
at	I-Premise
0.3	I-Premise
in	I-Premise
latanoprost-treated	I-Premise
eyes	I-Premise
and	I-Premise
0.2	I-Premise
in	I-Premise
timolol-treated	I-Premise
eyes.	I-Premise

A	B-Premise
remarkable	I-Premise
change	I-Premise
in	I-Premise
iris	I-Premise
color	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
both	I-Premise
eyes	I-Premise
of	I-Premise
1	I-Premise
of	I-Premise
the	I-Premise
18	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
latanoprost	I-Premise
and	I-Premise
none	I-Premise
of	I-Premise
the	I-Premise
18	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
timolol.	I-Premise

Darkening	O
of	O
the	O
peripheral	O
iris	O
stroma	O
was	O
suspected	O
in	O
two	O
patients	O
treated	O
with	O
latanoprost.	O

In	B-Premise
the	I-Premise
timolol	I-Premise
group,	I-Premise
heart	I-Premise
rate	I-Premise
was	I-Premise
significantly	I-Premise
reduced	I-Premise
from	I-Premise
72	I-Premise
+/-	I-Premise
9	I-Premise
at	I-Premise
baseline	I-Premise
to	I-Premise
67	I-Premise
+/-	I-Premise
10	I-Premise
beats	I-Premise
per	I-Premise
minute	I-Premise
at	I-Premise
12	I-Premise
months.	I-Premise

Although	O
further	B-Claim
studies	I-Claim
may	I-Claim
need	I-Claim
to	I-Claim
confirm	I-Claim
these	I-Claim
data	I-Claim
on	I-Claim
a	I-Claim
larger	I-Claim
sample	I-Claim
and	I-Claim
to	I-Claim
evaluate	I-Claim
the	I-Claim
side	I-Claim
effect	I-Claim
of	I-Claim
increased	I-Claim
iris	I-Claim
pigmentation	I-Claim
on	I-Claim
long-term	I-Claim
follow-up,	I-Claim
in	B-Claim
patients	I-Claim
with	I-Claim
pigmentary	I-Claim
glaucoma,	I-Claim
0.005%	I-Claim
latanoprost	I-Claim
taken	I-Claim
once	I-Claim
daily	I-Claim
was	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
more	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
than	I-Claim
0.5%	I-Claim
timolol	I-Claim
taken	I-Claim
twice	I-Claim
daily.	I-Claim

To	O
report	O
the	O
longer	O
term	O
results	O
of	O
a	O
randomized,	O
clinical	O
trial	O
comparing	O
the	O
350-mm2	O
and	O
the	O
500-mm2	O
Baerveldt	O
glaucoma	O
implants.	O

Extended	O
follow-up	O
on	O
a	O
randomized,	O
controlled	O
trial.	O

Between	O
March	O
1991	O
and	O
April	O
1993,	O
107	O
patients	O
with	O
uncontrolled	O
intraocular	O
pressure	O
(IOP)	O
due	O
to	O
non-neovascular	O
glaucoma	O
associated	O
with	O
aphakia,	O
pseudophakia,	O
or	O
failed	O
filters	O
were	O
randomly	O
assigned	O
for	O
surgical	O
placement	O
of	O
either	O
the	O
350-mm2	O
or	O
the	O
500-mm2	O
Baerveldt	O
implant	O
at	O
the	O
Doheny	O
Eye	O
Institute.	O

A	O
random-numbers	O
table	O
was	O
used	O
to	O
assign	O
each	O
patient	O
to	O
one	O
of	O
the	O
two	O
groups.	O

Preoperative	O
IOPs	O
and	O
visual	O
acuities	O
were	O
recorded.	O

Clinical	O
records	O
were	O
reviewed	O
to	O
ascertain	O
postoperative	O
IOPs,	O
visual	O
acuities,	O
number	O
of	O
medications	O
used,	O
and	O
implant-related	O
complications	O
that	O
occurred	O
throughout	O
the	O
follow-up	O
period.	O

Success	O
was	O
defined	O
as	O
IOP	O
of	O
6	O
mmHg	O
or	O
greater	O
and	O
of	O
21	O
mmHg	O
or	O
less	O
in	O
two	O
or	O
more	O
consecutive	O
follow-up	O
visits	O
without	O
further	O
glaucoma	O
surgery	O
or	O
loss	O
of	O
light	O
perception	O
attributable	O
to	O
glaucoma.	O

The	B-Premise
overall	I-Premise
success	I-Premise
rates	I-Premise
were	I-Premise
87%	I-Premise
for	I-Premise
the	I-Premise
350-mm2	I-Premise
group	I-Premise
and	I-Premise
70%	I-Premise
for	I-Premise
the	I-Premise
500-mm2	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.05).	I-Premise

Average	O
follow-up	O
was	O
37	O
months	O
(range,	O
1-76	O
months)	O
for	O
the	O
350-mm2	O
group	O
and	O
34	O
months	O
(range,	O
5-77	O
months)	O
for	O
the	O
500-mm2	O
group.	O

The	B-Premise
life-table	I-Premise
success	I-Premise
rates	I-Premise
declined	I-Premise
over	I-Premise
time	I-Premise
for	I-Premise
both	I-Premise
implant	I-Premise
groups,	I-Premise
from	I-Premise
a	I-Premise
high	I-Premise
of	I-Premise
98%	I-Premise
for	I-Premise
the	I-Premise
350-mm2	I-Premise
group	I-Premise
and	I-Premise
92%	I-Premise
for	I-Premise
the	I-Premise
500-mm2	I-Premise
group	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
to	I-Premise
a	I-Premise
cumulative	I-Premise
success	I-Premise
rate	I-Premise
of	I-Premise
79%	I-Premise
for	I-Premise
the	I-Premise
350-mm2	I-Premise
group	I-Premise
and	I-Premise
66%	I-Premise
for	I-Premise
the	I-Premise
500-mm2	I-Premise
group	I-Premise
at	I-Premise
5	I-Premise
years.	I-Premise

Visual	B-Premise
acuities	I-Premise
were	I-Premise
better	I-Premise
or	I-Premise
remained	I-Premise
the	I-Premise
same	I-Premise
in	I-Premise
50%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
350-mm2	I-Premise
group	I-Premise
and	I-Premise
46%	I-Premise
of	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
500-mm2	I-Premise
group.	I-Premise

Complications	O
during	O
the	O
5-year	O
follow-up	O
were	O
also	O
statistically	O
similar.	O

The	B-Claim
longer	I-Claim
term	I-Claim
results	I-Claim
show	I-Claim
that	I-Claim
the	I-Claim
350-mm2	I-Claim
Baerveldt	I-Claim
implant	I-Claim
is	I-Claim
more	I-Claim
successful	I-Claim
than	I-Claim
the	I-Claim
500-mm2	I-Claim
implant	I-Claim
for	I-Claim
overall	I-Claim
IOP	I-Claim
control.	I-Claim

Interval	B-Claim
comparisons	I-Claim
indicate	I-Claim
a	I-Claim
higher	I-Claim
rate	I-Claim
of	I-Claim
success	I-Claim
for	I-Claim
the	I-Claim
350-mm2	I-Claim
implant	I-Claim
in	I-Claim
the	I-Claim
first,	I-Claim
second,	I-Claim
third,	I-Claim
fourth,	I-Claim
and	I-Claim
fifth	I-Claim
years	I-Claim
of	I-Claim
implantation.	I-Claim

Visual	O
acuities,	O
implant-related	O
complications,	O
and	O
average	O
IOPs	O
were	O
statistically	O
indistinguishable	O
between	O
the	O
two	O
groups.	O

Oral	B-Claim
carbonic	I-Claim
anhydrase	I-Claim
inhibitors	I-Claim
used	I-Claim
to	I-Claim
treat	I-Claim
glaucoma	I-Claim
have	I-Claim
significant	I-Claim
systemic	I-Claim
side	I-Claim
effects.	I-Claim

Brinzolamide	O
1.0%,	O
a	O
new	O
topical	O
ocular	O
carbonic	O
anhydrase	O
inhibitor,	O
is	O
effective	O
apparently	O
without	O
significant	O
systemic	O
side	O
effects.	O

This	O
study	O
was	O
performed	O
to	O
establish	O
the	O
long-term	O
safety	O
and	O
efficacy	O
of	O
brinzolamide	O
1.0%	O
two	O
and	O
three	O
times	O
daily	O
for	O
primary	O
open-angle	O
glaucoma	O
and	O
ocular	O
hypertension.	O

An	O
18-month,	O
multicenter,	O
double-masked,	O
parallel,	O
controlled	O
study	O
was	O
conducted.	O

Patients	O
were	O
randomized	O
to	O
brinzolamide	O
two	O
or	O
three	O
times	O
daily	O
or	O
timolol	O
0.5%	O
twice	O
daily	O
in	O
a	O
2:2:1	O
ratio	O
(n	O
=	O
150,	O
153,	O
and	O
75,	O
respectively).	O

Intraocular	O
pressure	O
was	O
measured	O
at	O
8:00	O
AM	O
at	O
eligibility	O
and	O
months	O
1,	O
3,	O
6,	O
9,	O
12,	O
15,	O
and	O
18.	O

Efficacy	O
was	O
based	O
on	O
intraocular	O
pressure	O
reduction	O
from	O
baseline.	O

Safety	O
was	O
also	O
evaluated.	O

All	B-Premise
regimens	I-Premise
produced	I-Premise
clinically	I-Premise
relevant	I-Premise
and	I-Premise
statistically	I-Premise
significant	I-Premise
(P<.05)	I-Premise
intraocular	I-Premise
pressure	I-Premise
reductions	I-Premise
from	I-Premise
baseline.	I-Premise

Mean	B-Premise
changes	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
trough	I-Premise
measurements	I-Premise
ranged	I-Premise
from	I-Premise
-2.7	I-Premise
to	I-Premise
-3.9	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
brinzolamide	I-Premise
twice-daily	I-Premise
dosing	I-Premise
and	I-Premise
-2.8	I-Premise
to	I-Premise
-3.8	I-Premise
mm	I-Premise
Hg	I-Premise
three	I-Premise
times	I-Premise
daily	I-Premise
dosing	I-Premise
compared	I-Premise
with	I-Premise
-4.7	I-Premise
to	I-Premise
-5.6	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
timolol.	I-Premise

The	O
intraocular	O
pressure	O
reductions	O
with	O
brinzolamide	O
two	O
and	O
three	O
times	O
daily	O
were	O
clinically	O
and	O
statistically	O
equivalent.	O

One	O
hundred	O
forty-four	O
patients	O
were	O
discontinued	O
from	O
the	O
study	O
after	O
randomization	O
with	O
the	O
most	O
common	O
reasons	O
being	O
the	O
occurrence	O
of	O
an	O
adverse	O
event	O
(46),	O
inadequate	O
intraocular	O
pressure	O
control	O
(23),	O
patient	O
decision	O
unrelated	O
to	O
study	O
medication	O
(11),	O
lost	O
to	O
follow-up	O
(16),	O
and	O
noncompliance	O
(9).	O

Adverse	B-Premise
events	I-Premise
were	I-Premise
nonserious	I-Premise
and	I-Premise
resolved	I-Premise
without	I-Premise
sequelae.	I-Premise

There	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
safety	O
parameters.	O

Brinzolamide	B-Claim
produced	I-Claim
less	I-Claim
ocular	I-Claim
discomfort	I-Claim
(burning/stinging)	I-Claim
than	I-Claim
timolol,	I-Claim
and	I-Claim
total	I-Claim
carbonic	I-Claim
anhydrase	I-Claim
inhibition	I-Claim
levels	I-Claim
remained	I-Claim
below	I-Claim
that	I-Claim
known	I-Claim
to	I-Claim
cause	I-Claim
systemic	I-Claim
side	I-Claim
effects.	I-Claim

Brinzolamide	B-Claim
produced	I-Claim
significant	I-Claim
and	I-Claim
equivalent	I-Claim
reductions	I-Claim
in	I-Claim
intraocular	I-Claim
pressure	I-Claim
when	I-Claim
dosed	I-Claim
two	I-Claim
and	I-Claim
three	I-Claim
times	I-Claim
daily	I-Claim
for	I-Claim
18	I-Claim
months.	I-Claim

Brinzolamide	B-Claim
was	I-Claim
safe	I-Claim
and	I-Claim
well	I-Claim
tolerated	I-Claim
by	I-Claim
patients,	I-Claim
with	I-Claim
minimal	I-Claim
ocular	I-Claim
discomfort.	I-Claim

To	O
compare	O
the	O
effects	O
on	O
intraocular	O
pressure	O
(IOP)	O
and	O
side	O
effects	O
of	O
monotherapy	O
with	O
either	O
latanoprost	O
or	O
dorzolamide	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension.	O

224	O
patients	O
with	O
open	O
angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
were	O
recruited	O
to	O
a	O
3	O
month	O
open	O
labelled	O
study.	O

Previous	O
glaucoma	O
medications	O
were	O
washed	O
out	O
and	O
the	O
patients	O
were	O
randomised	O
to	O
receive	O
either	O
latanoprost	O
0.005%	O
once	O
daily	O
or	O
dorzolamide	O
2%	O
three	O
times	O
daily.	O

Of	O
224	O
patients	O
213	O
were	O
included	O
in	O
the	O
analysis	O
of	O
efficacy.	O

After	B-Premise
3	I-Premise
months,	I-Premise
latanoprost	I-Premise
reduced	I-Premise
mean	I-Premise
baseline	I-Premise
diurnal	I-Premise
IOP	I-Premise
from	I-Premise
27.2	I-Premise
(SD	I-Premise
3.0)	I-Premise
mm	I-Premise
Hg	I-Premise
by	I-Premise
8.5	I-Premise
(3.3)	I-Premise
mm	I-Premise
Hg.	I-Premise

The	B-Premise
corresponding	I-Premise
figures	I-Premise
for	I-Premise
dorzolamide	I-Premise
were	I-Premise
27.2	I-Premise
(3.4)	I-Premise
and	I-Premise
5.6	I-Premise
(2.6)	I-Premise
mm	I-Premise
Hg.	I-Premise

The	B-Premise
difference	I-Premise
of	I-Premise
2.9	I-Premise
mm	I-Premise
Hg	I-Premise
(95%	I-Premise
CI:	I-Premise
2.3-3.6)	I-Premise
was	I-Premise
highly	I-Premise
significant	I-Premise
(p<0.001,	I-Premise
ANCOVA).	I-Premise

Latanoprost	B-Premise
reduced	I-Premise
IOP	I-Premise
at	I-Premise
peak	I-Premise
by	I-Premise
8.6	I-Premise
mm	I-Premise
Hg	I-Premise
(32%)	I-Premise
compared	I-Premise
with	I-Premise
6.2	I-Premise
mm	I-Premise
Hg	I-Premise
(23%)	I-Premise
for	I-Premise
dorzolamide,	I-Premise
and	I-Premise
the	I-Premise
difference	I-Premise
of	I-Premise
2.4	I-Premise
mm	I-Premise
Hg	I-Premise
was	I-Premise
significant	I-Premise
(p<0.001,	I-Premise
ANCOVA).	I-Premise

The	B-Premise
corresponding	I-Premise
figures	I-Premise
at	I-Premise
trough	I-Premise
were	I-Premise
8.1	I-Premise
mm	I-Premise
Hg	I-Premise
(31%)	I-Premise
for	I-Premise
latanoprost	I-Premise
and	I-Premise
4.7	I-Premise
mm	I-Premise
Hg	I-Premise
(17%)	I-Premise
for	I-Premise
dorzolamide,	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
of	I-Premise
3.4	I-Premise
mm	I-Premise
Hg	I-Premise
(p<0.001,	I-Premise
ANCOVA).	I-Premise

Both	B-Claim
drugs	I-Claim
were	I-Claim
well	I-Claim
tolerated	I-Claim
systemically	I-Claim
and	I-Claim
locally.	I-Claim

Latanoprost	B-Claim
was	I-Claim
superior	I-Claim
to	I-Claim
dorzolamide	I-Claim
in	I-Claim
reducing	I-Claim
the	I-Claim
IOP,	I-Claim
judged	I-Claim
both	I-Claim
from	I-Claim
the	I-Claim
effect	I-Claim
on	I-Claim
IOP	I-Claim
at	I-Claim
peak	I-Claim
and	I-Claim
trough	I-Claim
and	I-Claim
by	I-Claim
the	I-Claim
effect	I-Claim
on	I-Claim
diurnal	I-Claim
IOP.	I-Claim

To	O
compare	O
the	O
clinical	O
success	O
rates	O
and	O
quality	O
of	O
life	O
impact	O
of	O
brimonidine	O
0.2%	O
with	O
timolol	O
0.5%	O
in	O
newly	O
diagnosed	O
patients	O
naive	O
to	O
glaucoma	O
therapy.	O

A	O
prospective,	O
multicenter,	O
randomized,	O
double-masked,	O
clinical	O
effectiveness	O
trial	O
in	O
which	O
the	O
clinical	O
outcomes	O
of	O
twice	O
daily	O
brimonidine	O
tartrate	O
0.2%	O
were	O
compared	O
with	O
those	O
of	O
timolol	O
maleate	O
0.5%	O
in	O
patients	O
with	O
glaucoma	O
and	O
ocular	O
hypertension	O
was	O
conducted.	O

Two	O
hundred	O
nineteen	O
patients	O
were	O
enrolled--111	O
in	O
the	O
brimonidine	O
group	O
and	O
108	O
in	O
the	O
timolol	O
group.	O

Patients	O
instilled	O
their	O
study	O
medications	O
twice	O
daily	O
for	O
4	O
months.	O

Factors	O
for	O
determining	O
clinical	O
success	O
were	O
reduction	O
of	O
intraocular	O
pressure	O
(IOP),	O
safety,	O
and	O
adverse	O
events.	O

Quality	O
of	O
life	O
effects	O
were	O
assessed	O
with	O
the	O
SF-36	O
Health	O
Survey	O
and	O
Glaucoma	O
Disability	O
Index	O
questionnaires.	O

Clinical	B-Premise
success	I-Premise
was	I-Premise
71%	I-Premise
(75/106)	I-Premise
with	I-Premise
brimonidine	I-Premise
and	I-Premise
70%	I-Premise
(73/105)	I-Premise
with	I-Premise
timolol	I-Premise
as	I-Premise
initial	I-Premise
treatment.	I-Premise

The	B-Premise
overall	I-Premise
mean	I-Premise
decrease	I-Premise
in	I-Premise
IOP	I-Premise
was	I-Premise
6.5	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
brimonidine	I-Premise
and	I-Premise
6.2	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
timolol.	I-Premise

Few	B-Premise
patients	I-Premise
reported	I-Premise
a	I-Premise
specific	I-Premise
adverse	I-Premise
event	I-Premise
and,	O
with	B-Premise
the	I-Premise
exception	I-Premise
of	I-Premise
a	I-Premise
slightly	I-Premise
higher	I-Premise
rate	I-Premise
of	I-Premise
ocular	I-Premise
burning	I-Premise
and	I-Premise
stinging	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group,	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
between-group	I-Premise
differences.	I-Premise

No	B-Premise
significant	I-Premise
chronotropic	I-Premise
effects	I-Premise
on	I-Premise
the	I-Premise
heart	I-Premise
were	I-Premise
seen	I-Premise
with	I-Premise
brimonidine,	I-Premise
while	O
small	B-Premise
but	I-Premise
significant	I-Premise
mean	I-Premise
decreases	I-Premise
in	I-Premise
heart	I-Premise
rate	I-Premise
were	I-Premise
seen	I-Premise
at	I-Premise
months	I-Premise
1	I-Premise
and	I-Premise
4	I-Premise
with	I-Premise
timolol.	I-Premise

Mean	B-Premise
systolic	I-Premise
and	I-Premise
diastolic	I-Premise
blood	I-Premise
pressure	I-Premise
remained	I-Premise
relatively	I-Premise
stable	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
remained	I-Premise
stable,	I-Premise
with	I-Premise
no	I-Premise
significant	I-Premise
between-group	I-Premise
differences.	I-Premise

As	B-Claim
a	I-Claim
first-line	I-Claim
agent	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
glaucoma	I-Claim
and	I-Claim
ocular	I-Claim
hypertension,	I-Claim
brimonidine	I-Claim
has	I-Claim
clinical	I-Claim
effectiveness	I-Claim
equivalent	I-Claim
to	I-Claim
timolol,	I-Claim
but	I-Claim
with	I-Claim
less	I-Claim
chronotropic	I-Claim
effect	I-Claim
on	I-Claim
the	I-Claim
heart.	I-Claim

Brimonidine	B-Claim
is	I-Claim
a	I-Claim
viable	I-Claim
alternative	I-Claim
to	I-Claim
timolol	I-Claim
for	I-Claim
first-line	I-Claim
therapy	I-Claim
in	I-Claim
glaucoma	I-Claim
and	I-Claim
ocular	I-Claim
hypertension.	I-Claim

To	O
compare	O
the	O
additional	O
intraocular	O
pressure-lowering	O
effect	O
of	O
latanoprost	O
0.005%	O
administered	O
once	O
daily	O
with	O
that	O
of	O
pilocarpine	O
2%	O
administered	O
three	O
times	O
daily	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
currently	O
on	O
monotherapy	O
with	O
timolol	O
0.5%	O
twice	O
daily.	O

In	O
a	O
6-month,	O
multicenter,	O
randomized,	O
open-label	O
study	O
242	O
patients	O
with	O
POAG	O
or	O
OH	O
whose	O
IOP	O
was	O
not	O
controlled	O
with	O
timolol	O
0.5%	O
b.i.d.	O

were	O
enrolled.	O

Eyes	O
had	O
not	O
been	O
treated	O
with	O
pilocarpine	O
and	O
latanoprost	O
for	O
at	O
least	O
2	O
years.	O

An	O
analysis	O
of	O
covariance	O
with	O
diurnal	O
IOP	O
change	O
from	O
baseline	O
to	O
month	O
6	O
for	O
study	O
eyes	O
was	O
performed.	O

Four	O
patients	O
on	O
latanoprost	O
0.005%	O
and	O
35	O
on	O
pilocarpine	O
2%	O
did	O
not	O
complete	O
the	O
study	O
(P<0.001).	O

Two	O
hundred	O
and	O
forty	O
patients	O
were	O
included	O
in	O
the	O
intent-to-treat	O
analysis.	O

For	B-Premise
both	I-Premise
treatments	I-Premise
the	I-Premise
diurnal	I-Premise
IOP	I-Premise
reduction	I-Premise
after	I-Premise
6	I-Premise
months	I-Premise
was	I-Premise
statistically	I-Premise
significant	I-Premise
(P<0.001).	I-Premise

IOP	B-Premise
(mean+/-SD)	I-Premise
was	I-Premise
reduced	I-Premise
from	I-Premise
23.3+/-2.8	I-Premise
to	I-Premise
17.8+/-2.8	I-Premise
(-5.6)	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
0.005%	I-Premise
group	I-Premise
and	I-Premise
from	I-Premise
23.0+/-3.2	I-Premise
to	I-Premise
18.5+/-2.4	I-Premise
(-4.8)	I-Premise
mmHg	I-Premise
in	I-Premise
pilocarpine	I-Premise
2%	I-Premise
t.i.d.-treated	I-Premise
eyes.	I-Premise

The	B-Premise
mean	I-Premise
difference	I-Premise
of	I-Premise
-0.8	I-Premise
mmHg	I-Premise
(per	I-Premise
protocol,	I-Premise
PP)	I-Premise
and	I-Premise
-1.6	I-Premise
mmHg	I-Premise
(intend-to-treat,	I-Premise
ITT)	I-Premise
was	I-Premise
statistically	I-Premise
significant	I-Premise
(P<0.04,	I-Premise
PP;	I-Premise
P<0.001,	I-Premise
ITT)	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
latanoprost	I-Premise
0.005%.	I-Premise

Two	B-Premise
eyes	I-Premise
treated	I-Premise
with	I-Premise
latanoprost	I-Premise
showed	I-Premise
an	I-Premise
iris	I-Premise
color	I-Premise
change.	I-Premise

Thirty-six	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
and	I-Premise
106	I-Premise
in	I-Premise
the	I-Premise
pilocarpine	I-Premise
2%	I-Premise
group	I-Premise
reported	I-Premise
ocular	I-Premise
adverse	I-Premise
events	I-Premise
(P<0.001).	I-Premise

From	B-Claim
the	I-Claim
data	I-Claim
we	I-Claim
conclude	I-Claim
that	I-Claim
the	I-Claim
additivity	I-Claim
of	I-Claim
latanoprost	I-Claim
0.005%	I-Claim
is	I-Claim
at	I-Claim
least	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
pilocarpine	I-Claim
2%	I-Claim
t.i.d.	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
when	I-Claim
added	I-Claim
to	I-Claim
eyes	I-Claim
currently	I-Claim
on	I-Claim
monotherapy	I-Claim
with	I-Claim
timolol	I-Claim
0.5%	I-Claim
b.i.d.	I-Claim

Latanoprost	B-Claim
was	I-Claim
better	I-Claim
tolerated	I-Claim
than	I-Claim
pilocarpine	I-Claim
2%	I-Claim
eye	I-Claim
drops	I-Claim
in	I-Claim
this	I-Claim
study.	I-Claim

The	B-Claim
increase	I-Claim
in	I-Claim
iris	I-Claim
pigmentation	I-Claim
requires	I-Claim
further	I-Claim
investigation.	I-Claim

To	O
compare	O
the	O
short-	O
and	O
intermediate-term	O
results	O
of	O
two	O
commonly	O
used	O
glaucoma	O
surgical	O
procedures,	O
trabeculectomy	O
and	O
Ahmed	O
glaucoma	O
valve	O
implant.	O

A	O
randomized	O
clinical	O
trial	O
was	O
performed	O
at	O
two	O
international	O
centers.	O

One	O
eye	O
each	O
of	O
consecutive	O
patients	O
requiring	O
glaucoma	O
surgery	O
for	O
intraocular	O
pressure	O
control	O
was	O
randomized	O
to	O
receive	O
either	O
trabeculectomy	O
or	O
the	O
Ahmed	O
implant.	O

Of	O
the	O
117	O
patients,	O
62	O
were	O
randomized	O
to	O
trabeculectomy	O
and	O
55	O
to	O
the	O
Ahmed	O
implant.	O

With	B-Premise
a	I-Premise
mean	I-Premise
follow-up	I-Premise
of	I-Premise
9.7	I-Premise
months,	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
had	I-Premise
statistically	I-Premise
lower	I-Premise
intraocular	I-Premise
pressures	I-Premise
at	I-Premise
weeks	I-Premise
6	I-Premise
to	I-Premise
15	I-Premise
(12.6	I-Premise
mm	I-Premise
Hg	I-Premise
vs	I-Premise
16.4	I-Premise
mm	I-Premise
Hg)	I-Premise
and	I-Premise
months	I-Premise
11	I-Premise
to	I-Premise
13	I-Premise
(11.4	I-Premise
mm	I-Premise
Hg	I-Premise
vs	I-Premise
17.2	I-Premise
mm	I-Premise
Hg)	I-Premise
than	I-Premise
the	I-Premise
Ahmed	I-Premise
implant	I-Premise
group.	I-Premise

Compared	B-Premise
with	I-Premise
preoperative	I-Premise
status,	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
were	I-Premise
noted	I-Premise
for	I-Premise
visual	I-Premise
acuity,	I-Premise
visual	I-Premise
field,	I-Premise
lens	I-Premise
status,	I-Premise
and	I-Premise
final	I-Premise
anterior	I-Premise
chamber	I-Premise
depth.	I-Premise

The	B-Premise
cumulative	I-Premise
probabilities	I-Premise
of	I-Premise
success	I-Premise
(intraocular	I-Premise
pressure	I-Premise
<21	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
at	I-Premise
least	I-Premise
15%	I-Premise
reduction	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
from	I-Premise
preoperative	I-Premise
level)	I-Premise
were	I-Premise
83.6%	I-Premise
for	I-Premise
trabeculectomy	I-Premise
and	I-Premise
88.1%	I-Premise
for	I-Premise
Ahmed	I-Premise
implant	I-Premise
(P	I-Premise
=.43).	I-Premise

However,	O
the	B-Premise
Ahmed	I-Premise
implant	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
greater	I-Premise
adjunctive	I-Premise
medication	I-Premise
requirement.	I-Premise

On	B-Premise
the	I-Premise
last	I-Premise
visit,	I-Premise
10	I-Premise
of	I-Premise
the	I-Premise
trabeculectomy	I-Premise
eyes	I-Premise
and	I-Premise
19	I-Premise
of	I-Premise
the	I-Premise
Ahmed	I-Premise
implant	I-Premise
eyes	I-Premise
required	I-Premise
at	I-Premise
least	I-Premise
one	I-Premise
topical	I-Premise
medication	I-Premise
(P	I-Premise
=.01).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
complications	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

Lower	B-Premise
mean	I-Premise
intraocular	I-Premise
pressures	I-Premise
were	I-Premise
noted	I-Premise
for	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group.	I-Premise

All	B-Premise
other	I-Premise
results,	I-Premise
including	I-Premise
success	I-Premise
(as	I-Premise
defined	I-Premise
in	I-Premise
this	I-Premise
study)	I-Premise
and	I-Premise
frequency	I-Premise
of	I-Premise
complications,	I-Premise
were	I-Premise
comparable	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

To	O
report	O
a	O
randomized	O
clinical	O
trial	O
of	O
postoperative	O
subconjunctival	O
injections	O
of	O
low-dose	O
5-fluorouracil	O
in	O
patients	O
undergoing	O
primary	O
trabeculectomy.	O

In	O
a	O
prospective,	O
randomized	O
clinical	O
trial,	O
40	O
eyes	O
of	O
40	O
patients	O
were	O
randomized	O
to	O
the	O
low-dose	O
5-fluorouracil	O
group	O
and	O
received	O
three	O
subconjunctival	O
injections	O
of	O
5	O
mg	O
each	O
over	O
11	O
postoperative	O
days,	O
and	O
40	O
eyes	O
of	O
40	O
patients	O
were	O
randomized	O
to	O
trabeculectomy	O
without	O
5-fluorouracil.	O

Mean	B-Premise
(+/-SD)	I-Premise
preoperative	I-Premise
and	I-Premise
1-year	I-Premise
postoperative	I-Premise
intraocular	I-Premise
pressures	I-Premise
in	I-Premise
the	I-Premise
5-fluorouracil	I-Premise
group	I-Premise
were	I-Premise
26.9	I-Premise
(+/-9.5)	I-Premise
and	I-Premise
15.3	I-Premise
(+/-5.8)	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively.	I-Premise

In	B-Premise
the	I-Premise
control	I-Premise
group	I-Premise
these	I-Premise
were	I-Premise
25.9	I-Premise
(+/-8.1)	I-Premise
mm	I-Premise
Hg,	I-Premise
and	I-Premise
15.8	I-Premise
(+/-5.1)	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively.	I-Premise

The	B-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
5-fluorouracil	I-Premise
had	I-Premise
a	I-Premise
mean	I-Premise
reduction	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
of	I-Premise
11.5	I-Premise
(+/-9.1)	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
52.3	I-Premise
weeks.	I-Premise

The	B-Premise
control	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
mean	I-Premise
reduction	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
of	I-Premise
10.2	I-Premise
(+/-8.7)	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
52.6	I-Premise
weeks.	I-Premise

These	B-Premise
differences	I-Premise
were	I-Premise
not	I-Premise
statistically	I-Premise
significant.	I-Premise

Three	B-Premise
postoperative	I-Premise
subconjunctival	I-Premise
5-fluorouracil	I-Premise
injections	I-Premise
of	I-Premise
5	I-Premise
mg	I-Premise
each	I-Premise
after	I-Premise
trabeculectomy	I-Premise
in	I-Premise
eyes	I-Premise
at	I-Premise
low	I-Premise
risk	I-Premise
for	I-Premise
failure	I-Premise
had	I-Premise
no	I-Premise
statistically	I-Premise
or	I-Premise
clinically	I-Premise
significant	I-Premise
effect	I-Premise
on	I-Premise
reduction	I-Premise
of	I-Premise
intraocular	I-Premise
pressure	I-Premise
with	I-Premise
1-year	I-Premise
follow-up.	I-Premise

Enhancement	B-Claim
of	I-Claim
success	I-Claim
in	I-Claim
this	I-Claim
group	I-Claim
of	I-Claim
patients	I-Claim
may	I-Claim
require	I-Claim
a	I-Claim
larger	I-Claim
total	I-Claim
dose	I-Claim
of	I-Claim
5-fluorouracil.	I-Claim

Increased	B-Claim
intraocular	I-Claim
pressure	I-Claim
(IOP)	I-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
be	I-Claim
one	I-Claim
of	I-Claim
the	I-Claim
most	I-Claim
important	I-Claim
risk	I-Claim
factors	I-Claim
for	I-Claim
developing	I-Claim
glaucoma.	I-Claim

Yet	O
it	O
has	O
not	O
been	O
clearly	O
demonstrated	O
that	O
IOP-lowering	O
treatment	O
can	O
reduce	O
the	O
incidence	O
of	O
glaucoma	O
damage	O
in	O
patients	O
with	O
ocular	O
hypertension.	O

The	O
aim	O
of	O
the	O
current	O
paper	O
was	O
to	O
report	O
the	O
results	O
of	O
a	O
long-term	O
study	O
addressing	O
this	O
very	O
problem.	O

We	O
conducted	O
a	O
randomised,	O
double-masked	O
study	O
comparing	O
timolol	O
and	O
placebo	O
treatment	O
in	O
90	O
patients	O
with	O
ocular	O
hypertension	O
plus	O
some	O
additional	O
risk	O
factor.	O

Patients	O
were	O
followed	O
at	O
3-month	O
intervals	O
prospectively	O
for	O
10	O
years	O
or	O
until	O
glaucomatous	O
field	O
loss	O
could	O
be	O
demonstrated	O
with	O
computerised	O
perimetry.	O

A	O
post-study	O
analysis	O
was	O
performed	O
including	O
all	O
available	O
data,	O
thus	O
extending	O
maximum	O
follow-up	O
to	O
17	O
years.	O

After	B-Premise
5	I-Premise
years	I-Premise
of	I-Premise
follow-up	I-Premise
eight	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
and	I-Premise
five	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
timolol	I-Premise
group	I-Premise
had	I-Premise
developed	I-Premise
glaucomatous	I-Premise
field	I-Premise
loss	I-Premise
(NS);	I-Premise
the	B-Premise
corresponding	I-Premise
figures	I-Premise
after	I-Premise
10	I-Premise
years	I-Premise
were	I-Premise
15	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
and	I-Premise
seven	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
timolol	I-Premise
group.	I-Premise

Survival	B-Premise
analysis	I-Premise
showed	I-Premise
a	I-Premise
tendency	I-Premise
but	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
treatment	I-Premise
groups	I-Premise
(P	I-Premise
=	I-Premise
0.07).	I-Premise

Study	B-Premise
attrition	I-Premise
was	I-Premise
large.	I-Premise

Eighteen	B-Premise
patients	I-Premise
in	I-Premise
each	I-Premise
group	I-Premise
had	I-Premise
developed	I-Premise
glaucomatous	I-Premise
field	I-Premise
loss	I-Premise
when	I-Premise
also	I-Premise
post-study	I-Premise
data	I-Premise
were	I-Premise
included.	I-Premise

IOP	B-Premise
reduction	I-Premise
was	I-Premise
greater	I-Premise
in	I-Premise
eyes	I-Premise
passing	I-Premise
the	I-Premise
10-year	I-Premise
visit	I-Premise
without	I-Premise
field	I-Premise
loss	I-Premise
(5.7	I-Premise
mmHg),	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
that	I-Premise
reached	I-Premise
an	I-Premise
end-point	I-Premise
(2.3	I-Premise
mmHg;	I-Premise
P	I-Premise
=	I-Premise
0.0002).	I-Premise

In	B-Claim
this	I-Claim
long-term	I-Claim
study	I-Claim
we	I-Claim
found	I-Claim
a	I-Claim
tendency	I-Claim
but	I-Claim
failed	I-Claim
to	I-Claim
prove	I-Claim
a	I-Claim
beneficial	I-Claim
effect	I-Claim
of	I-Claim
topical	I-Claim
timolol	I-Claim
treatment	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
elevated	I-Claim
IOP,	I-Claim
normal	I-Claim
visual	I-Claim
fields	I-Claim
and	I-Claim
some	I-Claim
additional	I-Claim
risk	I-Claim
factor.	I-Claim

The	B-Premise
intent-to-treat	I-Premise
analysis	I-Premise
showed	I-Premise
no	I-Premise
difference	I-Premise
between	I-Premise
treatment	I-Premise
groups.	I-Premise

The	B-Premise
high	I-Premise
attrition	I-Premise
shows	I-Premise
the	I-Premise
difficulties	I-Premise
associated	I-Premise
with	I-Premise
very	I-Premise
long	I-Premise
follow-up.	I-Premise

To	O
compare	O
viscocanalostomy,	O
a	O
nonpenetrating	O
procedure	O
for	O
glaucoma	O
treatment,	O
with	O
trabeculectomy.	O

Randomized	O
controlled	O
trial.	O

Twenty	O
white	O
subjects	O
(20	O
eyes)	O
with	O
open-angle	O
glaucoma	O
with	O
no	O
history	O
of	O
surgery	O
were	O
enrolled.	O

Ten	O
subjects	O
were	O
randomly	O
assigned	O
to	O
viscocanalostomy	O
according	O
to	O
Stegmann's	O
technique	O
and	O
10	O
subjects	O
to	O
a	O
modified	O
Cairns	O
trabeculectomy.	O

A	O
complete	O
ophthalmologic	O
examination	O
was	O
performed	O
the	O
day	O
before	O
surgery	O
and	O
postoperatively.	O

Further	O
visits	O
were	O
scheduled	O
monthly	O
for	O
6	O
to	O
8	O
months	O
after	O
surgery.	O

Success	O
was	O
defined	O
as	O
intraocular	O
pressure	O
(IOP)	O
between	O
7	O
and	O
20	O
mmHg,	O
with	O
no	O
medication.	O

After	B-Premise
a	I-Premise
mean	I-Premise
follow-up	I-Premise
of	I-Premise
6	I-Premise
months	I-Premise
(range,	I-Premise
6-8	I-Premise
months),	I-Premise
success	I-Premise
was	I-Premise
obtained	I-Premise
in	I-Premise
5	I-Premise
of	I-Premise
10	I-Premise
cases	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
and	I-Premise
in	I-Premise
0	I-Premise
of	I-Premise
10	I-Premise
case	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group.	I-Premise

With	B-Premise
Kaplan-Meier's	I-Premise
method,	I-Premise
subjects	I-Premise
with	I-Premise
viscocanalostomy	I-Premise
showed	I-Premise
shorter	I-Premise
postoperative	I-Premise
IOP-reduction	I-Premise
periods	I-Premise
than	I-Premise
subjects	I-Premise
undergoing	I-Premise
trabeculectomy.	I-Premise

According	B-Claim
to	I-Claim
the	I-Claim
results	I-Claim
of	I-Claim
this	I-Claim
short-term	I-Claim
study,	I-Claim
trabeculectomy	I-Claim
was	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
viscocanalostomy	I-Claim
in	I-Claim
lowering	I-Claim
IOP	I-Claim
in	I-Claim
glaucomatous	I-Claim
eyes	I-Claim
of	I-Claim
white	I-Claim
patients.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure	O
(IOP)	O
reducing	O
effect	O
and	O
safety	O
of	O
latanoprost	O
0.005%	O
once	O
daily	O
with	O
unoprostone	O
0.12%	O
twice	O
daily	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
(POAG)	O
or	O
ocular	O
hypertension	O
(OH).	O

An	O
8-week,	O
double-masked,	O
randomized,	O
parallel-group,	O
single-center	O
clinical	O
trial.	O

A	O
total	O
of	O
108	O
patients	O
with	O
POAG	O
or	O
OH	O
were	O
enrolled.	O

After	O
completing	O
a	O
wash-out	O
of	O
ocular	O
hypotensive	O
medications,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
latanoprost	O
once	O
daily	O
in	O
the	O
evening	O
plus	O
placebo	O
once	O
daily	O
in	O
the	O
morning,	O
or	O
unoprostone	O
twice	O
daily	O
(morning	O
and	O
evening).	O

IOP	O
was	O
measured	O
at	O
10:00	O
AM	O
and	O
at	O
5:00	O
PM	O
at	O
baseline	O
and	O
at	O
week	O
8,	O
and	O
before	O
12:00	O
noon	O
at	O
week	O
2.	O

Ocular	O
and	O
systemic	O
safety	O
assessments	O
were	O
performed.	O

From	B-Premise
an	I-Premise
overall	I-Premise
baseline	I-Premise
of	I-Premise
24.1	I-Premise
mmHg,	I-Premise
latanoprost	I-Premise
reduced	I-Premise
IOP	I-Premise
by	I-Premise
6.7	I-Premise
mmHg	I-Premise
(28%)	I-Premise
and	I-Premise
unoprostone	I-Premise
reduced	I-Premise
IOP	I-Premise
by	I-Premise
3.3	I-Premise
mmHg	I-Premise
(14%).	I-Premise

The	B-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
groups	I-Premise
of	I-Premise
3.4	I-Premise
mmHg	I-Premise
was	I-Premise
significant	I-Premise
(P:	I-Premise
<	I-Premise
0.001,	I-Premise
analysis	I-Premise
of	I-Premise
covariance;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]:	I-Premise
-4.7	I-Premise
to	I-Premise
-2.1)	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
latanoprost.	I-Premise

A	B-Premise
>/=30%	I-Premise
reduction	I-Premise
in	I-Premise
mean	I-Premise
IOP	I-Premise
from	I-Premise
baseline	I-Premise
was	I-Premise
achieved	I-Premise
by	I-Premise
44%	I-Premise
of	I-Premise
latanoprost-treated	I-Premise
patients	I-Premise
compared	I-Premise
with	I-Premise
8%	I-Premise
of	I-Premise
unoprostone-treated	I-Premise
patients.	I-Premise

The	O
incidence	O
of	O
adverse	O
events	O
was	O
low	O
and	O
comparable	O
between	O
the	O
groups.	O

Latanoprost	B-Claim
administered	I-Claim
once	I-Claim
daily	I-Claim
was	I-Claim
significantly	I-Claim
more	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
compared	I-Claim
with	I-Claim
unoprostone	I-Claim
administered	I-Claim
twice	I-Claim
daily	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
POAG	I-Claim
and	I-Claim
OH.	I-Claim

To	O
compare	O
the	O
effect	O
on	O
intraocular	O
pressure	O
of	O
latanoprost	O
versus	O
timolol	O
plus	O
dorzolamide	O
in	O
open-angle	O
glaucoma.	O

Thirty-five	O
patients	O
with	O
open-angle	O
glaucoma	O
were	O
randomized,	O
18	O
to	O
latanoprost	O
once	O
daily	O
and	O
17	O
to	O
timolol	O
plus	O
dorzolamide	O
twice	O
daily.	O

Intraocular	O
pressure	O
and	O
ocular	O
side	O
effects	O
were	O
recorded	O
at	O
baseline,	O
and	O
after	O
2	O
weeks	O
and	O
3	O
months	O
of	O
treatment.	O

Latanoprost	B-Premise
reduced	I-Premise
the	I-Premise
intraocular	I-Premise
pressure	I-Premise
1.09	I-Premise
and	I-Premise
1.58	I-Premise
mm	I-Premise
Hg	I-Premise
more	I-Premise
than	I-Premise
timolol	I-Premise
plus	I-Premise
dorzolamide	I-Premise
after	I-Premise
2	I-Premise
weeks	I-Premise
and	I-Premise
3	I-Premise
months	I-Premise
of	I-Premise
treatment,	I-Premise
respectively.	I-Premise

These	B-Premise
differences	I-Premise
were	I-Premise
statistically	I-Premise
significant	I-Premise
(p<0.05)	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
study.	I-Premise

After	B-Premise
3	I-Premise
months	I-Premise
of	I-Premise
treatment,	I-Premise
32.3%	I-Premise
of	I-Premise
the	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
reduced	I-Premise
the	I-Premise
intraocular	I-Premise
pressure	I-Premise
in	I-Premise
30%	I-Premise
or	I-Premise
more	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
baseline,	I-Premise
while	I-Premise
15.6%	I-Premise
of	I-Premise
the	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
timolol	I-Premise
plus	I-Premise
dorzolamide	I-Premise
group	I-Premise
achieved	I-Premise
this	I-Premise
reduction.	I-Premise

Latanoprost	B-Claim
administered	I-Claim
once	I-Claim
daily	I-Claim
reduced	I-Claim
the	I-Claim
intraocular	I-Claim
pressure	I-Claim
at	I-Claim
least	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
timolol	I-Claim
plus	I-Claim
dorzolamide	I-Claim
twice	I-Claim
daily	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
open-angle	I-Claim
glaucoma.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure)-lowering	O
effect	O
and	O
side	O
effects	O
of	O
latanoprost	O
0.005%	O
once	O
daily	O
with	O
unoprostone	O
0.12%	O
twice	O
daily.	O

Sixty	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
were	O
randomized	O
to	O
receive	O
either	O
latanoprost	O
once	O
daily	O
in	O
the	O
evening	O
and	O
placebo	O
once	O
daily	O
in	O
the	O
morning,	O
or	O
unoprostone	O
twice	O
daily	O
in	O
the	O
morning	O
and	O
evening.	O

The	O
study	O
was	O
double	O
masked	O
and	O
followed	O
a	O
crossover	O
design	O
with	O
two	O
treatment	O
periods	O
of	O
1	O
month	O
separated	O
by	O
a	O
3-week	O
washout	O
period.	O

The	O
intraocular	O
pressure	O
was	O
measured	O
at	O
9	O
AM	O
and	O
5	O
PM	O
on	O
the	O
baseline	O
and	O
day	O
28	O
visits,	O
and	O
at	O
9	O
AM	O
on	O
day	O
2	O
and	O
day	O
14	O
visits	O
of	O
each	O
treatment	O
period.	O

The	O
9	O
AM	O
measurement	O
was	O
taken	O
2	O
hours	O
and	O
13	O
hours	O
after	O
the	O
last	O
drop	O
of	O
unoprostone	O
and	O
latanoprost,	O
and	O
the	O
5	O
PM	O
measurement	O
was	O
at	O
10	O
and	O
21	O
hours,	O
respectively.	O

The	O
mean	O
of	O
the	O
measurements	O
was	O
calculated.	O

Safety	O
parameters	O
were	O
also	O
recorded.	O

Fifty-six	O
patients	O
completed	O
both	O
treatment	O
periods	O
and	O
had	O
intraocular	O
pressure	O
data	O
available	O
for	O
evaluation.	O

After	B-Premise
1	I-Premise
month	I-Premise
of	I-Premise
treatment,	I-Premise
latanoprost	I-Premise
significantly	I-Premise
reduced	I-Premise
intraocular	I-Premise
pressure	I-Premise
(mean	I-Premise
+/-	I-Premise
SEM)	I-Premise
by	I-Premise
6.1	I-Premise
+/-	I-Premise
0.5	I-Premise
mm	I-Premise
Hg	I-Premise
(P	I-Premise
<.001)	I-Premise
and	I-Premise
unoprostone	I-Premise
by	I-Premise
4.2	I-Premise
+/-	I-Premise
0.4	I-Premise
mm	I-Premise
Hg	I-Premise
(P	I-Premise
<.001)	I-Premise
adjusted	I-Premise
from	I-Premise
an	I-Premise
overall	I-Premise
baseline	I-Premise
of	I-Premise
22.3	I-Premise
+/-	I-Premise
0.5	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
23.2	I-Premise
+/-	I-Premise
0.4	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively.	I-Premise

The	B-Premise
difference	I-Premise
of	I-Premise
1.9	I-Premise
mm	I-Premise
Hg	I-Premise
between	I-Premise
treatments	I-Premise
was	I-Premise
statistically	I-Premise
significant	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
latanoprost	I-Premise
[P	I-Premise
=.003,	I-Premise
analysis	I-Premise
of	I-Premise
covariance	I-Premise
(ANCOVA)].	I-Premise

Unadjusted	B-Premise
analysis	I-Premise
of	I-Premise
responders	I-Premise
using	I-Premise
the	I-Premise
percentage	I-Premise
decrease	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
showed	I-Premise
that	I-Premise
the	I-Premise
proportion	I-Premise
of	I-Premise
responders	I-Premise
in	I-Premise
the	I-Premise
latanoprost-treated	I-Premise
group	I-Premise
was	I-Premise
greater	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
unoprostone-treated	I-Premise
group.	I-Premise

Adverse	B-Premise
ocular	I-Premise
symptoms	I-Premise
and	I-Premise
findings	I-Premise
were	I-Premise
mild	I-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
groups.	I-Premise

Eye	B-Premise
redness	I-Premise
and	I-Premise
ocular	I-Premise
irritation	I-Premise
were	I-Premise
the	I-Premise
most	I-Premise
frequently	I-Premise
reported	I-Premise
events.	I-Premise

Latanoprost	B-Claim
once	I-Claim
daily	I-Claim
was	I-Claim
significantly	I-Claim
more	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
intraocular	I-Claim
pressure	I-Claim
compared	I-Claim
with	I-Claim
unoprostone	I-Claim
twice	I-Claim
daily	I-Claim
after	I-Claim
1	I-Claim
month	I-Claim
of	I-Claim
treatment	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
primary	I-Claim
open-angle	I-Claim
glaucoma	I-Claim
and	I-Claim
ocular	I-Claim
hypertension.	I-Claim

Both	B-Claim
drugs	I-Claim
were	I-Claim
well	I-Claim
tolerated	I-Claim
with	I-Claim
few	I-Claim
ocular	I-Claim
adverse	I-Claim
events.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure-lowering	O
effect	O
of	O
latanoprost	O
with	O
that	O
of	O
dorzolamide	O
when	O
added	O
to	O
timolol.	O

This	O
randomized,	O
open-label	O
study	O
with	O
two	O
parallel	O
groups	O
was	O
conducted	O
in	O
five	O
centers	O
in	O
Greece.	O

The	O
study	O
enrolled	O
148	O
patients	O
with	O
inadequately	O
controlled	O
open-angle	O
or	O
pseudoexfoliation	O
glaucoma	O
(intraocular	O
pressure	O
of	O
at	O
least	O
22	O
mm	O
Hg)	O
or	O
ocular	O
hypertension	O
(intraocular	O
pressure	O
of	O
at	O
least	O
27	O
mm	O
Hg)	O
who	O
were	O
receiving	O
monotherapy	O
with	O
a	O
beta-blocker	O
or	O
dual	O
therapy	O
in	O
which	O
one	O
of	O
the	O
agents	O
was	O
a	O
beta-blocker.	O

The	O
patients	O
were	O
switched	O
to	O
timolol	O
0.5%	O
twice	O
daily	O
for	O
2	O
to	O
4	O
weeks	O
(run-in	O
period)	O
before	O
the	O
start	O
of	O
the	O
study	O
(baseline).	O

At	O
baseline,	O
the	O
patients	O
were	O
randomized	O
to	O
receive	O
latanoprost	O
0.005%	O
once	O
daily	O
or	O
dorzolamide	O
2%	O
twice	O
daily	O
as	O
add-on	O
therapy	O
to	O
timolol.	O

The	O
intraocular	O
pressure	O
was	O
recorded	O
at	O
9:30	O
AM,	O
12:30	O
PM,	O
and	O
3:30	O
PM	O
at	O
baseline	O
and	O
at	O
3	O
months.	O

Safety	O
was	O
followed	O
throughout	O
the	O
study.	O

The	B-Premise
diurnal	I-Premise
intraocular	I-Premise
pressure	I-Premise
reduction	I-Premise
was	I-Premise
significant	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

The	B-Premise
mean	I-Premise
intraocular	I-Premise
pressure	I-Premise
reduction	I-Premise
from	I-Premise
baseline	I-Premise
was	I-Premise
32%	I-Premise
for	I-Premise
the	I-Premise
latanoprost	I-Premise
plus	I-Premise
timolol	I-Premise
group	I-Premise
and	I-Premise
20%	I-Premise
for	I-Premise
the	I-Premise
dorzolamide	I-Premise
plus	I-Premise
timolol	I-Premise
group.	I-Premise

The	B-Premise
least	I-Premise
square	I-Premise
estimate	I-Premise
of	I-Premise
the	I-Premise
mean	I-Premise
diurnal	I-Premise
intraocular	I-Premise
pressure	I-Premise
reduction	I-Premise
after	I-Premise
3	I-Premise
months	I-Premise
was	I-Premise
-7.06	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
plus	I-Premise
timolol	I-Premise
group	I-Premise
and	I-Premise
-4.44	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
dorzolamide	I-Premise
plus	I-Premise
timolol	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

Drugs	B-Claim
administered	I-Claim
in	I-Claim
both	I-Claim
treatment	I-Claim
groups	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

This	B-Claim
study	I-Claim
clearly	I-Claim
showed	I-Claim
that	I-Claim
the	I-Claim
additive	I-Claim
diurnal	I-Claim
intraocular	I-Claim
pressure-lowering	I-Claim
effect	I-Claim
of	I-Claim
latanoprost	I-Claim
is	I-Claim
superior	I-Claim
to	I-Claim
that	I-Claim
of	I-Claim
dorzolamide	I-Claim
in	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
timolol.	I-Claim

To	O
evaluate	O
the	O
intraocular	O
pressure-lowering	O
efficacy	O
and	O
safety	O
of	O
travoprost	O
0.0015%	O
and	O
0.004%,	O
dosed	O
daily	O
in	O
the	O
evening	O
compared	O
with	O
vehicle,	O
in	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension,	O
whose	O
intraocular	O
pressure	O
was	O
not	O
adequately	O
controlled	O
on	O
timolol	O
0.5%	O
twice	O
daily	O
(twice	O
daily).	O

Subjects	O
who	O
qualified	O
at	O
screening	O
began	O
a	O
run-in	O
period	O
dosing	O
timolol	O
twice	O
daily	O
for	O
3	O
weeks.	O

If	O
the	O
subjects	O
had	O
an	O
intraocular	O
pressure	O
of	O
24	O
to	O
36	O
mm	O
Hg	O
at	O
8	O
AM	O
and	O
21	O
to	O
36	O
mm	O
Hg	O
at	O
10	O
AM	O
and	O
4	O
pm	O
in	O
at	O
least	O
one	O
eye	O
on	O
timolol,	O
they	O
were	O
randomized	O
to	O
one	O
of	O
two	O
concentrations	O
of	O
travoprost	O
(0.0015%	O
or	O
0.004%)	O
or	O
vehicle	O
solution	O
every	O
day	O
and	O
were	O
followed	O
for	O
6	O
months.	O

Four	O
hundred	O
twenty-six	O
subjects	O
were	O
randomized.	O

The	O
mean	O
intraocular	O
pressure	O
at	O
8	O
AM,	O
10	O
AM,	O
and	O
4	O
PM	O
in	O
the	O
patient's	O
eye	O
with	O
the	O
higher	O
intraocular	O
pressure	O
was	O
used	O
for	O
the	O
analysis.	O

Mean	B-Premise
baseline	I-Premise
values	I-Premise
(25	I-Premise
mm	I-Premise
Hg)	I-Premise
for	I-Premise
subjects	I-Premise
at	I-Premise
eligibility	I-Premise
(while	I-Premise
maintained	I-Premise
on	I-Premise
timolol)	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
(P	I-Premise
<.0001)	I-Premise
among	I-Premise
the	I-Premise
treatment	I-Premise
groups.	I-Premise

The	B-Premise
intraocular	I-Premise
pressure	I-Premise
was	I-Premise
lowered	I-Premise
an	I-Premise
additional	I-Premise
-5.7	I-Premise
to	I-Premise
-7.2	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
-5.1	I-Premise
to	I-Premise
-6.7	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
travoprost	I-Premise
0.004%	I-Premise
and	I-Premise
0.0015%	I-Premise
concentrations,	I-Premise
respectively.	I-Premise

These	B-Premise
changes	I-Premise
were	I-Premise
significantly	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=.0001)	I-Premise
different	I-Premise
from	I-Premise
the	I-Premise
vehicle	I-Premise
group	I-Premise
(-1.3	I-Premise
to	I-Premise
-2.8	I-Premise
mm	I-Premise
Hg).	I-Premise

The	B-Premise
intraocular	I-Premise
pressure	I-Premise
range	I-Premise
on	I-Premise
treatment	I-Premise
at	I-Premise
all	I-Premise
visit	I-Premise
times	I-Premise
over	I-Premise
the	I-Premise
6-month	I-Premise
treatment	I-Premise
period	I-Premise
ranged	I-Premise
from	I-Premise
17.9	I-Premise
to	I-Premise
19.2	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
travoprost	I-Premise
0.004%	I-Premise
and	I-Premise
18.3	I-Premise
to	I-Premise
20.1	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
travoprost	I-Premise
0.0015%	I-Premise
compared	I-Premise
with	I-Premise
22.4	I-Premise
to	I-Premise
24.1	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
vehicle.	I-Premise

Average	B-Premise
hyperemia	I-Premise
scores	I-Premise
ranged	I-Premise
from	I-Premise
trace	I-Premise
to	I-Premise
mild	I-Premise
(mean	I-Premise
0.5	I-Premise
on	I-Premise
a	I-Premise
scale	I-Premise
of	I-Premise
0	I-Premise
=	I-Premise
none/trace;	I-Premise
1=	I-Premise
mild;	I-Premise
2	I-Premise
=	I-Premise
moderate;	I-Premise
3	I-Premise
=	I-Premise
severe)	I-Premise
for	I-Premise
all	I-Premise
treatment	I-Premise
groups.	I-Premise

No	B-Premise
iris	I-Premise
pigmentation	I-Premise
changes	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
any	I-Premise
patient	I-Premise
during	I-Premise
this	I-Premise
study.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
clinically	I-Premise
or	I-Premise
statistically	I-Premise
significant	I-Premise
changes	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
visual	I-Premise
acuity,	I-Premise
ocular	I-Premise
cells	I-Premise
and	I-Premise
flare,	I-Premise
fundus	I-Premise
parameter,	I-Premise
cup-to-disk	I-Premise
ratio	I-Premise
and	I-Premise
visual	I-Premise
field	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
serious	I-Premise
adverse	I-Premise
events	I-Premise
reported	I-Premise
for	I-Premise
any	I-Premise
treatment	I-Premise
group.	I-Premise

Travoprost	B-Claim
produced	I-Claim
clinically	I-Claim
relevant	I-Claim
and	I-Claim
statistically	I-Claim
significant	I-Claim
additional	I-Claim
intraocular	I-Claim
pressure	I-Claim
reductions	I-Claim
from	I-Claim
baseline	I-Claim
when	I-Claim
used	I-Claim
adjunctively	I-Claim
with	I-Claim
timolol	I-Claim
in	I-Claim
subjects	I-Claim
with	I-Claim
open-angle	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension.	I-Claim

Many	O
physicians	O
recommend	O
either	O
brimonidine	O
or	O
latanoprost	O
as	O
firstline	O
therapy	O
for	O
chronic	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

However,	O
a	O
search	O
of	O
MEDLINE	O
indicates	O
that	O
there	O
have	O
been	O
few	O
head-to-head	O
comparisons	O
of	O
the	O
2	O
monotherapies	O
in	O
a	O
clinical	O
setting.	O

This	O
study	O
compared	O
the	O
clinical	O
efficacy	O
and	O
tolerability	O
of	O
brimonidine	O
0.2%	O
twice	O
daily	O
with	O
those	O
of	O
latanoprost	O
0.005%	O
once	O
daily	O
as	O
monotherapy	O
in	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

In	O
this	O
3-month,	O
multicenter,	O
double-masked,	O
parallel-group,	O
4-visit	O
study,	O
treatment-naive	O
and	O
previously	O
treated	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
and	O
bilateral	O
intraocular	O
pressure	O
(IOP)	O
after	O
washout	O
of	O
between	O
22	O
and	O
34	O
mm	O
Hg	O
were	O
randomized	O
to	O
receive	O
either	O
brimonidine	O
or	O
latanoprost.	O

Patients	O
who	O
had	O
received	O
previous	O
treatment	O
with	O
either	O
study	O
drug	O
were	O
excluded	O
from	O
the	O
study.	O

The	O
primary	O
outcome	O
measure	O
was	O
response	O
rate,	O
defined	O
as	O
the	O
percentage	O
of	O
patients	O
achieving	O
>	O
or	O
=	O
20%	O
reduction	O
in	O
IOP	O
from	O
baseline	O
to	O
month	O
3.	O

Secondary	O
outcome	O
measures	O
were	O
mean	O
IOP	O
reduction	O
from	O
baseline	O
to	O
month	O
3	O
and	O
clinical	O
success,	O
defined	O
as	O
the	O
investigator's	O
recommendation	O
that	O
the	O
patient	O
continue	O
using	O
the	O
assigned	O
study	O
medication.	O

A	O
total	O
of	O
127	O
patients	O
(55	O
treatment	O
naive)	O
were	O
enrolled,	O
66	O
in	O
the	O
brimonidine	O
group	O
and	O
61	O
in	O
the	O
latanoprost	O
group.	O

After	B-Premise
3	I-Premise
months	I-Premise
of	I-Premise
treatment,	I-Premise
80%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
and	I-Premise
74%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
had	I-Premise
achieved	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
20%	I-Premise
reduction	I-Premise
in	I-Premise
IOP	I-Premise
from	I-Premise
baseline.	I-Premise

The	B-Premise
mean	I-Premise
reduction	I-Premise
in	I-Premise
IOP	I-Premise
from	I-Premise
baseline	I-Premise
at	I-Premise
month	I-Premise
3	I-Premise
was	I-Premise
6.8	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
brimonidine	I-Premise
and	I-Premise
6.5	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
latanoprost	I-Premise
(27.8%	I-Premise
vs	I-Premise
27.0%,	I-Premise
respectively).	I-Premise

Among	B-Premise
treatment-naive	I-Premise
patients,	I-Premise
a	I-Premise
significantly	I-Premise
higher	I-Premise
percentage	I-Premise
of	I-Premise
brimonidine-treated	I-Premise
patients	I-Premise
achieved	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
20%	I-Premise
decrease	I-Premise
in	I-Premise
IOP	I-Premise
compared	I-Premise
with	I-Premise
latanoprost-treated	I-Premise
patients	I-Premise
(88%	I-Premise
vs	I-Premise
59%,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
0.01).	I-Premise

In	B-Premise
previously	I-Premise
treated	I-Premise
patients,	I-Premise
a	I-Premise
higher	I-Premise
percentage	I-Premise
of	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
achieved	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
20%	I-Premise
reduction	I-Premise
in	I-Premise
IOP	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
(88%	I-Premise
vs	I-Premise
74%,	I-Premise
respectively);	I-Premise
however,	B-Premise
the	I-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant.	I-Premise

Significantly	B-Premise
more	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
achieved	I-Premise
clinical	I-Premise
success	I-Premise
at	I-Premise
month	I-Premise
3	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
(91%	I-Premise
vs	I-Premise
74%;	I-Premise
P	I-Premise
=	I-Premise
0.01).	I-Premise

At	B-Premise
peak	I-Premise
effect,	I-Premise
brimonidine	I-Premise
twice	I-Premise
daily	I-Premise
was	I-Premise
as	I-Premise
effective	I-Premise
as	I-Premise
latanoprost	I-Premise
once	I-Premise
daily	I-Premise
in	I-Premise
lowering	I-Premise
IOP.	I-Premise

In	B-Premise
treatment-naive	I-Premise
patients,	I-Premise
latanoprost	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
significantly	I-Premise
higher	I-Premise
rate	I-Premise
of	I-Premise
nonresponse	I-Premise
after	I-Premise
3	I-Premise
months	I-Premise
of	I-Premise
treatment	I-Premise
compared	I-Premise
with	I-Premise
brimonidine.	I-Premise

This	B-Claim
suggests	I-Claim
that	I-Claim
brimonidine	I-Claim
may	I-Claim
be	I-Claim
the	I-Claim
more	I-Claim
reliable	I-Claim
choice	I-Claim
for	I-Claim
first-line	I-Claim
therapy	I-Claim
of	I-Claim
newly	I-Claim
diagnosed	I-Claim
open-angle	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension.	I-Claim

In	B-Premise
previously	I-Premise
treated	I-Premise
patients,	I-Premise
however,	I-Premise
latanoprost	I-Premise
provided	I-Premise
greater	I-Premise
mean	I-Premise
IOP	I-Premise
reduction	I-Premise
than	I-Premise
did	I-Premise
brimonidine.	I-Premise

Significantly	B-Claim
more	I-Claim
patients	I-Claim
achieved	I-Claim
clinical	I-Claim
success	I-Claim
with	I-Claim
brimonidine	I-Claim
monotherapy	I-Claim
than	I-Claim
with	I-Claim
latanoprost	I-Claim
monotherapy.	I-Claim

To	O
compare	O
the	O
effect	O
of	O
treatment	O
with	O
latanoprost	O
or	O
brimonidine	O
on	O
intraocular	O
pressure	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
and	O
intraocular	O
pressure	O
inadequately	O
controlled	O
by	O
monotherapy	O
or	O
dual	O
therapy.	O

Three	O
hundred	O
seventy-nine	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
were	O
recruited	O
for	O
this	O
6-month	O
prospective,	O
randomized,	O
observer-masked	O
multicenter	O
study	O
involving	O
30	O
eye	O
clinics.	O

All	O
patients	O
were	O
receiving	O
monotherapy	O
or	O
dual	O
therapy	O
that	O
did	O
not	O
adequately	O
control	O
intraocular	O
pressure.	O

After	O
appropriate	O
washout	O
periods,	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
latanoprost	O
once	O
daily	O
or	O
brimonidine	O
twice	O
daily.	O

The	O
main	O
outcome	O
measure	O
was	O
change	O
in	O
mean	O
diurnal	O
intraocular	O
pressure	O
after	O
6	O
months	O
of	O
treatment	O
compared	O
with	O
baseline.	O

Of	O
the	O
379	O
randomized	O
patients,	O
375	O
were	O
included	O
in	O
the	O
intent-to-treat	O
analysis.	O

From	B-Premise
an	I-Premise
overall	I-Premise
baseline	I-Premise
mean	I-Premise
intraocular	I-Premise
pressure	I-Premise
of	I-Premise
25.0	I-Premise
mm	I-Premise
Hg,	I-Premise
latanoprost	I-Premise
monotherapy	I-Premise
reduced	I-Premise
mean	I-Premise
diurnal	I-Premise
intraocular	I-Premise
pressure	I-Premise
by	I-Premise
7.1	I-Premise
+/-	I-Premise
3.3	I-Premise
mm	I-Premise
Hg	I-Premise
(mean	I-Premise
+/-	I-Premise
SD,	I-Premise
P	I-Premise
<	I-Premise
0.001),	I-Premise
whereas	I-Premise
brimonidine	I-Premise
monotherapy	I-Premise
yielded	I-Premise
an	I-Premise
intraocular-pressure	I-Premise
reduction	I-Premise
of	I-Premise
5.2	I-Premise
+/-	I-Premise
3.5	I-Premise
mm	I-Premise
Hg	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

This	B-Premise
1.9	I-Premise
mm	I-Premise
Hg	I-Premise
difference	I-Premise
in	I-Premise
intraocular-pressure	I-Premise
reduction	I-Premise
was	I-Premise
significantly	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
latanoprost	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

Ocular	B-Premise
allergy	I-Premise
(P	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
systemic	I-Premise
side	I-Premise
effects	I-Premise
(P	I-Premise
=	I-Premise
0.005)	I-Premise
were	I-Premise
reported	I-Premise
significantly	I-Premise
less	I-Premise
frequently	I-Premise
by	I-Premise
latanoprost-treated	I-Premise
patients	I-Premise
compared	I-Premise
with	I-Premise
brimonidine-treated	I-Premise
patients.	I-Premise

Both	B-Claim
latanoprost	I-Claim
and	I-Claim
brimonidine	I-Claim
reduced	I-Claim
intraocular	I-Claim
pressure	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension	I-Claim
after	I-Claim
6	I-Claim
months	I-Claim
of	I-Claim
treatment.	I-Claim

However,	B-Claim
latanoprost	I-Claim
once	I-Claim
daily	I-Claim
was	I-Claim
significantly	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
brimonidine	I-Claim
twice	I-Claim
daily	I-Claim
in	I-Claim
reducing	I-Claim
mean	I-Claim
diurnal	I-Claim
intraocular	I-Claim
pressure.	I-Claim

Latanoprost	B-Claim
was	I-Claim
better	I-Claim
tolerated	I-Claim
with	I-Claim
less	I-Claim
frequently	I-Claim
occurring	I-Claim
ocular	I-Claim
allergy	I-Claim
and	I-Claim
systemic	I-Claim
side	I-Claim
effects.	I-Claim

To	O
assess	O
the	O
intraocular	O
pressure-lowering	O
efficacy	O
and	O
the	O
postoperative	O
complication	O
profile	O
of	O
viscocanalostomy	O
versus	O
trabeculectomy.	O

Sixty	O
eyes	O
of	O
60	O
patients	O
with	O
medically	O
uncontrolled	O
open-angle	O
glaucoma	O
were	O
randomized	O
either	O
to	O
the	O
viscocanalostomy	O
or	O
to	O
the	O
trabeculectomy	O
group	O
of	O
the	O
trial.	O

Viscocanalostomy	O
was	O
performed	O
according	O
to	O
Stegmann's	O
technique	O
using	O
high-molecular-weight	O
sodium	O
hyaluronate	O
to	O
fill	O
the	O
ostia	O
of	O
the	O
Schlemm	O
canal.	O

For	O
trabeculectomy,	O
a	O
modified	O
Cairns-trabeculectomy	O
was	O
performed.	O

Examinations	O
were	O
performed	O
before	O
surgery	O
and	O
postoperatively	O
daily	O
for	O
1	O
week.	O

Follow-up	O
visits	O
were	O
scheduled	O
1,	O
6,	O
and	O
12	O
months	O
after	O
surgery.	O

The	O
mean	O
(SD)	O
preoperative	O
intraocular	O
pressure	O
was	O
27.1	O
(7.1)	O
mm	O
Hg	O
for	O
all	O
patients	O
enrolled.	O

One	B-Premise
day	I-Premise
after	I-Premise
surgery,	I-Premise
mean	I-Premise
(SD)	I-Premise
intraocular	I-Premise
pressure	I-Premise
was	I-Premise
15.9	I-Premise
(5.2)	I-Premise
for	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
(P	I-Premise
<0.001)	I-Premise
and	I-Premise
15.7	I-Premise
(3.6)	I-Premise
for	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
(P	I-Premise
<0.001),	I-Premise
respectively.	I-Premise

The	B-Premise
success	I-Premise
rate,	I-Premise
defined	I-Premise
as	I-Premise
an	I-Premise
intraocular	I-Premise
pressure	I-Premise
lower	I-Premise
than	I-Premise
22	I-Premise
mm	I-Premise
Hg	I-Premise
without	I-Premise
medication,	I-Premise
was	I-Premise
56.7%	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
and	I-Premise
30%	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
postoperatively	I-Premise
(P	I-Premise
=	I-Premise
0.041).	I-Premise

The	B-Premise
number	I-Premise
of	I-Premise
postoperative	I-Premise
complications	I-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group.	I-Premise

In	B-Claim
eyes	I-Claim
with	I-Claim
open-angle	I-Claim
glaucoma,	I-Claim
viscocanalostomy	I-Claim
is	I-Claim
less	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
intraocular	I-Claim
pressure	I-Claim
than	I-Claim
standard	I-Claim
filtering	I-Claim
surgery.	I-Claim

However,	O
postoperative	B-Claim
complications	I-Claim
are	I-Claim
more	I-Claim
frequent	I-Claim
after	I-Claim
filtering	I-Claim
surgery.	I-Claim

To	O
compare	O
the	O
safety	O
and	O
efficacy	O
of	O
intraoperative	O
5-fluorouracil	O
(5-FU)	O
or	O
Intraoperative	O
mitomycin	O
C	O
(MMC)	O
in	O
eyes	O
undergoing	O
primary	O
trabeculectomy.	O

Prospective	O
double-masked	O
randomized	O
clinical	O
trial.	O

One	O
hundred	O
fifteen	O
eyes	O
of	O
103	O
patients	O
with	O
uncontrolled	O
intraocular	O
pressure	O
(IOP)	O
despite	O
maximally	O
tolerated	O
medical	O
therapy	O
or	O
laser	O
were	O
prospectively	O
randomized	O
in	O
a	O
double-masked	O
fashion	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
in	O
a	O
single	O
institution	O
setting.	O

Subject's	O
eyes	O
underwent	O
primary	O
trabeculectomy	O
with	O
either	O
topical	O
5-FU	O
(50	O
mg/ml	O
for	O
5	O
minutes)	O
or	O
topical	O
MMC	O
(0.2	O
mg/ml	O
for	O
2	O
minutes).	O

Primary	O
outcome	O
measures	O
included	O
the	O
number	O
of	O
eyes	O
achieving	O
target	O
pressures	O
of	O
21,	O
18,	O
15,	O
and	O
12	O
mm	O
Hg	O
at	O
6	O
and	O
12	O
months	O
postoperatively.	O

Secondary	O
outcome	O
measures	O
included	O
IOP,	O
best-corrected	O
visual	O
acuity,	O
complications,	O
and	O
interventions.	O

Of	O
the	O
115	O
eyes,	O
57	O
received	O
5-FU	O
while	O
58	O
received	O
MMC.	O

A	B-Premise
target	I-Premise
IOP	I-Premise
of	I-Premise
21	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
53	I-Premise
of	I-Premise
56	I-Premise
(95%)	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
5-FU	I-Premise
group	I-Premise
and	I-Premise
54	I-Premise
of	I-Premise
57	I-Premise
(95%)	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
1.00).	I-Premise

At	B-Premise
12	I-Premise
months,	I-Premise
45	I-Premise
of	I-Premise
48	I-Premise
(94%)	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
5-FU	I-Premise
group	I-Premise
met	I-Premise
a	I-Premise
target	I-Premise
IOP	I-Premise
of	I-Premise
21	I-Premise
mm	I-Premise
Hg	I-Premise
while	I-Premise
48	I-Premise
of	I-Premise
54	I-Premise
(89%)	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
did	I-Premise
(P	I-Premise
=.49).	I-Premise

The	B-Premise
most	I-Premise
common	I-Premise
complications	I-Premise
in	I-Premise
each	I-Premise
group	I-Premise
were	I-Premise
persistent	I-Premise
choroidal	I-Premise
effusions	I-Premise
and	I-Premise
bleb	I-Premise
leak.	I-Premise

Our	B-Claim
study	I-Claim
suggests	I-Claim
that	I-Claim
intraoperative	I-Claim
topical	I-Claim
5-FU	I-Claim
is	I-Claim
at	I-Claim
least	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
intraoperative	I-Claim
topical	I-Claim
MMC	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
of	I-Claim
eyes	I-Claim
undergoing	I-Claim
primary	I-Claim
trabeculectomy.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure	O
(IOP)-lowering	O
effect	O
and	O
safety	O
of	O
latanoprost	O
0.005%	O
once	O
daily	O
with	O
that	O
of	O
unoprostone	O
0.15%	O
twice	O
daily	O
for	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

Randomized	O
clinical	O
trial.	O

In	O
a	O
prospective,	O
8-week,	O
investigator-masked,	O
parallel-group	O
study	O
conducted	O
at	O
numerous	O
centers	O
in	O
the	O
United	O
States,	O
165	O
previously	O
treated	O
patients	O
with	O
IOP	O
>or=	O
25	O
mm	O
Hg	O
in	O
one	O
or	O
both	O
eyes	O
after	O
washout	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
latanoprost	O
0.005%	O
once	O
daily	O
in	O
the	O
evening	O
or	O
unoprostone	O
0.15%	O
twice	O
daily.	O

Observations	O
procedures	O
were	O
Goldmann	O
applanation	O
tonometry,	O
best-corrected	O
visual	O
acuity,	O
slit	O
lamp	O
biomicroscopy,	O
and	O
ophthalmoscopy.	O

The	O
main	O
outcome	O
measure	O
was	O
change	O
in	O
the	O
mean	O
of	O
the	O
IOPs	O
measured	O
at	O
8:00	O
AM,	O
12	O
noon,	O
and	O
4:00	O
PM	O
between	O
baseline	O
(before	O
treatment)	O
and	O
after	O
8	O
weeks	O
of	O
treatment.	O

The	B-Premise
change	I-Premise
in	I-Premise
the	I-Premise
mean	I-Premise
+/-	I-Premise
SD	I-Premise
of	I-Premise
the	I-Premise
IOPs	I-Premise
measured	I-Premise
at	I-Premise
8:00	I-Premise
AM,	I-Premise
12	I-Premise
noon,	I-Premise
and	I-Premise
4:00	I-Premise
PM	I-Premise
was	I-Premise
-7.2	I-Premise
+/-	I-Premise
3.2	I-Premise
mm	I-Premise
Hg	I-Premise
(28%)	I-Premise
for	I-Premise
latanoprost	I-Premise
(25.3	I-Premise
+/-	I-Premise
2.8	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
baseline	I-Premise
to	I-Premise
18.2	I-Premise
+/-	I-Premise
2.8	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
8	I-Premise
weeks)	I-Premise
and	I-Premise
-3.9	I-Premise
+/-	I-Premise
2.6	I-Premise
mm	I-Premise
Hg	I-Premise
(15%)	I-Premise
for	I-Premise
unoprostone	I-Premise
(25.5	I-Premise
+/-	I-Premise
3.3	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
baseline	I-Premise
to	I-Premise
21.6	I-Premise
+/-	I-Premise
4.0	I-Premise
mm	I-Premise
Hg;	I-Premise
P	I-Premise
<or=.001.	I-Premise

No	B-Premise
serious	I-Premise
adverse	I-Premise
event	I-Premise
related	I-Premise
to	I-Premise
either	I-Premise
medication	I-Premise
was	I-Premise
reported.	I-Premise

Over	B-Claim
an	I-Claim
8-week	I-Claim
period,	I-Claim
latanoprost	I-Claim
0.005%	I-Claim
once	I-Claim
daily	I-Claim
lowered	I-Claim
IOP	I-Claim
more	I-Claim
than	I-Claim
unoprostone	I-Claim
0.15%	I-Claim
twice	I-Claim
daily	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
elevated	I-Claim
IOP.	I-Claim

Both	B-Claim
agents	I-Claim
were	I-Claim
safe	I-Claim
and	I-Claim
well	I-Claim
tolerated.	I-Claim

To	O
determine	O
whether	O
treatment	O
with	O
betaxolol	O
can	O
delay	O
or	O
prevent	O
the	O
conversion	O
from	O
ocular	O
hypertension	O
to	O
early	O
glaucoma	O
on	O
the	O
basis	O
of	O
visual	O
field	O
criteria,	O
by	O
means	O
of	O
a	O
prospective,	O
randomised,	O
placebo-controlled	O
trial.	O

Three	O
hundred	O
and	O
fifty-six	O
ocular	O
hypertensives	O
were	O
randomized	O
to	O
treatment	O
with	O
either	O
betaxolol	O
drops	O
or	O
placebo	O
drops	O
during	O
the	O
period	O
1992-1996.	O

Each	O
patient	O
was	O
followed	O
prospectively	O
with	O
4-monthly	O
visits.	O

Examination	O
at	O
each	O
visit	O
included	O
visual	O
field	O
testing,	O
intra-ocular	O
pressure	O
(IOP)	O
measurement	O
and	O
optic	O
disc	O
imaging.	O

Conversion	O
to	O
early	O
glaucoma	O
was	O
defined	O
on	O
the	O
basis	O
of	O
visual	O
field	O
change	O
by	O
AGIS	O
criteria.	O

An	O
intent-to-treat	O
analysis	O
compared	O
visual	O
field	O
conversion	O
after	O
3	O
years	O
in	O
the	O
treatment	O
and	O
placebo	O
arms.	O

Normal	O
visual	O
field	O
survival	O
analysis	O
was	O
also	O
performed.	O

The	O
IOP	O
characteristics	O
of	O
the	O
two	O
treatment	O
groups	O
were	O
compared.	O

Two	O
hundred	O
and	O
fifty-five	O
patients	O
completed	O
the	O
study,	O
which	O
ended	O
in	O
1998,	O
with	O
a	O
range	O
of	O
follow-up	O
of	O
2-6	O
years.	O

Sixteen	B-Premise
(13.2%)	I-Premise
of	I-Premise
121	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
converted	I-Premise
to	I-Premise
glaucoma,	I-Premise
compared	I-Premise
with	I-Premise
12	I-Premise
(9.0%)	I-Premise
of	I-Premise
134	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
betaxolol	I-Premise
group.	I-Premise

The	B-Premise
intent-to-treat	I-Premise
analysis	I-Premise
demonstrated	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
any	I-Premise
difference	I-Premise
in	I-Premise
conversion	I-Premise
rates	I-Premise
between	I-Premise
the	I-Premise
betaxolol	I-Premise
and	I-Premise
placebo	I-Premise
groups	I-Premise
after	I-Premise
3	I-Premise
years.	I-Premise

Visual	B-Premise
field	I-Premise
survival	I-Premise
analysis	I-Premise
demonstrated	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
betaxolol	I-Premise
and	I-Premise
placebo	I-Premise
groups.	I-Premise

The	B-Premise
betaxolol-treated	I-Premise
group	I-Premise
had	I-Premise
significantly	I-Premise
lower	I-Premise
post-treatment	I-Premise
IOP	I-Premise
values.	I-Premise

Converters	B-Premise
had	I-Premise
significantly	I-Premise
higher	I-Premise
pre-	I-Premise
and	I-Premise
post-treatment	I-Premise
IOP	I-Premise
values	I-Premise
than	I-Premise
non-converters.	I-Premise

Betaxolol	B-Premise
significantly	I-Premise
lowered	I-Premise
the	I-Premise
IOP	I-Premise
level	I-Premise
compared	I-Premise
with	I-Premise
placebo.	I-Premise

Conversion	B-Premise
to	I-Premise
glaucoma	I-Premise
was	I-Premise
found	I-Premise
to	I-Premise
be	I-Premise
related	I-Premise
to	I-Premise
both	I-Premise
the	I-Premise
baseline	I-Premise
and	I-Premise
post-treatment	I-Premise
IOP	I-Premise
levels.	I-Premise

However	O
the	B-Claim
intent-to-treat	I-Claim
analysis	I-Claim
did	I-Claim
not	I-Claim
demonstrate	I-Claim
a	I-Claim
statistically	I-Claim
significant	I-Claim
reduction	I-Claim
in	I-Claim
the	I-Claim
conversion	I-Claim
rate	I-Claim
in	I-Claim
the	I-Claim
betaxolol-treated	I-Claim
group.	I-Claim

Carteolol	O
is	O
a	O
beta-adrenoceptor	O
antagonist	O
with	O
intrinsic	O
sympathomimetic	O
activity.	O

Used	O
topically	O
to	O
reduce	O
intraocular	O
pressure,	O
it	O
is	O
typically	O
applied	O
twice	O
daily.	O

In	O
an	O
effort	O
to	O
provide	O
a	O
once-daily	O
dosing	O
regimen,	O
carteolol	O
was	O
formulated	O
with	O
1%	O
alginic	O
acid.	O

Sodium	O
alginate	O
is	O
a	O
natural	O
polymer	O
product	O
with	O
bioadhesive	O
properties	O
providing	O
increased	O
corneal	O
contact	O
time	O
and	O
a	O
better	O
carteolol	O
penetration	O
through	O
the	O
cornea.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
long-acting	O
1%	O
carteolol	O
alginate	O
solution	O
compared	O
to	O
standard	O
1%	O
carteolol	O
solution.	O

This	O
was	O
a	O
double-masked,	O
parallel	O
group,	O
multicentre	O
study.	O

Patients	O
with	O
ocular	O
hypertension	O
or	O
open	O
angle	O
glaucoma	O
(n=151)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
1%	O
carteolol	O
alginate	O
once	O
daily	O
(AM)	O
or	O
standard	O
1%	O
carteolol	O
solution	O
twice	O
daily	O
for	O
2	O
months.	O

The	O
masking	O
was	O
maintained	O
through	O
the	O
use	O
of	O
a	O
placebo	O
in	O
the	O
evening	O
for	O
the	O
alginate	O
group.	O

Entry	O
into	O
the	O
study	O
required	O
unmedicated	O
intraocular	O
pressure	O
(IOP)	O
between	O
23	O
mmHg	O
and	O
32	O
mmHg	O
at	O
9	O
AM	O
and	O
11	O
AM.	O

Patients	O
using	O
ocular	O
hypotensive	O
medication	O
were	O
required	O
to	O
undergo	O
a	O
washout.	O

All	O
patients	O
provided	O
written	O
informed	O
consent.	O

Excluded	O
from	O
the	O
study	O
were	O
patients	O
with	O
angle	O
closure,	O
congenital,	O
secondary	O
glaucoma	O
or	O
advanced	O
glaucoma;	O
any	O
intraocular	O
infection	O
or	O
inflammation,	O
ocular	O
trauma,	O
ocular	O
surgery	O
or	O
laser	O
trabeculoplasty	O
within	O
the	O
previous	O
3	O
months;	O
contraindications	O
to	O
the	O
use	O
of	O
beta	O
adrenoceptor	O
antagonists;	O
systemic	O
medications	O
likely	O
to	O
modify	O
IOP	O
prescribed	O
or	O
modified	O
during	O
the	O
previous	O
3	O
months;	O
ocular	O
steroid	O
use;	O
contact	O
lens	O
wear;	O
and	O
pregnant	O
and	O
lactating	O
women.	O

Patients	O
were	O
evaluated	O
at	O
baseline,	O
15	O
and	O
60	O
days,	O
with	O
IOP	O
measurements	O
at	O
9	O
AM	O
and	O
11	O
AM.	O

At	O
day	O
15	O
and	O
day	O
60,	O
IOP	O
was	O
measured	O
just	O
before	O
instillation	O
of	O
medication	O
(9	O
AM)	O
and	O
2	O
hours	O
after	O
(11	O
AM).	O

Slit	O
lamp	O
examinations	O
were	O
performed	O
at	O
each	O
follow-up	O
examination,	O
together	O
with	O
measurement	O
of	O
heart	O
rate	O
and	O
blood	O
pressure	O
(10	O
AM)	O
and	O
ocular	O
tolerance	O
after	O
medication	O
(11	O
AM).	O

The	O
primary	O
efficacy	O
criterion	O
was	O
the	O
decrease	O
in	O
IOP	O
from	O
baseline	O
at	O
day	O
60	O
for	O
each	O
measurement	O
at	O
9	O
AM	O
and	O
11	O
AM.	O

The	O
study	O
eye	O
was	O
the	O
eye	O
with	O
the	O
higher	O
IOP	O
at	O
day	O
0	O
or,	O
if	O
equal,	O
the	O
right	O
eye.	O

Efficacy-of	O
the	O
151	O
patients	O
included	O
in	O
the	O
study,	O
149	O
were	O
evaluated	O
(two	O
patients	O
were	O
lost	O
to	O
follow-up	O
after	O
day	O
0):	O
74	O
in	O
the	O
alginate	O
group	O
and	O
75	O
in	O
the	O
standard	O
group.	O

Both	O
treatment	O
groups	O
were	O
comparable	O
at	O
day	O
0	O
except	O
for	O
sex,	O
diastolic	O
blood	O
pressure,	O
and	O
IOP	O
in	O
the	O
fellow	O
eye.	O

At	B-Premise
09.00	I-Premise
hours	I-Premise
(presumed	I-Premise
trough)	I-Premise
on	I-Premise
day	I-Premise
60,	I-Premise
mean	I-Premise
reductions	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
were	I-Premise
6.32+/-2.87	I-Premise
and	I-Premise
5.67+/-3.30	I-Premise
mmHg	I-Premise
for	I-Premise
the	I-Premise
alginate	I-Premise
carteolol	I-Premise
and	I-Premise
standard	I-Premise
groups,	I-Premise
respectively.	I-Premise

At	B-Premise
11.00	I-Premise
hours	I-Premise
(presumed	I-Premise
peak),	I-Premise
mean	I-Premise
reductions	I-Premise
were	I-Premise
6.70+/-2.81	I-Premise
and	I-Premise
6.55+/-3.35	I-Premise
mmHg,	I-Premise
respectively.	I-Premise

At	B-Premise
each	I-Premise
evaluation	I-Premise
time,	I-Premise
the	I-Premise
two	I-Premise
unilateral	I-Premise
t	I-Premise
tests	I-Premise
were	I-Premise
highly	I-Premise
significant	I-Premise
(p<0.005),	I-Premise
confirming	O
the	O
equivalence	O
of	O
both	O
treatments.	O

Conclusions	O
were	O
not	O
modified	O
taking	O
into	O
account	O
sex	O
and	O
diastolic	O
blood	O
pressure.	O

Safety-	B-Premise
Slight	I-Premise
decreases	I-Premise
in	I-Premise
heart	I-Premise
rate	I-Premise
and	I-Premise
blood	I-Premise
pressure	I-Premise
means	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
at	I-Premise
follow-up	I-Premise
visits	I-Premise
with	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
groups.	I-Premise

Subjective	B-Premise
tolerance	I-Premise
upon	I-Premise
instillation	I-Premise
was	I-Premise
judged	I-Premise
good	I-Premise
or	I-Premise
very	I-Premise
good	I-Premise
at	I-Premise
day	I-Premise
60	I-Premise
by	I-Premise
100%	I-Premise
of	I-Premise
alginate	I-Premise
patients	I-Premise
and	I-Premise
by	I-Premise
98.7%	I-Premise
of	I-Premise
standard	I-Premise
patients.	I-Premise

Transient	B-Premise
discomfort	I-Premise
(mainly	I-Premise
stinging	I-Premise
or	I-Premise
burning	I-Premise
sensation)	I-Premise
was	I-Premise
reported	I-Premise
by	I-Premise
approximately	I-Premise
4%	I-Premise
-	I-Premise
6%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
each	I-Premise
treatment	I-Premise
group	I-Premise
at	I-Premise
each	I-Premise
visit.	I-Premise

A	B-Premise
blurred	I-Premise
vision	I-Premise
sensation	I-Premise
was	I-Premise
reported	I-Premise
by	I-Premise
2	I-Premise
out	I-Premise
of	I-Premise
74	I-Premise
patients	I-Premise
of	I-Premise
the	I-Premise
alginate	I-Premise
group.	I-Premise

Among	B-Premise
the	I-Premise
17	I-Premise
reported	I-Premise
adverse	I-Premise
events,	I-Premise
three	I-Premise
were	I-Premise
assessed	I-Premise
as	I-Premise
drug-related:	I-Premise
one	I-Premise
vertigo,	I-Premise
one	I-Premise
superficial	I-Premise
punctate	I-Premise
keratitis	I-Premise
in	I-Premise
the	I-Premise
alginate	I-Premise
group	I-Premise
and	I-Premise
one	I-Premise
decrease	I-Premise
in	I-Premise
blood	I-Premise
pressure	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
group.	I-Premise

No	B-Premise
serious	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
reported.	I-Premise

The	B-Claim
new	I-Claim
alginate	I-Claim
formulation	I-Claim
of	I-Claim
long-acting	I-Claim
carteolol	I-Claim
1%	I-Claim
given	I-Claim
once	I-Claim
daily	I-Claim
is	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
standard	I-Claim
1%	I-Claim
carteolol	I-Claim
given	I-Claim
twice	I-Claim
daily,	I-Claim
with	I-Claim
no	I-Claim
meaningful	I-Claim
differences	I-Claim
regarding	I-Claim
safety.	I-Claim

This	O
efficacy	O
wasy	O
was	O
verified	O
at	O
9	O
AM	O
(24	O
hours	O
after	O
the	O
last	O
drop	O
of	O
long-acting	O
carteolol	O
or	O
12	O
hours	O
after	O
that	O
of	O
standard	O
carteolol)	O
and	O
at	O
11	O
AM	O
(2	O
hours	O
after	O
the	O
morning	O
drop).	O

The	B-Claim
new	I-Claim
alginate	I-Claim
formulation	I-Claim
of	I-Claim
long-acting	I-Claim
carteolol	I-Claim
1%	I-Claim
given	I-Claim
once	I-Claim
a	I-Claim
day	I-Claim
is	I-Claim
effective	I-Claim
and	I-Claim
well	I-Claim
tolerated	I-Claim
by	I-Claim
glaucoma	I-Claim
patients	I-Claim
who	I-Claim
require	I-Claim
chronic	I-Claim
treatment.	I-Claim

To	O
compare	O
the	O
effectiveness	O
and	O
safety	O
of	O
viscocanalostomy	O
and	O
trabeculectomy	O
in	O
adults	O
with	O
uncontrolled	O
open-angle	O
glaucoma.	O

Single-masked,	O
parallel-group,	O
prospective,	O
randomized	O
24-month	O
trial,	O
with	O
90%	O
power	O
to	O
detect	O
a	O
clinically	O
important	O
difference	O
between	O
groups.	O

Fifty	O
consecutive	O
patients	O
(50	O
eyes)	O
with	O
primary	O
open-angle	O
or	O
pseudoexfoliative	O
glaucoma.	O

Eyes	O
were	O
assigned	O
randomly	O
to	O
either	O
viscocanalostomy	O
(group	O
1)	O
or	O
trabeculectomy	O
(group	O
2)	O
with	O
no	O
intraoperative	O
antifibrotics	O
in	O
the	O
study	O
eye.	O

In	O
group	O
1,	O
no	O
further	O
intervention	O
was	O
allowed,	O
whereas	O
trabeculectomy	O
eyes	O
could	O
receive	O
subconjunctival	O
5-fluorouracil	O
(5-FU)	O
injections	O
or	O
laser	O
suture	O
lysis	O
after	O
surgery.	O

Success	O
rate	O
based	O
on	O
intraocular	O
pressure	O
(IOP),	O
visual	O
acuity,	O
discomfort,	O
and	O
other	O
complications.	O

At	B-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
24-month	I-Premise
follow-up,	I-Premise
IOP	I-Premise
of	I-Premise
21	I-Premise
mmHg	I-Premise
or	I-Premise
less	I-Premise
and	I-Premise
more	I-Premise
than	I-Premise
6	I-Premise
mmHg	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
76%	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
(n	I-Premise
=	I-Premise
19)	I-Premise
and	I-Premise
in	I-Premise
80%	I-Premise
in	I-Premise
group	I-Premise
2	I-Premise
(n	I-Premise
=	I-Premise
20;	I-Premise
log-rank	I-Premise
P	I-Premise
=	I-Premise
0.60);	I-Premise
an	B-Premise
IOP	I-Premise
between	I-Premise
6	I-Premise
and	I-Premise
16	I-Premise
mmHg	I-Premise
was	I-Premise
obtained	I-Premise
in	I-Premise
56%	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
(n	I-Premise
=	I-Premise
14)	I-Premise
and	I-Premise
in	I-Premise
72%	I-Premise
in	I-Premise
group	I-Premise
2	I-Premise
(n	I-Premise
=	I-Premise
18;	I-Premise
log-rank	I-Premise
P	I-Premise
=	I-Premise
0.17;	I-Premise
Kaplan-Meier	I-Premise
cumulative	I-Premise
probability	I-Premise
of	I-Premise
success).	I-Premise

Complications	B-Premise
of	I-Premise
viscocanalostomy	I-Premise
included	I-Premise
one	I-Premise
intraoperative	I-Premise
conversion	I-Premise
into	I-Premise
trabeculectomy;	I-Premise
microruptures	I-Premise
in	I-Premise
Descemet's	I-Premise
membrane	I-Premise
in	I-Premise
five	I-Premise
eyes;	I-Premise
three	I-Premise
cases	I-Premise
of	I-Premise
iris	I-Premise
incarceration	I-Premise
in	I-Premise
the	I-Premise
Decemet's	I-Premise
window,	I-Premise
two	I-Premise
of	I-Premise
which	I-Premise
caused	I-Premise
early	I-Premise
failure	I-Premise
of	I-Premise
the	I-Premise
procedure	I-Premise
requiring	I-Premise
reoperation;	I-Premise
and	I-Premise
a	I-Premise
1-mm	I-Premise
to	I-Premise
2-mm	I-Premise
transient	I-Premise
self-resolving	I-Premise
hyphema	I-Premise
in	I-Premise
three	I-Premise
cases.	I-Premise

Complications	B-Premise
of	I-Premise
trabeculectomy	I-Premise
included	I-Premise
one	I-Premise
case	I-Premise
of	I-Premise
postoperative	I-Premise
bleb	I-Premise
bleeding	I-Premise
with	I-Premise
early	I-Premise
transient	I-Premise
IOP	I-Premise
spike;	I-Premise
one	I-Premise
early	I-Premise
hyphema;	I-Premise
five	I-Premise
cases	I-Premise
of	I-Premise
postoperative	I-Premise
hypotony,	I-Premise
two	I-Premise
of	I-Premise
which	I-Premise
had	I-Premise
a	I-Premise
positive	I-Premise
Seidel	I-Premise
test	I-Premise
from	I-Premise
the	I-Premise
conjunctival	I-Premise
suture;	I-Premise
three	I-Premise
cases	I-Premise
of	I-Premise
transient	I-Premise
choroidal	I-Premise
detachment,	I-Premise
two	I-Premise
of	I-Premise
which	I-Premise
had	I-Premise
shallow	I-Premise
anterior	I-Premise
chamber.	I-Premise

No	B-Premise
patient	I-Premise
required	I-Premise
reoperation.	I-Premise

Two	B-Premise
eyes	I-Premise
required	I-Premise
argon	I-Premise
laser	I-Premise
suture	I-Premise
lysis,	I-Premise
and	I-Premise
nine	I-Premise
underwent	I-Premise
one	I-Premise
or	I-Premise
more	I-Premise
5-FU	I-Premise
injections,	I-Premise
which	I-Premise
caused	I-Premise
punctate	I-Premise
keratopathy	I-Premise
in	I-Premise
three	I-Premise
eyes.	I-Premise

Viscocanalostomy	B-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
IOP-lowering	I-Claim
procedure	I-Claim
in	I-Claim
white	I-Claim
adults	I-Claim
affected	I-Claim
by	I-Claim
open-angle	I-Claim
glaucoma.	I-Claim

Trabeculectomy	B-Claim
with	I-Claim
postoperative	I-Claim
5-FU	I-Claim
can	I-Claim
probably	I-Claim
provides	I-Claim
lower	I-Claim
IOPs	I-Claim
but,	I-Claim
with	I-Claim
more	I-Claim
numerous	I-Claim
complications,	I-Claim
greater	I-Claim
discomfort,	I-Claim
and	I-Claim
more	I-Claim
intensive	I-Claim
postoperative	I-Claim
management.	I-Claim

Brimonidine	O
is	O
a	O
highly	O
selective	O
alpha-2	O
adrenergic	O
receptor	O
agonist	O
with	O
intraocular	O
pressure	O
(IOP)	O
reducing	O
effect.	O

We	O
conducted	O
this	O
study	O
in	O
Taiwan	O
to	O
compare	O
the	O
safety	O
and	O
efficacy	O
of	O
brimonidine	O
0.2%	O
with	O
timolol	O
0.5%	O
for	O
the	O
treatment	O
of	O
glaucoma.	O

A	O
prospective,	O
randomized,	O
single-masked,	O
1-month	O
clinical	O
efficacy	O
and	O
safety	O
trial	O
was	O
conducted	O
from	O
March	O
to	O
September	O
2000.	O

Forty	O
glaucoma	O
patients	O
were	O
enrolled--29	O
in	O
the	O
brimonidine	O
group	O
and	O
11	O
in	O
the	O
timolol	O
group.	O

Patients	O
instilled	O
their	O
study	O
medications	O
twice	O
daily	O
for	O
4	O
weeks,	O
and	O
were	O
followed	O
at	O
baseline	O
visit,	O
weeks	O
2	O
and	O
4.	O

Demographic	O
data,	O
reduction	O
of	O
IOP,	O
safety	O
and	O
adverse	O
events	O
were	O
obtained	O
and	O
analyzed.	O

Both	O
drugs	O
showed	O
sustained	O
ocular	O
hypotensive	O
efficacy	O
in	O
the	O
study	O
period.	O

At	B-Premise
baseline,	I-Premise
the	I-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
24.48	I-Premise
+/-	I-Premise
2.29	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
and	I-Premise
23.32	I-Premise
+/-	I-Premise
0.82	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
timolol	I-Premise
group.	I-Premise

The	B-Premise
IOP	I-Premise
readings	I-Premise
after	I-Premise
treatment	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
their	I-Premise
baseline	I-Premise
levels	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
at	I-Premise
all	I-Premise
visits	I-Premise
(p	I-Premise
<	I-Premise
0.001).	I-Premise

At	B-Premise
peak,	I-Premise
the	I-Premise
mean	I-Premise
decreases	I-Premise
from	I-Premise
the	I-Premise
baseline	I-Premise
IOP	I-Premise
ranged	I-Premise
from	I-Premise
5.22	I-Premise
+/-	I-Premise
0.30	I-Premise
mmHg	I-Premise
to	I-Premise
6.96	I-Premise
+/-	I-Premise
0.33	I-Premise
mmHg	I-Premise
for	I-Premise
brimonidine	I-Premise
and	I-Premise
from	I-Premise
4.55	I-Premise
+/-	I-Premise
0.49	I-Premise
mmHg	I-Premise
to	I-Premise
6.64	I-Premise
+/-	I-Premise
0.53	I-Premise
mmHg	I-Premise
for	I-Premise
timolol.	I-Premise

At	B-Premise
trough,	I-Premise
the	I-Premise
mean	I-Premise
decreases	I-Premise
from	I-Premise
baseline	I-Premise
ranged	I-Premise
from	I-Premise
3.72	I-Premise
+/-	I-Premise
0.32	I-Premise
mmHg	I-Premise
to	I-Premise
4.55	I-Premise
+/-	I-Premise
0.32	I-Premise
mmHg	I-Premise
for	I-Premise
brimonidine	I-Premise
and	I-Premise
3.82	I-Premise
+/-	I-Premise
0.52	I-Premise
mmHg	I-Premise
to	I-Premise
4.27	I-Premise
+/-	I-Premise
0.51	I-Premise
mmHg	I-Premise
for	I-Premise
timolol.	I-Premise

No	O
significant	O
between-group	O
differences	O
were	O
seen	O
at	O
peak	O
or	O
trough	O
at	O
all	O
visits.	O

The	B-Premise
clinical	I-Premise
success	I-Premise
rate	I-Premise
was	I-Premise
86.2%	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
and	I-Premise
81.8%	I-Premise
in	I-Premise
the	I-Premise
timolol	I-Premise
group,	I-Premise
making	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
them	I-Premise
(p	I-Premise
=	I-Premise
0.817).	I-Premise

17.2%	B-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
brimonidine	I-Premise
group	I-Premise
and	I-Premise
9.0%	I-Premise
patients	I-Premise
in	I-Premise
timolol	I-Premise
group	I-Premise
reported	I-Premise
mild	I-Premise
adverse	I-Premise
events.	I-Premise

Ocular	B-Premise
allergy	I-Premise
occurred	I-Premise
in	I-Premise
10.3%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
brimonidine	I-Premise
group.	I-Premise

No	B-Premise
significant	I-Premise
changes	I-Premise
in	I-Premise
visual	I-Premise
acuity,	I-Premise
biomicroscopy	I-Premise
or	I-Premise
ophthalmoscopy	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Mean	B-Premise
systolic	I-Premise
and	I-Premise
diastolic	I-Premise
blood	I-Premise
pressure	I-Premise
remained	I-Premise
relatively	I-Premise
stable	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
except	B-Premise
in	I-Premise
week	I-Premise
2	I-Premise
(p	I-Premise
=	I-Premise
0.016)	I-Premise
when	I-Premise
brimonidine	I-Premise
had	I-Premise
lower	I-Premise
systolic	I-Premise
blood	I-Premise
pressure.	I-Premise

However,	O
brimonidine	O
showed	O
no	O
significant	O
difference	O
in	O
week	O
4	O
from	O
baseline.	O

The	B-Premise
mean	I-Premise
heart	I-Premise
rate	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
was	I-Premise
relatively	I-Premise
unchanged	I-Premise
over	I-Premise
the	I-Premise
study	I-Premise
period.	I-Premise

Patients	B-Premise
receiving	I-Premise
timolol	I-Premise
experienced	I-Premise
statistically	I-Premise
significant	I-Premise
mean	I-Premise
heart	I-Premise
rate	I-Premise
decreases	I-Premise
from	I-Premise
baseline	I-Premise
(p	I-Premise
=	I-Premise
0.020)	I-Premise
in	I-Premise
week	I-Premise
4.	I-Premise

Topically	B-Claim
applied	I-Claim
twice	I-Claim
daily	I-Claim
for	I-Claim
one	I-Claim
month,	I-Claim
brimonidine	I-Claim
tartrate	I-Claim
0.2%	I-Claim
has	I-Claim
clinical	I-Claim
effectiveness	I-Claim
equivalent	I-Claim
to	I-Claim
timolol	I-Claim
0.5%	I-Claim
in	I-Claim
Taiwanese	I-Claim
patients	I-Claim
with	I-Claim
glaucoma.	I-Claim

It	B-Claim
has	I-Claim
a	I-Claim
safe	I-Claim
systemic	I-Claim
profile	I-Claim
with	I-Claim
minimum	I-Claim
effect	I-Claim
on	I-Claim
the	I-Claim
heart.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
topical	O
bimatoprost	O
(LUMIGAN;	O
Allergan,	O
Inc.,	O
Irvine,	O
CA)	O
once	O
daily	O
with	O
that	O
of	O
topical	O
combined	O
timolol	O
and	O
dorzolamide	O
(Cosopt;	O
Merck	O
and	O
Co,	O
Inc.,	O
Whitehouse	O
Station,	O
NJ)	O
twice	O
daily.	O

Prospective,	O
randomized,	O
double-masked,	O
multicenter	O
clinical	O
trial.	O

One	O
hundred	O
seventy-seven	O
patients	O
with	O
a	O
diagnosis	O
of	O
glaucoma	O
or	O
ocular	O
hypertension	O
and	O
inadequate	O
control	O
of	O
intraocular	O
pressure	O
(IOP)	O
after	O
at	O
least	O
2	O
weeks	O
of	O
topical	O
timolol	O
maleate	O
0.5%	O
monotherapy.	O

Patients	O
were	O
randomized	O
to	O
receive	O
bimatoprost	O
0.03%	O
once	O
daily	O
(n	O
=	O
90)	O
or	O
combined	O
timolol	O
0.5%	O
and	O
dorzolamide	O
2%	O
twice	O
daily	O
(n	O
=	O
87)	O
over	O
a	O
3-month	O
period.	O

Intraocular	O
pressure,	O
the	O
primary	O
end	O
point,	O
was	O
measured	O
at	O
8	O
AM	O
and	O
10	O
AM	O
at	O
baseline,	O
week	O
1,	O
and	O
months	O
1,	O
2,	O
and	O
3,	O
and	O
also	O
at	O
4	O
PM	O
and	O
8	O
PM	O
at	O
baseline	O
and	O
month	O
3.	O

Bimatoprost	B-Premise
provided	I-Premise
significantly	I-Premise
greater	I-Premise
IOP	I-Premise
lowering	I-Premise
compared	I-Premise
with	I-Premise
combined	I-Premise
timolol	I-Premise
and	I-Premise
dorzolamide.	I-Premise

At	B-Premise
the	I-Premise
8	I-Premise
AM	I-Premise
measurements,	I-Premise
bimatoprost	I-Premise
lowered	I-Premise
mean	I-Premise
IOP	I-Premise
6.8	I-Premise
mmHg	I-Premise
to	I-Premise
7.6	I-Premise
mmHg	I-Premise
from	I-Premise
baseline,	I-Premise
whereas	I-Premise
combined	I-Premise
timolol	I-Premise
and	I-Premise
dorzolamide	I-Premise
lowered	I-Premise
mean	I-Premise
IOP	I-Premise
4.4	I-Premise
to	I-Premise
5.0	I-Premise
mmHg	I-Premise
from	I-Premise
baseline	I-Premise
(P<0.001).	I-Premise

At	B-Premise
the	I-Premise
last	I-Premise
follow-up,	I-Premise
patients	I-Premise
had	I-Premise
better	I-Premise
diurnal	I-Premise
IOP	I-Premise
control	I-Premise
with	I-Premise
bimatoprost	I-Premise
than	I-Premise
combined	I-Premise
timolol	I-Premise
and	I-Premise
dorzolamide.	I-Premise

At	B-Premise
8	I-Premise
AM	I-Premise
at	I-Premise
the	I-Premise
3-month	I-Premise
visit,	I-Premise
the	I-Premise
percentages	I-Premise
of	I-Premise
patients	I-Premise
achieving	I-Premise
IOPs	I-Premise
of	I-Premise
<or	I-Premise
=13	I-Premise
mmHg,	I-Premise
<	I-Premise
or	I-Premise
=14	I-Premise
mmHg,	I-Premise
<	I-Premise
or	I-Premise
=15	I-Premise
mmHg,	I-Premise
or	I-Premise
<	I-Premise
or	I-Premise
=16	I-Premise
mmHg	I-Premise
were	I-Premise
more	I-Premise
than	I-Premise
twice	I-Premise
as	I-Premise
high	I-Premise
for	I-Premise
bimatoprost	I-Premise
than	I-Premise
for	I-Premise
combined	I-Premise
timolol	I-Premise
and	I-Premise
dorzolamide	I-Premise
(all	I-Premise
P<	I-Premise
or	I-Premise
=0.008).	I-Premise

Taste	B-Premise
perversion,	I-Premise
ocular	I-Premise
burning,	I-Premise
and	I-Premise
stinging	I-Premise
with	I-Premise
instillation	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
combined	I-Premise
timolol	I-Premise
and	I-Premise
dorzolamide,	I-Premise
whereas	I-Premise
conjunctival	I-Premise
hyperemia	I-Premise
was	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
bimatoprost.	I-Premise

In	B-Claim
individuals	I-Claim
with	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension,	I-Claim
uncontrolled	I-Claim
on	I-Claim
a	I-Claim
topical	I-Claim
beta-blocker	I-Claim
alone,	I-Claim
bimatoprost	I-Claim
lowered	I-Claim
IOP	I-Claim
more	I-Claim
consistently	I-Claim
than	I-Claim
did	I-Claim
combined	I-Claim
timolol	I-Claim
and	I-Claim
dorzolamide.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
intraocular	O
pressure	O
(IOP)	O
control	O
of	O
the	O
Baerveldt-350	O
implant	O
with	O
tube	O
ligature	O
and	O
the	O
Ahmed	O
valve	O
in	O
patients	O
with	O
refractory	O
glaucoma.	O

Four	O
hundred	O
seventy	O
glaucoma	O
drainage	O
device	O
procedures	O
from	O
July	O
1995	O
to	O
July	O
2001	O
(6	O
years)	O
were	O
reviewed	O
retrospectively.	O

Thirty-two	O
cases	O
of	O
Baerveldt-350	O
implantation	O
performed	O
in	O
patients	O
with	O
glaucoma	O
refractory	O
to	O
medical	O
treatment	O
and	O
filtering	O
procedures,	O
without	O
previous	O
drainage	O
device	O
or	O
cyclodestructive	O
procedures,	O
and	O
with	O
a	O
minimum	O
of	O
1-year	O
follow-up	O
were	O
identified.	O

Thirty-two	O
cases	O
of	O
Ahmed	O
valve	O
implantation	O
were	O
matched	O
case	O
by	O
case	O
with	O
32	O
Baerveldt-350	O
cases	O
for	O
age,	O
race,	O
gender,	O
glaucoma	O
subtype,	O
previous	O
ocular	O
history,	O
preoperative	O
IOP,	O
and	O
surgeon	O
who	O
performed	O
the	O
implantation.	O

The	O
two	O
groups	O
were	O
compared	O
for	O
IOP	O
control,	O
visual	O
outcome,	O
complication	O
rate,	O
and	O
surgical	O
success	O
rate.	O

Surgical	B-Premise
success	I-Premise
rate	I-Premise
was	I-Premise
defined	I-Premise
as	I-Premise
an	I-Premise
IOP	I-Premise
reduction	I-Premise
greater	I-Premise
than	I-Premise
or	I-Premise
equal	I-Premise
to	I-Premise
30%	I-Premise
and	I-Premise
final	I-Premise
IOP	I-Premise
more	I-Premise
than	I-Premise
5	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
less	I-Premise
than	I-Premise
22	I-Premise
mm	I-Premise
Hg,	I-Premise
without	I-Premise
devastating	I-Premise
complications.	I-Premise

Over	B-Premise
a	I-Premise
follow-up	I-Premise
period	I-Premise
of	I-Premise
1	I-Premise
year,	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
detected	I-Premise
between	I-Premise
the	I-Premise
Baerveldt-350	I-Premise
implant	I-Premise
versus	I-Premise
Ahmed	I-Premise
valve	I-Premise
for	I-Premise
IOP	I-Premise
control	I-Premise
(12.1	I-Premise
+/-	I-Premise
5.3	I-Premise
mm	I-Premise
Hg	I-Premise
vs	I-Premise
13.6	I-Premise
+/-	I-Premise
5.6	I-Premise
mm	I-Premise
Hg	I-Premise
respectively,	I-Premise
at	I-Premise
a	I-Premise
power	I-Premise
of	I-Premise
90%	I-Premise
to	I-Premise
detect	I-Premise
a	I-Premise
difference	I-Premise
of	I-Premise
3.2	I-Premise
mm	I-Premise
Hg	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.05),	I-Premise
surgical	I-Premise
success	I-Premise
rate	I-Premise
(65.6%	I-Premise
vs.	I-Premise
65.6%	I-Premise
respectively,	I-Premise
complete	I-Premise
and	I-Premise
qualified	I-Premise
combined),	I-Premise
postoperative	I-Premise
hypotony	I-Premise
rate	I-Premise
(37.5%	I-Premise
vs.	I-Premise
34.4%	I-Premise
respectively),	I-Premise
and	I-Premise
visual	I-Premise
acuity	I-Premise
changes	I-Premise
of	I-Premise
more	I-Premise
than	I-Premise
1	I-Premise
line	I-Premise
in	I-Premise
Snellen	I-Premise
visual	I-Premise
acuity	I-Premise
(43.3%	I-Premise
vs.	I-Premise
29.0%	I-Premise
respectively).	I-Premise

In	B-Claim
a	I-Claim
case-controlled	I-Claim
comparison,	I-Claim
the	I-Claim
Baerveldt-350	I-Claim
implant	I-Claim
and	I-Claim
the	I-Claim
Ahmed	I-Claim
valve	I-Claim
had	I-Claim
similar	I-Claim
IOP	I-Claim
control	I-Claim
and	I-Claim
surgical	I-Claim
outcomes	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
refractory	I-Claim
glaucoma	I-Claim
at	I-Claim
1-year	I-Claim
follow-up.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
the	O
fixed	O
dorzolamide	O
2%/timolol	O
0.5%	O
combination	O
(COSOPT)	O
versus	O
latanoprost	O
0.005%	O
(XALATAN).	O

Two	O
3-month,	O
parallel	O
group,	O
randomized,	O
observer-masked	O
and	O
patient-masked,	O
multicentre,	O
clinical	O
trials	O
were	O
performed	O
in	O
patients	O
with	O
ocular	O
hypertension	O
or	O
open-angle	O
glaucoma.	O

Study	O
1	O
(n=256)	O
was	O
conducted	O
in	O
the	O
United	O
States	O
and	O
Study	O
2	O
(n=288)	O
was	O
conducted	O
in	O
Europe/Israel.	O

Patients	O
could	O
be	O
included	O
whether	O
or	O
not	O
they	O
were	O
currently	O
taking	O
ocular	O
hypotensive	O
therapy,	O
and	O
regardless	O
of	O
the	O
effectiveness	O
of	O
any	O
previous	O
therapy.	O

Patients	O
were	O
washed	O
out	O
from	O
their	O
usual	O
ocular	O
hypotensive	O
medications	O
and	O
then	O
those	O
with	O
a	O
baseline	O
intraocular	O
pressure	O
(IOP)	O
>/=	O
24	O
mmHg	O
were	O
randomized	O
to	O
either	O
the	O
dorzolamide/timolol	O
combination	O
eye	O
drops	O
twice	O
daily	O
or	O
latanoprost	O
eye	O
drops	O
once	O
daily	O
in	O
both	O
eyes.	O

Efficacy	O
was	O
assessed	O
by	O
daytime	O
diurnal	O
IOP	O
(the	O
mean	O
of	O
measurements	O
made	O
at	O
0800,	O
1000,	O
1400	O
and	O
1600	O
h).	O

At	B-Premise
baseline,	I-Premise
the	I-Premise
mean	I-Premise
daytime	I-Premise
diurnal	I-Premise
IOP	I-Premise
was	I-Premise
26.1	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
combination	I-Premise
group	I-Premise
versus	I-Premise
25.6	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
in	I-Premise
Study	I-Premise
1,	I-Premise
and	I-Premise
25.3	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
combination	I-Premise
group	I-Premise
versus	I-Premise
24.7	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
in	I-Premise
Study	I-Premise
2.	I-Premise

After	B-Premise
3	I-Premise
months,	I-Premise
the	I-Premise
mean	I-Premise
daytime	I-Premise
diurnal	I-Premise
IOP	I-Premise
was	I-Premise
18.9	I-Premise
mmHg	I-Premise
for	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
combination	I-Premise
versus	I-Premise
18.4	I-Premise
mmHg	I-Premise
for	I-Premise
latanoprost	I-Premise
in	I-Premise
Study	I-Premise
1,	I-Premise
and	I-Premise
17.4	I-Premise
mmHg	I-Premise
for	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
combination	I-Premise
versus	I-Premise
17.5	I-Premise
for	I-Premise
latanoprost	I-Premise
in	I-Premise
Study	I-Premise
2.	I-Premise

The	B-Premise
difference	I-Premise
between	I-Premise
treatments	I-Premise
in	I-Premise
mean	I-Premise
IOP	I-Premise
change	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
was	I-Premise
-0.04	I-Premise
mmHg	I-Premise
[95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
-0.85,	I-Premise
0.77]	I-Premise
in	I-Premise
Study	I-Premise
1,	I-Premise
and	I-Premise
-0.57	I-Premise
mmHg	I-Premise
(95%	I-Premise
CI	I-Premise
-1.31,	I-Premise
0.16)	I-Premise
in	I-Premise
Study	I-Premise
2.	I-Premise

The	B-Premise
probability	I-Premise
that	I-Premise
the	I-Premise
true	I-Premise
difference	I-Premise
lay	I-Premise
between	I-Premise
-1.5	I-Premise
and	I-Premise
1.5	I-Premise
mmHg,	I-Premise
the	I-Premise
predefined	I-Premise
bounds	I-Premise
for	I-Premise
equivalence,	I-Premise
was	I-Premise
>0.950	I-Premise
in	I-Premise
both	I-Premise
studies.	I-Premise

Both	B-Claim
treatments	I-Claim
were	I-Claim
well	I-Claim
tolerated	I-Claim
over	I-Claim
3	I-Claim
months,	I-Claim
although	B-Premise
ocular	I-Premise
stinging	I-Premise
occurred	I-Premise
more	I-Premise
frequently	I-Premise
with	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
combination.	I-Premise

The	B-Claim
dorzolamide/timolol	I-Claim
combination	I-Claim
and	I-Claim
latanoprost	I-Claim
were	I-Claim
equally	I-Claim
effective	I-Claim
at	I-Claim
lowering	I-Claim
IOP.	I-Claim

To	O
compare	O
the	O
longitudinal	O
effects	O
of	O
treatment	O
on	O
intraocular	O
pressure	O
(IOP)	O
and	O
visual	O
field	O
performance	O
in	O
Japanese	O
normal-tension	O
glaucoma	O
(NTG)	O
between	O
latanoprost	O
and	O
timolol.	O

This	O
is	O
an	O
open-label,	O
randomized,	O
study.	O

A	O
total	O
of	O
62	O
NTG	O
patients	O
were	O
prospectively,	O
consecutively	O
enrolled.	O

All	O
study	O
subjects	O
were	O
randomly	O
assigned	O
to	O
0.005%	O
latanoprost	O
instillation	O
once	O
daily	O
in	O
the	O
morning	O
or	O
0.5%	O
timolol	O
instillation	O
twice	O
daily	O
for	O
a	O
prospective	O
3-year	O
follow-up,	O
and	O
underwent	O
a	O
routine	O
ocular	O
examination	O
every	O
month.	O

Automated	O
perimetry	O
was	O
performed	O
every	O
6	O
months	O
using	O
Humphrey	O
field	O
analysers.	O

Stereophotographs	O
of	O
optic	O
discs	O
were	O
also	O
obtained	O
every	O
6	O
months.	O

Percentage	B-Premise
of	I-Premise
IOP	I-Premise
reduction	I-Premise
or	I-Premise
the	I-Premise
magnitude	I-Premise
of	I-Premise
IOP	I-Premise
reduction	I-Premise
showed	I-Premise
no	I-Premise
intergroup	I-Premise
differences	I-Premise
either	I-Premise
at	I-Premise
any	I-Premise
time	I-Premise
point	I-Premise
(13-15%).	I-Premise

In	B-Premise
the	I-Premise
visual	I-Premise
field,	I-Premise
the	I-Premise
estimated	I-Premise
rate	I-Premise
of	I-Premise
change	I-Premise
in	I-Premise
the	I-Premise
MD	I-Premise
value	I-Premise
(dB/year)	I-Premise
was	I-Premise
-0.34+/-0.17	I-Premise
(SE)	I-Premise
for	I-Premise
the	I-Premise
latanoprost	I-Premise
group,	I-Premise
and	I-Premise
-0.10+/-0.18	I-Premise
(SE)	I-Premise
for	I-Premise
the	I-Premise
timolol	I-Premise
group.	I-Premise

The	B-Premise
estimated	I-Premise
rate	I-Premise
of	I-Premise
change	I-Premise
in	I-Premise
MD	I-Premise
showed	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
from	I-Premise
zero	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
and	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
statistical	I-Premise
intergroup	I-Premise
differences.	I-Premise

No	B-Premise
changes	I-Premise
in	I-Premise
the	I-Premise
optic	I-Premise
nerve	I-Premise
head	I-Premise
topography	I-Premise
in	I-Premise
the	I-Premise
vertical	I-Premise
cup-to-disc	I-Premise
ratio	I-Premise
and	I-Premise
rim	I-Premise
area	I-Premise
measured	I-Premise
by	I-Premise
image-analysis	I-Premise
techniques	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
either	I-Premise
group.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
patients	I-Premise
who	I-Premise
dropped	I-Premise
out	I-Premise
due	I-Premise
to	I-Premise
the	I-Premise
side	I-Premise
effects	I-Premise
of	I-Premise
treatment	I-Premise
regimens.	I-Premise

Both	B-Claim
latanoprost	I-Claim
and	I-Claim
timolol	I-Claim
single	I-Claim
treatments	I-Claim
reduced	I-Claim
IOP	I-Claim
by	I-Claim
13-15%	I-Claim
at	I-Claim
their	I-Claim
trough	I-Claim
effects	I-Claim
for	I-Claim
3	I-Claim
years	I-Claim
in	I-Claim
Japanese	I-Claim
NTG	I-Claim
patients;	I-Claim
both	B-Claim
showed	I-Claim
similar	I-Claim
effects	I-Claim
on	I-Claim
visual	I-Claim
field	I-Claim
performance.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
intraoperative	O
mitomycin	O
C	O
(MMC)	O
in	O
eyes	O
undergoing	O
Ahmed	O
Glaucoma	O
Valve	O
implantation.	O

Randomized	O
controlled	O
clinical	O
trial.	O

Sixty	O
patients	O
with	O
refractory	O
glaucoma.	O

Sixty	O
eyes	O
of	O
60	O
patients	O
with	O
refractory	O
glaucoma	O
were	O
randomized	O
to	O
receive	O
intraoperative	O
MMC	O
(0.5	O
mg/ml	O
for	O
5	O
minutes)	O
(n	O
=	O
34)	O
or	O
balanced	O
salt	O
solution	O
(n	O
=	O
26)	O
during	O
Ahmed	O
Glaucoma	O
Valve	O
implantation.	O

Surgical	O
success	O
was	O
defined	O
according	O
to	O
2	O
different	O
criteria:	O
(1)	O
postoperative	O
intraocular	O
pressure	O
(IOP)	O
between	O
6	O
and	O
21	O
mmHg,	O
with	O
or	O
without	O
antiglaucoma	O
medications,	O
and	O
(2)	O
IOP	O
reduction	O
of	O
at	O
least	O
30%	O
relative	O
to	O
preoperative	O
values.	O

Eyes	O
requiring	O
additional	O
glaucoma	O
surgery,	O
developing	O
phthisis,	O
or	O
showing	O
loss	O
of	O
light	O
perception	O
were	O
classified	O
as	O
failures.	O

Success	O
rates	O
in	O
both	O
groups	O
were	O
compared	O
using	O
Kaplan-Meier	O
survival	O
curves	O
and	O
the	O
log	O
rank	O
test.	O

Other	O
outcome	O
measures	O
were	O
mean	O
IOP,	O
number	O
of	O
glaucoma	O
medications,	O
and	O
complications.	O

After	B-Premise
a	I-Premise
mean	I-Premise
follow-up	I-Premise
of	I-Premise
12.3	I-Premise
months,	I-Premise
Kaplan-Meier	I-Premise
survival	I-Premise
analysis	I-Premise
showed	I-Premise
a	I-Premise
probability	I-Premise
of	I-Premise
success	I-Premise
of	I-Premise
59%	I-Premise
at	I-Premise
18	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
and	I-Premise
61%	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
when	I-Premise
the	I-Premise
first	I-Premise
criterion	I-Premise
for	I-Premise
success	I-Premise
was	I-Premise
used	I-Premise
(IOP	I-Premise
between	I-Premise
6	I-Premise
and	I-Premise
21	I-Premise
mmHg).	I-Premise

When	B-Premise
an	I-Premise
IOP	I-Premise
reduction	I-Premise
of	I-Premise
at	I-Premise
least	I-Premise
30%	I-Premise
was	I-Premise
used	I-Premise
as	I-Premise
the	I-Premise
criterion	I-Premise
to	I-Premise
define	I-Premise
success,	I-Premise
the	I-Premise
Kaplan-Meier	I-Premise
survival	I-Premise
analysis	I-Premise
demonstrated	I-Premise
a	I-Premise
probability	I-Premise
of	I-Premise
success	I-Premise
at	I-Premise
18	I-Premise
months	I-Premise
of	I-Premise
62%	I-Premise
for	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
and	I-Premise
67%	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
survival	I-Premise
rates	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
groups	I-Premise
with	I-Premise
either	I-Premise
criterion	I-Premise
(P	I-Premise
=	I-Premise
0.75	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.37,	I-Premise
respectively).	I-Premise

After	B-Premise
15	I-Premise
days	I-Premise
postoperatively,	I-Premise
the	I-Premise
mean	I-Premise
IOP	I-Premise
did	I-Premise
not	I-Premise
significantly	I-Premise
differ	I-Premise
for	I-Premise
both	I-Premise
MMC	I-Premise
and	I-Premise
control	I-Premise
eyes.	I-Premise

Mean	B-Premise
numbers	I-Premise
of	I-Premise
postoperative	I-Premise
antiglaucoma	I-Premise
medications	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
MMC-treated	I-Premise
eyes	I-Premise
and	I-Premise
controls.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
incidences	I-Premise
of	I-Premise
postoperative	I-Premise
complications	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Mitomycin	B-Claim
C	I-Claim
did	I-Claim
not	I-Claim
increase	I-Claim
the	I-Claim
short-	I-Claim
or	I-Claim
intermediate-term	I-Claim
success	I-Claim
rates	I-Claim
of	I-Claim
Ahmed	I-Claim
Glaucoma	I-Claim
Valve	I-Claim
implantation.	I-Claim

The	O
newer	O
ocular	O
hypotensive	O
agents	O
available	O
to	O
treat	O
glaucoma	O
and	O
ocular	O
hypertension	O
(OHT)	O
include	O
latanoprost,	O
a	O
prostaglandin	O
F(2alpha)	O
analogue,	O
and	O
the	O
fixed	O
combination	O
of	O
dorzolamide	O
hydrochloride,	O
a	O
carbonic	O
anhydrase	O
inhibitor,	O
and	O
timolol	O
maleate,	O
a	O
beta-blocker.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
latanoprost	O
with	O
that	O
of	O
the	O
fixed	O
combination	O
of	O
dorzolamide	O
and	O
timolol	O
over	O
8	O
weeks.	O

This	O
interventional,	O
8-week,	O
randomized,	O
open-label,	O
parallel-group	O
study	O
was	O
conducted	O
at	O
18	O
centers	O
in	O
6	O
Latin	O
American	O
countries.	O

Patients	O
with	O
unilateral	O
or	O
bilateral	O
primary	O
open-angle,	O
pigmentary,	O
or	O
exfoliative	O
glaucoma	O
or	O
OHT	O
were	O
randomized	O
to	O
receive	O
latanoprost,	O
1	O
drop	O
in	O
the	O
affected	O
eye	O
QD	O
(evening),	O
or	O
fixed	O
combination	O
dorzolamide/timolol,	O
1	O
drop	O
in	O
the	O
affected	O
eye	O
BID	O
(morning	O
and	O
evening).	O

Medications	O
were	O
self-administered,	O
1	O
drop	O
per	O
affected	O
eye.	O

At	O
baseline	O
and	O
week	O
8,	O
intraocular	O
pressure	O
(IOP)	O
was	O
measured	O
3	O
times	O
each	O
at	O
8:30	O
am,	O
10:00	O
am,	O
2:00	O
pm,	O
and	O
5:00	O
pm	O
and	O
after	O
the	O
water-drinking	O
test,	O
which	O
estimates	O
the	O
IOP	O
peak	O
of	O
diurnal	O
tension	O
curve,	O
performed	O
following	O
the	O
5:00	O
pm	O
IOP	O
assessment.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
change	O
in	O
diurnal	O
IOP	O
(the	O
mean	O
of	O
IOP	O
measurements)	O
from	O
baseline	O
to	O
week	O
8.	O

Adverse	O
effect	O
(AE)	O
data	O
were	O
recorded	O
at	O
each	O
visit.	O

A	O
total	O
of	O
229	O
patients	O
were	O
randomized	O
(latanoprost,	O
n	O
=	O
112;	O
dorzolamide/timolol,	O
n	O
=	O
117).	O

Mean	B-Premise
baseline	I-Premise
diurnal	I-Premise
IOP	I-Premise
values	I-Premise
were	I-Premise
similar	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
groups.	I-Premise

Mean	B-Premise
(SD)	I-Premise
diurnal	I-Premise
IOP	I-Premise
reductions	I-Premise
at	I-Premise
week	I-Premise
8	I-Premise
before	I-Premise
the	I-Premise
water-drinking	I-Premise
test	I-Premise
were	I-Premise
6.9	I-Premise
(3.0)	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
and	I-Premise
6.4	I-Premise
(3.2)	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
group.	I-Premise

Mean	B-Premise
IOP	I-Premise
values	I-Premise
were	I-Premise
similar	I-Premise
at	I-Premise
all	I-Premise
time	I-Premise
points	I-Premise
except	I-Premise
at	I-Premise
5:00	I-Premise
pm,	I-Premise
when	I-Premise
levels	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
latanoprost-treated	I-Premise
patients	I-Premise
(P	I-Premise
=	I-Premise
0.025).	I-Premise

After	B-Premise
the	I-Premise
water-drinking	I-Premise
test,	I-Premise
the	I-Premise
increase	I-Premise
in	I-Premise
IOP	I-Premise
values	I-Premise
was	I-Premise
similar	I-Premise
between	I-Premise
groups	I-Premise
at	I-Premise
baseline	I-Premise
but	I-Premise
lower	I-Premise
in	I-Premise
latanoprost-treated	I-Premise
patients	I-Premise
at	I-Premise
week	I-Premise
8	I-Premise
(adjusted	I-Premise
difference,	I-Premise
1.08	I-Premise
mm	I-Premise
Hg;	I-Premise
P	I-Premise
=	I-Premise
0.012).	I-Premise

Fewer	B-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
latanoprost	I-Premise
reported	I-Premise
ocular	I-Premise
or	I-Premise
systemic	I-Premise
AEs	I-Premise
(P	I-Premise
=	I-Premise
0.025	I-Premise
and	I-Premise
P	I-Premise
<	I-Premise
0.001,	I-Premise
respectively).	I-Premise

In	B-Claim
this	I-Claim
study	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
unilateral	I-Claim
or	I-Claim
bilateral	I-Claim
primary	I-Claim
open-angle,	I-Claim
pigmentary,	I-Claim
or	I-Claim
exfoliative	I-Claim
glaucoma	I-Claim
or	I-Claim
OHT	I-Claim
IOP	I-Claim
reductions	I-Claim
generally	I-Claim
were	I-Claim
similar	I-Claim
between	I-Claim
treatment	I-Claim
groups,	I-Claim
except	B-Claim
at	I-Claim
5:00	I-Claim
pm,	I-Claim
when	I-Claim
the	I-Claim
mean	I-Claim
IOP	I-Claim
level	I-Claim
was	I-Claim
significantly	I-Claim
lower	I-Claim
in	I-Claim
latanoprost-treated	I-Claim
patients.	I-Claim

Latanoprost	B-Claim
was	I-Claim
better	I-Claim
tolerated	I-Claim
than	I-Claim
fixed-combination	I-Claim
dorzolamide	I-Claim
and	I-Claim
timolol.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
Baerveldt	O
and	O
Ahmed	O
glaucoma	O
drainage	O
implants	O
in	O
Asian	O
patients	O
with	O
refractory	O
glaucoma.	O

Retrospective	O
nonrandomized	O
study.	O

Forty-one	O
patients.	O

The	O
authors	O
reviewed	O
the	O
insertion	O
of	O
18	O
Ahmed	O
glaucoma	O
valved	O
(AGV-S2)	O
implants	O
and	O
24	O
350	O
mm(2)	O
Baerveldt	O
glaucoma	O
implants	O
performed	O
by	O
a	O
single	O
surgeon	O
at	O
the	O
Department	O
of	O
Ophthalmology,	O
National	O
University	O
Hospital,	O
Singapore,	O
from	O
January	O
1,	O
2000,	O
to	O
December	O
31,	O
2000.	O

A	O
total	O
of	O
42	O
glaucoma	O
drainage	O
implants	O
was	O
inserted	O
into	O
the	O
eyes	O
of	O
41	O
patients.	O

All	O
patients	O
had	O
at	O
least	O
6	O
months	O
of	O
follow-up.	O

Intraocular	O
pressure	O
(IOP),	O
visual	O
acuity,	O
and	O
complications.	O

Both	B-Premise
drainage	I-Premise
implants	I-Premise
achieved	I-Premise
remarkable	I-Premise
reductions	I-Premise
in	I-Premise
IOP;	I-Premise
from	I-Premise
pretreatment	I-Premise
IOP	I-Premise
of	I-Premise
40.1+/-13.8	I-Premise
mmHg	I-Premise
and	I-Premise
43.7+/-9.3	I-Premise
mmHg	I-Premise
to	I-Premise
postoperative	I-Premise
IOP	I-Premise
of	I-Premise
17.4+/-6.2	I-Premise
and	I-Premise
14.9+/-5.5	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
Baerveldt	I-Premise
and	I-Premise
Ahmed	I-Premise
groups,	I-Premise
respectively.	I-Premise

A	B-Premise
decrease	I-Premise
in	I-Premise
IOP	I-Premise
of	I-Premise
56.6%	I-Premise
and	I-Premise
65.9%	I-Premise
had	I-Premise
been	I-Premise
achieved.	I-Premise

Success	B-Premise
rates	I-Premise
were	I-Premise
20	I-Premise
(83.3%)	I-Premise
for	I-Premise
Baerveldt	I-Premise
and	I-Premise
12	I-Premise
(66.7%)	I-Premise
for	I-Premise
Ahmed	I-Premise
implants,	I-Premise
whereas	I-Premise
qualified	I-Premise
success	I-Premise
occurred	I-Premise
in	I-Premise
1	I-Premise
(4.2%)	I-Premise
Baerveldt	I-Premise
and	I-Premise
3	I-Premise
(16.7%)	I-Premise
Ahmed	I-Premise
implants.	I-Premise

Conversely,	B-Premise
failure	I-Premise
to	I-Premise
control	I-Premise
IOP	I-Premise
occurred	I-Premise
in	I-Premise
3	I-Premise
(12.5%)	I-Premise
Baerveldt	I-Premise
implants	I-Premise
and	I-Premise
3	I-Premise
(16.7%)	I-Premise
Ahmed	I-Premise
implants.	I-Premise

More	B-Premise
than	I-Premise
80%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
had	I-Premise
maintained	I-Premise
or	I-Premise
improved	I-Premise
visual	I-Premise
function,	I-Premise
whereas	I-Premise
only	I-Premise
4	I-Premise
(16.0%)	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
with	I-Premise
Baerveldt	I-Premise
implants	I-Premise
and	I-Premise
2	I-Premise
(16.7%)	I-Premise
patients	I-Premise
with	I-Premise
Ahmed	I-Premise
implants	I-Premise
had	I-Premise
loss	I-Premise
of	I-Premise
more	I-Premise
than	I-Premise
1	I-Premise
Snellen	I-Premise
line.	I-Premise

Both	B-Claim
Baerveldt	I-Claim
and	I-Claim
Ahmed	I-Claim
glaucoma	I-Claim
drainage	I-Claim
implants	I-Claim
performed	I-Claim
well	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
IOP	I-Claim
control,	I-Claim
preservation	I-Claim
of	I-Claim
visual	I-Claim
function,	I-Claim
and	I-Claim
having	I-Claim
low	I-Claim
complication	I-Claim
rates.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
viscocanalostomy	O
and	O
trabeculectomy	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
(POAG).	O

Department	O
of	O
Ophthalmology,	O
Ankara	O
Education	O
and	O
Research	O
Hospital,	O
Ankara,	O
Turkey.	O

In	O
this	O
prospective	O
randomized	O
trial,	O
50	O
eyes	O
of	O
50	O
patients	O
with	O
medically	O
uncontrolled	O
POAG	O
were	O
randomized	O
to	O
have	O
a	O
trabeculectomy	O
(25	O
eyes)	O
or	O
a	O
viscocanalostomy	O
(25	O
eyes).	O

Visual	O
acuity,	O
intraocular	O
pressure	O
(IOP),	O
and	O
slitlamp	O
examinations	O
were	O
performed	O
before	O
surgery	O
and	O
1	O
day,	O
1	O
week,	O
1,	O
3,	O
and	O
6	O
months,	O
and	O
1,	O
2,	O
and	O
3	O
years	O
postoperatively.	O

At	B-Premise
3	I-Premise
years,	I-Premise
the	I-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
16.0	I-Premise
mmHg	I-Premise
+/-	I-Premise
7.07	I-Premise
(SD)	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
and	I-Premise
17.8	I-Premise
+/-	I-Premise
4.6	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
(P=.694).	I-Premise

Complete	B-Premise
success	I-Premise
(IOP	I-Premise
6	I-Premise
to	I-Premise
21	I-Premise
mm	I-Premise
Hg	I-Premise
without	I-Premise
medication)	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
66.2%	I-Premise
of	I-Premise
eyes	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
55.1%	I-Premise
at	I-Premise
3	I-Premise
years	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
and	I-Premise
in	I-Premise
52.9%	I-Premise
and	I-Premise
35.3%,	I-Premise
respectively,	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
(P>.05).	I-Premise

Qualified	B-Premise
success	I-Premise
(IOP	I-Premise
6	I-Premise
to	I-Premise
21	I-Premise
mmHg	I-Premise
with	I-Premise
medication)	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
95.8%	I-Premise
of	I-Premise
eyes	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
79.2%	I-Premise
at	I-Premise
3	I-Premise
years	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
and	I-Premise
in	I-Premise
90.7%	I-Premise
and	I-Premise
73.9%,	I-Premise
respectively,	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
(P>.05).	I-Premise

Postoperative	B-Premise
hypotony	I-Premise
and	I-Premise
cataract	I-Premise
formation	I-Premise
occurred	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
(P=.002).	I-Premise

Primary	B-Claim
trabeculectomy	I-Claim
lowered	I-Claim
IOP	I-Claim
more	I-Claim
than	I-Claim
viscocanalostomy	I-Claim
in	I-Claim
POAG	I-Claim
patients.	I-Claim

However,	O
the	B-Claim
complication	I-Claim
rate	I-Claim
was	I-Claim
lower	I-Claim
in	I-Claim
the	I-Claim
viscocanalostomy	I-Claim
group.	I-Claim

Approximately	O
40%	O
of	O
patients	O
with	O
glaucoma	O
are	O
concomitantly	O
prescribed	O
>or=2	O
different	O
intraocular	O
pressure	O
(IOP)-lowering	O
medications.	O

An	O
effective	O
and	O
well-tolerated	O
fixed	O
combination	O
of	O
agents	O
requiring	O
once-daily	O
instillation	O
may	O
improve	O
patient	O
compliance.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
the	O
fixed	O
combination	O
latanoprost	O
0.005%	O
+	O
timolol	O
maleate	O
0.5%	O
QD	O
with	O
those	O
of	O
latanoprost	O
0.005%	O
monotherapy	O
QD	O
in	O
patients	O
whose	O
elevated	O
IOP	O
(>or=21	O
mm	O
Hg)	O
was	O
inadequately	O
controlled	O
by	O
latanoprost.	O

This	O
21-day,	O
randomized,	O
double-masked,	O
active-control	O
study	O
was	O
conducted	O
at	O
49	O
study	O
sites	O
in	O
Argentina,	O
Brazil,	O
Colombia,	O
Mexico,	O
Peru,	O
the	O
United	O
States,	O
and	O
Venezuela.	O

Adults	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
who	O
had	O
failed	O
to	O
reach	O
an	O
IOP	O
of	O
<21	O
mm	O
Hg	O
while	O
receiving	O
latanoprost	O
for	O
at	O
least	O
28	O
days	O
were	O
enrolled.	O

After	O
an	O
additional	O
28	O
days	O
of	O
latanoprost	O
run-in,	O
patients	O
were	O
randomly	O
assigned	O
to	O
continue	O
latanoprost	O
monotherapy	O
or	O
to	O
switch	O
to	O
the	O
fixed	O
combination	O
for	O
21	O
days.	O

The	O
intent-to-treat	O
(ITT)	O
population	O
included	O
all	O
patients	O
who	O
received	O
at	O
least	O
1	O
dose	O
of	O
double-masked	O
study	O
medication;	O
the	O
per-protocol	O
(PP)	O
analysis	O
included	O
patients	O
who	O
completed	O
the	O
study	O
without	O
a	O
major	O
protocol	O
violation	O
and	O
who	O
had	O
IOP	O
measurements	O
both	O
at	O
baseline	O
and	O
at	O
day	O
21.	O

The	O
primary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
whose	O
IOP	O
was	O
decreased	O
>or=2	O
mm	O
Hg	O
from	O
the	O
baseline	O
level	O
on	O
day	O
21.	O

Proportions	O
of	O
patients	O
demonstrating	O
IOP	O
decreases	O
>or=3,	O
>or=4,	O
or	O
>or=5	O
mm	O
Hg	O
from	O
the	O
baseline	O
level	O
and	O
of	O
patients	O
reaching	O
an	O
10P	O
<or=18	O
mm	O
Hg	O
were	O
evaluated.	O

Adverse	O
events	O
(AEs)	O
were	O
also	O
assessed.	O

A	O
total	O
of	O
350	O
patients	O
were	O
enrolled.	O

In	O
all,	O
348	O
patients	O
were	O
included	O
in	O
the	O
ITT	O
and	O
tolerability	O
analyses	O
(fixed	O
combination,	O
n	O
=	O
175;	O
latanoprost,	O
n	O
=	O
173;	O
mean	O
[SD]	O
age,	O
64.4	O
[13.2]	O
and	O
63.2	O
[14.0]	O
years,	O
respectively;	O
103	O
women	O
in	O
each	O
group).	O

Baseline	O
demographic	O
and	O
clinical	O
characteristics	O
were	O
similar	O
between	O
groups.	O

A	B-Premise
higher	I-Premise
percentage	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
the	I-Premise
fixed	I-Premise
combination	I-Premise
had	I-Premise
IOP	I-Premise
decreases	I-Premise
of	I-Premise
2	I-Premise
mm	I-Premise
Hg	I-Premise
on	I-Premise
day	I-Premise
21	I-Premise
relative	I-Premise
to	I-Premise
baseline	I-Premise
compared	I-Premise
with	I-Premise
latanoprost-treated	I-Premise
patients	I-Premise
(79.4%	I-Premise
vs	I-Premise
51.4%,	I-Premise
respectively;	I-Premise
P	I-Premise
<	I-Premise
0.001).	I-Premise

PP	B-Premise
analyses	I-Premise
found	I-Premise
that	I-Premise
more	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
fixed-combination	I-Premise
group	I-Premise
had	I-Premise
IOP	I-Premise
decreases	I-Premise
>or=3,	I-Premise
>or=4,	I-Premise
or	I-Premise
>or=5	I-Premise
mm	I-Premise
Hg	I-Premise
(for	I-Premise
each	I-Premise
target	I-Premise
level,	I-Premise
P	I-Premise
<	I-Premise
0.001	I-Premise
vs	I-Premise
latanoprost	I-Premise
group)	I-Premise
or	I-Premise
final	I-Premise
IOP	I-Premise
18	I-Premise
mm	I-Premise
Hg	I-Premise
(fixed	I-Premise
-combination,	I-Premise
35.1%;	I-Premise
latanoprost,	I-Premise
17.8%;	I-Premise
P	I-Premise
<	I-Premise
0.001).	I-Premise

Both	B-Claim
treatments	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

Similar	B-Premise
proportions	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
fixed-combination	I-Premise
and	I-Premise
latanoprost	I-Premise
groups	I-Premise
reported	I-Premise
at	I-Premise
least	I-Premise
1	I-Premise
treatment-emergent	I-Premise
AE	I-Premise
(10.9%	I-Premise
and	I-Premise
12.1%,	I-Premise
respectively).	I-Premise

In	O
this	O
selected	O
population	O
of	O
patients	B-Claim
with	I-Claim
an	I-Claim
inadequate	I-Claim
initial	I-Claim
IOP	I-Claim
response	I-Claim
to	I-Claim
latanoprost,	I-Claim
switching	I-Claim
to	I-Claim
fixed-combination	I-Claim
latanoprosttimolol	I-Claim
resulted	I-Claim
in	I-Claim
a	I-Claim
greater	I-Claim
decrease	I-Claim
in	I-Claim
IOP	I-Claim
and	I-Claim
similar	I-Claim
tolerability	I-Claim
compared	I-Claim
with	I-Claim
continuing	I-Claim
latanoprost	I-Claim
therapy.	I-Claim

In	O
a	O
randomized	O
clinical	O
trial,	O
the	O
authors	O
compared	O
the	O
use	O
of	O
postoperative	O
subconjunctival	O
injections	O
of	O
5-fluorouracil	O
(5-FU)	O
in	O
19	O
eyes	O
with	O
a	O
single	O
intraoperative	O
application	O
of	O
subconjunctival	O
mitomycin	O
(MMC)	O
at	O
the	O
filtering	O
site	O
in	O
20	O
eyes	O
at	O
high	O
risk	O
for	O
failure	O
of	O
glaucoma	O
filtering	O
surgery.	O

Six	B-Premise
months	I-Premise
after	I-Premise
surgery,	I-Premise
intraocular	I-Premise
pressures	I-Premise
averaged	I-Premise
10.9	I-Premise
+/-	I-Premise
5.3	I-Premise
mmHg	I-Premise
(mean	I-Premise
+/-	I-Premise
standard	I-Premise
deviation)	I-Premise
in	I-Premise
the	I-Premise
MMC-treated	I-Premise
eyes	I-Premise
versus	I-Premise
14.2	I-Premise
+/-	I-Premise
5.5	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
5-FU-treated	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.08)	I-Premise
and	I-Premise
were	I-Premise
less	I-Premise
than	I-Premise
or	I-Premise
equal	I-Premise
to	I-Premise
12	I-Premise
mmHg	I-Premise
in	I-Premise
60.0%	I-Premise
of	I-Premise
MMC-treated	I-Premise
eyes	I-Premise
and	I-Premise
21.1%	I-Premise
of	I-Premise
5-FU-treated	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.03).	I-Premise

Mitomycin-treated	O
eyes	O
were	O
receiving	O
an	O
average	O
of	O
0.3	O
+/-	O
0.5	O
medications	O
for	O
intraocular	O
pressure	O
control,	O
and	O
5-FU-treated	O
eyes	O
were	O
receiving	O
an	O
average	O
of	O
1.1	O
+/-	O
1.1	O
medications	O
(P	O
=	O
0.01).	O

Drug-induced	B-Premise
corneal	I-Premise
epithelial	I-Premise
defects	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
nine	I-Premise
5-FU-treated	I-Premise
eyes	I-Premise
and	I-Premise
in	I-Premise
no	I-Premise
MMC-treated	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.0004).	I-Premise

These	B-Claim
results	I-Claim
suggest	I-Claim
that	I-Claim
intraoperative	I-Claim
MMC	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
viable	I-Claim
alternative	I-Claim
to	I-Claim
postoperative	I-Claim
5-FU,	I-Claim
with	I-Claim
lower	I-Claim
overall	I-Claim
intraocular	I-Claim
pressures,	I-Claim
decreased	I-Claim
dependence	I-Claim
on	I-Claim
postoperative	I-Claim
ocular	I-Claim
antihypertensive	I-Claim
medications,	I-Claim
and	I-Claim
decreased	I-Claim
corneal	I-Claim
toxicity.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
latanoprost	O
or	O
brimonidine	O
in	O
patients	O
with	O
elevated	O
intraocular	O
pressure	O
(IOP).	O

This	O
prospective,	O
randomized,	O
masked-evaluator,	O
parallel-group,	O
multicenter	O
study	O
in	O
the	O
United	O
States	O
included	O
patients	O
with	O
primary	O
open	O
angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

Patients	O
received	O
latanoprost	O
0.005%	O
once	O
daily	O
(8:00	O
AM;	O
n	O
=	O
152)	O
or	O
brimonidine	O
tartrate	O
0.2%	O
twice	O
daily	O
(8:00	O
AM	O
and	O
8:00	O
PM;	O
n	O
=	O
151).	O

Patients	O
underwent	O
evaluation	O
at	O
screening,	O
baseline	O
(randomization),	O
and	O
after	O
0.5,	O
3,	O
and	O
6	O
months	O
of	O
treatment.	O

IOP	O
was	O
measured	O
at	O
8:00	O
AM,	O
10:00	O
AM,	O
noon,	O
and	O
4:00	O
PM	O
at	O
baseline	O
and	O
the	O
months	O
3	O
and	O
6	O
visits,	O
and	O
at	O
8:00	O
AM	O
only	O
at	O
week	O
2.	O

The	O
main	O
outcome	O
measure	O
was	O
the	O
difference	O
in	O
diurnal	O
IOP	O
change	O
from	O
baseline	O
to	O
month	O
6	O
between	O
treatment	O
groups.	O

Adverse	O
events	O
were	O
recorded	O
at	O
each	O
visit.	O

Baseline	O
mean	O
diurnal	O
IOP	O
levels	O
were	O
similar	O
between	O
groups.	O

At	B-Premise
month	I-Premise
6,	I-Premise
the	I-Premise
adjusted	I-Premise
mean	I-Premise
(+/-	I-Premise
SEM)	I-Premise
diurnal	I-Premise
IOP	I-Premise
reduction	I-Premise
was	I-Premise
5.7	I-Premise
+/-	I-Premise
0.3	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
and	I-Premise
3.1	I-Premise
+/-	I-Premise
0.3	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
brimonidine	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

The	B-Premise
mean	I-Premise
difference	I-Premise
in	I-Premise
diurnal	I-Premise
IOP	I-Premise
reduction	I-Premise
was	I-Premise
2.5	I-Premise
+/-	I-Premise
0.3	I-Premise
mm	I-Premise
Hg	I-Premise
(95%	I-Premise
CI:	I-Premise
1.9,	I-Premise
3.2;	I-Premise
P	I-Premise
<	I-Premise
0.001).	I-Premise

Five	B-Premise
times	I-Premise
more	I-Premise
patients	I-Premise
receiving	I-Premise
brimonidine	I-Premise
than	I-Premise
latanoprost	I-Premise
were	I-Premise
withdrawn	I-Premise
from	I-Premise
the	I-Premise
study	I-Premise
due	I-Premise
to	I-Premise
adverse	I-Premise
events.	I-Premise

Latanoprost	B-Claim
instilled	I-Claim
once	I-Claim
daily	I-Claim
is	I-Claim
more	I-Claim
effective	I-Claim
and	I-Claim
better	I-Claim
tolerated	I-Claim
than	I-Claim
brimonidine	I-Claim
administered	I-Claim
twice	I-Claim
daily	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension.	I-Claim

During	B-Claim
therapy,	I-Claim
the	I-Claim
range	I-Claim
of	I-Claim
daily	I-Claim
fluctuation	I-Claim
of	I-Claim
IOP	I-Claim
is	I-Claim
less	I-Claim
for	I-Claim
latanoprost	I-Claim
compared	I-Claim
with	I-Claim
brimonidine.	I-Claim

To	O
compare	O
selective	O
laser	O
trabeculoplasty	O
(SLT)	O
and	O
argon	O
laser	O
trabeculoplasty	O
(ALT),	O
in	O
terms	O
of	O
intraocular	O
pressure	O
(IOP)	O
lowering,	O
in	O
patients	O
with	O
open-angle	O
glaucoma.	O

176	O
eyes	O
of	O
152	O
patients	O
were	O
enrolled	O
in	O
this	O
study,	O
89	O
in	O
the	O
SLT	O
and	O
87	O
in	O
the	O
ALT	O
groups.	O

Patients	O
were	O
randomised	O
to	O
receive	O
either	O
SLT	O
or	O
ALT	O
treatment	O
to	O
180	O
degrees	O
of	O
the	O
trabecular	O
meshwork.	O

Patients	O
were	O
followed	O
up	O
to	O
12	O
months	O
after	O
treatment.	O

The	O
main	O
outcome	O
measured	O
was	O
IOP	O
lowering	O
at	O
12	O
months	O
after	O
treatment,	O
compared	O
between	O
the	O
SLT	O
and	O
ALT	O
groups.	O

No	B-Premise
significant	I-Premise
difference	I-Premise
(p	I-Premise
=	I-Premise
0.846)	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
mean	I-Premise
decrease	I-Premise
in	I-Premise
IOP	I-Premise
between	I-Premise
the	I-Premise
SLT	I-Premise
(5.86	I-Premise
mm	I-Premise
Hg)	I-Premise
and	I-Premise
ALT	I-Premise
(6.04	I-Premise
mm	I-Premise
Hg)	I-Premise
groups	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
or	I-Premise
at	I-Premise
any	I-Premise
other	I-Premise
time	I-Premise
points,	I-Premise
nor	I-Premise
were	I-Premise
there	I-Premise
any	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
early	I-Premise
or	I-Premise
late	I-Premise
complications	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

SLT	B-Claim
is	I-Claim
equivalent	I-Claim
to	I-Claim
ALT	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
IOP	I-Claim
lowering	I-Claim
at	I-Claim
1	I-Claim
year,	I-Claim
and	I-Claim
is	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
procedure	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
open-angle	I-Claim
glaucoma.	I-Claim

To	O
report	O
one-year	O
results	O
of	O
the	O
Tube	O
Versus	O
Trabeculectomy	O
(TVT)	O
Study.	O

Multicenter	O
randomized	O
clinical	O
trial.	O

Setting:	O
17	O
Clinical	O
Centers.	O

Study	O
Population:	O
Patients	O
18	O
to	O
85	O
years	O
of	O
age	O
who	O
had	O
previous	O
trabeculectomy	O
and/or	O
cataract	O
extraction	O
with	O
intraocular	O
lens	O
implantation	O
and	O
uncontrolled	O
glaucoma	O
with	O
intraocular	O
pressure	O
(IOP)	O
>	O
or	O
=18	O
mm	O
Hg	O
and	O
<	O
or	O
=40	O
mm	O
Hg	O
on	O
maximum	O
tolerated	O
medical	O
therapy.	O

Interventions:	O
350	O
mm(2)	O
Baerveldt	O
glaucoma	O
implant	O
or	O
trabeculectomy	O
with	O
mitomycin	O
C	O
(MMC).	O

Main	O
Outcome	O
Measures:	O
IOP,	O
visual	O
acuity,	O
and	O
reoperation	O
for	O
glaucoma.	O

A	O
total	O
of	O
212	O
eyes	O
of	O
212	O
patients	O
were	O
enrolled,	O
including	O
107	O
in	O
the	O
tube	O
group	O
and	O
105	O
in	O
the	O
trabeculectomy	O
group.	O

At	O
one	O
year,	O
IOP	O
(mean	O
+/-	O
SD)	O
was	O
12.4	O
+/-	O
3.9	O
mm	O
Hg	O
in	O
the	O
tube	O
group	O
and	O
12.7	O
+/-	O
5.8	O
mm	O
Hg	O
in	O
the	O
trabeculectomy	O
group	O
(P	O
=	O
.73).	O

The	B-Premise
number	I-Premise
of	I-Premise
glaucoma	I-Premise
medications	I-Premise
(mean	I-Premise
+/-	I-Premise
SD)	I-Premise
was	I-Premise
1.3	I-Premise
+/-	I-Premise
1.3	I-Premise
in	I-Premise
the	I-Premise
tube	I-Premise
group	I-Premise
and	I-Premise
0.5	I-Premise
+/-	I-Premise
0.9	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

The	B-Premise
cumulative	I-Premise
probability	I-Premise
of	I-Premise
failure	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
of	I-Premise
follow-up	I-Premise
was	I-Premise
3.9%	I-Premise
in	I-Premise
the	I-Premise
tube	I-Premise
group	I-Premise
and	I-Premise
13.5%	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
.017).	I-Premise

Nonvalved	B-Premise
tube	I-Premise
shunt	I-Premise
surgery	I-Premise
was	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
maintain	I-Premise
IOP	I-Premise
control	I-Premise
and	I-Premise
avoid	I-Premise
persistent	I-Premise
hypotony	I-Premise
or	I-Premise
reoperation	I-Premise
for	I-Premise
glaucoma	I-Premise
than	I-Premise
trabeculectomy	I-Premise
with	I-Premise
MMC	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
of	I-Premise
follow-up	I-Premise
in	I-Premise
the	I-Premise
TVT	I-Premise
Study.	I-Premise

Both	B-Claim
surgical	I-Claim
procedures	I-Claim
produced	I-Claim
similar	I-Claim
IOP	I-Claim
reduction	I-Claim
at	I-Claim
one	I-Claim
year,	I-Claim
but	O
there	B-Claim
was	I-Claim
less	I-Claim
need	I-Claim
for	I-Claim
supplemental	I-Claim
medical	I-Claim
therapy	I-Claim
following	I-Claim
trabeculectomy	I-Claim
with	I-Claim
MMC.	I-Claim

To	O
compare	O
the	O
ocular	O
hypotensive	O
efficacy	O
and	O
safety	O
of	O
topical	O
bimatoprost	O
and	O
timolol-dorzolamide	O
combination	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
(POAG)	O
or	O
ocular	O
hypertension	O
during	O
6	O
months	O
of	O
treatment.	O

A	O
sample	O
of	O
65	O
patients	O
with	O
a	O
diagnosis	O
of	O
POAG	O
or	O
ocular	O
hypertension	O
were	O
randomized	O
to	O
receive	O
either	O
bimatoprost	O
0.03%	O
once	O
daily	O
or	O
timolol-dorzolamide	O
combination	O
twice	O
daily.	O

Study	O
visits	O
occurred	O
at	O
baseline	O
and	O
after	O
2	O
weeks	O
and	O
1,	O
3	O
and	O
6	O
months	O
of	O
therapy.	O

Intraocular	O
pressure	O
(IOP)	O
measurements	O
were	O
performed	O
at	O
12.00	O
hours	O
at	O
all	O
study	O
visits	O
and	O
also	O
at	O
08.00	O
hours	O
and	O
16.00	O
hours	O
at	O
baseline	O
and	O
6-month	O
visits.	O

At	O
each	O
visit,	O
local	O
and	O
systemic	O
side-effects	O
that	O
occurred	O
during	O
the	O
treatment	O
period	O
were	O
recorded.	O

Student's	O
t-test	O
was	O
used	O
to	O
compare	O
the	O
differences	O
between	O
IOP	O
values.	O

Differences	O
in	O
IOP	O
between	O
the	O
bimatoprost	O
and	O
timolol-dorzolamide	O
groups	O
were	O
statistically	O
insignificant	O
at	O
all	O
study	O
visits	O
(p	O
>	O
0.05).	O

In	B-Premise
the	I-Premise
bimatoprost-treated	I-Premise
group,	I-Premise
the	I-Premise
IOP	I-Premise
reduction	I-Premise
was	I-Premise
6.2	I-Premise
+/-	I-Premise
1.8	I-Premise
mmHg,	I-Premise
whereas	I-Premise
it	I-Premise
was	I-Premise
6.5	I-Premise
+/-	I-Premise
2.3	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
timolol-dorzolamide	I-Premise
group	I-Premise
after	I-Premise
6	I-Premise
months	I-Premise
of	I-Premise
treatment.	I-Premise

The	B-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(p	I-Premise
=	I-Premise
0.48).	I-Premise

The	B-Premise
IOP-lowering	I-Premise
efficacies	I-Premise
of	I-Premise
bimatoprost	I-Premise
and	I-Premise
timolol-dorzolamide	I-Premise
combination	I-Premise
were	I-Premise
similar	I-Premise
over	I-Premise
a	I-Premise
6-month	I-Premise
follow-up.	I-Premise

Both	B-Claim
bimatoprost	I-Claim
and	I-Claim
the	I-Claim
timolol-dorzolamide	I-Claim
combination	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

Bimatoprost	B-Claim
can	I-Claim
be	I-Claim
used	I-Claim
as	I-Claim
a	I-Claim
longterm	I-Claim
monotherapy	I-Claim
agent	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
POAG	I-Claim
and	I-Claim
ocular	I-Claim
hypertension.	I-Claim

The	O
purpose	O
of	O
this	O
randomized	O
clinical	O
trial	O
was	O
to	O
compare	O
the	O
effectiveness	O
and	O
safety	O
of	O
viscocanalostomy	O
(visco)	O
with	O
trabeculectomy	O
(trab)	O
in	O
the	O
management	O
of	O
primary	O
open	O
angle	O
glaucoma	O
(POAG).	O

Patients	O
were	O
randomized	O
to	O
have	O
a	O
viscocanalostomy	O
(25	O
eyes)	O
or	O
a	O
trabeculectomy	O
(25	O
eyes)	O
performed	O
by	O
one	O
surgeon	O
(TDM)	O
and	O
followed	O
up	O
prospectively.	O

Patients	O
were	O
examined	O
preoperatively,	O
at	O
day	O
1,	O
day	O
3	O
if	O
required,	O
day	O
6,	O
week	O
2	O
and	O
thereafter	O
as	O
near	O
as	O
possible	O
to	O
1,	O
3,	O
6,	O
12,	O
18,	O
24,	O
30,	O
36,	O
48,	O
54,	O
and	O
60	O
months.	O

We	O
recorded	O
intraocular	O
pressure	O
(IOP),	O
presence	O
or	O
absence	O
of	O
any	O
complications,	O
presence	O
and	O
description	O
of	O
any	O
bleb,	O
visual	O
acuity	O
with	O
glasses,	O
and	O
full	O
examinations	O
as	O
routine	O
to	O
monitor	O
any	O
progression	O
of	O
the	O
glaucoma.	O

Bleb	O
interventions	O
including	O
needling	O
and	O
antimetabolites	O
were	O
allowed	O
and	O
recorded	O
in	O
both	O
groups.	O

YAG	O
laser	O
goniopuncture	O
was	O
allowed	O
in	O
the	O
viscocanalostomy	O
group.	O

Mean	O
follow-up	O
was	O
40	O
months	O
(SD	O
15),	O
with	O
a	O
range	O
from	O
6	O
to	O
60	O
months.	O

Forty-two	B-Premise
percent	I-Premise
(n=10)	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
successful	I-Premise
outcome	I-Premise
(IOP<18	I-Premise
mm	I-Premise
Hg	I-Premise
with	I-Premise
no	I-Premise
treatment)	I-Premise
at	I-Premise
last	I-Premise
follow-up	I-Premise
visit,	I-Premise
compared	I-Premise
to	I-Premise
21%	I-Premise
(n=5)	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group.	I-Premise

IOP	B-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
trab	I-Premise
group	I-Premise
with	I-Premise
differences	I-Premise
in	I-Premise
IOP	I-Premise
being	I-Premise
statistically	I-Premise
significant	I-Premise
at	I-Premise
month	I-Premise
12	I-Premise
(P=<0.001),	I-Premise
24	I-Premise
(P=<0.001),	I-Premise
30	I-Premise
(P=0.030),	I-Premise
36	I-Premise
(P=<0.001),	I-Premise
and	I-Premise
48	I-Premise
(P=0.018).	I-Premise

The	B-Premise
trabeculectomy	I-Premise
group	I-Premise
required	I-Premise
less	I-Premise
postoperative	I-Premise
topical	I-Premise
IOP-lowering	I-Premise
medication	I-Premise
(P=0.011).	I-Premise

In	O
this	O
study,	O
we	B-Claim
found	I-Claim
trabeculectomy	I-Claim
to	I-Claim
be	I-Claim
more	I-Claim
effective	I-Claim
at	I-Claim
lowering	I-Claim
IOP	I-Claim
than	I-Claim
viscocanalostomy	I-Claim
in	I-Claim
POAG	I-Claim
patients.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure	O
(IOP)-lowering	O
effect	O
of	O
combined	O
viscocanalostomy	O
and	O
phacoemulsification	O
and	O
combined	O
trabeculectomy	O
and	O
phacoemulsification	O
with	O
mitomycin	O
C	O
in	O
eyes	O
with	O
primary	O
open-angle	O
glaucoma.	O

Prospective	O
randomized	O
1-year	O
trial.	O

Forty	O
consecutive	O
patients	O
(40	O
eyes)	O
with	O
primary	O
open-angle	O
glaucoma	O
and	O
cataract.	O

Eyes	O
were	O
assigned	O
randomly	O
either	O
to	O
trabeculectomy	O
with	O
mitomycin	O
C	O
or	O
to	O
viscocanalostomy	O
in	O
combination	O
with	O
phacoemulsification	O
and	O
intraocular	O
lens	O
implantation.	O

Success	O
rate	O
based	O
on	O
IOP.	O

Mean	B-Premise
baseline	I-Premise
IOP	I-Premise
was	I-Premise
24.0+/-2.0	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
and	I-Premise
23.7+/-2.6	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.7).	I-Premise
Mean	I-Premise
postoperative	I-Premise
IOP	I-Premise
was	I-Premise
13.7+/-2.2	I-Premise
mmHg	I-Premise
at	I-Premise
3	I-Premise
months,	I-Premise
14.8+/-3.3	I-Premise
mmHg	I-Premise
at	I-Premise
6	I-Premise
months,	I-Premise
and	I-Premise
14.9+/-3.0	I-Premise
mmHg	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
and	I-Premise
12.1+/-4.0	I-Premise
mmHg	I-Premise
at	I-Premise
3	I-Premise
months,	I-Premise
13.8+/-4.7	I-Premise
mmHg	I-Premise
at	I-Premise
6	I-Premise
months,	I-Premise
and	I-Premise
14.1+/-4.4	I-Premise
mmHg	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group.	I-Premise

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
IOP	O
between	O
the	O
groups	O
at	O
any	O
time.	O

At	B-Premise
12	I-Premise
months,	I-Premise
17	I-Premise
patients	I-Premise
(85%)	I-Premise
in	I-Premise
the	I-Premise
viscocanalostomy	I-Premise
group	I-Premise
and	I-Premise
16	I-Premise
patients	I-Premise
(80%)	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
achieved	I-Premise
an	I-Premise
IOP	I-Premise
of	I-Premise
20	I-Premise
mmHg	I-Premise
or	I-Premise
less	I-Premise
without	I-Premise
medication	I-Premise
(P	I-Premise
=	I-Premise
0.7).	I-Premise

Complications	O
included	O
2	O
cases	O
(10%)	O
of	O
flat/shallow	O
anterior	O
chamber	O
and	O
4	O
cases	O
(20%)	O
of	O
hypotony	O
in	O
the	O
trabeculectomy	O
group,	O
whereas	O
intraoperative	O
microperforation	O
of	O
Descemet's	O
membrane	O
occurred	O
in	O
3	O
cases	O
(15%)	O
in	O
the	O
viscocanalostomy	O
group.	O

There	B-Claim
was	I-Claim
no	I-Claim
significant	I-Claim
difference	I-Claim
in	I-Claim
IOP	I-Claim
reduction	I-Claim
between	I-Claim
viscocanalostomy	I-Claim
and	I-Claim
trabeculectomy	I-Claim
with	I-Claim
mitomycin	I-Claim
C	I-Claim
in	I-Claim
combination	I-Claim
with	I-Claim
phacoemulsification	I-Claim
and	I-Claim
intraocular	I-Claim
lens	I-Claim
implantation	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
primary	I-Claim
open-angle	I-Claim
glaucoma.	I-Claim

To	O
compare	O
the	O
ocular	O
hypotensive	O
activity	O
and	O
safety	O
profile	O
of	O
long-acting	O
1%	O
carteolol	O
hydrochloride	O
eye	O
drops	O
(long-acting	O
formulation)	O
to	O
those	O
of	O
1%	O
carteolol	O
hydrochloride	O
eye	O
drops(currently	O
prescribed	O
drug)	O
for	O
reduction	O
of	O
intraocular	O
pressure.	O

Patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
(146	O
cases)	O
were	O
assigned	O
randomly	O
to	O
the	O
long-acting	O
drug	O
group	O
(74	O
cases)	O
and	O
the	O
currently-prescribed	O
drug	O
group	O
(72	O
cases).	O

Long-acting	O
eye	O
drops	O
were	O
instilled	O
once	O
a	O
day	O
in	O
the	O
morning	O
(along	O
with	O
one	O
drop	O
of	O
placebo	O
at	O
night),	O
and	O
currently-prescribed	O
eye	O
drops	O
were	O
instilled	O
twice	O
a	O
day	O
in	O
the	O
morning	O
and	O
at	O
night.	O

Eye	O
drops	O
were	O
administered	O
for	O
8	O
weeks.	O

Intraocular	O
pressure	O
was	O
monitored	O
at	O
2,	O
4,	O
and	O
8	O
weeks	O
after	O
the	O
initiation	O
of	O
drug	O
instillation	O
for	O
evaluation	O
of	O
equivalence.	O

Intraocular	B-Premise
pressure	I-Premise
was	I-Premise
significantly	I-Premise
reduced	I-Premise
during	I-Premise
the	I-Premise
entire	I-Premise
follow-up	I-Premise
period	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

In	B-Premise
the	I-Premise
long-acting	I-Premise
drug	I-Premise
group,	I-Premise
the	I-Premise
reduction	I-Premise
of	I-Premise
intraocular	I-Premise
pressure	I-Premise
was	I-Premise
-3.5	I-Premise
+/-	I-Premise
0.2,	I-Premise
-4.3	I-Premise
+/-	I-Premise
0.2	I-Premise
and	I-Premise
-4.6	I-Premise
+/-	I-Premise
0.3	I-Premise
mmHg	I-Premise
at	I-Premise
2,	I-Premise
4,	I-Premise
and	I-Premise
8	I-Premise
weeks,	I-Premise
respectively	I-Premise
(paired	I-Premise
t	I-Premise
test).	I-Premise

In	B-Premise
the	I-Premise
currently-prescribed	I-Premise
drug	I-Premise
group,	I-Premise
the	I-Premise
reduction	I-Premise
of	I-Premise
intraocular	I-Premise
pressure	I-Premise
was	I-Premise
-4.1	I-Premise
+/-	I-Premise
0.2,	I-Premise
-4.4	I-Premise
+/-	I-Premise
0.3	I-Premise
and--4.6	I-Premise
+/-	I-Premise
0.2	I-Premise
mmHg	I-Premise
at	I-Premise
2,	I-Premise
4,	I-Premise
and	I-Premise
8	I-Premise
weeks(paired	I-Premise
t	I-Premise
test).	I-Premise

The	B-Claim
safety	I-Claim
profile	I-Claim
was	I-Claim
similar	I-Claim
in	I-Claim
both	I-Claim
groups,	I-Claim
and	I-Claim
the	I-Claim
tolerance	I-Claim
for	I-Claim
the	I-Claim
long-acting	I-Claim
eye	I-Claim
drops	I-Claim
was	I-Claim
as	I-Claim
good	I-Claim
as	I-Claim
for	I-Claim
the	I-Claim
currently-prescribed	I-Claim
eye	I-Claim
drops.	I-Claim

Because	B-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
both	I-Claim
drugs	I-Claim
was	I-Claim
equivalent,	I-Claim
with	I-Claim
an	I-Claim
identical	I-Claim
safety	I-Claim
profile,	I-Claim
the	B-Claim
long-acting	I-Claim
eye	I-Claim
drops	I-Claim
seem	I-Claim
to	I-Claim
be	I-Claim
an	I-Claim
efficacious	I-Claim
formulation	I-Claim
for	I-Claim
clinical	I-Claim
use	I-Claim
in	I-Claim
Japanese	I-Claim
glaucoma	I-Claim
patients.	I-Claim

To	O
compare	O
intraocular	O
pressure	O
(IOP)	O
control	O
and	O
other	O
clinical	O
outcomes	O
after	O
1-site	O
fornix-based	O
and	O
2-site	O
limbus-based	O
phacotrabeculectomy.	O

Prospective	O
randomized	O
controlled	O
trial.	O

A	O
total	O
of	O
90	O
eyes	O
of	O
76	O
patients	O
with	O
cataract	O
and	O
glaucoma	O
were	O
treated.	O

Forty-four	O
eyes	O
were	O
assigned	O
randomly	O
to	O
receive	O
a	O
1-site	O
phacotrabeculectomy	O
with	O
a	O
fornix-based	O
conjunctival	O
flap,	O
and	O
46	O
eyes	O
were	O
assigned	O
randomly	O
to	O
receive	O
a	O
2-site	O
phacotrabeculectomy	O
with	O
a	O
limbus-based	O
conjunctival	O
flap.	O

All	O
operations	O
were	O
performed	O
with	O
mitomycin	O
C.	O

Intraocular	O
pressure	O
and	O
number	O
of	O
antiglaucoma	O
medications	O
were	O
recorded	O
at	O
baseline	O
and	O
during	O
a	O
3-year	O
follow-up	O
period.	O

Mean	B-Premise
preoperative	I-Premise
IOP	I-Premise
was	I-Premise
20.1+/-3.8	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
1-site	I-Premise
group	I-Premise
and	I-Premise
19.5+/-5.3	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
2-site	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.56)	I-Premise
using	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
2.3+/-0.9	I-Premise
and	I-Premise
2.5+/-0.9	I-Premise
antiglaucoma	I-Premise
medications,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.27).	I-Premise

After	B-Premise
3	I-Premise
years	I-Premise
of	I-Premise
follow-up,	I-Premise
the	I-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
12.6+/-4.8	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
1-site	I-Premise
group	I-Premise
and	I-Premise
11.7+/-4.0	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
2-site	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.40),	I-Premise
receiving	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
0.3+/-0.7	I-Premise
and	I-Premise
0.4+/-0.9	I-Premise
medications,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.59).	I-Premise

At	B-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
study,	I-Premise
73%	I-Premise
of	I-Premise
1-site	I-Premise
eyes	I-Premise
and	I-Premise
78.4%	I-Premise
of	I-Premise
2-site	I-Premise
eyes	I-Premise
had	I-Premise
IOPs	I-Premise
of	I-Premise
less	I-Premise
than	I-Premise
18	I-Premise
mmHg	I-Premise
while	I-Premise
receiving	I-Premise
no	I-Premise
antiglaucoma	I-Premise
medications	I-Premise
(P	I-Premise
=	I-Premise
0.59).	I-Premise

Visual	B-Premise
acuity	I-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
both	I-Premise
groups	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
after	I-Premise
surgery.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
need	I-Premise
for	I-Premise
digital	I-Premise
pressure,	I-Premise
postoperative	I-Premise
bleb	I-Premise
needling	I-Premise
with	I-Premise
5-fluorouracil,	I-Premise
or	I-Premise
number	I-Premise
of	I-Premise
postoperative	I-Premise
visits.	I-Premise

There	O
were	O
2	O
major	O
complications	O
in	O
each	O
group	O
during	O
follow-up.	O

Early	B-Premise
leaks	I-Premise
of	I-Premise
the	I-Premise
conjunctival	I-Premise
wound	I-Premise
closure	I-Premise
occurred	I-Premise
in	I-Premise
6	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
1-site	I-Premise
group	I-Premise
and	I-Premise
in	I-Premise
0	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
2-site	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.03).	I-Premise

Operating	O
time	O
(in	O
minutes)	O
was	O
less	O
in	O
the	O
1-site	O
surgery	O
group	O
(P<0.0001).	O

Day	O
one	O
postoperative	O
IOP	O
was	O
higher	O
in	O
the	O
2-site	O
group	O
(P	O
=	O
0.0.01).	O

One-site	B-Claim
fornix-based	I-Claim
and	I-Claim
2-site	I-Claim
limbus-based	I-Claim
phacotrabeculectomy	I-Claim
were	I-Claim
similarly	I-Claim
effective	I-Claim
in	I-Claim
lowering	I-Claim
IOP	I-Claim
and	I-Claim
reducing	I-Claim
the	I-Claim
need	I-Claim
for	I-Claim
antiglaucoma	I-Claim
medications	I-Claim
over	I-Claim
a	I-Claim
3-year	I-Claim
follow-up	I-Claim
period.	I-Claim

To	O
evaluate	O
the	O
long-term	O
intraocular	O
pressure	O
(IOP)	O
control	O
of	O
trabeculectomy	O
and	O
triple	O
procedure	O
(cataract	O
extraction	O
by	O
phacoemulsification,	O
intraocular	O
lens	O
implantation	O
and	O
trabeculectomy),	O
1,542	O
eyes	O
of	O
900	O
patients	O
with	O
primary	O
open	O
angle	O
glaucoma	O
(POAG)	O
or	O
chronic	O
primary	O
angle	O
closure	O
glaucoma	O
(CPACG)	O
were	O
included.	O

When	O
success	O
was	O
defined	O
as	O
an	O
IOP	O
reduction	O
of	O
at	O
least	O
30%	O
from	O
baseline,	O
with	O
or	O
without	O
antiglaucoma	O
medications,	O
the	B-Premise
overall	I-Premise
probability	I-Premise
of	I-Premise
success	I-Premise
of	I-Premise
trabeculectomy	I-Premise
and	I-Premise
triple	I-Premise
procedure	I-Premise
was	I-Premise
0.613	I-Premise
and	I-Premise
0.733	I-Premise
at	I-Premise
15	I-Premise
years,	I-Premise
respectively.	I-Premise

The	B-Premise
success	I-Premise
probability	I-Premise
of	I-Premise
trabeculectomy	I-Premise
and	I-Premise
triple	I-Premise
procedure	I-Premise
in	I-Premise
reducing	I-Premise
IOP	I-Premise
below	I-Premise
18	I-Premise
mm	I-Premise
Hg	I-Premise
was	I-Premise
0.748	I-Premise
and	I-Premise
0.825	I-Premise
at	I-Premise
15	I-Premise
years,	I-Premise
respectively.	I-Premise

In	B-Claim
POAG	I-Claim
and	I-Claim
CPACG	I-Claim
patients,	I-Claim
trabeculectomy	I-Claim
and	I-Claim
triple	I-Claim
procedure	I-Claim
were	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
for	I-Claim
up	I-Claim
to	I-Claim
15	I-Claim
years	I-Claim
after	I-Claim
surgery.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
the	O
Ahmed	O
S2	O
Glaucoma	O
Valve	O
with	O
the	O
Baerveldt	O
250-mm(2)	O
Glaucoma	O
Implant	O
in	O
the	O
treatment	O
of	O
adult	O
glaucoma.	O

Comparative	O
case	O
series.	O

Fifty-nine	O
eyes	O
of	O
59	O
patients	O
who	O
received	O
the	O
Ahmed	O
S2	O
Glaucoma	O
Valve	O
and	O
133	O
eyes	O
of	O
133	O
patients	O
who	O
received	O
the	O
Baerveldt	O
250-mm(2)	O
Glaucoma	O
Implant	O
by	O
the	O
Indiana	O
University	O
Glaucoma	O
Service	O
from	O
1996	O
to	O
2003.	O

Eyes	O
that	O
had	O
previous	O
drainage	O
implant	O
procedures	O
were	O
excluded	O
from	O
both	O
groups.	O

If	O
both	O
eyes	O
of	O
a	O
single	O
patient	O
received	O
an	O
implant,	O
the	O
second	O
eye	O
to	O
undergo	O
implantation	O
was	O
excluded	O
from	O
the	O
study.	O

Kaplan-Meier	O
survival	O
with	O
success	O
defined	O
as	O
intraocular	O
pressure	O
(IOP)	O
>	O
5	O
mmHg	O
and	O
<	O
22	O
mmHg	O
and	O
at	O
least	O
20%	O
reduction	O
from	O
preoperative	O
IOP	O
(with	O
or	O
without	O
antiglaucoma	O
medications)	O
and	O
without	O
loss	O
of	O
light	O
perception.	O

Secondary	O
outcome	O
measures	O
included	O
intraocular	O
pressure,	O
visual	O
acuity,	O
number	O
of	O
glaucoma	O
medications,	O
and	O
surgical	O
complications.	O

The	O
2	O
groups	O
were	O
similar	O
with	O
regards	O
to	O
age,	O
gender,	O
race,	O
neovascular	O
glaucoma	O
diagnosis,	O
number	O
of	O
prior	O
ocular	O
surgeries,	O
preoperative	O
IOP,	O
and	O
number	O
of	O
preoperative	O
glaucoma	O
medications.	O

Mean	O
durations	O
of	O
follow-up	O
were	O
20.0	O
months	O
for	O
Ahmed	O
eyes	O
and	O
22.9	O
months	O
for	O
Baerveldt	O
eyes.	O

Cumulative	B-Premise
successes	I-Premise
in	I-Premise
the	I-Premise
Ahmed	I-Premise
group	I-Premise
were	I-Premise
0.73	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
and	I-Premise
0.62	I-Premise
at	I-Premise
2	I-Premise
years,	I-Premise
whereas	I-Premise
cumulative	I-Premise
successes	I-Premise
in	I-Premise
the	I-Premise
Baerveldt	I-Premise
group	I-Premise
were	I-Premise
0.92	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
and	I-Premise
0.85	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
(Kaplan-Meier	I-Premise
survival	I-Premise
functions:	I-Premise
P	I-Premise
=	I-Premise
0.03,	I-Premise
log	I-Premise
rank	I-Premise
test).	I-Premise

Male	B-Claim
gender,	I-Claim
African	I-Claim
descent,	I-Claim
neovascular	I-Claim
glaucoma,	I-Claim
and	I-Claim
Ahmed	I-Claim
implantation	I-Claim
were	I-Claim
found	I-Claim
to	I-Claim
be	I-Claim
significant	I-Claim
predictors	I-Claim
of	I-Claim
failure.	I-Claim

At	B-Premise
last	I-Premise
follow-up	I-Premise
visit,	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
Ahmed	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
significantly	I-Premise
higher	I-Premise
mean	I-Premise
IOP	I-Premise
(19.8+/-9.5	I-Premise
vs.	I-Premise
15.8+/-7.9	I-Premise
mmHg,	I-Premise
P	I-Premise
=	I-Premise
0.003,	I-Premise
t	I-Premise
test)	I-Premise
and	I-Premise
more	I-Premise
antiglaucoma	I-Premise
medications	I-Premise
(1.4+/-1.2	I-Premise
vs.	I-Premise
0.9+/-1.1	I-Premise
medications,	I-Premise
P	I-Premise
=	I-Premise
0.008,	I-Premise
Mann-Whitney	I-Premise
test)	I-Premise
than	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
Baerveldt	I-Premise
group.	I-Premise

Two	O
methods	O
for	O
avoiding	O
hypotony	O
after	O
Baerveldt	O
250-mm(2)	O
implantation	O
had	O
similar	O
outcomes.	O

Our	B-Claim
study	I-Claim
suggests	I-Claim
that	I-Claim
the	I-Claim
Ahmed	I-Claim
S2	I-Claim
Glaucoma	I-Claim
Valve	I-Claim
may	I-Claim
be	I-Claim
less	I-Claim
effective	I-Claim
at	I-Claim
lowering	I-Claim
IOP	I-Claim
than	I-Claim
the	I-Claim
Baerveldt	I-Claim
250-mm(2)	I-Claim
Glaucoma	I-Claim
Implant.	I-Claim

Efficacy	O
of	O
the	O
latanoprost	O
versus	O
timolol/dorzolamide	O
combination	O
therapy	O
in	O
patients	O
with	O
primary	O
open	O
angle	O
glaucoma	O

The	O
study	O
was	O
designed	O
as	O
a	O
6	O
months	O
randomized,	O
observer-masked	O
study	O
comprising	O
120	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
in	O
Feiz	O
Hospital,	O
Isfahan,	O
Iran,	O
from	O
2006	O
to	O
2007.	O

The	O
patients	O
were	O
randomized	O
(latanoprost,	O
n	O
=	O
60;	O
dorzolamide/timolol,	O
n	O
=	O
60)	O
to	O
treatment	O
with	O
either	O
latanoprost,	O
0.005%	O
once	O
daily,	O
or	O
the	O
combination	O
of	O
timolol	O
0.5%	O
twice	O
daily,	O
and	O
dorzolamide	O
2%	O
3	O
times	O
daily.	O

The	O
mean	O
intraocular	O
pressure	O
(IOP)	O
after	O
one,	O
3,	O
and	O
6	O
months	O
of	O
treatment	O
was	O
compared	O
with	O
baseline	O
in	O
the	O
2	O
groups.	O

A	O
total	O
of	O
120	O
patients	O
were	O
randomized	O
to	O
2	O
equal	O
treatment	O
groups.	O

The	O
mean	O
baseline	O
IOP	O
values	O
were	O
similar	O
between	O
the	O
2	O
groups.	O

The	B-Premise
mean	I-Premise
(standard	I-Premise
error	I-Premise
of	I-Premise
mean	I-Premise
[SE])	I-Premise
IOP	I-Premise
reductions	I-Premise
at	I-Premise
months	I-Premise
one	I-Premise
was	I-Premise
7.2	I-Premise
(0.4),	I-Premise
at	I-Premise
month	I-Premise
3	I-Premise
was	I-Premise
7.3	I-Premise
(0.4),	I-Premise
and	I-Premise
at	I-Premise
month	I-Premise
6	I-Premise
was	I-Premise
7.1	I-Premise
(0.3)	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
and	I-Premise
7.5	I-Premise
(0.3),	I-Premise
7.8	I-Premise
(0.3),	I-Premise
and	I-Premise
7.4	I-Premise
(0.3)	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
group.	I-Premise

The	B-Claim
2	I-Claim
therapies	I-Claim
were	I-Claim
similarly	I-Claim
effective.	I-Claim

The	B-Claim
latanoprost	I-Claim
and	I-Claim
dorzolamide/timolol	I-Claim
combination	I-Claim
were	I-Claim
equally	I-Claim
effective	I-Claim
at	I-Claim
lowering	I-Claim
IOP	I-Claim
compared	I-Claim
to	I-Claim
untreated	I-Claim
baseline.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
brimonidine	O
purite	O
0.1%	O
in	O
comparison	O
to	O
brinzolamide	O
1%	O
when	O
used	O
as	O
adjunctive	O
therapy	O
to	O
latanoprost	O
0.005%	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension.	O

Randomized,	O
single-center,	O
investigator-masked,	O
parallel-group	O
clinical	O
study.	O

Patients	O
with	O
IOP	O
>or=	O
18	O
mmHg	O
while	O
on	O
once-daily	O
latanoprost	O
were	O
randomized	O
to	O
adjunctive	O
treatment	O
with	O
brimonidine	O
purite	O
TID	O
(n	O
=	O
20)	O
or	O
brinzolamide	O
TID	O
(n	O
=	O
20)	O
for	O
3	O
months.	O

Intraocular	O
pressure	O
(IOP)	O
was	O
measured	O
at	O
8	O
a.m.,	O
10	O
a.m.,	O
and	O
4	O
p.m.	O
at	O
latanoprost-treated	O
baseline	O
and	O
after	O
1	O
and	O
3	O
months	O
of	O
latanoprost	O
and	O
adjunctive	O
therapy.	O

A	O
patient	O
questionnaire	O
was	O
administered	O
to	O
evaluate	O
the	O
tolerability	O
of	O
eye	O
drop	O
instillation.	O

Baseline	B-Premise
mean	I-Premise
diurnal	I-Premise
IOP	I-Premise
(+/-	I-Premise
standard	I-Premise
deviation,	I-Premise
mmHg)	I-Premise
on	I-Premise
latanoprost	I-Premise
was	I-Premise
comparable	I-Premise
between	I-Premise
groups	I-Premise
(brimonidine	I-Premise
purite:	I-Premise
19.6	I-Premise
+/-	I-Premise
2.94;	I-Premise
brinzolamide:	I-Premise
19.8	I-Premise
+/-	I-Premise
3.25;	I-Premise
p	I-Premise
=	I-Premise
0.846).	I-Premise

Mean	B-Premise
diurnal	I-Premise
IOP	I-Premise
at	I-Premise
Month	I-Premise
3	I-Premise
was	I-Premise
16.3	I-Premise
+/-	I-Premise
2.63	I-Premise
mmHg	I-Premise
with	I-Premise
brimonidine	I-Premise
purite	I-Premise
and	I-Premise
17.8	I-Premise
+/-	I-Premise
2.19	I-Premise
mmHg	I-Premise
with	I-Premise
brinzolamide	I-Premise
(p	I-Premise
=	I-Premise
0.028).	I-Premise

Adjunctive	B-Premise
use	I-Premise
of	I-Premise
brimonidine	I-Premise
purite	I-Premise
provided	I-Premise
greater	I-Premise
IOP	I-Premise
lowering	I-Premise
than	I-Premise
brinzolamide	I-Premise
at	I-Premise
10	I-Premise
a.m.	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
4	I-Premise
p.m.	I-Premise
(p	I-Premise
=	I-Premise
0.050)	I-Premise
and	I-Premise
equivalent	I-Premise
IOP	I-Premise
lowering	I-Premise
to	I-Premise
brinzolamide	I-Premise
at	I-Premise
8	I-Premise
a.m.	I-Premise
(p	I-Premise
=	I-Premise
0.716).	I-Premise

Blurred	B-Premise
vision	I-Premise
at	I-Premise
Month	I-Premise
1	I-Premise
and	I-Premise
bitter	I-Premise
taste	I-Premise
at	I-Premise
Months	I-Premise
1	I-Premise
and	I-Premise
3	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
upon	I-Premise
instillation	I-Premise
of	I-Premise
brinzolamide	I-Premise
eye	I-Premise
drops.	I-Premise

Brimonidine	B-Claim
purite	I-Claim
0.1%	I-Claim
provided	I-Claim
significantly	I-Claim
lower	I-Claim
IOP	I-Claim
compared	I-Claim
with	I-Claim
brinzolamide	I-Claim
1%	I-Claim
when	I-Claim
used	I-Claim
as	I-Claim
adjunctive	I-Claim
therapy	I-Claim
to	I-Claim
latanoprost.	I-Claim

Both	B-Claim
adjunctive	I-Claim
therapies	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

Limitations	B-Premise
of	I-Premise
this	I-Premise
study	I-Premise
include	I-Premise
the	I-Premise
use	I-Premise
of	I-Premise
a	I-Premise
single	I-Premise
site	I-Premise
and	I-Premise
the	I-Premise
sample	I-Premise
size.	I-Premise

Additional	B-Claim
studies	I-Claim
are	I-Claim
needed	I-Claim
to	I-Claim
further	I-Claim
evaluate	I-Claim
these	I-Claim
drugs	I-Claim
as	I-Claim
adjunctive	I-Claim
therapy	I-Claim
to	I-Claim
prostaglandin	I-Claim
analogs.	I-Claim

We	O
conducted	O
a	O
prospective,	O
randomized	O
study	O
to	O
compare	O
mitomycin	O
with	O
fluorouracil	O
for	O
efficacy	O
and	O
safety	O
as	O
an	O
adjunct	O
to	O
trabeculectomy	O
in	O
eyes	O
with	O
glaucoma	O
with	O
poor	O
surgical	O
prognosis.	O

Thirty-two	O
eyes	O
of	O
32	O
patients	O
were	O
randomly	O
allocated	O
to	O
either	O
mitomycin	O
(17	O
eyes)	O
or	O
fluorouracil	O
therapy	O
(15	O
eyes).	O

Mitomycin	O
(0.2	O
mg)	O
was	O
applied	O
only	O
once	O
during	O
trabeculectomy,	O
and	O
fluorouracil	O
(5	O
mg)	O
was	O
subconjunctivally	O
injected	O
10	O
times	O
in	O
the	O
2	O
weeks	O
after	O
surgery.	O

Fifteen	B-Premise
eyes	I-Premise
(88%)	I-Premise
in	I-Premise
the	I-Premise
mitomycin	I-Premise
group	I-Premise
and	I-Premise
seven	I-Premise
(47%)	I-Premise
in	I-Premise
the	I-Premise
fluorouracil	I-Premise
group	I-Premise
achieved	I-Premise
an	I-Premise
intraocular	I-Premise
pressure	I-Premise
of	I-Premise
less	I-Premise
than	I-Premise
or	I-Premise
equal	I-Premise
to	I-Premise
20	I-Premise
mm	I-Premise
Hg	I-Premise
without	I-Premise
antiglaucoma	I-Premise
medication.	I-Premise

The	O
follow-up	O
period	O
was	O
7	O
to	O
12	O
months.	O

Corneal	B-Premise
complications	I-Premise
were	I-Premise
less	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
group	I-Premise
given	I-Premise
mitomycin	I-Premise
than	I-Premise
in	I-Premise
that	I-Premise
given	I-Premise
fluorouracil	I-Premise
(12%	I-Premise
vs	I-Premise
53%).	I-Premise

The	B-Claim
incidence	I-Claim
of	I-Claim
other	I-Claim
complications	I-Claim
was	I-Claim
similar	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
groups.	I-Claim

Trabeculectomy	O
is	O
a	O
commonly	O
used	O
surgical	O
treatment	O
for	O
glaucoma.	O

To	O
evaluate	O
the	O
effectiveness	O
of	O
combination	O
of	O
permanent	O
and	O
releasable	O
scleral	O
flap	O
sutures	O
to	O
minimize	O
the	O
immediate	O
postoperative	O
complications	O
of	O
trabeculectomy.	O

This	O
study	O
was	O
carried	O
out	O
in	O
Department	O
of	O
Ophthalmology,	O
B	O
P	O
Koirala	O
Institute	O
of	O
Health	O
Sciences,	O
Dharan,	O
Nepal.	O

Forty	O
one	O
eyes	O
of	O
34	O
patients	O
undergoing	O
trabeculectomy	O
were	O
randomized	O
to	O
undergo	O
either	O
conventional	O
trabeculectomy	O
(Group	O
A=	O
20	O
eyes)	O
or	O
trabeculectomy	O
with	O
combination	O
of	O
permanent	O
and	O
releasable	O
scleral	O
flap	O
sutures	O
(Group	O
B	O
=21	O
eyes).	O

The	O
parameters	O
studied	O
were	O
intraocular	O
pressure	O
(IOP),	O
anterior	O
chamber	O
depth	O
(ACD)	O
and	O
surgical	O
complications	O
over	O
a	O
period	O
of	O
6	O
weeks.	O

Significantly	B-Premise
higher	I-Premise
number	I-Premise
of	I-Premise
eyes	I-Premise
belonging	I-Premise
to	I-Premise
group	I-Premise
A	I-Premise
(14	I-Premise
eyes)	I-Premise
had	I-Premise
shallower	I-Premise
anterior	I-Premise
chamber	I-Premise
than	I-Premise
group	I-Premise
B	I-Premise
(7	I-Premise
eyes)	I-Premise
on	I-Premise
first	I-Premise
post	I-Premise
operative	I-Premise
day	I-Premise
(p=0.042).	I-Premise

Six	B-Premise
eyes	I-Premise
(30%)	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
had	I-Premise
peripheral	I-Premise
or	I-Premise
central	I-Premise
irido-corneal	I-Premise
touch	I-Premise
in	I-Premise
early	I-Premise
postoperative	I-Premise
period	I-Premise
as	I-Premise
compared	I-Premise
to	I-Premise
only	I-Premise
one	I-Premise
in	I-Premise
Group	I-Premise
B.	I-Premise
Hypotony	B-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
3	I-Premise
eyes	I-Premise
in	I-Premise
each	I-Premise
group.	I-Premise

Two	O
patients	O
in	O
group	O
A	O
required	O
reformation	O
of	O
anterior	O
chamber.	O

Other	O
surgical	O
complications	O
in	O
the	O
two	O
groups	O
were	O
similar.	O

Both	B-Claim
the	I-Claim
groups	I-Claim
had	I-Claim
a	I-Claim
significant	I-Claim
drop	I-Claim
in	I-Claim
IOP	I-Claim
following	I-Claim
surgery.	I-Claim

However,	O
there	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
IOP	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
after	I-Premise
6	I-Premise
weeks	I-Premise
(Group	I-Premise
A:	I-Premise
10.95	I-Premise
+/-	I-Premise
3.03	I-Premise
mmHg	I-Premise
vs.	I-Premise
Group	I-Premise
B:	I-Premise
12.29	I-Premise
+/-	I-Premise
4.67	I-Premise
mmHg;	I-Premise
p=0.87).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
drop	I-Premise
in	I-Premise
IOP	I-Premise
following	I-Premise
removal	I-Premise
of	I-Premise
sutures	I-Premise
(15.19	I-Premise
+/-	I-Premise
6.15	I-Premise
mmHg	I-Premise
to	I-Premise
13.19	I-Premise
+/-	I-Premise
6.13	I-Premise
mmHg;	I-Premise
p=006)	I-Premise
in	I-Premise
group	I-Premise
B.	I-Premise

Use	B-Claim
of	I-Claim
combination	I-Claim
of	I-Claim
permanent	I-Claim
and	I-Claim
releasable	I-Claim
scleral	I-Claim
flap	I-Claim
sutures	I-Claim
is	I-Claim
a	I-Claim
safe	I-Claim
technique	I-Claim
that	I-Claim
significantly	I-Claim
reduces	I-Claim
the	I-Claim
incidence	I-Claim
of	I-Claim
immediate	I-Claim
postoperative	I-Claim
shallow	I-Claim
anterior	I-Claim
chamber	I-Claim
after	I-Claim
trabeculectomy.	I-Claim

To	O
compare	O
the	O
IOP-lowering	O
efficacy	O
of	O
a.m.-dosed	O
travoprost	O
and	O
latanoprost	O
at	O
24-h	O
post-dose.	O

Open-angle	O
glaucoma	O
patients	O
not	O
nave	O
to	O
prostaglandin	O
therapy	O
and	O
currently	O
controlled	O
on	O
p.m.-dosed	O
(2100)	O
latanoprost	O
(n	O
=	O
21)	O
or	O
travoprost	O
(n	O
=	O
30)	O
had	O
baseline	O
IOPs	O
measured	O
at	O
0900.	O

In	O
a	O
randomized,	O
single-masked,	O
crossover	O
design,	O
patients	O
received	O
travoprost	O
(Travatan	O
	O
)	O
or	O
latanoprost	O
(Xalatan	O
	O
)	O
at	O
0900	O
for	O
4	O
weeks,	O
then	O
were	O
crossed	O
over	O
to	O
receive	O
the	O
second	O
prostaglandin	O
for	O
another	O
4	O
weeks.	O

Treatment	O
IOP	O
was	O
measured	O
at	O
0900	O
prior	O
to	O
morning	O
dose	O
at	O
both	O
4	O
and	O
8	O
week	O
visits.	O

Patient	O
dosing	O
preference	O
(a.m./p.m.)	O

was	O
surveyed	O
on	O
exit.	O

Main	O
outcome	O
measure:	O
Intraocular	O
pressure	O
(IOP).	O

	O
Travatan	O
is	O
a	O
registered	O
trade	O
name	O
of	O
Alcon	O
Laboratories,	O
Inc.,	O
Fort	O
Worth,	O
TX,	O
USA	O
	O
Xalatan	O
is	O
a	O
registered	O
trade	O
name	O
of	O
Pfizer,	O
New	O
York,	O
NY,	O
USA.	O

The	B-Premise
mean	I-Premise
IOP	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
period	I-Premise
when	I-Premise
all	I-Premise
patients	I-Premise
were	I-Premise
dosed	I-Premise
in	I-Premise
the	I-Premise
evening	I-Premise
was	I-Premise
assessed	I-Premise
12	I-Premise
h	I-Premise
after	I-Premise
dosing	I-Premise
at	I-Premise
09:00	I-Premise
and	I-Premise
it	I-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
groups	I-Premise
(mean	I-Premise
+/-	I-Premise
standard	I-Premise
deviation:	I-Premise
17.9	I-Premise
+/-	I-Premise
2.7	I-Premise
mmHg	I-Premise
for	I-Premise
travoprost	I-Premise
versus	I-Premise
17.7	I-Premise
+/-	I-Premise
2.5	I-Premise
mmHg	I-Premise
for	I-Premise
latanoprost,	I-Premise
p	I-Premise
=	I-Premise
0.812).	I-Premise

In	B-Premise
the	I-Premise
a.m.-dosing	I-Premise
crossover	I-Premise
comparison,	I-Premise
the	I-Premise
24-h	I-Premise
post-dose	I-Premise
IOP	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
(	I-Premise
p	I-Premise
<	I-Premise
0.001)	I-Premise
on	I-Premise
travoprost	I-Premise
(16.9	I-Premise
+/-	I-Premise
3.1	I-Premise
mmHg)	I-Premise
compared	I-Premise
to	I-Premise
latanoprost	I-Premise
(18.6	I-Premise
+/-	I-Premise
3.3	I-Premise
mmHg).	I-Premise

In	O
the	O
exit	O
survey,	O
51%	O
of	O
patients	O
preferred	O
a.m.-dosing.	O

a.m.-dosed	B-Claim
travoprost	I-Claim
is	I-Claim
superior	I-Claim
to	I-Claim
a.m.-dosed	I-Claim
latanoprost	I-Claim
by	I-Claim
1.7	I-Claim
mmHg	I-Claim
at	I-Claim
24-h	I-Claim
post-dose.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
the	O
fixed	O
combination	O
of	O
timolol	O
maleate	O
0.5%/brimonidine	O
tartrate	O
0.2%	O
versus	O
fixed	O
combination	O
of	O
timolol	O
maleate	O
0.5%/dorzolamide	O
2%	O
in	O
patients	O
with	O
elevated	O
intraocular	O
pressure	O
(IOP)	O
over	O
8	O
weeks.	O

This	O
8-week,	O
multicentric,	O
interventional,	O
randomized,	O
open-label,	O
parallel	O
group	O
study	O
was	O
conducted	O
at	O
4	O
centers	O
in	O
Brazil	O
and	O
1	O
center	O
in	O
Argentina.	O

Patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
were	O
randomized	O
to	O
receive	O
bilaterally	O
fixed	O
combination	O
of	O
brimonidine/timolol	O
maleate	O
0.5%	O
or	O
fixed	O
combination	O
of	O
dorzolamide	O
2%/timolol	O
0.5%	O
twice	O
daily	O
at	O
8:00	O
AM	O
and	O
8:00	O
PM.	O

A	O
modified	O
diurnal	O
tension	O
curve	O
(8:00	O
AM,	O
10:30	O
AM,	O
02:00	O
PM,	O
and	O
4:00	O
PM)	O
followed	O
by	O
the	O
water	O
drinking	O
test	O
(WDT),	O
which	O
estimates	O
IOP	O
peak	O
of	O
diurnal	O
tension	O
curve,	O
were	O
performed	O
in	O
the	O
baseline	O
and	O
week-8	O
visits.	O

Adverse	O
events	O
data	O
were	O
recorded	O
at	O
each	O
visit.	O

A	O
total	O
of	O
210	O
patients	O
were	O
randomized	O
(brimonidine/timolol,	O
n=111;	O
dorzolamide/timolol,	O
n=99).	O

Mean	O
baseline	O
IOP	O
was	O
23.43+/-3.22	O
mm	O
Hg	O
and	O
23.43+/-4.06	O
mm	O
Hg	O
in	O
the	O
patients	O
treated	O
with	O
brimonidine/timolol	O
and	O
dorzolamide/timolol,	O
respectively	O
(P=0.993).	O

Mean	B-Premise
diurnal	I-Premise
IOP	I-Premise
reduction	I-Premise
after	I-Premise
8	I-Premise
weeks	I-Premise
were	I-Premise
7.02+/-3.06	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
6.91+/-3.67	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively	I-Premise
(P=0.811).	I-Premise

The	B-Premise
adjusted	I-Premise
difference	I-Premise
between	I-Premise
groups	I-Premise
(analysis	I-Premise
of	I-Premise
covariance)	I-Premise
at	I-Premise
week	I-Premise
8	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(P=0.847).	I-Premise

Mean	B-Premise
baseline	I-Premise
WDT	I-Premise
peak	I-Premise
was	I-Premise
27.79+/-4.29	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
brimonidine/timolol	I-Premise
group	I-Premise
and	I-Premise
27.68+/-5.46	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
dorzolamide/timolol	I-Premise
group.	I-Premise

After	B-Premise
8	I-Premise
weeks	I-Premise
of	I-Premise
treatment,	I-Premise
mean	I-Premise
WDT	I-Premise
peaks	I-Premise
were	I-Premise
20.94+/-3.76	I-Premise
mm	I-Premise
Hg	I-Premise
(P<0.001)	I-Premise
and	I-Premise
20.98+/-4.19	I-Premise
(P<0.001),	I-Premise
respectively.	I-Premise

The	O
adjusted	O
difference	O
between	O
groups	O
(analysis	O
of	O
covariance)	O
was	O
not	O
statistically	O
significant	O
(P=0.469).	O

No	B-Premise
statistical	I-Premise
difference	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
was	I-Premise
found	I-Premise
between	I-Premise
groups.	I-Premise

Both	B-Claim
fixed	I-Claim
combinations	I-Claim
were	I-Claim
capable	I-Claim
of	I-Claim
significantly	I-Claim
reducing	I-Claim
the	I-Claim
mean	I-Claim
diurnal	I-Claim
IOP,	I-Claim
mean	I-Claim
diurnal	I-Claim
peak,	I-Claim
and	I-Claim
mean	I-Claim
WDT	I-Claim
peak	I-Claim
after	I-Claim
8	I-Claim
weeks	I-Claim
of	I-Claim
treatment.	I-Claim

Also,	O
both	B-Claim
fixed	I-Claim
combinations	I-Claim
are	I-Claim
well	I-Claim
tolerated	I-Claim
with	I-Claim
few	I-Claim
side	I-Claim
effects.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
once-daily	O
evening	O
dose	O
of	O
bimatoprost/timolol	O
fixed	O
combination	O
(BTFC)	O
with	O
that	O
of	O
a	O
once-daily	O
evening	O
dose	O
of	O
latanoprost/timolol	O
fixed	O
combination	O
(LTFC)	O
in	O
patients	O
not	O
controlled	O
with	O
prostaglandins	O
analogues	O
monotherapy.	O

A	O
total	O
of	O
82	O
patients	O
on	O
prostaglandin	O
analogues	O
monotherapy	O
were	O
enrolled	O
in	O
this	O
prospective,	O
multicenter,	O
investigator	O
masked,	O
clinical	O
study	O
and	O
were	O
randomized	O
to	O
either	O
BTFC	O
(n=47)	O
or	O
LTFC	O
(n=35)	O
topical	O
therapy	O
once	O
at	O
night	O
for	O
12	O
weeks.	O

The	O
primary	O
endpoint	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
mean	O
daily	O
intraocular	O
pressure	O
(IOP)	O
reduction	O
from	O
baseline	O
between	O
the	O
two	O
treatment	O
arms.	O

Secondary	O
endpoints	O
included	O
the	O
mean	O
daily	O
IOP	O
at	O
1	O
and	O
3	O
months	O
compared	O
to	O
baseline	O
and	O
the	O
percentage	O
of	O
patients	O
showing	O
a	O
mean	O
IOP	O
reduction	O
from	O
baseline	O
greater	O
than	O
or	O
equal	O
to	O
15%	O
or	O
20%.	O

Mean	O
IOP	O
at	O
baseline	O
was	O
22.7+/-2.0	O
and	O
22.1+/-2.6	O
mmHg	O
in	O
the	O
BTFC	O
and	O
LTFC	O
groups,	O
respectively	O
(p=0.23).	O

Both	O
treatments	O
were	O
effective	O
in	O
reducing	O
the	O
IOP	O
from	O
baseline.	O

The	B-Premise
mean	I-Premise
IOP	I-Premise
reduction	I-Premise
was	I-Premise
significantly	I-Premise
greater	I-Premise
in	I-Premise
the	I-Premise
BTFC	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
LTFC	I-Premise
group	I-Premise
(-21.4%	I-Premise
vs	I-Premise
-13.7%,	I-Premise
p<0.001).	I-Premise

A	B-Premise
higher	I-Premise
percentage	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
BTFC	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
mean	I-Premise
IOP	I-Premise
reduction	I-Premise
from	I-Premise
baseline	I-Premise
>or=15%	I-Premise
(72.3%	I-Premise
vs	I-Premise
40.0%)	I-Premise
and	I-Premise
>or=20%	I-Premise
(61.7%	I-Premise
vs	I-Premise
17.1%)	I-Premise
compared	I-Premise
to	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
LTFC	I-Premise
group.	I-Premise

Both	B-Claim
BTFC	I-Claim
and	I-Claim
LTFC	I-Claim
were	I-Claim
more	I-Claim
effective	I-Claim
versus	I-Claim
the	I-Claim
monotherapy	I-Claim
with	I-Claim
prostaglandin	I-Claim
analogues.	I-Claim

BTFC	B-Claim
demonstrated	I-Claim
higher	I-Claim
performance	I-Claim
than	I-Claim
LTFC	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
relative	I-Claim
IOP	I-Claim
reduction.	I-Claim

To	O
compare	O
phacoemulsification	O
alone	O
versus	O
combined	O
phacotrabeculectomy	O
in	O
medically	O
uncontrolled	O
chronic	O
angle	O
closure	O
glaucoma	O
(CACG)	O
with	O
coexisting	O
cataract.	O

Prospective	O
randomized	O
clinical	O
trial.	O

Fifty-one	O
medically	O
uncontrolled	O
CACG	O
eyes	O
with	O
coexisting	O
cataract	O
of	O
51	O
patients.	O

Recruited	O
patients	O
were	O
randomized	O
into	O
group	O
1	O
(phacoemulsification	O
alone)	O
or	O
group	O
2	O
(combined	O
phacotrabeculectomy	O
with	O
adjunctive	O
mitomycin	O
C).	O

Postoperatively,	O
patients	O
were	O
reviewed	O
every	O
3	O
months	O
for	O
2	O
years.	O

Intraocular	O
pressure	O
(IOP)	O
and	O
requirement	O
for	O
topical	O
glaucoma	O
drugs.	O

Twenty-seven	O
CACG	O
eyes	O
were	O
randomized	O
into	O
group	O
1,	O
and	O
24	O
CACG	O
eyes	O
were	O
randomized	O
into	O
group	O
2.	O

Combined	B-Premise
phacotrabeculectomy	I-Premise
resulted	I-Premise
in	I-Premise
lower	I-Premise
mean	I-Premise
postoperative	I-Premise
IOP	I-Premise
than	I-Premise
phacoemulsification	I-Premise
alone	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
(14.0	I-Premise
vs	I-Premise
17.0	I-Premise
mmHg,	I-Premise
P	I-Premise
=	I-Premise
0.01),	I-Premise
15	I-Premise
months	I-Premise
(13.2	I-Premise
vs	I-Premise
15.4	I-Premise
mmHg,	I-Premise
P	I-Premise
=	I-Premise
0.02),	I-Premise
and	I-Premise
18	I-Premise
months	I-Premise
(13.6	I-Premise
vs	I-Premise
15.9	I-Premise
mmHg,	I-Premise
P	I-Premise
=	I-Premise
0.01).	I-Premise

Combined	B-Premise
phacotrabeculectomy	I-Premise
resulted	I-Premise
in	I-Premise
1.25	I-Premise
fewer	I-Premise
topical	I-Premise
glaucoma	I-Premise
drugs	I-Premise
(P<0.001)	I-Premise
in	I-Premise
the	I-Premise
24-month	I-Premise
postoperative	I-Premise
period,	I-Premise
compared	I-Premise
with	I-Premise
phacoemulsification	I-Premise
alone.	I-Premise

Combined	B-Premise
surgery	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
more	I-Premise
postoperative	I-Premise
complications	I-Premise
(P<0.001)	I-Premise
and	I-Premise
more	I-Premise
progression	I-Premise
of	I-Premise
optic	I-Premise
neuropathy	I-Premise
(P	I-Premise
=	I-Premise
0.03),	I-Premise
compared	I-Premise
with	I-Premise
phacoemulsification	I-Premise
alone.	I-Premise

Combined	B-Claim
phacotrabeculectomy	I-Claim
with	I-Claim
adjunctive	I-Claim
mitomycin	I-Claim
C	I-Claim
is	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
phacoemulsification	I-Claim
alone	I-Claim
in	I-Claim
controlling	I-Claim
IOP	I-Claim
in	I-Claim
medically	I-Claim
uncontrolled	I-Claim
CACG	I-Claim
eyes	I-Claim
with	I-Claim
coexisting	I-Claim
cataract.	I-Claim

Combined	B-Claim
phacotrabeculectomy	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
more	I-Claim
postoperative	I-Claim
complications.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure	O
(IOP)	O
lowering	O
efficacy	O
and	O
side	O
effects	O
of	O
latanoprost	O
0.005%	O
and	O
bimatoprost	O
0.03%	O
in	O
subjects	O
with	O
chronic	O
primary	O
angle	O
closure	O
glaucoma	O
(PACG).	O

This	O
was	O
an	O
observer-masked	O
randomised	O
crossover	O
study	O
of	O
60	O
PACG	O
subjects	O
who	O
received	O
either	O
latanoprost	O
or	O
bimatoprost	O
for	O
6	O
weeks,	O
after	O
which	O
they	O
were	O
crossed	O
over	O
to	O
the	O
other	O
medication	O
for	O
another	O
6	O
weeks.	O

The	O
IOP-reducing	O
effect	O
of	O
the	O
medications	O
was	O
assessed	O
by	O
the	O
reduction	O
in	O
IOP	O
after	O
6	O
weeks	O
of	O
treatment	O
compared	O
with	O
baseline.	O

Fifty-four	O
subjects	O
(80	O
eyes)	O
completed	O
the	O
study.	O

Latanoprost	B-Premise
reduced	I-Premise
IOP	I-Premise
(mean	I-Premise
(SD))	I-Premise
by	I-Premise
8.4	I-Premise
(3.8)	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
bimatoprost	I-Premise
by	I-Premise
8.9	I-Premise
(3.9)	I-Premise
mm	I-Premise
Hg	I-Premise
from	I-Premise
a	I-Premise
baseline	I-Premise
of	I-Premise
25.2	I-Premise
(3.6)	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
25.2	I-Premise
(3.6)	I-Premise
mm	I-Premise
Hg	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
0.23).	I-Premise

Adverse	B-Premise
events	I-Premise
were	I-Premise
mild	I-Premise
in	I-Premise
both	I-Premise
groups;	I-Premise
however	B-Premise
there	I-Premise
were	I-Premise
twice	I-Premise
as	I-Premise
many	I-Premise
reports	I-Premise
of	I-Premise
an	I-Premise
adverse	I-Premise
event	I-Premise
in	I-Premise
the	I-Premise
bimatoprost	I-Premise
group	I-Premise
(81%)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
(40%,	I-Premise
p<0.01).	I-Premise

Ocular	O
irritation	O
was	O
the	O
most	O
frequently	O
reported	O
adverse	O
event	O
in	O
both	O
groups;	O
22	B-Premise
subjects	I-Premise
(37.9%)	I-Premise
treated	I-Premise
with	I-Premise
bimatoprost	I-Premise
experienced	I-Premise
ocular	I-Premise
hyperaemia	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
13	I-Premise
subjects	I-Premise
(22.4%)	I-Premise
treated	I-Premise
with	I-Premise
latanoprost	I-Premise
(p	I-Premise
=	I-Premise
0.11).	I-Premise

Bimatoprost	B-Claim
once	I-Claim
daily	I-Claim
was	I-Claim
similarly	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
compared	I-Claim
with	I-Claim
latanoprost	I-Claim
once	I-Claim
daily	I-Claim
in	I-Claim
subjects	I-Claim
with	I-Claim
chronic	I-Claim
PACG.	I-Claim

Both	B-Claim
drugs	I-Claim
were	I-Claim
well	I-Claim
tolerated	I-Claim
with	I-Claim
mild	I-Claim
ocular	I-Claim
adverse	I-Claim
events.	I-Claim

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
establish	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
Ex-PRESS	O
(Optonol	O
Ltd.,	O
Neve	O
Ilan,	O
Israel)	O
mini	O
glaucoma	O
shunt	O
in	O
open-angle	O
glaucoma.	O

This	O
was	O
a	O
prospective,	O
randomized	O
trial.	O

Eyes	O
from	O
enrolled	O
patients	O
were	O
randomly	O
assigned	O
to	O
either	O
Ex-PRESS	O
implantation	O
under	O
a	O
scleral	O
flap,	O
or	O
trabeculectomy.	O

The	O
main	O
outcome	O
measures	O
were:	O
mean	O
intraocular	O
pressure	O
(IOP),	O
postoperative	O
medication	O
use,	O
visual	O
acuity,	O
and	O
incidence	O
of	O
complications.	O

Complete	O
success	O
was	O
defined	O
as	O
an	O
IOP	O
of	O
>4	O
mmHg	O
and	O
<or=18	O
mmHg	O
without	O
the	O
use	O
of	O
antiglaucoma	O
medications.	O

A	O
more	O
stringent	O
target	O
of	O
IOP	O
>4	O
mmHg	O
and	O
<or=15	O
mmHg	O
was	O
also	O
noted.	O

There	O
were	O
78	O
patients	O
(80	O
eyes)	O
with	O
primary	O
open-angle,	O
pseudoexfoliative,	O
or	O
pigmentary	O
glaucoma	O
enrolled	O
in	O
the	O
study.	O

A	O
total	O
of	O
84.6%	O
of	O
patients	O
receiving	O
Ex-PRESS	O
and	O
60.0%	O
of	O
patients	O
receiving	O
trabeculectomy	O
(P=0.0230)	O
achieved	O
complete	O
success.	O

The	O
respective	O
proportions	O
of	O
patients	O
achieving	O
an	O
IOP	O
>4	O
mmHg	O
and	O
<or=15	O
mmHg	O
were	O
76.9%	O
and	O
50.0%	O
(P=0.0193).	O

At	B-Premise
1-year	I-Premise
follow-up,	I-Premise
complete	I-Premise
success	I-Premise
rates	I-Premise
were	I-Premise
81.8%	I-Premise
for	I-Premise
Ex-PRESS	I-Premise
and	I-Premise
47.5%	I-Premise
for	I-Premise
trabeculectomy	I-Premise
(P=0.0020),	I-Premise
and	I-Premise
71.7%	I-Premise
and	I-Premise
37.5%	I-Premise
(P=0.0070),	I-Premise
respectively,	I-Premise
for	I-Premise
the	I-Premise
more	I-Premise
stringent	I-Premise
target.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
similar	I-Premise
level	I-Premise
of	I-Premise
postoperative	I-Premise
interventions	I-Premise
and	I-Premise
complications	I-Premise
for	I-Premise
each	I-Premise
group.	I-Premise

In	B-Claim
open-angle	I-Claim
glaucoma,	I-Claim
the	I-Claim
Ex-PRESS	I-Claim
mini	I-Claim
glaucoma	I-Claim
shunt	I-Claim
implanted	I-Claim
under	I-Claim
a	I-Claim
superficial	I-Claim
scleral	I-Claim
flap	I-Claim
produces	I-Claim
significantly	I-Claim
higher	I-Claim
success	I-Claim
rates,	I-Claim
and	I-Claim
a	I-Claim
similar	I-Claim
complication	I-Claim
rate,	I-Claim
compared	I-Claim
with	I-Claim
trabeculectomy.	I-Claim

The	B-Claim
Ex-PRESS	I-Claim
is	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
device	I-Claim
for	I-Claim
treating	I-Claim
open-angle	I-Claim
glaucoma.	I-Claim

To	O
compare	O
the	O
long-term	O
efficacy	O
and	O
safety	O
of	O
combined	O
trabeculectomy	O
and	O
cataract	O
extraction	O
versus	O
trabeculectomy	O
alone	O
in	O
primary	O
angle-closure	O
glaucoma	O
(PACG).	O

Hospital	O
files	O
were	O
retrospectively	O
examined	O
for	O
99	O
Chinese	O
PACG	O
patients;	O
75	O
patients	O
underwent	O
combined	O
surgery	O
and	O
24	O
underwent	O
trabeculectomy	O
alone.	O

Success	O
rates	O
were	O
assessed	O
with	O
the	O
Kaplan-Meier	O
survival	O
analysis.	O

The	O
main	O
outcome	O
was	O
the	O
complete	O
success	O
rate	O
defined	O
as	O
either	O
a	O
>20%	O
reduction	O
in	O
intraocular	O
pressure	O
(IOP)	O
or	O
an	O
IOP	O
that	O
remained	O
below	O
15	O
mm	O
Hg,	O
with	O
no	O
medications	O
required.	O

Patients	O
in	O
the	O
combined	O
group	O
and	O
trabeculectomy	O
group	O
had	O
a	O
mean	O
follow-up	O
period	O
of	O
25.8	O
(SD	O
10.8)	O
months	O
and	O
31.4	O
(8.9)	O
months,	O
respectively.	O

Survival	O
analysis	O
showed	O
that	O
the	O
complete	O
success	O
rate	O
at	O
3	O
years	O
was	O
56%	O
in	O
the	O
combined	O
group	O
and	O
54%	O
in	O
the	O
trabeculectomy	O
group	O
(p	O
=	O
0.903).	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
either	O
IOP	O
or	O
the	O
number	O
of	O
glaucoma	O
medications	O
throughout	O
the	O
3-year	O
follow-up.	O

The	B-Premise
incidences	I-Premise
of	I-Premise
postoperative	I-Premise
complications	I-Premise
were	I-Premise
similar	I-Premise
between	I-Premise
groups	I-Premise
(p	I-Premise
=	I-Premise
0.232).	I-Premise

No	B-Premise
additional	I-Premise
IOP-lowering	I-Premise
surgical	I-Premise
procedures	I-Premise
were	I-Premise
required	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
group,	I-Premise
while	I-Premise
13	I-Premise
(54%)	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
trabeculectomy	I-Premise
group	I-Premise
required	I-Premise
either	I-Premise
cataract	I-Premise
extraction	I-Premise
or	I-Premise
further	I-Premise
IOP-lowering	I-Premise
surgical	I-Premise
procedures	I-Premise
(p	I-Premise
<0.001).	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
PACG,	I-Claim
the	I-Claim
long-term	I-Claim
IOP-lowering	I-Claim
effect	I-Claim
and	I-Claim
surgical	I-Claim
complications	I-Claim
of	I-Claim
combined	I-Claim
trabeculectomy	I-Claim
and	I-Claim
cataract	I-Claim
extraction	I-Claim
are	I-Claim
comparable	I-Claim
with	I-Claim
those	I-Claim
of	I-Claim
trabeculectomy	I-Claim
alone.	I-Claim

However,	B-Claim
the	I-Claim
combined	I-Claim
surgery	I-Claim
incurred	I-Claim
fewer	I-Claim
subsequent	I-Claim
surgical	I-Claim
interventions.	I-Claim

To	O
compare	O
latanoprost	O
and	O
timolol	O
with	O
regard	O
to	O
changes	O
in	O
the	O
intervisit	O
intraocular	O
pressure	O
(IOP)	O
range,	O
a	O
measure	O
of	O
long-term	O
IOP	O
fluctuation.	O

Post	O
hoc	O
analysis	O
of	O
three	O
6-month,	O
multicenter,	O
randomized	O
(1:1),	O
double-masked	O
registration	O
trials	O
of	O
latanoprost	O
(n	O
=	O
313)	O
vs	O
timolol	O
(n	O
=	O
318).	O

Analyses	O
included	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
who	O
instilled	O
latanoprost	O
once	O
daily	O
in	O
the	O
evening	O
and	O
vehicle	O
in	O
the	O
morning	O
and	O
those	O
instilling	O
timolol	O
twice	O
daily.	O

Pretreatment	O
intervisit	O
IOP	O
range:	O
highest	O
IOP	O
minus	O
lowest	O
IOP	O
of	O
4	O
measurements	O
obtained	O
at	O
screening	O
and	O
baseline.	O

Posttreatment	O
intervisit	O
IOP	O
range:	O
highest	O
IOP	O
minus	O
lowest	O
IOP	O
of	O
4	O
measurements	O
obtained	O
at	O
weeks	O
18	O
and	O
26.	O

Ranges	O
were	O
dichotomized	O
to	O
high	O
(>	O
6	O
mm	O
Hg)	O
and	O
low	O
(<	O
or	O
=	O
6	O
mm	O
Hg).	O

Both	B-Claim
treatments	I-Claim
resulted	I-Claim
in	I-Claim
significant	I-Claim
reductions	I-Claim
in	I-Claim
mean	I-Claim
intervisit	I-Claim
IOP	I-Claim
range	I-Claim
during	I-Claim
26	I-Claim
weeks.	I-Claim

Pretreatment,	O
comparable	O
proportions	O
of	O
patients	O
treated	O
with	O
latanoprost	O
and	O
timolol	O
had	O
high	O
intervisit	O
IOP	O
ranges	O
(22%	O
[70/313]	O
and	O
23%	O
[72/318],	O
respectively;	O
P	O
=	O
.934).	O

After	B-Premise
treatment,	I-Premise
6%	I-Premise
(19/313)	I-Premise
and	I-Premise
11%	I-Premise
(35/318)	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
and	I-Premise
timolol	I-Premise
groups,	I-Premise
respectively,	I-Premise
had	I-Premise
high	I-Premise
intervisit	I-Premise
IOP	I-Premise
ranges	I-Premise
(P	I-Premise
=	I-Premise
.026).	I-Premise

Significant	B-Premise
risk	I-Premise
factors	I-Premise
for	I-Premise
high	I-Premise
posttreatment	I-Premise
intervisit	I-Premise
range	I-Premise
(multivariate	I-Premise
logistic	I-Premise
regression)	I-Premise
were	I-Premise
high	I-Premise
pretreatment	I-Premise
intervisit	I-Premise
IOP	I-Premise
range,	I-Premise
treatment	I-Premise
with	I-Premise
timolol,	I-Premise
Black	I-Premise
race,	I-Premise
longer	I-Premise
time	I-Premise
since	I-Premise
diagnosis,	I-Premise
and	I-Premise
higher	I-Premise
mean	I-Premise
pretreatment	I-Premise
IOP.	I-Premise

Compared	B-Claim
with	I-Claim
timolol,	I-Claim
treatment	I-Claim
with	I-Claim
latanoprost	I-Claim
results	I-Claim
in	I-Claim
significantly	I-Claim
fewer	I-Claim
patients	I-Claim
with	I-Claim
a	I-Claim
high	I-Claim
IOP	I-Claim
fluctuation.	I-Claim

The	O
impact	O
of	O
reducing	O
high	O
IOP	O
fluctuation	O
on	O
progressive	O
glaucomatous	O
damage	O
deserves	O
further	O
investigation	O
in	O
prospective	O
studies.	O

Fixed	B-Claim
combinations	I-Claim
of	I-Claim
0.2%	I-Claim
brimonidine-0.5%	I-Claim
timolol	I-Claim
and	I-Claim
2%	I-Claim
dorzolamide-0.5%	I-Claim
timolol	I-Claim
are	I-Claim
used	I-Claim
to	I-Claim
lower	I-Claim
intraocular	I-Claim
pressure	I-Claim
(IOP).	I-Claim

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
IOP-lowering	O
efficacy	O
and	O
ocular	O
tolerability	O
of	O
brimonidine-timolol	O
compared	O
with	O
dorzolamide-timolol	O
when	O
used	O
as	O
monotherapy	O
or	O
as	O
adjunctive	O
therapy	O
to	O
a	O
prostaglandin	O
analog	O
(PGA)	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension.	O

Pooled	O
data	O
analysis	O
of	O
two	O
randomized,	O
investigator-masked,	O
3-month,	O
parallel-group	O
studies	O
with	O
identical	O
protocols	O
(ten	O
sites).	O

In	O
all,	O
180	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
who	O
were	O
in	O
need	O
of	O
lower	O
IOP	O
received	O
topical	O
brimonidine-timolol	O
BID	O
or	O
dorzolamide-timolol	O
BID	O
as	O
monotherapy	O
(n	O
=	O
101)	O
or	O
as	O
adjunctive	O
therapy	O
to	O
a	O
PGA	O
(latanoprost,	O
bimatoprost,	O
or	O
travoprost)	O
(n	O
=	O
79).	O

IOP	O
was	O
measured	O
at	O
10	O
a.m.	O
(peak	O
effect)	O
at	O
baseline	O
and	O
at	O
months	O
1	O
and	O
3.	O

Tolerability/comfort	O
was	O
evaluated	O
using	O
a	O
patient	O
questionnaire.	O

There	O
were	O
no	O
statistically	O
significant	O
between-group	O
differences	O
in	O
patient	O
demographics.	O

Most	O
patients	O
were	O
Caucasian,	O
and	O
the	O
mean	O
age	O
was	O
68	O
years.	O

There	O
were	O
also	O
no	O
statistically	O
significant	O
differences	O
between	O
treatment	O
groups	O
in	O
baseline	O
IOP.	O

At	B-Premise
month	I-Premise
3,	I-Premise
the	I-Premise
mean	I-Premise
(SD)	I-Premise
reduction	I-Premise
from	I-Premise
baseline	I-Premise
IOP	I-Premise
for	I-Premise
patients	I-Premise
on	I-Premise
fixed-combination	I-Premise
monotherapy	I-Premise
was	I-Premise
7.7	I-Premise
(4.2)	I-Premise
mmHg	I-Premise
(32.3%)	I-Premise
with	I-Premise
brimonidine-timolol	I-Premise
versus	I-Premise
6.7	I-Premise
(5.0)	I-Premise
mmHg	I-Premise
(26.1%)	I-Premise
with	I-Premise
dorzolamide-timolol	I-Premise
(p	I-Premise
=	I-Premise
0.040).	I-Premise

The	B-Premise
mean	I-Premise
reduction	I-Premise
from	I-Premise
PGA-treated	I-Premise
baseline	I-Premise
IOP	I-Premise
for	I-Premise
patients	I-Premise
on	I-Premise
fixed-combination	I-Premise
adjunctive	I-Premise
therapy	I-Premise
was	I-Premise
6.9	I-Premise
(4.8)	I-Premise
mmHg	I-Premise
(29.3%)	I-Premise
with	I-Premise
brimonidine-timolol	I-Premise
versus	I-Premise
5.2	I-Premise
(3.7)	I-Premise
mmHg	I-Premise
(23.5%)	I-Premise
with	I-Premise
dorzolamide-timolol	I-Premise
(p	I-Premise
=	I-Premise
0.213).	I-Premise

Patients	B-Premise
on	I-Premise
brimonidine-timolol	I-Premise
reported	I-Premise
less	I-Premise
burning	I-Premise
(p	I-Premise
<	I-Premise
0.001),	I-Premise
stinging	I-Premise
(p	I-Premise
<	I-Premise
0.001),	I-Premise
and	I-Premise
unusual	I-Premise
taste	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
than	I-Premise
patients	I-Premise
on	I-Premise
dorzolamide-timolol.	I-Premise

Fixed-combination	B-Claim
brimonidine-timolol	I-Claim
provided	I-Claim
the	I-Claim
same	I-Claim
or	I-Claim
greater	I-Claim
IOP	I-Claim
lowering	I-Claim
compared	I-Claim
with	I-Claim
fixed-combination	I-Claim
dorzolamide-timolol.	I-Claim

Both	B-Claim
fixed-combination	I-Claim
medications	I-Claim
were	I-Claim
safe	I-Claim
and	I-Claim
well-tolerated.	I-Claim

Brimonidine-timolol	O
received	O
higher	O
ratings	O
of	O
ocular	O
comfort	O
than	O
dorzolamide-timolol.	O

The	O
duration	O
of	O
the	O
studies	O
was	O
3	O
months,	O
and	O
additional	O
studies	O
will	O
be	O
needed	O
to	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
brimonidine-timolol	O
and	O
dorzolamide-timolol	O
during	O
long-term	O
treatment.	O

To	O
compare	O
the	O
effectiveness	O
and	O
safety	O
of	O
excimer	O
laser	O
trabeculotomy	O
(ELT)	O
ab	O
interno	O
vs	O
selective	O
laser	O
trabeculoplasty	O
(SLT)	O
over	O
24	O
months	O
of	O
follow-up	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
(POAG)	O
refractory	O
to	O
medical	O
therapy.	O

This	O
prospective,	O
randomized	O
study	O
included	O
30	O
consecutive	O
eyes	O
assigned	O
randomly	O
to	O
either	O
ELT	O
or	O
SLT	O
group.	O

ELT	O
was	O
carried	O
out	O
using	O
a	O
XeCl	O
Excimer	O
Laser	O
with	O
an	O
emission	O
wavelength	O
of	O
308	O
nm.	O

Eight	O
spots	O
were	O
equally	O
distributed	O
at	O
a	O
distance	O
of	O
500	O
microm	O
from	O
one	O
another	O
over	O
the	O
anterior	O
trabeculum.	O

The	O
SLT	O
patients	O
were	O
treated	O
with	O
a	O
frequency-doubled	O
q-switched	O
neodymium:yytrium-aluminum-garnet	O
laser	O
(wavelength	O
532	O
nm).	O

Approximately	O
50	O
adjacent,	O
but	O
not	O
overlapping,	O
laser	O
spots	O
were	O
distributed	O
over	O
180	O
degrees	O
of	O
the	O
trabecular	O
meshwork,	O
using	O
an	O
energy	O
level	O
ranging	O
from	O
0.7	O
to	O
1.0	O
mJ	O
per	O
pulse.	O

The	O
main	O
outcome	O
measure	O
was	O
intraocular	O
pressure	O
(IOP)	O
lowering	O
after	O
ELT	O
and	O
SLT.	O

Success	O
was	O
defined	O
as	O
>or=20%	O
reduction	O
in	O
IOP	O
without	O
further	O
glaucoma	O
intervention.	O

At	B-Premise
24	I-Premise
months,	I-Premise
complete	I-Premise
success	I-Premise
rates	I-Premise
were	I-Premise
53.3%	I-Premise
for	I-Premise
the	I-Premise
ELT	I-Premise
group	I-Premise
and	I-Premise
40%	I-Premise
for	I-Premise
the	I-Premise
SLT	I-Premise
group	I-Premise
(P=0.35,	I-Premise
Fisher's	I-Premise
exact	I-Premise
test);	I-Premise
qualified	B-Premise
success	I-Premise
rates	I-Premise
were	I-Premise
33.3%	I-Premise
for	I-Premise
the	I-Premise
ELT	I-Premise
and	I-Premise
26.6%	I-Premise
for	I-Premise
the	I-Premise
SLT	I-Premise
group	I-Premise
(P=0.5,	I-Premise
Fisher's	I-Premise
exact	I-Premise
test).	I-Premise

Mean	B-Premise
IOP	I-Premise
decreased	I-Premise
from	I-Premise
25.0+/-1.9	I-Premise
to	I-Premise
17.6+/-2.2	I-Premise
mmHg	I-Premise
(-29.6%;	I-Premise
P<0.0001)	I-Premise
in	I-Premise
the	I-Premise
ELT	I-Premise
group	I-Premise
and	I-Premise
from	I-Premise
23.9+/-0.9	I-Premise
to	I-Premise
19.1+/-1.8	I-Premise
mmHg	I-Premise
(-21%;	I-Premise
P<0.0001)	I-Premise
in	I-Premise
the	I-Premise
SLT	I-Premise
group.	I-Premise

Both	B-Claim
ELT	I-Claim
and	I-Claim
SLT	I-Claim
proved	I-Claim
to	I-Claim
be	I-Claim
effective	I-Claim
techniques	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
POAG	I-Claim
refractory	I-Claim
to	I-Claim
medical	I-Claim
therapy.	I-Claim

Bimatoprost	O
and	O
the	O
fixed	O
combination	O
of	O
latanoprost	O
with	O
timolol	O
maleate	O
are	O
2	O
medications	O
widely	O
used	O
to	O
treat	O
glaucoma	O
and	O
ocular	O
hypertension	O
(OHT).	O

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
compare	O
the	O
efficacy	O
of	O
these	O
2	O
drugs	O
in	O
reducing	O
intraocular	O
pressure	O
(IOP)	O
after	O
8	O
weeks	O
of	O
treatment	O
in	O
patients	O
with	O
primary	O
open	O
angle	O
glaucoma	O
(POAG)	O
or	O
OHT.	O

In	O
this	O
randomized,	O
open-label	O
trial,	O
44	O
patients	O
with	O
POAG	O
or	O
OHT	O
were	O
allocated	O
to	O
receive	O
either	O
bimatoprost	O
(1	O
drop	O
QD)	O
or	O
latanoprost/timolol	O
(1	O
drop	O
QD).	O

Primary	O
outcome	O
was	O
the	O
mean	O
diurnal	O
IOP	O
measurement	O
at	O
the	O
8th	O
week,	O
calculated	O
as	O
the	O
mean	O
IOP	O
measurements	O
taken	O
at	O
8:00	O
am,	O
10:00	O
am,	O
and	O
12:00	O
pm	O
Secondary	O
outcomes	O
included	O
the	O
baseline	O
change	O
in	O
IOP	O
measured	O
3	O
times	O
a	O
day,	O
after	O
the	O
water-drinking	O
test	O
(performed	O
after	O
the	O
last	O
IOP	O
measurement),	O
and	O
the	O
assessment	O
of	O
side	O
effects	O
of	O
each	O
therapy.	O

The	B-Premise
mean	I-Premise
IOP	I-Premise
levels	I-Premise
of	I-Premise
latanoprost/timolol	I-Premise
(13.83,	I-Premise
SD	I-Premise
=	I-Premise
2.54)	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
of	I-Premise
bimatoprost	I-Premise
(16.16,	I-Premise
SD	I-Premise
=	I-Premise
3.28;	I-Premise
P	I-Premise
<	I-Premise
0.0001)	I-Premise
at	I-Premise
week	I-Premise
8.	I-Premise

Also,	O
the	B-Premise
change	I-Premise
in	I-Premise
mean	I-Premise
IOP	I-Premise
values	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
latanoprost/timolol	I-Premise
group	I-Premise
at	I-Premise
10:00	I-Premise
am	I-Premise
(P	I-Premise
=	I-Premise
0.013)	I-Premise
and	I-Premise
12:00	I-Premise
pm	I-Premise
(P	I-Premise
=	I-Premise
0.01),	I-Premise
but	I-Premise
not	I-Premise
at	I-Premise
8:00	I-Premise
am	I-Premise
(P	I-Premise
=	I-Premise
ns).	I-Premise

During	O
the	O
water-drinking	O
test,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
IOP	O
increase	O
(absolute	O
and	O
percentage)	O
between	O
groups;	O
however,	O
there	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
mean	I-Premise
heart	I-Premise
rate	I-Premise
in	I-Premise
the	I-Premise
latanoprost/timolol	I-Premise
group.	I-Premise

Finally,	O
no	B-Premise
significant	I-Premise
changes	I-Premise
in	I-Premise
blood	I-Premise
pressure	I-Premise
and	I-Premise
lung	I-Premise
spirometry	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
either	I-Premise
groups.	I-Premise

The	B-Claim
fixed	I-Claim
combination	I-Claim
of	I-Claim
latanoprost/timolol	I-Claim
was	I-Claim
significantly	I-Claim
superior	I-Claim
to	I-Claim
bimatoprost	I-Claim
alone	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
POAG	I-Claim
or	I-Claim
OHT.	I-Claim

Further	B-Claim
studies	I-Claim
with	I-Claim
large	I-Claim
sample	I-Claim
sizes	I-Claim
should	I-Claim
be	I-Claim
taken	I-Claim
to	I-Claim
support	I-Claim
the	I-Claim
superior	I-Claim
efficacy	I-Claim
of	I-Claim
latanoprost/timolol,	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
to	I-Claim
better	I-Claim
assess	I-Claim
its	I-Claim
profile	I-Claim
of	I-Claim
side	I-Claim
effects.	I-Claim

To	O
compare	O
the	O
effect	O
of	O
time	O
on	O
therapy,	O
efficacy,	O
tolerability	O
and	O
resource	O
utilization	O
of	O
latanoprost	O
or	O
non-prostaglandin	O
analogues	O
(non-PGs)	O
in	O
patients	O
who	O
required	O
a	O
change	O
in	O
intraocular	O
pressure	O
(IOP)-lowering	O
monotherapy.	O

This	O
open-label,	O
multicentre	O
study	O
(Sweden,	O
19	O
sites;	O
Finland,	O
seven	O
sites)	O
included	O
adults	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
with	O
mean	O
diurnal	O
IOP	O
>	O
or	O
=	O
21	O
mmHg	O
on	O
ocular	O
hypotensive	O
monotherapy.	O

Patients	O
were	O
randomized	O
to	O
latanoprost	O
monotherapy	O
or	O
non-PG	O
therapy	O
(commercially	O
available	O
therapy	O
other	O
than	O
a	O
PG)	O
and	O
followed	O
for	O
36	O
months.	O

End-points	O
included:	O
time	O
to	O
treatment	O
failure	O
(baseline	O
to	O
visit	O
with	O
a	O
change	O
in/addition	O
to	O
treatment);	O
diurnal	O
IOP	O
(mean	O
of	O
08.00,	O
12.00	O
and	O
16:00	O
hr	O
measurements)	O
at	O
months	O
6,	O
12,	O
24	O
and	O
36;	O
tolerability;	O
and	O
resource	O
utilization,	O
where	O
analyses	O
used	O
Swedish	O
and	O
Finnish	O
2006	O
unit	O
costs.	O

Three	O
hundred	O
and	O
twenty-six	O
patients	O
received	O
>or	O
=	O
1	O
dose	O
of	O
latanoprost	O
(n	O
=	O
162)	O
or	O
non-PGs	O
(n	O
=	O
164).	O

Median	O
time	O
to	O
treatment	O
failure	O
was	O
longer	O
for	O
latanoprost	O
(36	O
months)	O
than	O
for	O
non-PGs	O
(12	O
months;	O
p	O
<	O
0.001);	O
51%	O
and	O
24%	O
of	O
patients	O
remained	O
on	O
randomized	O
therapy	O
after	O
36	O
months,	O
respectively	O
(p	O
<	O
0.001).	O

Decreases	B-Premise
in	I-Premise
mean	I-Premise
diurnal	I-Premise
IOP	I-Premise
from	I-Premise
baseline	I-Premise
were	I-Premise
significantly	I-Premise
greater	I-Premise
for	I-Premise
latanoprost	I-Premise
than	I-Premise
for	I-Premise
non-PGs	I-Premise
at	I-Premise
months	I-Premise
6	I-Premise
and	I-Premise
12	I-Premise
(p	I-Premise
<	I-Premise
0.01).	I-Premise

No	B-Premise
serious	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
judged	I-Premise
to	I-Premise
be	I-Premise
treatment-related.	I-Premise

Mean	B-Premise
total	I-Premise
36-month	I-Premise
direct	I-Premise
costs	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
patients	I-Premise
initiated	I-Premise
with	I-Premise
latanoprost	I-Premise
and	I-Premise
non-PGs.	I-Premise

Patients	B-Premise
who	I-Premise
failed	I-Premise
previous	I-Premise
monotherapy	I-Premise
remained	I-Premise
on	I-Premise
therapy	I-Premise
longer	I-Premise
when	I-Premise
switched	I-Premise
to	I-Premise
latanoprost.	I-Premise

The	B-Claim
IOP-reducing	I-Claim
effect	I-Claim
of	I-Claim
latanoprost	I-Claim
and	I-Claim
tolerability	I-Claim
were	I-Claim
sustained	I-Claim
over	I-Claim
the	I-Claim
long	I-Claim
term.	I-Claim

Resource	B-Claim
utilization	I-Claim
and	I-Claim
costs	I-Claim
were	I-Claim
generally	I-Claim
similar	I-Claim
in	I-Claim
those	I-Claim
initiating	I-Claim
latanoprost	I-Claim
or	I-Claim
non-PG	I-Claim
therapy.	I-Claim

To	O
determine	O
if	O
postoperative	O
topical	O
cyclosporine	O
0.05%	O
has	O
any	O
beneficial	O
effect	O
following	O
trabeculectomy.	O

This	O
was	O
an	O
interventional,	O
randomized,	O
prospective,	O
double-masked	O
clinical	O
trial	O
of	O
44	O
consecutive	O
patients	O
with	O
uncontrolled	O
glaucoma	O
requiring	O
filtration	O
surgery.	O

Ocular	O
surface	O
disease	O
index	O
questionnaire	O
and	O
comprehensive	O
ocular	O
exam,	O
including	O
Schirmer's	O
tear	O
test	O
1,	O
were	O
performed.	O

Patients	O
underwent	O
routine	O
trabeculectomy,	O
with	O
or	O
without	O
phacoemulsification.	O

The	O
study	O
group	O
(n	O
=	O
22)	O
received	O
cyclosporine	O
0.05%,	O
and	O
the	O
control	O
group	O
(n	O
=	O
22)	O
received	O
artificial	O
tears.	O

Patients	O
were	O
evaluated	O
at	O
1	O
and	O
6	O
months	O
post	O
surgery.	O

Outcome	O
measures	O
were	O
intraocular	O
pressure,	O
success	O
rate,	O
bleb	O
appearance,	O
ocular	O
surface	O
disease	O
index,	O
Schirmer's	O
tear	O
test	O
1	O
and	O
conjunctival	O
inflammation.	O

Thirty-nine	O
patients	O
completed	O
the	O
study	O
(19	O
in	O
the	O
study	O
group,	O
20	O
in	O
the	O
control	O
group).	O

The	B-Premise
mean	I-Premise
baseline	I-Premise
intraocular	I-Premise
pressure	I-Premise
was	I-Premise
23.8	I-Premise
+/-	I-Premise
12.6	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
study	I-Premise
group	I-Premise
and	I-Premise
25.9	I-Premise
+/-	I-Premise
10.6	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.513).	I-Premise

Mean	B-Premise
intraocular	I-Premise
pressure	I-Premise
at	I-Premise
postoperative	I-Premise
month	I-Premise
6	I-Premise
was	I-Premise
14.88	I-Premise
+/-	I-Premise
6.2	I-Premise
and	I-Premise
14.62	I-Premise
+/-	I-Premise
5.46	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
study	I-Premise
group	I-Premise
and	I-Premise
control	I-Premise
group,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.837).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
mean	I-Premise
values	I-Premise
of	I-Premise
Schirmer's	I-Premise
tear	I-Premise
test	I-Premise
1	I-Premise
and	I-Premise
the	I-Premise
level	I-Premise
of	I-Premise
conjunctival	I-Premise
hyperaemia	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
at	I-Premise
baseline,	I-Premise
months	I-Premise
1	I-Premise
and	I-Premise
6	I-Premise
post	I-Premise
surgery.	I-Premise

The	B-Premise
treatment	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
ocular	I-Premise
surface	I-Premise
disease	I-Premise
index	I-Premise
score	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.003),	I-Premise
indicating	I-Premise
less	I-Premise
severity	I-Premise
of	I-Premise
dry	I-Premise
eye	I-Premise
symptoms	I-Premise
and	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
ocular	I-Premise
pain.	I-Premise

Topical	B-Claim
cyclosporine	I-Claim
0.05%	I-Claim
had	I-Claim
no	I-Claim
effect	I-Claim
on	I-Claim
postoperative	I-Claim
bleb	I-Claim
function	I-Claim
and	I-Claim
intraocular	I-Claim
pressure	I-Claim
following	I-Claim
trabeculectomy,	I-Claim
but	I-Claim
improved	I-Claim
subjective	I-Claim
ocular	I-Claim
surface	I-Claim
symptoms	I-Claim
in	I-Claim
these	I-Claim
patients.	I-Claim

To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
fixed-combination	O
latanoprost-timolol	O
(FCLT)	O
vs	O
latanoprost	O
or	O
timolol	O
monotherapy.	O

This	O
12-week,	O
randomized,	O
double-masked,	O
parallel-group	O
study	O
included	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
treated	O
with	O
a	O
beta-blocker	O
and	O
with	O
baseline	O
intraocular	O
pressure	O
(IOP)	O
of	O
26	O
through	O
36	O
mm	O
Hg.	O

Following	O
washout,	O
eligible	O
patients	O
were	O
randomized	O
to	O
once-daily	O
FCLT	O
in	O
the	O
evening,	O
latanoprost	O
in	O
the	O
evening,	O
or	O
timolol	O
in	O
the	O
morning.	O

Postbaseline	O
IOP	O
assessments	O
at	O
8	O
am,	O
10	O
am,	O
and	O
4	O
pm	O
at	O
weeks	O
2,	O
6,	O
and	O
12;	O
statistical	O
superiority	O
of	O
FCLT	O
for	O
the	O
18	O
pairwise	O
comparisons	O
between	O
FCLT	O
and	O
the	O
2	O
monotherapies,	O
using	O
analysis	O
of	O
variance.	O

All	O
therapies	O
resulted	O
in	O
significant	O
IOP	O
reductions	O
from	O
baseline.	O

Pairwise	O
comparisons	O
favored	O
FCLT	O
at	O
all	O
time	O
points.	O

When	O
the	O
18	O
comparisons	O
were	O
tested	O
simultaneously,	O
FCLT	B-Premise
was	I-Premise
statistically	I-Premise
superior	I-Premise
to	I-Premise
latanoprost	I-Premise
at	I-Premise
7	I-Premise
of	I-Premise
9	I-Premise
time	I-Premise
points	I-Premise
and	I-Premise
at	I-Premise
all	I-Premise
9	I-Premise
time	I-Premise
points	I-Premise
when	I-Premise
compared	I-Premise
with	I-Premise
timolol.	I-Premise

In	O
addition,	O
FCLT	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
greater	I-Premise
percentage	I-Premise
reductions	I-Premise
in	I-Premise
diurnal	I-Premise
IOP	I-Premise
levels	I-Premise
and	I-Premise
a	I-Premise
greater	I-Premise
likelihood	I-Premise
of	I-Premise
achieving	I-Premise
lower	I-Premise
mean	I-Premise
diurnal	I-Premise
IOP	I-Premise
levels.	I-Premise

Diurnal	B-Premise
IOP	I-Premise
reductions	I-Premise
of	I-Premise
30%	I-Premise
or	I-Premise
more	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
week	I-Premise
12	I-Premise
were	I-Premise
achieved	I-Premise
by	I-Premise
73.5%,	I-Premise
57.5%,	I-Premise
and	I-Premise
32.8%	I-Premise
of	I-Premise
those	I-Premise
treated	I-Premise
with	I-Premise
FCLT,	I-Premise
latanoprost,	I-Premise
and	I-Premise
timolol,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
.007	I-Premise
for	I-Premise
FCLT	I-Premise
vs	I-Premise
timolol;	I-Premise
P	I-Premise
<	I-Premise
.001	I-Premise
for	I-Premise
FCLT	I-Premise
vs	I-Premise
latanoprost).	I-Premise

All	B-Claim
therapies	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

Fixed-combination	B-Claim
latanoprost-timolol	I-Claim
therapy	I-Claim
is	I-Claim
as	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
in	I-Claim
lowering	I-Claim
IOP	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
either	I-Claim
ocular	I-Claim
hypertension	I-Claim
or	I-Claim
glaucoma	I-Claim
as	I-Claim
monotherapy	I-Claim
with	I-Claim
latanoprost	I-Claim
or	I-Claim
timolol.	I-Claim

Combination	B-Claim
therapy	I-Claim
can	I-Claim
be	I-Claim
used	I-Claim
to	I-Claim
treat	I-Claim
patients	I-Claim
for	I-Claim
whom	I-Claim
monotherapy	I-Claim
does	I-Claim
not	I-Claim
provide	I-Claim
sufficient	I-Claim
IOP	I-Claim
reduction.	I-Claim

The	B-Claim
simplicity,	I-Claim
efficacy,	I-Claim
and	I-Claim
tolerability	I-Claim
of	I-Claim
FCLT	I-Claim
contribute	I-Claim
to	I-Claim
its	I-Claim
utility	I-Claim
in	I-Claim
clinical	I-Claim
practice.	I-Claim

To	O
compare	O
phacoemulsification	O
alone	O
and	O
phacoemulsification	O
with	O
micro-bypass	O
stent	O
implantation	O
in	O
eyes	O
with	O
primary	O
open-angle	O
glaucoma.	O

Instituto	O
di	O
Fisiopatologia	O
Clinica,	O
Clinica	O
Oculistica,	O
Universita'	O
di	O
Torino,	O
Torino,	O
Italy.	O

In	O
this	O
prospective	O
double-masked	O
randomized	O
clinical	O
trial,	O
patients	O
had	O
phacoemulsification	O
alone	O
(control	O
group)	O
or	O
phacoemulsification	O
with	O
iStent	O
implantation	O
(combined	O
group).	O

Primary	O
outcomes	O
were	O
intraocular	O
pressure	O
(IOP)	O
and	O
reduction	O
in	O
medication	O
use	O
over	O
15	O
months	O
and	O
IOP	O
after	O
a	O
1-month	O
washout	O
of	O
ocular	O
hypotensive	O
agents	O
(ie,	O
16	O
months	O
postoperatively).	O

The	O
baseline	O
IOP	O
was	O
similar	O
between	O
groups	O
(combined	O
group:	O
17.9	O
mm	O
Hg	O
+/-	O
2.6	O
[SD];	O
control	O
group:	O
17.3	O
+/-	O
3.0	O
mm	O
Hg)	O
(P	O
=	O
.512).	O

Three	O
patients	O
in	O
the	O
control	O
group	O
were	O
lost	O
to	O
follow-up.	O

The	B-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
14.8	I-Premise
+/-	I-Premise
1.2	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
group	I-Premise
and	I-Premise
15.7	I-Premise
+/-	I-Premise
1.1	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
at	I-Premise
15	I-Premise
months	I-Premise
and	I-Premise
16.6	I-Premise
+/-	I-Premise
3.1	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
19.2	I-Premise
+/-	I-Premise
3.5	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively,	I-Premise
after	I-Premise
washout;	I-Premise
the	B-Premise
IOP	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
at	I-Premise
both	I-Premise
time	I-Premise
points	I-Premise
(P	I-Premise
=	I-Premise
.031	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
.042,	I-Premise
respectively).	I-Premise

At	B-Premise
15	I-Premise
months,	I-Premise
the	I-Premise
mean	I-Premise
number	I-Premise
of	I-Premise
medications	I-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(0.4	I-Premise
+/-	I-Premise
0.7	I-Premise
and	I-Premise
1.3	I-Premise
+/-	I-Premise
1.0,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.007),	I-Premise
as	I-Premise
was	I-Premise
the	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
on	I-Premise
ocular	I-Premise
hypotensive	I-Premise
medication	I-Premise
(33%	I-Premise
and	I-Premise
76%,	I-Premise
respectively).	I-Premise

Phacoemulsification	B-Claim
with	I-Claim
stent	I-Claim
implantation	I-Claim
was	I-Claim
more	I-Claim
effective	I-Claim
in	I-Claim
controlling	I-Claim
IOP	I-Claim
than	I-Claim
phacoemulsification	I-Claim
alone;	I-Claim
the	O
safety	O
profiles	O
were	O
similar.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
long-term	O
efficacy	O
and	O
safety	O
of	O
tafluprost	O
0.0015%	O
with	O
latanoprost	O
0.005%	O
eye	O
drops	O
in	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

This	O
double-masked,	O
active-controlled,	O
parallel-group,	O
multinational,	O
multicentre,	O
phase	O
III	O
study	O
was	O
conducted	O
at	O
49	O
centres	O
in	O
8	O
countries.	O

Eligible	O
patients	O
were	O
assigned	O
to	O
treatment	O
administered	O
once	O
daily	O
at	O
20:00	O
hrs	O
for	O
up	O
to	O
24	O
months.	O

Change	O
from	O
baseline	O
intraocular	O
pressure	O
(IOP)	O
was	O
the	O
primary	O
efficacy	O
variable.	O

Adverse	O
events	O
were	O
recorded	O
and	O
ocular	O
safety	O
was	O
evaluated.	O

Both	O
tafluprost	O
and	O
latanoprost	O
were	O
preserved	O
with	O
benzalkonium	O
chloride.	O

From	O
533	O
patients	O
randomized,	O
402	O
patients	O
completed	O
24	O
months	O
of	O
therapy.	O

Both	B-Premise
treatments	I-Premise
had	I-Premise
a	I-Premise
substantial	I-Premise
IOP-lowering	I-Premise
effect	I-Premise
which	I-Premise
persisted	I-Premise
throughout	I-Premise
the	I-Premise
study	I-Premise
(-7.1	I-Premise
mmHg	I-Premise
for	I-Premise
tafluprost	I-Premise
and	I-Premise
-7.7	I-Premise
mmHg	I-Premise
for	I-Premise
latanoprost	I-Premise
at	I-Premise
24	I-Premise
months).	I-Premise

Although	O
the	B-Claim
IOP-lowering	I-Claim
effect	I-Claim
during	I-Claim
the	I-Claim
study	I-Claim
was	I-Claim
slightly	I-Claim
larger	I-Claim
with	I-Claim
latanoprost,	I-Claim
this	B-Premise
difference	I-Premise
was	I-Premise
clinically	I-Premise
small	I-Premise
and	I-Premise
the	I-Premise
noninferiority	I-Premise
of	I-Premise
tafluprost	I-Premise
to	I-Premise
latanoprost	I-Premise
over	I-Premise
all	I-Premise
diurnal	I-Premise
IOP	I-Premise
measurements	I-Premise
was	I-Premise
shown	I-Premise
with	I-Premise
anova	I-Premise
and	I-Premise
almost	I-Premise
reached	I-Premise
with	I-Premise
ancova	I-Premise
(upper	I-Premise
limits	I-Premise
of	I-Premise
the	I-Premise
95%	I-Premise
confidence	I-Premise
intervals	I-Premise
1.38	I-Premise
and	I-Premise
1.52	I-Premise
for	I-Premise
the	I-Premise
overall	I-Premise
period,	I-Premise
respectively).	I-Premise

The	O
noninferiority	O
limit	O
was	O
1.5	O
mmHg.	O

Tafluprost	B-Claim
is	I-Claim
a	I-Claim
new	I-Claim
effective	I-Claim
and	I-Claim
well-tolerated	I-Claim
treatment	I-Claim
for	I-Claim
glaucoma	I-Claim
and	I-Claim
ocular	I-Claim
hypertension.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
laser	O
peripheral	O
iridotomy	O
with	O
or	O
without	O
laser	O
peripheral	O
iridoplasty	O
in	O
the	O
treatment	O
of	O
eyes	O
with	O
synechial	O
primary	O
angle-closure	O
or	O
primary	O
angle-closure	O
glaucoma.	O

Randomized,	O
controlled	O
clinical	O
trial.	O

Consecutive	O
patients	O
older	O
than	O
40	O
years	O
with	O
synechial	O
primary	O
angle-closure	O
or	O
primary	O
angle	O
closure	O
glaucoma	O
were	O
recruited.	O

Eligible	O
patients	O
were	O
randomized	O
to	O
1	O
of	O
2	O
treatment	O
options,	O
iridotomy	O
or	O
iridotomy	O
plus	O
iridoplasty,	O
and	O
were	O
followed	O
up	O
for	O
1	O
year.	O

Main	O
outcome	O
measures	O
were	O
intraocular	O
pressure	O
(IOP),	O
peripheral	O
anterior	O
synechiae,	O
corneal	O
endothelial	O
cell	O
count,	O
and	O
complications.	O

Seventy-seven	O
eyes	O
(77	O
patients)	O
were	O
randomized	O
to	O
the	O
iridotomy	O
group,	O
and	O
81	O
eyes	O
(81	O
patients)	O
were	O
randomized	O
to	O
the	O
iridotomy	O
plus	O
iridoplasty	O
group.	O

Sixty-one	O
patients	O
(79.2%)	O
in	O
the	O
iridotomy	O
and	O
65	O
patients	O
(80.2%)	O
from	O
the	O
iridotomy	O
plus	O
iridoplasty	O
groups	O
completed	O
1	O
year	O
of	O
follow-up.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
the	O
baseline	O
data.	O

IOP	B-Premise
was	I-Premise
reduced	I-Premise
from	I-Premise
24.66	I-Premise
+/-	I-Premise
13.76	I-Premise
mm	I-Premise
Hg	I-Premise
to	I-Premise
19.03	I-Premise
+/-	I-Premise
6.21	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
iridotomy	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
and	I-Premise
from	I-Premise
27.96	I-Premise
+/-	I-Premise
13.06	I-Premise
mm	I-Premise
Hg	I-Premise
to	I-Premise
20.45	I-Premise
+/-	I-Premise
7.26	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
iridotomy	I-Premise
plus	I-Premise
iridoplasty	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

Extent	B-Premise
of	I-Premise
peripheral	I-Premise
anterior	I-Premise
synechiae	I-Premise
was	I-Premise
decreased	I-Premise
by	I-Premise
1	I-Premise
more	I-Premise
clock-hour	I-Premise
after	I-Premise
iridoplasty	I-Premise
compared	I-Premise
with	I-Premise
that	I-Premise
after	I-Premise
iridotomy	I-Premise
in	I-Premise
the	I-Premise
iridotomy	I-Premise
plus	I-Premise
iridoplasty	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
IOP,	I-Premise
medications,	I-Premise
need	I-Premise
for	I-Premise
surgery,	I-Premise
or	I-Premise
visual	I-Premise
function	I-Premise
between	I-Premise
groups	I-Premise
at	I-Premise
the	I-Premise
1-year	I-Premise
visit.	I-Premise

In	B-Claim
eyes	I-Claim
with	I-Claim
synechial	I-Claim
primary	I-Claim
angle-closure	I-Claim
or	I-Claim
primary	I-Claim
angle-closure	I-Claim
glaucoma,	I-Claim
both	I-Claim
iridotomy	I-Claim
alone	I-Claim
or	I-Claim
combined	I-Claim
with	I-Claim
iridoplasty	I-Claim
provide	I-Claim
a	I-Claim
significant	I-Claim
and	I-Claim
equivalent	I-Claim
reduction	I-Claim
in	I-Claim
IOP.	I-Claim

There	B-Claim
is	I-Claim
also	I-Claim
a	I-Claim
possible	I-Claim
reduction	I-Claim
in	I-Claim
peripheral	I-Claim
anterior	I-Claim
synechiae,	I-Claim
more	I-Claim
so	I-Claim
in	I-Claim
the	I-Claim
iridoplasty	I-Claim
group.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
0.0015%	O
tafluprost	O
ophthalmic	O
solution	O
(Tafluprost)	O
with	O
Placebo	O
ophthalmic	O
solution	O
(Placebo)	O
in	O
normal	O
tension	O
glaucoma	O
(NTG).	O

Total	O
of	O
94	O
patients	O
enrolled	O
in	O
a	O
randomized,	O
double-blind,	O
parallel-group	O
and	O
multicenter	O
study.	O

Patients	O
with	O
NTG	O
were	O
randomly	O
assigned	O
to	O
either	O
Tafluprost	O
or	O
Placebo.	O

Both	O
ophthalmic	O
solutions	O
were	O
instilled	O
once	O
a	O
day	O
in	O
the	O
morning	O
for	O
4	O
weeks.	O

Mean	B-Premise
intraocular	I-Premise
pressure	I-Premise
(IOP)	I-Premise
changes	I-Premise
from	I-Premise
baseline	I-Premise
were	I-Premise
-4.0	I-Premise
+/-	I-Premise
1.7	I-Premise
mmHg	I-Premise
in	I-Premise
Tafluprost	I-Premise
administered	I-Premise
patients	I-Premise
and	I-Premise
-1.4	I-Premise
+/-	I-Premise
1.8	I-Premise
mmHg	I-Premise
in	I-Premise
Placebo	I-Premise
administered	I-Premise
patients	I-Premise
at	I-Premise
4	I-Premise
weeks,	I-Premise
with	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
(p<0.001).	I-Premise

IOP	B-Premise
change	I-Premise
at	I-Premise
4	I-Premise
weeks,	I-Premise
%	I-Premise
IOP	I-Premise
reduction	I-Premise
at	I-Premise
2	I-Premise
and	I-Premise
4	I-Premise
weeks	I-Premise
were	I-Premise
also	I-Premise
significantly	I-Premise
greater	I-Premise
in	I-Premise
Tafluprost	I-Premise
than	I-Premise
in	I-Premise
Placebo.	I-Premise

A	B-Premise
total	I-Premise
of	I-Premise
51.0%	I-Premise
in	I-Premise
Tafluprost	I-Premise
treated	I-Premise
group	I-Premise
and	I-Premise
8.9%	I-Premise
in	I-Premise
Placebo	I-Premise
treated	I-Premise
group	I-Premise
reported	I-Premise
adverse	I-Premise
drug	I-Premise
reactions.	I-Premise

These	B-Claim
results	I-Claim
indicate	I-Claim
that	I-Claim
Tafluprost	I-Claim
is	I-Claim
clinically	I-Claim
useful	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
NTG.	I-Claim

To	O
compare	O
two	O
intraocular	O
irrigating	O
solutions,	O
Balanced	O
Salt	O
Solution	O
Plus	O
(BSS	O
Plus)	O
versus	O
Lactated	O
Ringer's	O
(Ringer),	O
for	O
the	O
preservation	O
of	O
corneal	O
integrity	O
after	O
phacoemulsification.	O

110	O
patients	O
undergoing	O
phacoemulsification	O
were	O
randomised	O
to	O
either	O
BSS	O
Plus	O
(n=55)	O
or	O
Ringer	O
(n=55)	O
as	O
the	O
irrigating	O
solution.	O

Patients	O
were	O
examined	O
at	O
baseline	O
and	O
at	O
1,	O
8,	O
15,	O
30	O
and	O
60	O
days	O
postoperatively.	O

Evaluations	O
included	O
specular	O
microscopy	O
to	O
evaluate	O
endothelial	O
cell	O
density	O
(ECD)	O
and	O
endothelial	O
cell	O
size	O
variability	O
(CV),	O
and	O
corneal	O
pachymetry	O
for	O
central	O
corneal	O
thickness	O
(CCT)	O
measurement.	O

Groups	O
were	O
well	O
balanced	O
regarding	O
baseline	O
ECD,	O
CV	O
and	O
CCT	O
(p>0.05).	O

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
ECD	I-Premise
reduction	I-Premise
in	I-Premise
group	I-Premise
BSS	I-Premise
Plus	I-Premise
13.1	I-Premise
	I-Premise
2.0%	I-Premise
and	I-Premise
Ringer	I-Premise
9.2	I-Premise
	I-Premise
1.9%	I-Premise
(p<0.05)	I-Premise
at	I-Premise
day	I-Premise
60	I-Premise
or	I-Premise
in	I-Premise
any	I-Premise
study	I-Premise
visit.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
CV	I-Premise
increase	I-Premise
in	I-Premise
group	I-Premise
BSS	I-Premise
Plus	I-Premise
23.0	I-Premise
	I-Premise
3.0%	I-Premise
and	I-Premise
Ringer	I-Premise
20.2	I-Premise
	I-Premise
4.0%	I-Premise
(p<0.05)	I-Premise
at	I-Premise
day	I-Premise
60	I-Premise
or	I-Premise
in	I-Premise
any	I-Premise
study	I-Premise
visit.	I-Premise

CCT	B-Premise
was	I-Premise
significantly	I-Premise
increased	I-Premise
(p<0.05)	I-Premise
at	I-Premise
1,	I-Premise
8,	I-Premise
15	I-Premise
and	I-Premise
30	I-Premise
days	I-Premise
postoperatively,	I-Premise
returning	I-Premise
to	I-Premise
baseline	I-Premise
at	I-Premise
60	I-Premise
days	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
CCT	I-Premise
increase	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
at	I-Premise
any	I-Premise
visit.	I-Premise

Interestingly,	O
there	B-Premise
were	I-Premise
statistically	I-Premise
significant	I-Premise
correlations	I-Premise
between	I-Premise
ECD	I-Premise
loss	I-Premise
and	I-Premise
phacoemulsification	I-Premise
time	I-Premise
(p<0.0001)	I-Premise
and	I-Premise
ECD	I-Premise
loss	I-Premise
and	I-Premise
irrigation	I-Premise
solution	I-Premise
volume	I-Premise
(p<0.0001)	I-Premise
in	I-Premise
the	I-Premise
Ringer	I-Premise
group,	I-Premise
but	I-Premise
not	I-Premise
in	I-Premise
the	I-Premise
BSS	I-Premise
Plus	I-Premise
group.	I-Premise

Ringers	B-Claim
solution	I-Claim
was	I-Claim
similar	I-Claim
to	I-Claim
BSS	I-Claim
Plus	I-Claim
for	I-Claim
corneal	I-Claim
preservation	I-Claim
in	I-Claim
atraumatic	I-Claim
cataract	I-Claim
surgery.	I-Claim

However,	B-Claim
our	I-Claim
study	I-Claim
demonstrates	I-Claim
that	I-Claim
there	I-Claim
is	I-Claim
a	I-Claim
trend	I-Claim
towards	I-Claim
lower	I-Claim
postoperative	I-Claim
endothelial	I-Claim
cell	I-Claim
density	I-Claim
for	I-Claim
surgeries	I-Claim
with	I-Claim
longer	I-Claim
phacoemulsification	I-Claim
time	I-Claim
and	I-Claim
higher	I-Claim
irrigation	I-Claim
volumes	I-Claim
if	I-Claim
Ringer	I-Claim
is	I-Claim
used.	I-Claim

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
efficacy	O
and	O
complications	O
of	O
trabeculectomy	O
with	O
a	O
biodegradable	O
implant	O
(ologen	O
implant)	O
vs	O
trabeculectomy	O
using	O
mitomycin	O
C	O
(MMC)	O
in	O
patients	O
with	O
medically	O
uncontrolled	O
open-angle	O
glaucoma	O
in	O
a	O
prospective	O
randomised	O
clinical	O
trial.	O

In	O
the	O
MMC	O
group	O
(10	O
patients),	O
trabeculectomy	O
was	O
performed	O
according	O
to	O
standard	O
protocols.	O

In	O
the	O
ologen	O
group	O
(10	O
patients)	O
after	O
standard	O
trabeculectomy	O
the	O
implant	O
was	O
positioned	O
on	O
top	O
of	O
the	O
scleral	O
flap	O
and	O
no	O
MMC	O
was	O
applied.	O

Follow-up	O
was	O
continued	O
for	O
12	O
months	O
after	O
surgery	O
and	O
included	O
testing	O
of	O
intraocular	O
pressure	O
(IOP),	O
visual	O
acuity,	O
visual	O
field,	O
ultrasound	O
biomicroscopy,	O
and	O
filtering	O
bleb	O
score.	O

The	O
mean	O
preoperative	O
IOP	O
was	O
24.8+/-8.9	O
mm	O
Hg	O
for	O
all	O
patients	O
enrolled.	O

At	B-Premise
1	I-Premise
year	I-Premise
after	I-Premise
surgery,	I-Premise
the	I-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
15.6+/-2.4mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
ologen	I-Premise
group	I-Premise
(P<0.01,	I-Premise
43%	I-Premise
reduction)	I-Premise
and	I-Premise
11.5+/-4.1	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
(P<0.01,	I-Premise
50%	I-Premise
reduction).	I-Premise

No	B-Premise
anti-glaucomatous	I-Premise
medication	I-Premise
was	I-Premise
necessary	I-Premise
in	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
of	I-Premise
follow-up,	I-Premise
whereas	I-Premise
five	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
ologen	I-Premise
group	I-Premise
required	I-Premise
topical	I-Premise
treatment.	I-Premise

The	B-Premise
absolute	I-Premise
success	I-Premise
rate	I-Premise
was	I-Premise
100%	I-Premise
in	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
and	I-Premise
50%	I-Premise
in	I-Premise
the	I-Premise
ologen	I-Premise
group	I-Premise
(P=0.01).	I-Premise

After	B-Premise
1	I-Premise
year,	I-Premise
filtering	I-Premise
blebs	I-Premise
developed	I-Premise
significantly	I-Premise
more	I-Premise
avascular	I-Premise
areas	I-Premise
in	I-Premise
the	I-Premise
MMC	I-Premise
group	I-Premise
(score=1.4)	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
ologen	I-Premise
group	I-Premise
(score=2.8;	I-Premise
P<0.01).	I-Premise

The	B-Claim
complete	I-Claim
success	I-Claim
rate	I-Claim
using	I-Claim
trabeculectomy	I-Claim
with	I-Claim
the	I-Claim
ologen	I-Claim
implant	I-Claim
is	I-Claim
lower	I-Claim
than	I-Claim
that	I-Claim
achieved	I-Claim
by	I-Claim
trabeculectomy	I-Claim
with	I-Claim
MMC.	I-Claim

However,	B-Claim
the	I-Claim
bleb	I-Claim
morphology	I-Claim
caused	I-Claim
more	I-Claim
problems	I-Claim
in	I-Claim
the	I-Claim
MMC	I-Claim
group	I-Claim
(avascularity	I-Claim
score).	I-Claim

To	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
iStent	O
trabecular	O
micro-bypass	O
stent	O
(Glaukos	O
Corporation,	O
Laguna	O
Hills,	O
CA)	O
in	O
combination	O
with	O
cataract	O
surgery	O
in	O
subjects	O
with	O
mild	O
to	O
moderate	O
open-angle	O
glaucoma.	O

Prospective,	O
randomized,	O
open-label,	O
controlled,	O
multicenter	O
clinical	O
trial.	O

A	O
total	O
of	O
240	O
eyes	O
with	O
mild	O
to	O
moderate	O
open-angle	O
glaucoma	O
with	O
intraocular	O
pressure	O
(IOP)	O
=24	O
mmHg	O
controlled	O
on	O
1	O
to	O
3	O
medications	O
were	O
randomized	O
to	O
undergo	O
cataract	O
surgery	O
with	O
iStent	O
implantation	O
(treatment	O
group)	O
or	O
cataract	O
surgery	O
only	O
(control).	O

Fifty	O
additional	O
subjects	O
were	O
enrolled	O
to	O
undergo	O
cataract	O
surgery	O
with	O
iStent	O
implantation	O
under	O
protocol	O
expansion.	O

Data	O
in	O
this	O
report	O
are	O
based	O
on	O
the	O
first	O
240	O
eyes	O
enrolled.	O

Implantation	O
of	O
the	O
iStent	O
trabecular	O
micro-bypass	O
stent	O
in	O
conjunction	O
with	O
cataract	O
surgery	O
or	O
cataract	O
surgery	O
only.	O

The	O
primary	O
efficacy	O
measure	O
was	O
unmedicated	O
IOP	O
21	O
mmHg	O
at	O
1	O
year.	O

A	O
secondary	O
measure	O
was	O
unmedicated	O
IOP	O
reduction	O
20%	O
at	O
1	O
year.	O

Safety	O
measures	O
included	O
best-corrected	O
visual	O
acuity	O
(BCVA),	O
slit-lamp	O
observations,	O
complications,	O
and	O
adverse	O
events.	O

The	O
study	O
met	O
the	O
primary	O
outcome,	O
with	O
72%	O
of	O
treatment	O
eyes	O
versus	O
50%	O
of	O
control	O
eyes	O
achieving	O
the	O
criterion	O
(P<0.001).	O

At	B-Premise
1	I-Premise
year,	I-Premise
IOP	I-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
groups	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
lower	I-Premise
from	I-Premise
baseline	I-Premise
values.	I-Premise

Sixty-six	B-Premise
percent	I-Premise
of	I-Premise
treatment	I-Premise
eyes	I-Premise
versus	I-Premise
48%	I-Premise
of	I-Premise
control	I-Premise
eyes	I-Premise
achieved	I-Premise
=20%	I-Premise
IOP	I-Premise
reduction	I-Premise
without	I-Premise
medication	I-Premise
(P	I-Premise
=	I-Premise
0.003).	I-Premise

The	B-Premise
overall	I-Premise
incidence	I-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
was	I-Premise
similar	I-Premise
between	I-Premise
groups	I-Premise
with	I-Premise
no	I-Premise
unanticipated	I-Premise
adverse	I-Premise
device	I-Premise
effects.	I-Premise

Pressure	B-Claim
reduction	I-Claim
on	I-Claim
fewer	I-Claim
medications	I-Claim
was	I-Claim
clinically	I-Claim
and	I-Claim
statistically	I-Claim
significantly	I-Claim
better	I-Claim
1	I-Claim
year	I-Claim
after	I-Claim
stent	I-Claim
plus	I-Claim
cataract	I-Claim
surgery	I-Claim
versus	I-Claim
cataract	I-Claim
surgery	I-Claim
alone,	I-Claim
with	I-Claim
an	I-Claim
overall	I-Claim
safety	I-Claim
profile	I-Claim
similar	I-Claim
to	I-Claim
that	I-Claim
of	I-Claim
cataract	I-Claim
surgery	I-Claim
alone.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
bimatoprost	O
and	O
travoprost	O
on	O
intraocular	O
pressure	O
(IOP)	O
reduction	O
in	O
an	O
Egyptian	O
population.	O

Patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
were	O
randomized	O
to	O
receive	O
either	O
bimatoprost	O
0.03%	O
or	O
travoprost	O
0.004%	O
once	O
daily.	O

IOPs	O
were	O
measured	O
at	O
baseline;	O
2	O
weeks;	O
and	O
1,	O
2,	O
4,	O
and	O
6	O
months	O
using	O
Goldman	O
applanation	O
tonometery.	O

Seventy-two	O
patients	O
were	O
included:	O
34	O
and	O
38	O
(P=0.142)	O
with	O
a	O
baseline	O
mean	O
IOP	O
26.52	O
	O
5.185	O
and	O
26.36	O
	O
1.605	O
mm	O
Hg	O
(P=0.629)	O
for	O
bimatoprost	O
and	O
travoprost,	O
respectively.	O

Both	B-Premise
drops	I-Premise
provided	I-Premise
statistically	I-Premise
significant	I-Premise
IOP	I-Premise
reductions	I-Premise
from	I-Premise
baseline	I-Premise
at	I-Premise
all	I-Premise
visits	I-Premise
(P<0.001).	I-Premise

Bimatoprost	B-Claim
provided	I-Claim
greater	I-Claim
(nonsignificant)	I-Claim
mean	I-Claim
IOP	I-Claim
reductions	I-Claim
from	I-Claim
baseline	I-Claim
than	I-Claim
travoprost	I-Claim
at	I-Claim
each	I-Claim
visit.	I-Claim

Mean	B-Premise
IOP	I-Premise
reduction	I-Premise
was	I-Premise
8.77	I-Premise
mm	I-Premise
Hg	I-Premise
(33.39%)	I-Premise
and	I-Premise
8.42	I-Premise
mm	I-Premise
Hg	I-Premise
(31.54%)	I-Premise
at	I-Premise
2	I-Premise
weeks	I-Premise
(P	I-Premise
=	I-Premise
0.703),	I-Premise
and	I-Premise
8.47	I-Premise
mm	I-Premise
Hg	I-Premise
(31.61%)	I-Premise
and	I-Premise
7.84	I-Premise
mm	I-Premise
Hg	I-Premise
(29.50%)	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.536)	I-Premise
for	I-Premise
bimatoprost	I-Premise
and	I-Premise
travoprost,	I-Premise
respectively.	I-Premise

IOPs	B-Premise
at	I-Premise
2	I-Premise
weeks	I-Premise
were	I-Premise
18	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
20	I-Premise
(58.8%)	I-Premise
versus	I-Premise
19	I-Premise
(50%)	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.603),	I-Premise
and	I-Premise
16	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
12	I-Premise
(35%)	I-Premise
versus	I-Premise
12	I-Premise
(32%)	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.456);	I-Premise
and	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
18	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
22	I-Premise
(65%)	I-Premise
versus	I-Premise
14	I-Premise
(37%)	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.045),	I-Premise
and	I-Premise
16	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
12	I-Premise
(35%)	I-Premise
versus	I-Premise
7	I-Premise
(18%)	I-Premise
eyes	I-Premise
(P	I-Premise
=	I-Premise
0.037)	I-Premise
for	I-Premise
bimatoprost	I-Premise
and	I-Premise
travoprost,	I-Premise
respectively.	I-Premise

Ocular	B-Claim
adverse	I-Claim
and	I-Claim
clinical	I-Claim
success	I-Claim
occurred	I-Claim
equally	I-Claim
with	I-Claim
both	I-Claim
drops.	I-Claim

Both	B-Claim
drops	I-Claim
lowered	I-Claim
IOP	I-Claim
effectively	I-Claim
but	B-Claim
bimatoprost	I-Claim
showed	I-Claim
a	I-Claim
greater	I-Claim
non-significant	I-Claim
reductions	I-Claim
in	I-Claim
mean	I-Claim
IOP	I-Claim
from	I-Claim
baseline.	I-Claim

To	O
test	O
the	O
hypothesis	O
that	O
neodymium:yttrium-aluminum-garnet	B-Claim
(Nd:YAG)	I-Claim
laser	I-Claim
peripheral	I-Claim
iridotomy	I-Claim
(LPI)	I-Claim
significantly	I-Claim
reduces	I-Claim
the	I-Claim
incidence	I-Claim
of	I-Claim
conversion	I-Claim
from	I-Claim
pigment	I-Claim
dispersion	I-Claim
syndrome	I-Claim
(PDS)	I-Claim
with	I-Claim
ocular	I-Claim
hypertension	I-Claim
(OHT)	I-Claim
to	I-Claim
pigmentary	I-Claim
glaucoma	I-Claim
(PG).	I-Claim

Prospective,	O
randomized,	O
controlled	O
3-year	O
trial.	O

One	O
hundred	O
sixteen	O
eyes	O
of	O
116	O
patients	O
with	O
PDS	O
and	O
OHT.	O

Patients	O
were	O
assigned	O
randomly	O
either	O
to	O
Nd:YAG	O
LPI	O
or	O
to	O
a	O
control	O
group	O
(no	O
laser).	O

The	O
primary	O
outcome	O
measure	O
was	O
conversion	O
to	O
PG	O
within	O
3	O
years,	O
based	O
on	O
full-threshold	O
visual	O
field	O
(VF)	O
analysis	O
using	O
the	O
Ocular	O
Hypertension	O
Treatment	O
Study	O
criteria.	O

Secondary	O
outcome	O
measures	O
were	O
whether	O
eyes	O
required	O
topical	O
antiglaucoma	O
medications	O
during	O
the	O
study	O
period	O
and	O
the	O
time	O
to	O
conversion	O
or	O
medication.	O

Fifty-seven	O
patients	O
were	O
randomized	O
to	O
undergo	O
laser	O
treatment	O
and	O
59	O
were	O
randomized	O
to	O
no	O
laser	O
(controls).	O

Age,	O
gender,	O
spherical	O
equivalent	O
refraction,	O
and	O
intraocular	O
pressure	O
at	O
baseline	O
were	O
similar	O
between	O
groups.	O

Outcome	O
data	O
were	O
available	O
for	O
105	O
(90%)	O
of	O
recruited	O
subjects,	O
52	O
in	O
the	O
laser	O
treatment	O
group	O
and	O
53	O
in	O
the	O
no	O
laser	O
treatment	O
group.	O

Patients	O
were	O
followed	O
up	O
for	O
a	O
median	O
of	O
35.9	O
months	O
(range,	O
10-36	O
months)	O
in	O
the	O
laser	O
arm	O
and	O
35.9	O
months	O
(range,	O
1-36	O
months)	O
in	O
the	O
control	O
arm.	O

Eight	B-Premise
eyes	I-Premise
(15%)	I-Premise
in	I-Premise
the	I-Premise
laser	I-Premise
group	I-Premise
and	I-Premise
3	I-Premise
eyes	I-Premise
(6%)	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
converted	I-Premise
to	I-Premise
glaucoma	I-Premise
in	I-Premise
the	I-Premise
study	I-Premise
period.	I-Premise

The	B-Premise
proportion	I-Premise
of	I-Premise
eyes	I-Premise
started	I-Premise
on	I-Premise
medical	I-Premise
treatment	I-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
2	I-Premise
groups:	I-Premise
8	I-Premise
eyes	I-Premise
(15%)	I-Premise
in	I-Premise
the	I-Premise
laser	I-Premise
group	I-Premise
and	I-Premise
9	I-Premise
eyes	I-Premise
(17%)	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Survival	B-Claim
analyses	I-Claim
showed	I-Claim
no	I-Claim
evidence	I-Claim
of	I-Claim
any	I-Claim
difference	I-Claim
in	I-Claim
time	I-Claim
to	I-Claim
VF	I-Claim
progression	I-Claim
or	I-Claim
commencement	I-Claim
of	I-Claim
topical	I-Claim
therapy	I-Claim
between	I-Claim
the	I-Claim
2	I-Claim
groups.	I-Claim

Cataract	B-Premise
extraction	I-Premise
was	I-Premise
performed	I-Premise
on	I-Premise
1	I-Premise
patient	I-Premise
in	I-Premise
the	I-Premise
laser	I-Premise
group	I-Premise
and	I-Premise
in	I-Premise
1	I-Premise
patient	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
period	I-Premise
(laser	I-Premise
eye	I-Premise
at	I-Premise
18	I-Premise
months;	I-Premise
control	I-Premise
eye	I-Premise
at	I-Premise
34	I-Premise
months).	I-Premise

This	B-Claim
study	I-Claim
suggests	I-Claim
that	I-Claim
there	I-Claim
was	I-Claim
no	I-Claim
benefit	I-Claim
of	I-Claim
Nd:YAG	I-Claim
LPI	I-Claim
in	I-Claim
preventing	I-Claim
progression	I-Claim
from	I-Claim
PDS	I-Claim
with	I-Claim
OHT	I-Claim
to	I-Claim
PG	I-Claim
within	I-Claim
3	I-Claim
years	I-Claim
of	I-Claim
follow-up.	I-Claim

trabeculectomy	O
is	O
the	O
standard	O
surgical	O
procedure	O
for	O
management	O
of	O
glaucoma.	O

to	O
compare	O
the	O
outcome	O
of	O
triangular	O
and	O
rectangular	O
scleral	O
flaps	O
in	O
trabeculectomy.	O

this	O
study	O
was	O
carried	O
out	O
in	O
the	O
Department	O
ofOphthalmology,	O
BPKIHS,	O
Dharan,	O
over	O
a	O
period	O
of	O
one	O
year.	O

A	O
total	O
of	O
22	O
patients	O
undergoing	O
trabeculectomy	O
were	O
randomized	O
to	O
undergo	O
either	O
trabeculectomy	O
with	O
triangular	O
scleral	O
flap	O
(Group	O
A=	O
11	O
eyes)	O
or	O
trabeculectomy	O
with	O
rectangular	O
flap	O
(Group	O
B	O
=	O
11	O
eyes).	O

the	O
parameters	O
studied	O
were	O
intraocular	O
pressure	O
(IOP),	O
anterior	O
chamber	O
depth	O
(ACD),	O
bleb	O
characteristics	O
and	O
surgical	O
complications.	O

P	O
value	O
of<0.05	O
was	O
considered	O
significant.	O

All	O
calculations	O
were	O
executed	O
using	O
SPSS	O
11.0	O
software	O
program.	O

the	O
age	O
ranged	O
between	O
40	O
to	O
76	O
years	O
with	O
the	O
mean	O
of	O
56.5	O
+/-	O
9.25	O
years.	O

The	O
most	O
common	O
preoperative	O
diagnosis	O
was	O
angle	O
closure	O
glaucoma.	O

The	B-Premise
postoperative	I-Premise
percentage	I-Premise
of	I-Premise
IOP	I-Premise
reduction	I-Premise
(Group	I-Premise
A	I-Premise
68.9%;	I-Premise
Group	I-Premise
B	I-Premise
66.51%)	I-Premise
was	I-Premise
statically	I-Premise
significant	I-Premise
in	I-Premise
both	I-Premise
the	I-Premise
groups	I-Premise
(p=0.001).	I-Premise

Trabeculectomy	B-Premise
was	I-Premise
almost	I-Premise
equally	I-Premise
effective	I-Premise
with	I-Premise
complete	I-Premise
surgical	I-Premise
success	I-Premise
of	I-Premise
91%	I-Premise
in	I-Premise
group	I-Premise
A,	I-Premise
and	I-Premise
82%	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
(p=0.534).	I-Premise

Final	B-Premise
bleb	I-Premise
scores	I-Premise
were	I-Premise
almost	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
the	I-Premise
groups	I-Premise
with	I-Premise
3.27	I-Premise
+/-	I-Premise
1.5	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
and	I-Premise
3.36	I-Premise
+/-	I-Premise
1.21	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
(p=0.877).	I-Premise

Hypotony	B-Premise
with	I-Premise
the	I-Premise
IOP	I-Premise
less	I-Premise
than	I-Premise
6	I-Premise
mmHg	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
post-operative	I-Premise
day	I-Premise
in	I-Premise
2	I-Premise
patients	I-Premise
in	I-Premise
Group	I-Premise
A	I-Premise
and	I-Premise
in	I-Premise
1	I-Premise
in	I-Premise
Group	I-Premise
B.	I-Premise

All	O
of	O
them	O
improved	O
spontaneously	O
within	O
a	O
week.	O

both	B-Claim
triangular	I-Claim
and	I-Claim
rectangular	I-Claim
scleral	I-Claim
flaps	I-Claim
in	I-Claim
trabeculectomy	I-Claim
are	I-Claim
equally	I-Claim
effective	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
post	I-Claim
surgical	I-Claim
IOP	I-Claim
control,	I-Claim
bleb	I-Claim
characteristics	I-Claim
and	I-Claim
complications.	I-Claim

To	O
determine	O
the	O
analgesic	O
effect	O
of	O
supplemental	O
intracameral	O
lidocaine	O
1%	O
during	O
phacoemulsification	O
under	O
topical	O
anaesthesia,	O
and	O
to	O
assess	O
the	O
risk	O
factors	O
associated	O
with	O
pain.	O

In	O
a	O
double-masked,	O
randomised,	O
clinical	O
trial,	O
506	O
patients	O
undergoing	O
phacoemulsification	O
under	O
topical	O
anaesthesia	O
were	O
randomised	O
to	O
receive	O
a	O
supplemental	O
intracameral	O
injection	O
of	O
either	O
0.5	O
cc	O
of	O
1%	O
lidocaine	O
(277	O
patients,	O
54.7%)	O
or	O
balanced	O
salt	O
solution	O
(BSS)	O
(229	O
patients,	O
45.3%).	O

Patients	O
were	O
interviewed	O
by	O
a	O
trained	O
interviewer	O
using	O
a	O
standardised	O
questionnaire.	O

The	O
main	O
outcome	O
measure	O
was	O
intraoperative	O
pain,	O
scored	O
on	O
a	O
visual	O
analogue	O
scale	O
of	O
0-10.	O

Logistic	O
regression	O
was	O
performed	O
to	O
assess	O
ORs.	O

125	B-Premise
of	I-Premise
277	I-Premise
patients	I-Premise
(45.1%)	I-Premise
experienced	I-Premise
pain	I-Premise
in	I-Premise
the	I-Premise
lidocaine	I-Premise
group,	I-Premise
compared	I-Premise
with	I-Premise
123	I-Premise
of	I-Premise
229	I-Premise
patients	I-Premise
(53.7%)	I-Premise
in	I-Premise
the	I-Premise
BSS	I-Premise
group.	I-Premise

The	B-Claim
proportion	I-Claim
of	I-Claim
patients	I-Claim
who	I-Claim
experienced	I-Claim
pain	I-Claim
was	I-Claim
significantly	I-Claim
lower	I-Claim
in	I-Claim
the	I-Claim
intracameral	I-Claim
lidocaine	I-Claim
group	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
BSS	I-Claim
group	I-Claim
(multivariate	I-Claim
OR	I-Claim
0.68,	I-Claim
95%	I-Claim
CI	I-Claim
0.47	I-Claim
to	I-Claim
0.97;	I-Claim
p=0.034).	I-Claim

The	B-Premise
median	I-Premise
pain	I-Premise
score	I-Premise
(range)	I-Premise
was	I-Premise
0.0	I-Premise
for	I-Premise
intracameral	I-Premise
lidocaine	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
1.0	I-Premise
for	I-Premise
BSS	I-Premise
group	I-Premise
(p=0.039).	I-Premise

Pain	B-Premise
was	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
females	I-Premise
(54.3%	I-Premise
vs	I-Premise
43.6%;	I-Premise
OR	I-Premise
1.56),	I-Premise
non-Chinese	I-Premise
(62.3%	I-Premise
vs	I-Premise
46.9%;	I-Premise
OR	I-Premise
2.13)	I-Premise
and	I-Premise
those	I-Premise
who	I-Premise
had	I-Premise
previous	I-Premise
cataract	I-Premise
surgery	I-Premise
to	I-Premise
the	I-Premise
fellow	I-Premise
eye	I-Premise
(55.3%	I-Premise
vs	I-Premise
44.7%;	I-Premise
OR	I-Premise
1.61).	I-Premise

The	B-Claim
use	I-Claim
of	I-Claim
0.5	I-Claim
cc	I-Claim
of	I-Claim
1%	I-Claim
intracameral	I-Claim
lidocaine	I-Claim
during	I-Claim
phacoemulsification	I-Claim
under	I-Claim
topical	I-Claim
anaesthesia	I-Claim
significantly	I-Claim
reduces	I-Claim
pain	I-Claim
experienced	I-Claim
by	I-Claim
patients.	I-Claim

Risk	B-Claim
factors	I-Claim
for	I-Claim
pain	I-Claim
include	I-Claim
females,	I-Claim
non-Chinese	I-Claim
and	I-Claim
previous	I-Claim
cataract	I-Claim
surgery.	I-Claim

To	O
compare	O
the	O
alpha2-adrenergic	O
agonist	O
brimonidine	O
tartrate	O
0.2%	O
to	O
the	O
beta-adrenergic	O
antagonist	O
timolol	O
maleate	O
0.5%	O
in	O
preserving	O
visual	O
function	O
in	O
low-pressure	O
glaucoma.	O

Randomized,	O
double-masked,	O
multicenter	O
clinical	O
trial.	O

Exclusion	O
criteria	O
included	O
untreated	O
intraocular	O
pressure	O
(IOP)	O
>21	O
mm	O
Hg,	O
visual	O
field	O
mean	O
deviation	O
worse	O
than	O
-16	O
decibels,	O
or	O
contraindications	O
to	O
study	O
medications.	O

Both	O
eyes	O
received	O
twice-daily	O
monotherapy	O
randomized	O
in	O
blocks	O
of	O
7	O
(4	O
brimonidine	O
to	O
3	O
timolol).	O

Standard	O
automated	O
perimetry	O
and	O
tonometry	O
were	O
performed	O
at	O
4-month	O
intervals.	O

Main	O
outcome	O
measure	O
was	O
field	O
progression	O
in	O
either	O
eye,	O
defined	O
as	O
the	O
same	O
3	O
or	O
more	O
points	O
with	O
a	O
negative	O
slope	O
-1	O
dB/year	O
at	O
P<5%,	O
on	O
3	O
consecutive	O
tests,	O
assessed	O
by	O
pointwise	O
linear	O
regression.	O

Secondary	O
outcome	O
measures	O
were	O
progression	O
based	O
on	O
glaucoma	O
change	O
probability	O
maps	O
(GCPM)	O
of	O
pattern	O
deviation	O
and	O
the	O
3-omitting	O
method	O
for	O
pointwise	O
linear	O
regression.	O

Ninety-nine	O
patients	O
were	O
randomized	O
to	O
brimonidine	O
and	O
79	O
to	O
timolol.	O

Mean	O
(+/-	O
SE)	O
months	O
of	O
follow-up	O
for	O
all	O
patients	O
was	O
30.0	O
+/-	O
2.	O

Statistically	B-Premise
fewer	I-Premise
brimonidine-treated	I-Premise
patients	I-Premise
(9,	I-Premise
9.1%)	I-Premise
had	I-Premise
visual	I-Premise
field	I-Premise
progression	I-Premise
by	I-Premise
pointwise	I-Premise
linear	I-Premise
regression	I-Premise
than	I-Premise
timolol-treated	I-Premise
patients	I-Premise
(31,	I-Premise
39.2%,	I-Premise
log-rank	I-Premise
12.4,	I-Premise
P=.001).	I-Premise

Mean	B-Premise
treated	I-Premise
IOP	I-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
brimonidine-	I-Premise
and	I-Premise
timolol-treated	I-Premise
patients	I-Premise
at	I-Premise
all	I-Premise
time	I-Premise
points.	I-Premise

More	B-Premise
brimonidine-treated	I-Premise
(28,	I-Premise
28.3%)	I-Premise
than	I-Premise
timolol-treated	I-Premise
(9,	I-Premise
11.4%)	I-Premise
patients	I-Premise
discontinued	I-Premise
study	I-Premise
participation	I-Premise
because	I-Premise
of	I-Premise
drug-related	I-Premise
adverse	I-Premise
events	I-Premise
(P=.008).	I-Premise

Similar	B-Claim
differences	I-Claim
in	I-Claim
progression	I-Claim
were	I-Claim
observed	I-Claim
when	I-Claim
analyzed	I-Claim
by	I-Claim
GCPM	I-Claim
and	I-Claim
the	I-Claim
3-omitting	I-Claim
method.	I-Claim

Low-pressure	B-Claim
glaucoma	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
brimonidine	I-Claim
0.2%	I-Claim
who	I-Claim
do	I-Claim
not	I-Claim
develop	I-Claim
ocular	I-Claim
allergy	I-Claim
are	I-Claim
less	I-Claim
likely	I-Claim
to	I-Claim
have	I-Claim
field	I-Claim
progression	I-Claim
than	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
timolol	I-Claim
0.5%.	I-Claim

To	O
compare	O
the	O
effect	O
on	O
intraocular	O
pressure	O
(IOP)	O
of	O
the	O
silicone	O
Ahmed	O
glaucoma	O
valve	O
with	O
and	O
without	O
an	O
intravitreal	O
injection	O
of	O
triamcinolone	O
acetonide.	O

Forty-nine	O
patients	O
with	O
clinically	O
uncontrolled	O
neovascular	O
glaucoma	O
were	O
included	O
in	O
the	O
study;	O
22	O
were	O
randomly	O
assigned	O
to	O
the	O
study	O
group	O
(silicone	O
Ahmed	O
glaucoma	O
valve	O
implant	O
with	O
intravitreal	O
triamcinolone	O
acetonide)	O
and	O
27	O
to	O
the	O
control	O
group	O
(silicone	O
Ahmed	O
glaucoma	O
valve).	O

IOP	O
was	O
the	O
primary	O
outcome	O
measure	O
in	O
this	O
study.	O

The	O
secondary	O
outcome	O
measure	O
was	O
success,	O
defined	O
by	O
IOP	O
lower	O
than	O
22	O
mm	O
Hg	O
and	O
higher	O
than	O
5	O
mm	O
Hg,	O
and	O
no	O
serious	O
complications.	O

Success	O
rates	O
in	O
both	O
the	O
groups	O
were	O
compared	O
using	O
Kaplan-Meier	O
survival	O
curves	O
and	O
the	O
log-rank	O
test.	O

IOP	O
levels	O
were	O
compared	O
using	O
mixed	O
linear	O
model	O
analysis	O
to	O
correct	O
for	O
repeated	O
measures	O
correlation.	O

Forty-three	O
patients,	O
18	O
in	O
the	O
study	O
group	O
and	O
25	O
in	O
the	O
control	O
group,	O
completed	O
the	O
study	O
(follow-up	O
of	O
12	O
mo).	O

The	B-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
after	I-Premise
1	I-Premise
year	I-Premise
in	I-Premise
both	I-Premise
the	I-Premise
groups	I-Premise
(P<0.001).	I-Premise

The	B-Premise
mean	I-Premise
IOP	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
month	I-Premise
of	I-Premise
follow-up	I-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
study	I-Premise
group	I-Premise
(control;	I-Premise
20.49.7,	I-Premise
study;	I-Premise
13.66.5,	I-Premise
P<0.01).	I-Premise

The	B-Premise
success	I-Premise
rate	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
was	I-Premise
78%	I-Premise
for	I-Premise
the	I-Premise
study	I-Premise
group	I-Premise
and	I-Premise
76%	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P=0.82).	I-Premise

Complication	B-Premise
rates	I-Premise
were	I-Premise
not	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
groups.	I-Premise

Intravitreal	B-Claim
injection	I-Claim
of	I-Claim
triamcinolone	I-Claim
acetonide	I-Claim
in	I-Claim
neovascular	I-Claim
glaucoma	I-Claim
did	I-Claim
not	I-Claim
affect	I-Claim
the	I-Claim
intermediate-term	I-Claim
success	I-Claim
of	I-Claim
the	I-Claim
silicone	I-Claim
Ahmed	I-Claim
valve	I-Claim
nor	I-Claim
reduce	I-Claim
the	I-Claim
incidence	I-Claim
of	I-Claim
complications.	I-Claim

The	B-Premise
mean	I-Premise
IOP	I-Premise
spike	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
month	I-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
triamcinolone	I-Premise
group.	I-Premise

To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
oral	O
clonidine	O
in	O
decreasing	O
the	O
prevalence	O
and	O
intensity	O
of	O
postoperative	O
intraocular	O
pressure	O
(IOP)	O
rise	O
in	O
those	O
undergoing	O
phacoemulsification.	O

This	O
was	O
a	O
prospective	O
randomized,	O
double-blind,	O
placebo-controlled,	O
clinical	O
trial	O
including	O
62	O
patients	O
(each	O
with	O
1	O
affected	O
aye)	O
with	O
senile	O
cataract	O
scheduled	O
for	O
phacoemulsification	O
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
preoperative	O
oral	O
clonidine	O
(5g/kg,	O
31	O
patients)	O
or	O
placebo	O
(1	O
tablet,	O
31	O
patients).	O

The	O
IOP	O
was	O
measured	O
preoperatively	O
and	O
at	O
6,	O
12,	O
and	O
24h	O
postoperatively.	O

The	O
prevalence	O
and	O
intensity	O
of	O
the	O
acute	O
postoperative	O
IOP	O
rise	O
was	O
compared	O
between	O
and	O
within	O
the	O
groups.	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
study	I-Premise
groups	I-Premise
regarding	I-Premise
the	I-Premise
baseline	I-Premise
characteristics	I-Premise
and	I-Premise
the	I-Premise
baseline	I-Premise
IOP	I-Premise
(P=0.628).	I-Premise

Patients	B-Premise
who	I-Premise
received	I-Premise
placebo	I-Premise
as	I-Premise
premedication	I-Premise
had	I-Premise
significantly	I-Premise
higher	I-Premise
IOP	I-Premise
at	I-Premise
6	I-Premise
(17.965.49	I-Premise
vs	I-Premise
13.614.09;	I-Premise
P<0.001)	I-Premise
and	I-Premise
12	I-Premise
(16.904.11	I-Premise
vs	I-Premise
13.963.25;	I-Premise
P=0.003)	I-Premise
h	I-Premise
postoperatively	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
oral	I-Premise
clonidine.	I-Premise

However,	O
there	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
groups	I-Premise
regarding	I-Premise
the	I-Premise
IOP	I-Premise
at	I-Premise
24h	I-Premise
after	I-Premise
operation	I-Premise
(15.413.96	I-Premise
vs	I-Premise
16.013.41;	I-Premise
P=0.0539).	I-Premise

The	B-Premise
prevalence	I-Premise
of	I-Premise
acute	I-Premise
IOP	I-Premise
rise	I-Premise
(>21	I-Premise
mmHg)	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
placebo	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
clonidine	I-Premise
group	I-Premise
(25.8%	I-Premise
vs	I-Premise
9.6%;	I-Premise
P=0.091).	I-Premise

Administering	B-Claim
preoperative	I-Claim
oral	I-Claim
clonidine	I-Claim
in	I-Claim
a	I-Claim
dosage	I-Claim
of	I-Claim
5g/kg,	I-Claim
2h	I-Claim
before	I-Claim
phacoemulsification,	I-Claim
significantly	I-Claim
decreases	I-Claim
the	I-Claim
prevalence	I-Claim
and	I-Claim
intensity	I-Claim
of	I-Claim
acute	I-Claim
postoperative	I-Claim
IOP	I-Claim
rise	I-Claim
in	I-Claim
those	I-Claim
undergoing	I-Claim
general	I-Claim
anesthesia.	I-Claim

Oral	B-Claim
clonidine	I-Claim
is	I-Claim
safe,	I-Claim
cheap,	I-Claim
and	I-Claim
easily	I-Claim
accessible	I-Claim
and,	I-Claim
thus,	I-Claim
it	I-Claim
is	I-Claim
recommended	I-Claim
for	I-Claim
controlling	I-Claim
the	I-Claim
IOP	I-Claim
after	I-Claim
phacoemulsification,	I-Claim
especially	I-Claim
in	I-Claim
high-risk	I-Claim
patients.	I-Claim

To	O
compare	O
outcomes	O
of	O
selective	O
laser	O
trabeculoplasty	O
(SLT)	O
with	O
drug	O
therapy	O
for	O
glaucoma	O
patients	O
in	O
a	O
prospective	O
randomized	O
clinical	O
trial.	O

Sixty-nine	O
patients	O
(127	O
eyes)	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
were	O
randomized	O
to	O
SLT	O
or	O
medical	O
therapy.	O

Target	O
intraocular	O
pressure	O
(IOP)	O
was	O
determined	O
using	O
the	O
Collaborative	O
Initial	O
Glaucoma	O
Treatment	O
Study	O
formula.	O

Patients	O
were	O
treated	O
with	O
SLT	O
(100	O
applications	O
360	O
degrees)	O
or	O
medical	O
therapy	O
(prostaglandin	O
analog).	O

Six	O
visits	O
over	O
1	O
year	O
followed	O
initial	O
treatment.	O

If	O
target	O
IOP	O
range	O
was	O
not	O
attained	O
with	O
SLT,	O
additional	O
SLT	O
was	O
the	O
next	O
step,	O
or	O
in	O
the	O
medical	O
arm	O
additional	O
medications	O
were	O
added.	O

Primary	O
outcome:	O
IOP;	O
secondary:	O
number	O
of	O
steps.	O

Sixty-nine	O
patients	O
were	O
treated.	O

Data	O
collection	O
terminated	O
with	O
54	O
patients	O
reaching	O
9	O
to	O
12-months	O
follow-up.	O

Twenty-nine	O
patients	O
were	O
in	O
the	O
SLT	O
group,	O
25	O
patients	O
in	O
the	O
medical	O
group.	O

Baseline	B-Premise
mean	I-Premise
IOP	I-Premise
for	I-Premise
all	I-Premise
eyes	I-Premise
was	I-Premise
24.5	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
SLT	I-Premise
group,	I-Premise
24.7	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
medical	I-Premise
group.	I-Premise
Mean	I-Premise
IOP	I-Premise
(both	I-Premise
eyes)	I-Premise
at	I-Premise
last	I-Premise
follow-up	I-Premise
was	I-Premise
18.2	I-Premise
mm	I-Premise
Hg	I-Premise
(6.3	I-Premise
mm	I-Premise
Hg	I-Premise
reduction)	I-Premise
in	I-Premise
the	I-Premise
SLT	I-Premise
arm,	I-Premise
17.7	I-Premise
mm	I-Premise
Hg	I-Premise
(7.0	I-Premise
mm	I-Premise
Hg	I-Premise
reduction)	I-Premise
in	I-Premise
the	I-Premise
medical	I-Premise
arm.	I-Premise

By	B-Premise
last	I-Premise
follow-up,	I-Premise
11%	I-Premise
of	I-Premise
eyes	I-Premise
received	I-Premise
additional	I-Premise
SLT,	I-Premise
27%	I-Premise
required	I-Premise
additional	I-Premise
medication.	I-Premise

There	B-Premise
was	I-Premise
not	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
SLT	I-Premise
and	I-Premise
medication	I-Premise
groups.	I-Premise

IOP	B-Premise
reduction	I-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
after	I-Premise
9	I-Premise
to	I-Premise
12-months	I-Premise
follow-up.	I-Premise

More	O
treatment	O
steps	O
were	O
necessary	O
to	O
maintain	O
target	O
IOP	O
in	O
the	O
medication	O
group,	O
although	O
there	O
was	O
not	O
a	O
statistically	O
significant	O
difference	O
between	O
groups.	O

These	B-Claim
results	I-Claim
support	I-Claim
the	I-Claim
option	I-Claim
of	I-Claim
SLT	I-Claim
as	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
initial	I-Claim
therapy	I-Claim
in	I-Claim
open-angle	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
augmenting	O
trabeculectomy	O
with	O
subconjunctival	O
mitomycin	O
C	O
(TMMC)	O
versus	O
5-fluorouracil	O
(T5-FU)	O
in	O
lowering	O
intraocular	O
pressure	O
(IOP).	O

Forty	O
eyes	O
from	O
40	O
patients	O
referred	O
to	O
the	O
Nikoukari	O
Ophthalmology	O
University	O
Hospital,	O
Tabriz	O
University	O
of	O
Medical	O
Sciences,	O
Tabriz,	O
Iran,	O
were	O
enrolled	O
in	O
a	O
randomized	O
clinical	O
trial.	O

Patients	O
with	O
high-risk	O
open	O
angle	O
glaucoma	O
were	O
allocated	O
to	O
receive	O
either	O
subconjunctival	O
TMMC	O
or	O
T5-FU.	O

Mean	O
overall	O
preoperative	O
IOP	O
was	O
30.8	O
mmHg.	O

Mean	B-Premise
preoperative	I-Premise
IOPs	I-Premise
in	I-Premise
the	I-Premise
TMMC	I-Premise
and	I-Premise
T5-FU	I-Premise
groups	I-Premise
were	I-Premise
31.2	I-Premise
	I-Premise
9.8	I-Premise
and	I-Premise
30.6	I-Premise
	I-Premise
9.9	I-Premise
mmHg,	I-Premise
respectively.	I-Premise
Postoperatively,	I-Premise
mean	I-Premise
IOPs	I-Premise
were	I-Premise
11.4	I-Premise
	I-Premise
4.9	I-Premise
and	I-Premise
13.6	I-Premise
	I-Premise
3.9	I-Premise
mmHg,	I-Premise
respectively	I-Premise
for	I-Premise
TMMC	I-Premise
and	I-Premise
T5-FU	I-Premise
groups	I-Premise
after	I-Premise
6	I-Premise
months.	I-Premise

In	O
spite	O
of	O
some	O
existing	O
descriptive	O
differences	O
in	O
IOP	O
between	O
the	O
groups,	O
statistical	B-Premise
tests	I-Premise
showed	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
mean	I-Premise
and	I-Premise
median	I-Premise
IOP.	I-Premise

Three	B-Premise
cases	I-Premise
of	I-Premise
hypotonia	I-Premise
(IOP	I-Premise
<	I-Premise
6	I-Premise
mmHg)	I-Premise
and	I-Premise
1	I-Premise
case	I-Premise
of	I-Premise
epithelial	I-Premise
keratitis	I-Premise
were	I-Premise
detected.	I-Premise

TMMC	B-Claim
and	I-Claim
T5-FU	I-Claim
appeared	I-Claim
to	I-Claim
have	I-Claim
similar	I-Claim
efficacy	I-Claim
in	I-Claim
lowering	I-Claim
IOP.	I-Claim

To	O
determine	O
the	O
effect	O
of	O
scleral	O
flap	O
size	O
on	O
the	O
medium-term	O
intraocular	O
pressure	O
control	O
and	O
complication	O
rates	O
after	O
augmented	O
trabeculectomy.	O

Prospective	O
randomized	O
clinical	O
trial.	O

Glaucoma	O
patients	O
undergoing	O
primary	O
trabeculectomy.	O

Exclusion	O
criteria	O
included	O
previous	O
ocular	O
surgery	O
apart	O
from	O
cataract	O
surgery,	O
secondary	O
glaucoma	O
and	O
age	O
under	O
18.	O

Patients	O
were	O
randomized	O
to	O
either	O
standard	O
trabeculectomy	O
(4	O
	O
4	O
mm	O
scleral	O
flap)	O
or	O
microtrabeculectomy	O
(2	O
	O
2	O
mm	O
scleral	O
flap),	O
both	O
with	O
adjustable	O
sutures	O
and	O
antimetabolites.	O

Bleb	O
needling	O
was	O
performed	O
as	O
required.	O

Patients	O
were	O
evaluated	O
at	O
day	O
1,	O
weeks	O
1,	O
3,	O
6	O
and	O
months	O
3,	O
6,	O
12,	O
18	O
and	O
24	O
postoperatively.	O

Vision,	O
intraocular	O
pressure,	O
complications	O
and	O
failure	O
(intraocular	O
pressure	O
	O
21	O
mmHg	O
or	O
not	O
reduced	O
by	O
20%	O
from	O
baseline,	O
intraocular	O
pressure	O
	O
5	O
mmHg,	O
repeat	O
glaucoma	O
surgery	O
and	O
no	O
light	O
perception	O
vision).	O

Forty-one	O
patients	O
were	O
recruited;	O
20	O
had	O
standard	O
trabeculectomy,	O
and	O
21	O
had	O
microtrabeculectomy.	O

At	B-Premise
2	I-Premise
years,	I-Premise
the	I-Premise
mean	I-Premise
intraocular	I-Premise
pressure	I-Premise
and	I-Premise
cumulative	I-Premise
probability	I-Premise
of	I-Premise
failure	I-Premise
was	I-Premise
12.4	I-Premise
	I-Premise
4.6	I-Premise
mmHg	I-Premise
and	I-Premise
0.28	I-Premise
for	I-Premise
standard	I-Premise
trabeculectomy,	I-Premise
and	I-Premise
11.5	I-Premise
	I-Premise
3.6	I-Premise
mmHg	I-Premise
and	I-Premise
0.27	I-Premise
for	I-Premise
microtrabeculectomy	I-Premise
(P	I-Premise
=	I-Premise
0.50	I-Premise
and	I-Premise
0.89,	I-Premise
respectively).	I-Premise

One	B-Premise
patient	I-Premise
in	I-Premise
each	I-Premise
group	I-Premise
required	I-Premise
Baerveldt	I-Premise
device	I-Premise
implantation.	I-Premise

Vision	B-Premise
reduced	I-Premise
2	I-Premise
Snellen	I-Premise
lines	I-Premise
in	I-Premise
15%	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
trabeculectomy	I-Premise
group	I-Premise
and	I-Premise
25%	I-Premise
in	I-Premise
the	I-Premise
microtrabeculectomy	I-Premise
group,	I-Premise
mainly	I-Premise
from	I-Premise
cataract	I-Premise
(P	I-Premise
=	I-Premise
0.48).	I-Premise

Both	B-Claim
trabeculectomy	I-Claim
techniques	I-Claim
achieved	I-Claim
good	I-Claim
intraocular	I-Claim
pressure	I-Claim
reduction	I-Claim
and	I-Claim
had	I-Claim
similar	I-Claim
complication	I-Claim
rates.	I-Claim

Scleral	B-Claim
flap	I-Claim
size	I-Claim
had	I-Claim
no	I-Claim
significant	I-Claim
effect	I-Claim
on	I-Claim
medium-term	I-Claim
intraocular	I-Claim
pressure	I-Claim
control	I-Claim
and	I-Claim
complication	I-Claim
profile.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
latanoprost	O
versus	O
timolol	O
in	O
pediatric	O
patients	O
with	O
glaucoma.	O

Prospective,	O
randomized,	O
double-masked,	O
12-week,	O
multicenter	O
study.	O

Individuals	O
aged	O
<18	O
years	O
with	O
glaucoma.	O

Stratified	O
by	O
age,	O
diagnosis,	O
and	O
intraocular	O
pressure	O
(IOP)	O
level,	O
subjects	O
were	O
randomized	O
(1:1)	O
to	O
latanoprost	O
vehicle	O
at	O
8	O
am	O
and	O
latanoprost	O
0.005%	O
at	O
8	O
pm	O
or	O
timolol	O
0.5%	O
(0.25%	O
for	O
those	O
aged	O
<3	O
years)	O
twice	O
daily	O
(8	O
am,	O
8	O
pm).	O

At	O
baseline	O
and	O
weeks	O
1,	O
4,	O
and	O
12,	O
IOP	O
and	O
ocular	O
safety	O
were	O
assessed	O
and	O
adverse	O
events	O
were	O
recorded.	O

Therapy	O
was	O
switched	O
to	O
open-label	O
latanoprost	O
pm	O
and	O
timolol	O
am	O
and	O
pm	O
for	O
uncontrolled	O
IOP.	O

Mean	O
IOP	O
reduction	O
from	O
baseline	O
to	O
week	O
12.	O

Latanoprost	O
was	O
considered	O
noninferior	O
to	O
timolol	O
if	O
the	O
lower	O
limit	O
of	O
the	O
95%	O
confidence	O
interval	O
(CI)	O
of	O
the	O
difference	O
was	O
>-3	O
mmHg.	O

A	O
proportion	O
of	O
responders	O
(subjects	O
with	O
15%	O
IOP	O
reduction	O
at	O
weeks	O
4	O
and	O
12)	O
were	O
evaluated.	O

Analyses	O
were	O
performed	O
in	O
diagnosis	O
subgroups:	O
primary	O
congenital	O
glaucoma	O
(PCG)	O
and	O
non-PCG.	O

In	O
total,	O
137	O
subjects	O
were	O
treated	O
(safety	O
population;	O
12-18	O
years,	O
n=48;	O
3-<12	O
years,	O
n=55;	O
0-<3	O
years,	O
n=34).	O

Mean	O
age	O
was	O
8.85.5	O
years,	O
and	O
mean	O
baseline	O
IOP	O
was	O
27.76.17	O
mmHg;	O
125	O
subjects	O
completed	O
the	O
study,	O
and	O
107	O
subjects	O
were	O
in	O
the	O
per	O
protocol	O
population.	O

Mean	B-Premise
IOP	I-Premise
reductions	I-Premise
for	I-Premise
latanoprost	I-Premise
and	I-Premise
timolol	I-Premise
at	I-Premise
week	I-Premise
12	I-Premise
were	I-Premise
7.2	I-Premise
and	I-Premise
5.7	I-Premise
mmHg,	I-Premise
respectively,	I-Premise
with	I-Premise
a	I-Premise
difference	I-Premise
of	I-Premise
1.5	I-Premise
mmHg	I-Premise
(95%	I-Premise
CI,	I-Premise
-0.8	I-Premise
to	I-Premise
3.7;	I-Premise
P=0.21).	I-Premise

Responder	B-Premise
rates	I-Premise
were	I-Premise
60%	I-Premise
for	I-Premise
latanoprost	I-Premise
and	I-Premise
52%	I-Premise
for	I-Premise
timolol	I-Premise
(P=0.33).	I-Premise

Between-treatment	B-Premise
differences	I-Premise
in	I-Premise
mean	I-Premise
IOP	I-Premise
reduction	I-Premise
for	I-Premise
PCG	I-Premise
and	I-Premise
non-PCG	I-Premise
subgroups	I-Premise
were	I-Premise
0.6	I-Premise
mmHg	I-Premise
(95%	I-Premise
CI,	I-Premise
-2.3	I-Premise
to	I-Premise
3.4)	I-Premise
and	I-Premise
2.6	I-Premise
mmHg	I-Premise
(95%	I-Premise
CI,	I-Premise
-0.8	I-Premise
to	I-Premise
6.1),	I-Premise
respectively.	I-Premise

Responder	B-Premise
rates	I-Premise
for	I-Premise
latanoprost	I-Premise
versus	I-Premise
timolol	I-Premise
were	I-Premise
50%	I-Premise
versus	I-Premise
46%	I-Premise
for	I-Premise
the	I-Premise
PCG	I-Premise
group	I-Premise
and	I-Premise
72%	I-Premise
versus	I-Premise
57%	I-Premise
for	I-Premise
the	I-Premise
non-PCG	I-Premise
group.	I-Premise

Both	B-Claim
therapies	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

Latanoprost	B-Claim
0.005%	I-Claim
is	I-Claim
not	I-Claim
inferior	I-Claim
(i.e.,	I-Claim
is	I-Claim
either	I-Claim
more	I-Claim
or	I-Claim
similarly	I-Claim
effective)	I-Claim
to	I-Claim
timolol	I-Claim
and	I-Claim
produces	I-Claim
clinically	I-Claim
relevant	I-Claim
IOP	I-Claim
reductions	I-Claim
across	I-Claim
pediatric	I-Claim
patients	I-Claim
with	I-Claim
and	I-Claim
without	I-Claim
PCG.	I-Claim

Both	B-Claim
latanoprost	I-Claim
and	I-Claim
timolol	I-Claim
had	I-Claim
favorable	I-Claim
safety	I-Claim
profiles	I-Claim
over	I-Claim
the	I-Claim
duration	I-Claim
of	I-Claim
this	I-Claim
3-month	I-Claim
trial.	I-Claim

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
safety	O
and	O
intraocular	O
pressure	O
(IOP)-lowering	O
efficacy	O
of	O
travoprost/timolol	O
in	O
a	O
benzalkonium	O
chloride	O
(BAK)-free	O
fixed	O
combination	O
preserved	O
with	O
polyquaternium-1	O
(TRA/TIM	O
BAK-free),	O
with	O
travoprost/timolol-fixed	O
combination	O
preserved	O
with	O
BAK	O
(TRA/TIM),	O
in	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

In	O
this	O
prospective	O
randomized	O
controlled	O
trial,	O
subjects	O
with	O
IOP	O
of	O
at	O
least	O
22	O
mm	O
Hg	O
in	O
one	O
or	O
both	O
eyes	O
at	O
0900	O
h,	O
and	O
IOP	O
of	O
at	O
least	O
21	O
mm	O
Hg	O
in	O
one	O
or	O
both	O
eyes	O
at	O
1100	O
h	O
and	O
1600	O
h	O
at	O
two	O
eligibility	O
visits	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
TRA/TIM	O
BAK-free	O
(n=195)	O
or	O
TRA/TIM	O
(n=193),	O
dosed	O
once	O
daily	O
in	O
the	O
morning	O
(0900	O
h)	O
for	O
6	O
weeks.	O

IOP	O
was	O
assessed	O
at	O
0900	O
h,	O
1100	O
h,	O
and	O
1600	O
h	O
at	O
each	O
scheduled	O
visit	O
(baseline,	O
2	O
and	O
6	O
weeks	O
after	O
randomization).	O

Mean	B-Premise
IOP	I-Premise
reduction	I-Premise
across	I-Premise
all	I-Premise
visits	I-Premise
and	I-Premise
time	I-Premise
points	I-Premise
was	I-Premise
8.0	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
TRA/TIM	I-Premise
BAK-free	I-Premise
group	I-Premise
and	I-Premise
8.4	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
TRA/TIM	I-Premise
group	I-Premise
(P=0.0943).	I-Premise

The	B-Premise
difference	I-Premise
in	I-Premise
mean	I-Premise
IOP	I-Premise
between	I-Premise
groups	I-Premise
ranged	I-Premise
from	I-Premise
0.2	I-Premise
to	I-Premise
0.7	I-Premise
mm	I-Premise
Hg	I-Premise
across	I-Premise
visits	I-Premise
and	I-Premise
time	I-Premise
points,	I-Premise
with	I-Premise
a	I-Premise
mean	I-Premise
pooled	I-Premise
difference	I-Premise
of	I-Premise
0.4	I-Premise
mm	I-Premise
Hg	I-Premise
(95%	I-Premise
CI:	I-Premise
-0.1	I-Premise
to	I-Premise
0.8),	I-Premise
demonstrating	O
equivalence	O
of	O
the	O
two	O
formulations.	O

The	B-Premise
most	I-Premise
common	I-Premise
drug-related	I-Premise
adverse	I-Premise
event	I-Premise
was	I-Premise
hyperemia	I-Premise
of	I-Premise
the	I-Premise
eye	I-Premise
(ocular	I-Premise
hyperemia	I-Premise
and	I-Premise
conjunctival	I-Premise
hyperemia	I-Premise
combined),	I-Premise
occurring	I-Premise
in	I-Premise
11.8%	I-Premise
of	I-Premise
the	I-Premise
TRA/TIM	I-Premise
BAK-free	I-Premise
group	I-Premise
and	I-Premise
13.0%	I-Premise
of	I-Premise
the	I-Premise
TRA/TIM	I-Premise
group.	I-Premise

Travoprost/timolol	B-Claim
BAK-free	I-Claim
demonstrated	I-Claim
equivalence	I-Claim
to	I-Claim
travoprost/timolol	I-Claim
preserved	I-Claim
with	I-Claim
BAK	I-Claim
in	I-Claim
efficacy.	I-Claim

No	B-Claim
clinically	I-Claim
relevant	I-Claim
differences	I-Claim
in	I-Claim
the	I-Claim
safety	I-Claim
profiles	I-Claim
of	I-Claim
travoprost/timolol	I-Claim
BAK-free	I-Claim
and	I-Claim
travoprost/timolol	I-Claim
preserved	I-Claim
with	I-Claim
BAK	I-Claim
were	I-Claim
identified.	I-Claim

To	O
evaluate	O
the	O
additive	O
intraocular	O
pressure	O
(IOP)-lowering	O
efficacy	O
and	O
safety	O
of	O
fixed	O
combination	O
brimonidine	O
0.2%/timolol	O
0.5%	O
compared	O
with	O
timolol	O
0.5%	O
at	O
peak	O
and	O
trough	O
effect	O
when	O
used	O
as	O
therapy	O
adjunctive	O
to	O
latanoprost	O
0.005%	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
who	O
require	O
additional	O
IOP	O
lowering.	O

In	O
this	O
prospective,	O
randomized,	O
multicenter,	O
investigator-masked,	O
parallel-group	O
study,	O
patients	O
were	O
treated	O
with	O
latanoprost	O
monotherapy	O
for	O
at	O
least	O
four	O
weeks	O
prior	O
to	O
baseline.	O

At	O
baseline	O
on	O
latanoprost,	O
patients	O
with	O
IOP	O
21	O
mmHg	O
in	O
at	O
least	O
one	O
eye	O
were	O
randomized	O
to	O
twice-daily	O
fixed	O
brimonidine-timolol	O
(n	O
=	O
102)	O
or	O
timolol	O
(n	O
=	O
102),	O
each	O
adjunctive	O
to	O
latanoprost	O
for	O
12	O
weeks.	O

IOP	O
was	O
measured	O
at	O
8	O
am	O
and	O
10	O
am	O
at	O
baseline,	O
week	O
6,	O
and	O
week	O
12	O
and	O
evaluated	O
in	O
the	O
per	O
protocol	O
population.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
peak	O
IOP	O
lowering	O
at	O
10	O
am,	O
week	O
12.	O

Safety	O
measures	O
included	O
adverse	O
events.	O

Baseline	O
mean	O
IOP	O
was	O
similar	O
at	O
10	O
am	O
in	O
the	O
treatment	O
groups	O
(brimonidine-timolol	O
23.4	O
mmHg;	O
timolol	O
23.0	O
mmHg).	O

The	B-Premise
mean	I-Premise
additional	I-Premise
reduction	I-Premise
from	I-Premise
latanoprost-treated	I-Premise
baseline	I-Premise
IOP	I-Premise
was	I-Premise
8.3	I-Premise
mmHg	I-Premise
(35.5%)	I-Premise
with	I-Premise
fixed	I-Premise
brimonidine-timolol	I-Premise
and	I-Premise
6.2	I-Premise
mmHg	I-Premise
(27.0%)	I-Premise
with	I-Premise
timolol	I-Premise
at	I-Premise
10	I-Premise
am,	I-Premise
week	I-Premise
12	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
fixed	I-Premise
brimonidine-timolol	I-Premise
adjunctive	I-Premise
to	I-Premise
latanoprost	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
likely	I-Premise
than	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
adjunctive	I-Premise
timolol	I-Premise
to	I-Premise
achieve	I-Premise
an	I-Premise
IOP	I-Premise
<18	I-Premise
mmHg	I-Premise
(P	I-Premise
=	I-Premise
0.028)	I-Premise
and	I-Premise
a	I-Premise
20%	I-Premise
reduction	I-Premise
in	I-Premise
IOP	I-Premise
from	I-Premise
baseline	I-Premise
(P	I-Premise
=	I-Premise
0.047)	I-Premise
at	I-Premise
both	I-Premise
8	I-Premise
am	I-Premise
and	I-Premise
10	I-Premise
am	I-Premise
in	I-Premise
week	I-Premise
12.	I-Premise

Adverse	B-Premise
events	I-Premise
occurred	I-Premise
in	I-Premise
14.7%	I-Premise
of	I-Premise
fixed	I-Premise
brimonidine-timolol	I-Premise
patients	I-Premise
and	I-Premise
12.7%	I-Premise
of	I-Premise
timolol	I-Premise
patients.	I-Premise

Biomicroscopy	B-Premise
findings	I-Premise
were	I-Premise
similar	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
after	I-Premise
12	I-Premise
weeks	I-Premise
of	I-Premise
treatment.	I-Premise

Fixed-combination	B-Claim
brimonidine-timolol	I-Claim
reduced	I-Claim
IOP	I-Claim
significantly	I-Claim
more	I-Claim
effectively	I-Claim
than	I-Claim
timolol	I-Claim
when	I-Claim
used	I-Claim
as	I-Claim
adjunctive	I-Claim
therapy	I-Claim
to	I-Claim
latanoprost	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
glaucoma	I-Claim
and	I-Claim
ocular	I-Claim
hypertension.	I-Claim

Both	B-Claim
fixed	I-Claim
brimonidine-timolol	I-Claim
and	I-Claim
timolol	I-Claim
were	I-Claim
well	I-Claim
tolerated	I-Claim
as	I-Claim
agents	I-Claim
adjunctive	I-Claim
to	I-Claim
latanoprost.	I-Claim

To	O
verify	O
the	O
safety	O
and	O
efficacy	O
of	O
Ologen	O
(OLO)	O
implant	O
as	O
adjuvant	O
compared	O
with	O
low-dosage	O
mitomycin-C	O
(MMC)	O
in	O
trabeculectomy.	O

This	O
was	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
with	O
a	O
24-month	O
follow-up.	O

Forty	O
glaucoma	O
patients	O
(40	O
eyes)	O
were	O
assigned	O
to	O
trabeculectomy	O
with	O
MMC	O
or	O
OLO.	O

Primary	O
outcome	O
includes	O
target	O
IOP	O
at	O
21,	O
17,	O
and	O
15	O
mmHg;	O
complete	O
(target	O
IOP	O
without	O
medications),	O
and	O
qualified	O
success	O
(target	O
IOP	O
regardless	O
of	O
medications).	O

Secondary	O
outcomes	O
include	O
bleb	O
evaluation,	O
according	O
to	O
Moorfields	O
Bleb	O
Grading	O
System	O
(MBGS);	O
spectral	O
domain	O
optical	O
coherence	O
tomography	O
(SD-OCT)	O
examination;	O
number	O
of	O
glaucoma	O
medications;	O
and	O
frequency	O
of	O
postoperative	O
adjunctive	O
procedures	O
and	O
complications.	O

The	O
mean	O
preoperative	O
IOP	O
was	O
26.5	O
(5.2)	O
in	O
MMC	O
and	O
27.3	O
(6.0)	O
in	O
OLO	O
eyes,	O
without	O
statistical	O
significance.	O

One-day	B-Premise
postoperatively,	I-Premise
the	I-Premise
IOP	I-Premise
dropped	I-Premise
to	I-Premise
5.2	I-Premise
(3.5)	I-Premise
and	I-Premise
9.2	I-Premise
(5.5)	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively	I-Premise
(P=0.009).	I-Premise

The	B-Premise
IOP	I-Premise
reduction	I-Premise
was	I-Premise
significant	I-Premise
at	I-Premise
end	I-Premise
point	I-Premise
in	I-Premise
all	I-Premise
groups	I-Premise
(P=0.01),	I-Premise
with	I-Premise
a	I-Premise
mean	I-Premise
IOP	I-Premise
of	I-Premise
16.0	I-Premise
(2.9)	I-Premise
and	I-Premise
16.5	I-Premise
(2.1)	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
MMC	I-Premise
and	I-Premise
OLO,	I-Premise
respectively.	I-Premise

The	B-Premise
rates	I-Premise
and	I-Premise
Kaplan-Meier	I-Premise
curves	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
for	I-Premise
both	I-Premise
complete	I-Premise
and	I-Premise
qualified	I-Premise
success	I-Premise
at	I-Premise
any	I-Premise
target	I-Premise
IOP.	I-Premise

The	B-Premise
bleb	I-Premise
height	I-Premise
in	I-Premise
OLO	I-Premise
group	I-Premise
was	I-Premise
higher	I-Premise
than	I-Premise
MMC	I-Premise
one	I-Premise
(P<0.05).	I-Premise

SD-OCT	B-Premise
analysis	I-Premise
of	I-Premise
successful/unsuccessful	I-Premise
bleb	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
or	I-Premise
without	I-Premise
complete	I-Premise
success	I-Premise
at	I-Premise
IOP	I-Premise
=17	I-Premise
mm	I-Premise
Hg	I-Premise
indicated	I-Premise
a	I-Premise
sensitivity	I-Premise
of	I-Premise
83%	I-Premise
and	I-Premise
73%	I-Premise
and	I-Premise
a	I-Premise
specificity	I-Premise
of	I-Premise
75%	I-Premise
and	I-Premise
67%,	I-Premise
respectively,	I-Premise
for	I-Premise
MMC	I-Premise
and	I-Premise
OLO	I-Premise
groups.	I-Premise

No	B-Premise
adverse	I-Premise
reaction	I-Premise
to	I-Premise
OLO	I-Premise
was	I-Premise
noted.	I-Premise

Our	B-Claim
results	I-Claim
suggest	I-Claim
that	I-Claim
OLO	I-Claim
implant	I-Claim
could	I-Claim
be	I-Claim
a	I-Claim
new,	I-Claim
safe,	I-Claim
and	I-Claim
effective	I-Claim
alternative	I-Claim
to	I-Claim
MMC,	I-Claim
with	I-Claim
similar	I-Claim
long-term	I-Claim
success	I-Claim
rate.	I-Claim

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
tafluprost,	O
a	O
preservative-free	O
(PF)	O
prostaglandin	O
analogue,	O
with	O
PF	O
timolol	O
in	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

Randomized,	O
double-masked,	O
multicenter	O
clinical	O
trial.	O

After	O
discontinuation	O
and	O
washout	O
of	O
existing	O
ocular	O
hypotensive	O
treatment,	O
patients	O
who	O
had	O
intraocular	O
pressure	O
(IOP)	O
=23	O
and	O
=36	O
mm	O
Hg	O
in	O
at	O
least	O
1	O
eye	O
at	O
the	O
08:00	O
hour	O
time	O
point	O
were	O
randomized	O
1:1	O
to	O
12	O
weeks	O
of	O
treatment	O
with	O
either	O
PF	O
tafluprost	O
0.0015%	O
or	O
PF	O
timolol	O
0.5%.	O

IOP	O
was	O
measured	O
3	O
times	O
during	O
the	O
day	O
(08:00,	O
10:00,	O
16:00	O
hours)	O
at	O
baseline	O
and	O
at	O
weeks	O
2,	O
6,	O
and	O
12.	O

It	O
was	O
hypothesized	O
that	O
PF	O
tafluprost	O
would	O
be	O
noninferior	O
to	O
PF	O
timolol	O
over	O
12	O
weeks	O
with	O
regard	O
to	O
change	O
from	O
baseline	O
IOP.	O

The	O
trial	O
was	O
powered	O
for	O
a	O
noninferiority	O
margin	O
of	O
1.5	O
mm	O
Hg	O
at	O
each	O
of	O
the	O
9	O
time	O
points	O
assessed.	O

A	O
total	O
of	O
643	O
patients	O
were	O
randomized	O
and	O
618	O
completed	O
(PF	O
tafluprost	O
=	O
306,	O
PF	O
timolol	O
=	O
312).	O

IOPs	B-Premise
at	I-Premise
the	I-Premise
3	I-Premise
time	I-Premise
points	I-Premise
assessed	I-Premise
during	I-Premise
the	I-Premise
baseline	I-Premise
visit	I-Premise
ranged	I-Premise
from	I-Premise
23.8	I-Premise
to	I-Premise
26.1	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
PF	I-Premise
tafluprost	I-Premise
group	I-Premise
and	I-Premise
23.5	I-Premise
to	I-Premise
26.0	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
the	I-Premise
PF	I-Premise
timolol	I-Premise
group.	I-Premise

IOPs	B-Premise
at	I-Premise
the	I-Premise
3	I-Premise
time	I-Premise
points	I-Premise
assessed	I-Premise
during	I-Premise
the	I-Premise
12-week	I-Premise
visit	I-Premise
ranged	I-Premise
from	I-Premise
17.4	I-Premise
to	I-Premise
18.6	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
PF	I-Premise
tafluprost	I-Premise
and	I-Premise
17.9	I-Premise
to	I-Premise
18.5	I-Premise
mm	I-Premise
Hg	I-Premise
for	I-Premise
PF	I-Premise
timolol.	I-Premise

At	O
all	O
9	O
time	O
points,	O
the	O
upper	O
limits	O
of	O
the	O
2-sided	O
95%	O
confidence	O
intervals	O
for	O
the	O
difference	O
between	O
treatments	O
in	O
IOP	O
lowering	O
were	O
less	O
than	O
the	O
prespecified	O
noninferiority	O
margin.	O

Similar	B-Premise
percentages	I-Premise
of	I-Premise
PF	I-Premise
tafluprost	I-Premise
and	I-Premise
PF	I-Premise
timolol	I-Premise
patients	I-Premise
reported	I-Premise
ocular	I-Premise
pain/stinging/irritation	I-Premise
(4.4%	I-Premise
vs	I-Premise
4.6%)	I-Premise
and	I-Premise
pruritus	I-Premise
(2.5%	I-Premise
vs	I-Premise
1.5%).	I-Premise

The	B-Premise
percentages	I-Premise
of	I-Premise
PF	I-Premise
tafluprost	I-Premise
and	I-Premise
PF	I-Premise
timolol	I-Premise
patients	I-Premise
reporting	I-Premise
conjunctival	I-Premise
hyperemia	I-Premise
were	I-Premise
4.4%	I-Premise
vs	I-Premise
1.2%	I-Premise
(nominal	I-Premise
P	I-Premise
=	I-Premise
.016).	I-Premise

The	B-Claim
IOP-lowering	I-Claim
effect	I-Claim
of	I-Claim
PF	I-Claim
tafluprost	I-Claim
was	I-Claim
noninferior	I-Claim
to	I-Claim
that	I-Claim
of	I-Claim
PF	I-Claim
timolol.	I-Claim

PF	B-Claim
tafluprost	I-Claim
is	I-Claim
an	I-Claim
efficacious	I-Claim
and	I-Claim
generally	I-Claim
well-tolerated	I-Claim
ocular	I-Claim
hypotensive	I-Claim
agent.	I-Claim

To	O
compare	O
intraocular	O
pressure	O
(IOP)	O
over	O
time	O
after	O
standard	O
trabeculectomy	O
vs	O
Ex-PRESS	O
implantation	O
in	O
patients	O
with	O
bilateral	O
primary	O
open-angle	O
glaucoma	O
(POAG).	O

Prospective,	O
randomised	O
study.	O

This	O
study	O
included	O
adult	O
patients	O
with	O
bilateral	O
POAG	O
necessitating	O
surgery.	O

Each	O
patient	O
underwent	O
trabeculectomy	O
in	O
one	O
eye	O
and	O
Ex-PRESS	O
implantation	O
under	O
a	O
scleral	O
flap	O
in	O
the	O
other	O
eye	O
according	O
to	O
randomised	O
contralateral	O
allocations.	O

Efficacy	O
was	O
assessed	O
by	O
IOP	O
values	O
and	O
success	O
rates	O
(IOP	O
threshold	O
and/or	O
need	O
for	O
topical	O
glaucoma	O
medication)	O
during	O
30	O
months.	O

Statistical	O
analysis	O
included	O
Generalised	O
Estimate	O
Equation	O
and	O
Cox	O
Survival	O
models,	O
and	O
paired	O
t-tests.	O

Thirty	O
eyes	O
of	O
15	O
patients	O
were	O
studied	O
for	O
a	O
mean	O
of	O
23.6	O
months	O
(SD,	O
	O
6.9).	O

At	B-Premise
the	I-Premise
last	I-Premise
follow-up	I-Premise
visit,	I-Premise
mean	I-Premise
pre-operative	I-Premise
IOP	I-Premise
decreased	I-Premise
from	I-Premise
31.1	I-Premise
(	I-Premise
14.2)	I-Premise
to	I-Premise
16.2	I-Premise
(	I-Premise
1.5)	I-Premise
mm	I-Premise
Hg	I-Premise
after	I-Premise
trabeculectomy,	I-Premise
and	I-Premise
from	I-Premise
28.1	I-Premise
(	I-Premise
9.0)	I-Premise
to	I-Premise
15.7	I-Premise
(	I-Premise
1.8)	I-Premise
mm	I-Premise
Hg	I-Premise
after	I-Premise
Ex-PRESS	I-Premise
implantation	I-Premise
(P=0.001).	I-Premise

The	B-Premise
mean	I-Premise
number	I-Premise
of	I-Premise
anti-glaucoma	I-Premise
medicines	I-Premise
prescribed	I-Premise
at	I-Premise
the	I-Premise
last	I-Premise
follow-up	I-Premise
decreased	I-Premise
from	I-Premise
3.7	I-Premise
pre-operatively	I-Premise
(both	I-Premise
groups)	I-Premise
to	I-Premise
0.9	I-Premise
after	I-Premise
trabeculectomy	I-Premise
vs	I-Premise
0.3	I-Premise
after	I-Premise
Ex-PRESS	I-Premise
implantation	I-Premise
(P=0.001).	I-Premise

Complete	B-Premise
success	I-Premise
rates	I-Premise
(5<IOP<18	I-Premise
mm	I-Premise
Hg	I-Premise
without	I-Premise
medications)	I-Premise
were	I-Premise
higher	I-Premise
with	I-Premise
Ex-PRESS	I-Premise
compared	I-Premise
with	I-Premise
trabeculectomy	I-Premise
(P=0.0024).	I-Premise

Postoperative	B-Premise
complications	I-Premise
were	I-Premise
more	I-Premise
frequent	I-Premise
after	I-Premise
trabeculectomy	I-Premise
(33%)	I-Premise
compared	I-Premise
with	I-Premise
Ex-PRESS	I-Premise
(20%),	I-Premise
with	I-Premise
four	I-Premise
trabeculectomy	I-Premise
eyes	I-Premise
(27%)	I-Premise
needing	I-Premise
postoperative	I-Premise
interventions,	I-Premise
compared	I-Premise
with	I-Premise
none	I-Premise
with	I-Premise
Ex-PRESS.	I-Premise

Trabeculectomy	B-Claim
and	I-Claim
Ex-PRESS	I-Claim
implantation	I-Claim
provided	I-Claim
similar	I-Claim
IOP	I-Claim
control,	I-Claim
but	O
the	B-Claim
Ex-PRESS	I-Claim
group	I-Claim
had	I-Claim
a	I-Claim
lower	I-Claim
rate	I-Claim
of	I-Claim
complications,	I-Claim
fewer	I-Claim
postoperative	I-Claim
interventions,	I-Claim
and	I-Claim
needed	I-Claim
less	I-Claim
glaucoma	I-Claim
medications.	I-Claim

To	O
evaluate	O
the	O
intraocular	O
pressure	O
(IOP)-lowering	O
efficacy	O
and	O
safety	O
of	O
fixed-combination	O
brimonidine	O
0.2%-timolol	O
0.5%	O
compared	O
with	O
latanoprost	O
0.005%	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension.	O

This	O
was	O
a	O
prospective,	O
randomized,	O
multicenter,	O
investigator-masked	O
clinical	O
trial.	O

After	O
washout	O
of	O
any	O
previous	O
IOP-lowering	O
medications,	O
patients	O
with	O
IOP	O
of	O
24	O
mmHg	O
or	O
higher	O
were	O
randomized	O
to	O
twice-daily	O
fixed-combination	O
brimonidine	O
0.2%-timolol	O
0.5%	O
(n	O
=	O
73)	O
or	O
once-daily	O
latanoprost	O
0.005%	O
(n	O
=	O
75,	O
dosed	O
in	O
the	O
evening,	O
with	O
vehicle	O
control	O
in	O
the	O
morning	O
to	O
maintain	O
masking)	O
for	O
12	O
weeks.	O

IOP	O
was	O
measured	O
at	O
8	O
a.m.	O
(before	O
dosing),	O
10	O
a.m.,	O
and	O
3	O
p.m.	O
at	O
baseline,	O
week	O
6,	O
and	O
week	O
12.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
diurnal	O
IOP	O
(averaged	O
over	O
8	O
a.m.,	O
10	O
a.m.,	O
and	O
3	O
p.m.)	O
at	O
week	O
12.	O

Safety	O
measures	O
included	O
biomicroscopy.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
treatment	O
groups	O
in	O
mean	O
diurnal	O
IOP	O
at	O
baseline	O
(p	O
=	O
0.118).	O

At	B-Premise
week	I-Premise
12,	I-Premise
the	I-Premise
mean	I-Premise
(SD)	I-Premise
diurnal	I-Premise
IOP	I-Premise
was	I-Premise
17.8	I-Premise
(2.9)	I-Premise
mmHg	I-Premise
with	I-Premise
brimonidine-timolol	I-Premise
and	I-Premise
17.9	I-Premise
(3.9)	I-Premise
mmHg	I-Premise
with	I-Premise
latanoprost	I-Premise
(p	I-Premise
=	I-Premise
0.794).	I-Premise

The	B-Premise
percentage	I-Premise
of	I-Premise
patients	I-Premise
achieving	I-Premise
at	I-Premise
least	I-Premise
a	I-Premise
20%	I-Premise
decrease	I-Premise
from	I-Premise
baseline	I-Premise
diurnal	I-Premise
IOP	I-Premise
at	I-Premise
week	I-Premise
12	I-Premise
was	I-Premise
87.7%	I-Premise
in	I-Premise
the	I-Premise
brimonidine-timolol	I-Premise
group	I-Premise
and	I-Premise
77.3%	I-Premise
in	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
(p	I-Premise
=	I-Premise
0.131).	I-Premise

Measured	B-Premise
biomicroscopic	I-Premise
changes	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
week	I-Premise
12	I-Premise
were	I-Premise
infrequent	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Fixed-combination	B-Claim
brimonidine-timolol	I-Claim
was	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
latanoprost	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
glaucoma	I-Claim
or	I-Claim
ocular	I-Claim
hypertension.	I-Claim

Both	B-Claim
treatments	I-Claim
demonstrated	I-Claim
favorable	I-Claim
ocular	I-Claim
tolerability.	I-Claim

The	O
duration	O
of	O
the	O
study	O
was	O
12	O
weeks,	O
and	O
additional	O
studies	O
will	O
be	O
needed	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
fixed-combination	O
brimonidine-timolol	O
and	O
latanoprost	O
during	O
long-term	O
treatment.	O

Ocular	O
blood	O
flow	O
dysregulation	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
glaucoma.	O

Whereas	O
the	O
effect	O
of	O
single	O
antiglaucoma	O
substances	O
on	O
ocular	O
blood	O
flow	O
has	O
been	O
addressed	O
in	O
various	O
experiments,	O
evidence	O
for	O
fixed	O
combinations	O
is	O
sparse.	O

In	O
the	O
present	O
study,	O
we	O
set	O
out	O
to	O
compare	O
the	O
effects	O
of	O
latanoprost	O
0.005%/timolol	O
0.5%	O
(LT)	O
fixed	O
combination	O
and	O
brimonidine	O
0.2%/timolol	O
0.5%	O
(BT)	O
fixed	O
combination	O
on	O
intraocular	O
pressure	O
(IOP)	O
and	O
ocular	O
blood	O
flow.	O

In	O
the	O
present	O
study,	O
which	O
followed	O
a	O
randomized,	O
double-masked	O
2-way	O
crossover	O
design,	O
16	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
and	O
2	O
patients	O
with	O
ocular	O
hypertension	O
were	O
included.	O

The	O
patients	O
underwent	O
a	O
6-week	O
treatment	O
with	O
LT	O
and	O
a	O
6-week	O
treatment	O
with	O
BT	O
after	O
a	O
washout	O
for	O
previous	O
antiglaucoma	O
medication.	O

Optic	O
nerve	O
head	O
blood	O
flow	O
(ONHBF)	O
was	O
measured	O
using	O
laser	O
Doppler	O
flowmetry;	O
retrobulbar	O
flow	O
velocities	O
were	O
measured	O
using	O
color	O
Doppler	O
imaging	O
in	O
the	O
ophthalmic	O
artery,	O
the	O
central	O
retinal	O
artery,	O
and	O
the	O
posterior	O
ciliary	O
arteries.	O

IOP	O
was	O
measured	O
at	O
8	O
AM,	O
12	O
PM,	O
and	O
4	O
PM.	O

The	O
mean	O
baseline	O
IOP	O
was	O
25.3	O
2.8	O
mmHg.	O

Both	B-Premise
drugs	I-Premise
were	I-Premise
equally	I-Premise
effective	I-Premise
in	I-Premise
reducing	I-Premise
IOP	I-Premise
(LT:	I-Premise
-35.0%	I-Premise
10.0%;	I-Premise
BT:	I-Premise
-33.6%	I-Premise
8.8%,	I-Premise
P=0.463	I-Premise
between	I-Premise
groups).	I-Premise

In	O
addition,	O
no	B-Premise
difference	I-Premise
in	I-Premise
ocular	I-Premise
perfusion	I-Premise
pressure	I-Premise
was	I-Premise
observed	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
treatment	I-Premise
groups	I-Premise
(P=0.1,	I-Premise
between	I-Premise
groups).	I-Premise

Neither	B-Premise
LT	I-Premise
nor	I-Premise
BT	I-Premise
altered	I-Premise
ONHBF	I-Premise
(P=0.4,	I-Premise
baseline	I-Premise
vs.	I-Premise
treatment)	I-Premise
and	O
no	B-Premise
effect	I-Premise
on	I-Premise
flow	I-Premise
velocities	I-Premise
in	I-Premise
the	I-Premise
retrobulbar	I-Premise
vessels	I-Premise
was	I-Premise
seen	I-Premise
with	I-Premise
either	I-Premise
of	I-Premise
the	I-Premise
2	I-Premise
treatments.	I-Premise

In	O
the	O
present	O
study,	O
a	B-Claim
6-week	I-Claim
treatment	I-Claim
with	I-Claim
LT	I-Claim
or	I-Claim
BT	I-Claim
was	I-Claim
equally	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
IOP.	I-Claim

In	O
addition,	O
none	B-Claim
of	I-Claim
the	I-Claim
administered	I-Claim
drugs	I-Claim
induced	I-Claim
a	I-Claim
significant	I-Claim
effect	I-Claim
on	I-Claim
ocular	I-Claim
blood	I-Claim
flow	I-Claim
parameters.	I-Claim

To	O
assess	O
the	O
long-term	O
safety	O
and	O
efficacy	O
of	O
a	O
single	O
trabecular	O
micro-bypass	O
stent	O
with	O
concomitant	O
cataract	O
surgery	O
versus	O
cataract	O
surgery	O
alone	O
for	O
mild	O
to	O
moderate	O
open-angle	O
glaucoma.	O

Twenty-nine	O
investigational	O
sites,	O
United	O
States.	O

Prospective	O
randomized	O
controlled	O
multicenter	O
clinical	O
trial.	O

Eyes	O
with	O
mild	O
to	O
moderate	O
glaucoma	O
with	O
an	O
unmedicated	O
intraocular	O
pressure	O
(IOP)	O
of	O
22	O
mm	O
Hg	O
or	O
higher	O
and	O
36	O
mm	O
Hg	O
or	O
lower	O
were	O
randomly	O
assigned	O
to	O
have	O
cataract	O
surgery	O
with	O
iStent	O
trabecular	O
micro-bypass	O
stent	O
implantation	O
(stent	O
group)	O
or	O
cataract	O
surgery	O
alone	O
(control	O
group).	O

Patients	O
were	O
followed	O
for	O
24	O
months	O
postoperatively.	O

The	B-Premise
incidence	I-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
was	I-Premise
low	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
through	I-Premise
24	I-Premise
months	I-Premise
of	I-Premise
follow-up.	I-Premise

At	B-Premise
24	I-Premise
months,	I-Premise
the	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
an	I-Premise
IOP	I-Premise
of	I-Premise
21	I-Premise
mm	I-Premise
Hg	I-Premise
or	I-Premise
lower	I-Premise
without	I-Premise
ocular	I-Premise
hypotensive	I-Premise
medications	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
stent	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P=.036).	I-Premise

Overall,	O
the	B-Premise
mean	I-Premise
IOP	I-Premise
was	I-Premise
stable	I-Premise
between	I-Premise
12	I-Premise
months	I-Premise
and	I-Premise
24	I-Premise
months	I-Premise
(17.0	I-Premise
mm	I-Premise
Hg	I-Premise
	I-Premise
2.8	I-Premise
[SD]	I-Premise
and	I-Premise
17.1	I-Premise
	I-Premise
2.9	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively)	I-Premise
in	I-Premise
the	I-Premise
stent	I-Premise
group	I-Premise
but	I-Premise
increased	I-Premise
(17.0	I-Premise
	I-Premise
3.1	I-Premise
mm	I-Premise
Hg	I-Premise
to	I-Premise
17.8	I-Premise
	I-Premise
3.3	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively)	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Ocular	B-Premise
hypotensive	I-Premise
medication	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
stent	I-Premise
group	I-Premise
at	I-Premise
12	I-Premise
months;	I-Premise
it	I-Premise
was	I-Premise
also	I-Premise
lower	I-Premise
at	I-Premise
24	I-Premise
months,	I-Premise
although	I-Premise
the	I-Premise
difference	I-Premise
was	I-Premise
no	I-Premise
longer	I-Premise
statistically	I-Premise
significant.	I-Premise

Patients	B-Claim
with	I-Claim
combined	I-Claim
single	I-Claim
trabecular	I-Claim
micro-bypass	I-Claim
stent	I-Claim
and	I-Claim
cataract	I-Claim
surgery	I-Claim
had	I-Claim
significantly	I-Claim
better	I-Claim
IOP	I-Claim
control	I-Claim
on	I-Claim
no	I-Claim
medication	I-Claim
through	I-Claim
24	I-Claim
months	I-Claim
than	I-Claim
patients	I-Claim
having	I-Claim
cataract	I-Claim
surgery	I-Claim
alone.	I-Claim

Both	B-Claim
groups	I-Claim
had	I-Claim
a	I-Claim
similar	I-Claim
favorable	I-Claim
long-term	I-Claim
safety	I-Claim
profile.	I-Claim

To	O
investigate	O
risk	O
factors	O
associated	O
with	O
visual	O
field	O
progression	O
in	O
the	O
Low-pressure	O
Glaucoma	O
Treatment	O
Study,	O
a	O
prospective	O
trial	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
the	O
alpha2-adrenergic	O
agonist	O
brimonidine	O
tartrate	O
0.2%	O
to	O
the	O
beta-adrenergic	O
antagonist	O
timolol	O
maleate	O
0.5%	O
on	O
visual	O
function	O
in	O
low-pressure	O
glaucoma.	O

Prospective	O
cohort	O
study.	O

Low-pressure	O
Glaucoma	O
Treatment	O
Study	O
patients	O
with	O
5	O
visual	O
field	O
tests	O
during	O
follow-up	O
were	O
included.	O

Progression	O
was	O
determined	O
using	O
pointwise	O
linear	O
regression	O
analysis,	O
defined	O
as	O
the	O
same	O
3	O
or	O
more	O
visual	O
field	O
locations	O
with	O
a	O
slope	O
more	O
negative	O
than	O
-1.0	O
dB/year	O
at	O
P	O
<	O
5%,	O
on	O
3	O
consecutive	O
tests.	O

Ocular	O
and	O
systemic	O
risk	O
factors	O
were	O
analyzed	O
using	O
Cox	O
proportional	O
hazards	O
model	O
and	O
further	O
tested	O
for	O
independence	O
in	O
a	O
multivariate	O
model.	O

A	O
total	O
of	O
253	O
eyes	O
of	O
127	O
subjects	O
(mean	O
age,	O
64.7	O
10.9	O
years;	O
mean	O
follow-up,	O
40.6	O
12	O
months)	O
were	O
analyzed.	O

Eyes	B-Premise
randomized	I-Premise
to	I-Premise
timolol	I-Premise
progressed	I-Premise
faster	I-Premise
than	I-Premise
those	I-Premise
randomized	I-Premise
to	I-Premise
brimonidine	I-Premise
(mean	I-Premise
rates	I-Premise
of	I-Premise
progression,	I-Premise
-0.38	I-Premise
0.9	I-Premise
vs	I-Premise
0.02	I-Premise
0.7	I-Premise
dB/y,	I-Premise
P	I-Premise
<	I-Premise
.01).	I-Premise

In	O
the	O
final	O
multivariate	O
model	O
adjusting	O
for	O
all	O
tested	O
covariates,	O
older	B-Premise
age	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
=	I-Premise
1.41/decade	I-Premise
older,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
1.05	I-Premise
to	I-Premise
1.90,	I-Premise
P	I-Premise
=	I-Premise
.022),	I-Premise
use	I-Premise
of	I-Premise
systemic	I-Premise
antihypertensives	I-Premise
(HR	I-Premise
=	I-Premise
2.53,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
1.32	I-Premise
to	I-Premise
4.87,	I-Premise
P	I-Premise
=	I-Premise
.005),	I-Premise
and	I-Premise
mean	I-Premise
ocular	I-Premise
perfusion	I-Premise
pressure	I-Premise
(HR	I-Premise
=	I-Premise
1.21/mm	I-Premise
Hg	I-Premise
lower,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
1.12	I-Premise
to	I-Premise
1.31,	I-Premise
P	I-Premise
<	I-Premise
.001)	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
progression	I-Premise
whereas	O
randomization	B-Premise
to	I-Premise
brimonidine	I-Premise
revealed	I-Premise
a	I-Premise
protective	I-Premise
effect	I-Premise
(HR	I-Premise
=	I-Premise
0.26,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.12	I-Premise
to	I-Premise
0.55,	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

While	O
randomization	B-Premise
to	I-Premise
brimonidine	I-Premise
0.2%	I-Premise
was	I-Premise
protective	I-Premise
compared	I-Premise
to	I-Premise
timolol	I-Premise
0.5%,	I-Premise
lower	B-Premise
mean	I-Premise
ocular	I-Premise
perfusion	I-Premise
pressure	I-Premise
increased	I-Premise
the	I-Premise
risk	I-Premise
for	I-Premise
reaching	I-Premise
a	I-Premise
progression	I-Premise
outcome	I-Premise
in	I-Premise
the	I-Premise
Low-pressure	I-Premise
Glaucoma	I-Premise
Treatment	I-Premise
Study.	I-Premise

This	B-Claim
suggests	I-Claim
that	I-Claim
the	I-Claim
beneficial	I-Claim
effect	I-Claim
of	I-Claim
randomization	I-Claim
to	I-Claim
the	I-Claim
brimonidine	I-Claim
arm	I-Claim
was	I-Claim
independent	I-Claim
of	I-Claim
possible	I-Claim
differences	I-Claim
in	I-Claim
ocular	I-Claim
perfusion	I-Claim
pressures	I-Claim
between	I-Claim
the	I-Claim
2	I-Claim
treatment	I-Claim
arms.	I-Claim

The	B-Claim
current	I-Claim
results	I-Claim
and	I-Claim
large	I-Claim
number	I-Claim
of	I-Claim
drop-outs	I-Claim
in	I-Claim
the	I-Claim
brimonidine	I-Claim
0.2%	I-Claim
arm	I-Claim
suggest	I-Claim
that	I-Claim
more	I-Claim
research	I-Claim
is	I-Claim
necessary	I-Claim
before	I-Claim
altering	I-Claim
clinical	I-Claim
practice	I-Claim
paradigms.	I-Claim

To	O
compare	O
phacoemulsification	O
versus	O
trabeculectomy	O
with	O
adjunctive	O
mitomycin	O
C	O
in	O
medically	O
uncontrolled	O
chronic	O
angle-closure	O
glaucoma	O
(CACG)	O
without	O
cataract.	O

Prospective,	O
randomized	O
clinical	O
trial.	O

Fifty	O
medically	O
uncontrolled	O
CACG	O
eyes	O
without	O
cataract	O
of	O
50	O
patients.	O

Patients	O
were	O
randomized	O
into	O
undergoing	O
either	O
phacoemulsification	O
or	O
trabeculectomy	O
with	O
adjunctive	O
mitomycin	O
C.	O
After	O
surgery,	O
patients	O
were	O
followed	O
up	O
every	O
3	O
months	O
for	O
2	O
years.	O

Intraocular	O
pressure	O
(IOP)	O
and	O
requirement	O
for	O
glaucoma	O
drugs.	O

Twenty-six	O
CACG	O
eyes	O
were	O
randomized	O
to	O
receive	O
phacoemulsification,	O
and	O
24	O
eyes	O
underwent	O
trabeculectomy	O
with	O
mitomycin	O
C.	O
Phacoemulsification	B-Premise
and	I-Premise
trabeculectomy	I-Premise
resulted	I-Premise
in	I-Premise
significant	I-Premise
and	I-Premise
comparable	I-Premise
IOP	I-Premise
reduction	I-Premise
at	I-Premise
24	I-Premise
months	I-Premise
after	I-Premise
surgery	I-Premise
(reduction	I-Premise
of	I-Premise
8.4	I-Premise
mmHg	I-Premise
or	I-Premise
34%	I-Premise
for	I-Premise
phacoemulsification	I-Premise
vs	I-Premise
8.9	I-Premise
mmHg	I-Premise
or	I-Premise
36%	I-Premise
for	I-Premise
trabeculectomy;	I-Premise
P=0.76).	I-Premise

Over	B-Premise
first	I-Premise
24	I-Premise
months,	I-Premise
trabeculectomy-treated	I-Premise
eyes	I-Premise
required	I-Premise
on	I-Premise
average	I-Premise
1.1	I-Premise
fewer	I-Premise
drugs	I-Premise
than	I-Premise
phacoemulsification-treated	I-Premise
eyes	I-Premise
(P<0.001).	I-Premise

However,	O
trabeculectomy	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
significantly	I-Premise
more	I-Premise
surgical	I-Premise
complications	I-Premise
than	I-Premise
phacoemulsification	I-Premise
(46%	I-Premise
vs	I-Premise
4%;	I-Premise
P=0.001).	I-Premise

Eight	B-Premise
(33%)	I-Premise
of	I-Premise
24	I-Premise
trabeculectomy	I-Premise
eyes	I-Premise
demonstrated	I-Premise
cataract	I-Premise
during	I-Premise
follow-up.	I-Premise

Both	B-Claim
phacoemulsification	I-Claim
and	I-Claim
trabeculectomy	I-Claim
are	I-Claim
effective	I-Claim
in	I-Claim
reducing	I-Claim
IOP	I-Claim
in	I-Claim
medically	I-Claim
uncontrolled	I-Claim
CACG	I-Claim
eyes	I-Claim
without	I-Claim
cataract.	I-Claim

Trabeculectomy	B-Claim
is	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
phacoemulsification	I-Claim
in	I-Claim
reducing	I-Claim
dependence	I-Claim
on	I-Claim
glaucoma	I-Claim
drugs,	I-Claim
but	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
more	I-Claim
complications.	I-Claim

To	O
compare	O
the	O
postoperative	O
intraocular	O
pressure	O
(IOP)	O
and	O
incidence	O
of	O
early	O
complications	O
after	O
trabeculectomy	O
with	O
releasable	O
suture	O
to	O
standard	O
trabeculectomy	O
in	O
Chinese	O
patients	O
with	O
primary	O
angle-closure	O
glaucoma.	O

One	O
hundred	O
seventy-five	O
patients	O
diagnosed	O
as	O
primary	O
angle-closure	O
glaucoma	O
with	O
6	O
clock-hours	O
or	O
more	O
of	O
peripheral	O
anterior	O
synechia	O
were	O
randomly	O
allocated	O
to	O
2	O
treatment	O
groups:	O
87	O
underwent	O
standard	O
trabeculectomy	O
(S	O
group:	O
2	O
interrupted	O
permanent	O
sutures	O
to	O
the	O
scleral	O
flap)	O
and	O
88	O
received	O
trabeculectomy	O
with	O
2	O
permanent	O
and	O
2	O
releasable	O
sutures	O
(R	O
group).	O

The	O
postoperative	O
IOP	O
and	O
complications	O
during	O
the	O
first	O
3	O
months	O
after	O
surgery	O
were	O
compared.	O

One	O
hundred	O
seventy-one	O
patients	O
(97.7%)	O
attended	O
the	O
3-month	O
visit.	O

The	B-Premise
IOP	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
week	I-Premise
after	I-Premise
trabeculectomy	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
R	I-Premise
group:	I-Premise
day	I-Premise
1,	I-Premise
17.3	I-Premise
	I-Premise
8.6	I-Premise
versus	I-Premise
12.7	I-Premise
	I-Premise
6.0	I-Premise
mm	I-Premise
Hg	I-Premise
(P<0.001);	I-Premise
day	I-Premise
3,	I-Premise
18.0	I-Premise
	I-Premise
7.3	I-Premise
versus	I-Premise
12.9	I-Premise
	I-Premise
6.3	I-Premise
mm	I-Premise
Hg	I-Premise
(P<0.001);	I-Premise
day	I-Premise
7,	I-Premise
14.8	I-Premise
	I-Premise
6.3	I-Premise
versus	I-Premise
12.0	I-Premise
	I-Premise
4.9	I-Premise
mm	I-Premise
Hg	I-Premise
(P=0.001),	I-Premise
but	O
no	B-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
after	I-Premise
the	I-Premise
second	I-Premise
week	I-Premise
(P=0.659	I-Premise
to	I-Premise
0.753).	I-Premise

The	B-Premise
incidence	I-Premise
of	I-Premise
transient	I-Premise
hypotony	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
S	I-Premise
group	I-Premise
(20.4%)	I-Premise
than	I-Premise
the	I-Premise
R	I-Premise
group	I-Premise
(9.1%)	I-Premise
(P=0.046);	I-Premise
hypotony	B-Premise
recovered	I-Premise
in	I-Premise
80.8%	I-Premise
(21/26)	I-Premise
within	I-Premise
1	I-Premise
week.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
occurrence	I-Premise
of	I-Premise
shallow	I-Premise
chamber,	I-Premise
choroidal	I-Premise
detachment,	I-Premise
macular	I-Premise
edema,	I-Premise
additional	I-Premise
surgery,	I-Premise
or	I-Premise
hyphema	I-Premise
(P=0.56	I-Premise
to	I-Premise
1.0).	I-Premise

The	B-Claim
technique	I-Claim
of	I-Claim
releasable	I-Claim
sutures	I-Claim
for	I-Claim
trabeculectomy	I-Claim
used	I-Claim
in	I-Claim
this	I-Claim
study	I-Claim
did	I-Claim
not	I-Claim
demonstrate	I-Claim
significant	I-Claim
advantages	I-Claim
over	I-Claim
standard	I-Claim
trabeculectomy.	I-Claim

Releasable	B-Claim
sutures	I-Claim
were	I-Claim
associated	I-Claim
with	I-Claim
some	I-Claim
decrease	I-Claim
in	I-Claim
visual	I-Claim
acuity	I-Claim
and	I-Claim
increase	I-Claim
in	I-Claim
postoperative	I-Claim
complaints.	I-Claim

To	O
compare	O
efficacy	O
(intraocular	O
pressure	O
(IOP)	O
reduction)	O
and	O
safety	O
of	O
preservative-free	O
latanoprost	O
(T2345)	O
to	O
benzalkonium	O
chloride	O
(BAK)-preserved	O
latanoprost	O
(BPL;	O
Xalatan)	O
in	O
ocular	O
hypertension	O
(OHT)	O
or	O
primary	O
open	O
angle	O
glaucoma	O
(POAG)	O
patients.	O

Prospective,	O
international,	O
multicentre,	O
randomised,	O
investigator-masked,	O
parallel-group	O
trial.	O

After	O
a	O
wash-out	O
period,	O
POAG	O
or	O
OHT	O
patients,	O
previously	O
managed	O
by	O
BPL	O
monotherapy,	O
randomly	O
received	O
T2345	O
or	O
BPL	O
(one	O
drop	O
into	O
the	O
affected	O
eye(s))	O
once	O
daily	O
from	O
D0	O
to	O
D84.	O

Change	O
in	O
IOP	O
was	O
measured	O
at	O
09:00	O
(	O
1	O
h)	O
from	O
D0	O
to	O
D84	O
in	O
the	O
worse	O
eye.	O

Mean	B-Premise
IOP	I-Premise
reduction	I-Premise
(D0-D84)	I-Premise
was	I-Premise
-8.6	I-Premise
2.6	I-Premise
mm	I-Premise
Hg	I-Premise
(-36%)	I-Premise
on	I-Premise
T2345	I-Premise
and	I-Premise
-9.0	I-Premise
2.4	I-Premise
mm	I-Premise
Hg	I-Premise
(-38%)	I-Premise
on	I-Premise
BPL,	I-Premise
confirming	I-Premise
non-inferiority	I-Premise
of	I-Premise
T2345	I-Premise
to	I-Premise
BPL.	I-Premise

Non-inferiority	O
of	O
T2345	O
was	O
observed	O
from	O
D15.	O

The	B-Premise
most	I-Premise
frequent	I-Premise
ocular	I-Premise
adverse	I-Premise
event,	I-Premise
drug	I-Premise
intolerance,	I-Premise
was	I-Premise
reported	I-Premise
in	I-Premise
1	I-Premise
(0.5%)	I-Premise
patient	I-Premise
on	I-Premise
T2345	I-Premise
versus	I-Premise
4	I-Premise
(2.1%)	I-Premise
patients	I-Premise
on	I-Premise
BPL.	I-Premise

Moderate	B-Premise
to	I-Premise
severe	I-Premise
conjunctival	I-Premise
hyperaemia	I-Premise
was	I-Premise
less	I-Premise
frequent	I-Premise
on	I-Premise
T2345	I-Premise
than	I-Premise
on	I-Premise
BPL	I-Premise
at	I-Premise
D42	I-Premise
(20.2%	I-Premise
vs	I-Premise
30.6%;	I-Premise
p=0.003)	I-Premise
and	I-Premise
D84	I-Premise
(21.4%	I-Premise
vs	I-Premise
29.1%;	I-Premise
p=0.02).	I-Premise

Upon	B-Premise
instillation,	I-Premise
the	I-Premise
global	I-Premise
subjective	I-Premise
ocular	I-Premise
symptom	I-Premise
score	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
on	I-Premise
T2345	I-Premise
than	I-Premise
BPL	I-Premise
on	I-Premise
D42	I-Premise
(0.15	I-Premise
vs	I-Premise
0.41;	I-Premise
p=0.001)	I-Premise
and	I-Premise
D84	I-Premise
(0.18	I-Premise
vs	I-Premise
0.46;	I-Premise
p=0.001).	I-Premise

Preservative-free	B-Claim
latanoprost	I-Claim
has	I-Claim
the	I-Claim
same	I-Claim
efficacy	I-Claim
as	I-Claim
BPL,	I-Claim
with	I-Claim
improved	I-Claim
local	I-Claim
tolerance.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure	O
(IOP)-lowering	O
effect	O
and	O
safety	O
of	O
topical	O
brimonidine	O
to	O
that	O
of	O
timolol,	O
and	O
to	O
study	O
the	O
additive	O
effect	O
of	O
topical	O
brimonidine	O
to	O
topical	O
prostaglandin	O
(PG)	O
analogues	O
in	O
475	O
patients	O
with	O
either	O
ocular	O
hypertension	O
or	O
primary	O
open	O
angle	O
glaucoma.	O

The	O
primary	O
endpoint	O
was	O
the	O
mean	O
IOP	O
change	O
from	O
the	O
baseline	O
at	O
0	O
and	O
2	O
hours	O
at	O
week	O
4.	O

The	B-Premise
mean	I-Premise
changes	I-Premise
were	I-Premise
-4.7	I-Premise
+/-	I-Premise
2.1	I-Premise
(S.	I-Premise
D.)	I-Premise
in	I-Premise
the	I-Premise
timolol	I-Premise
and	I-Premise
-4.0	I-Premise
+/-	I-Premise
2.0	I-Premise
mmHg	I-Premise
in	I-Premise
the	I-Premise
brimonidine	I-Premise
group	I-Premise
(p	I-Premise
=	I-Premise
0.0138).	I-Premise

The	B-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
of	I-Premise
the	I-Premise
inter-group	I-Premise
difference	I-Premise
was	I-Premise
greater	I-Premise
than	I-Premise
the	I-Premise
pre-determined	I-Premise
criterion	I-Premise
of	I-Premise
non-inferiority	I-Premise
of	I-Premise
brimonidine	I-Premise
to	I-Premise
timolol.	I-Premise

When	B-Premise
added	I-Premise
to	I-Premise
PG	I-Premise
analogues,	I-Premise
the	I-Premise
IOP-lowering	I-Premise
effect	I-Premise
of	I-Premise
brimonidine	I-Premise
(-2.9	I-Premise
+/-	I-Premise
1.8	I-Premise
mmHg)	I-Premise
was	I-Premise
greater	I-Premise
than	I-Premise
that	I-Premise
of	I-Premise
the	I-Premise
placebo	I-Premise
(-2.1	I-Premise
+/-	I-Premise
1.8	I-Premise
mmHg)	I-Premise
(p	I-Premise
=	I-Premise
0.0010).	I-Premise

No	O
appreciable	O
adverse	O
side	O
effects	O
were	O
encountered.	O

Topical	B-Claim
brimonidine	I-Claim
showed	I-Claim
an	I-Claim
additive	I-Claim
IOP-lowering	I-Claim
effect	I-Claim
to	I-Claim
topical	I-Claim
PG	I-Claim
analogues,	I-Claim
although	B-Claim
its	I-Claim
IOP-lowering	I-Claim
effect	I-Claim
was	I-Claim
inferior	I-Claim
to	I-Claim
topical	I-Claim
timolol	I-Claim
as	I-Claim
monotherapy.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
bimatoprost/timolol	O
(BTFC)	O
or	O
travoprost/timolol	O
(TTFC)	O
fixed	O
combinations	O
on	O
intraocular	O
pressure	O
(IOP)	O
reduction	O
in	O
an	O
Egyptian	O
population.	O

Patients	O
with	O
primary	O
open	O
angle	O
glaucoma	O
were	O
randomized	O
to	O
receive	O
either	O
BTFC	O
or	O
TTFC.	O

IOPs	O
were	O
measured	O
at	O
baseline,	O
2	O
weeks,	O
and	O
1,	O
2,	O
4,	O
and	O
6	O
months.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
mean	O
change	O
in	O
IOP	O
from	O
baseline	O
at	O
each	O
visit.	O

Secondary	O
outcome	O
measures	O
included	O
the	O
incidence	O
of	O
adverse	O
events.	O

Eighty	O
patients	O
(80	O
eyes)	O
were	O
included	O
finally:	O
40	O
eyes	O
in	O
each	O
group.	O

Baseline	O
mean	O
IOPs	O
were	O
24.783.53	O
and	O
25.263.51	O
mm	O
Hg	O
for	O
BTFC	O
and	O
TTFC,	O
respectively	O
(P=0.344).	O

Both	B-Premise
drops	I-Premise
provided	I-Premise
statistically	I-Premise
significant	I-Premise
IOP	I-Premise
reductions	I-Premise
from	I-Premise
baseline	I-Premise
at	I-Premise
all	I-Premise
visits	I-Premise
(P<0.001).	I-Premise

BTFC	B-Premise
provided	I-Premise
greater	I-Premise
significant	I-Premise
mean	I-Premise
IOP	I-Premise
reductions	I-Premise
from	I-Premise
baseline	I-Premise
than	I-Premise
TTFC	I-Premise
at	I-Premise
each	I-Premise
visit	I-Premise
(P<0.001).	I-Premise

Mean	B-Premise
IOP	I-Premise
reductions	I-Premise
were	I-Premise
11.34	I-Premise
and	I-Premise
6.42	I-Premise
mm	I-Premise
Hg	I-Premise
at	I-Premise
2	I-Premise
weeks	I-Premise
(P=0.000),	I-Premise
and	I-Premise
11.17	I-Premise
and	I-Premise
7.89	I-Premise
mmHg	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
(P=0.001)	I-Premise
for	I-Premise
BTFC	I-Premise
and	I-Premise
TTFC,	I-Premise
respectively.	I-Premise

IOPs	B-Premise
at	I-Premise
2	I-Premise
weeks	I-Premise
were	I-Premise
18	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
36	I-Premise
(90.8%)	I-Premise
versus	I-Premise
22	I-Premise
(55%)	I-Premise
eyes	I-Premise
and	I-Premise
16	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
28	I-Premise
(70%)	I-Premise
versus	I-Premise
16	I-Premise
(40%)	I-Premise
eyes	I-Premise
(P<0.001),	I-Premise
and	I-Premise
at	I-Premise
6	I-Premise
months,	I-Premise
18	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
38	I-Premise
(95%)	I-Premise
versus	I-Premise
28	I-Premise
(70%)	I-Premise
eyes	I-Premise
and	I-Premise
16	I-Premise
mm	I-Premise
Hg	I-Premise
in	I-Premise
30	I-Premise
(75%)	I-Premise
versus	I-Premise
18	I-Premise
(45%)	I-Premise
eyes	I-Premise
for	I-Premise
BTFC	I-Premise
and	I-Premise
TTFC,	I-Premise
respectively	I-Premise
(P<0.001).	I-Premise

Both	B-Claim
drops	I-Claim
provided	I-Claim
effective	I-Claim
IOP	I-Claim
reduction	I-Claim
that	I-Claim
was	I-Claim
greater	I-Claim
and	O
patients	B-Claim
were	I-Claim
more	I-Claim
likely	I-Claim
to	I-Claim
achieve	I-Claim
lower	I-Claim
target	I-Claim
pressures	I-Claim
with	I-Claim
BTFC	I-Claim
than	I-Claim
with	I-Claim
TTFC.	I-Claim

To	O
compare	O
the	O
effect	O
of	O
selective	O
laser	O
trabeculoplasty	O
(SLT)	O
and	O
travoprost	O
on	O
24-hour	O
IOP	O
fluctuations	O
in	O
primary	O
open-angle	O
glaucoma	O
(POAG)	O
and	O
normal-tension	O
glaucoma	O
(NTG).	O

Sixty	O
eyes	O
were	O
included.	O

Sixteen	O
and	O
14	O
eyes	O
of	O
POAG	O
patients	O
were	O
randomized	O
to	O
receive	O
360	O
SLT	O
or	O
0.004%	O
travoprost,	O
respectively.	O

Fourteen	O
and	O
16	O
eyes	O
of	O
NTG	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
SLT	O
or	O
travoprost,	O
respectively.	O

The	O
24-hour	O
IOP	O
data	O
were	O
collected	O
before	O
treatment	O
and	O
6	O
to	O
8	O
weeks	O
after	O
treatment.	O

IOP	O
was	O
measured	O
at	O
2	O
hours	O
intervals	O
in	O
the	O
sitting	O
position	O
during	O
daytime	O
(9	O
AM	O
to	O
7	O
PM)	O
and	O
in	O
the	O
supine	O
position	O
during	O
nighttime	O
(9	O
PM	O
to	O
7	O
AM).	O

Main	O
outcome	O
measure	O
was	O
the	O
percentage	O
of	O
eyes	O
that	O
achieved	O
posttreatment	O
24-hour	O
IOP	O
fluctuations	O
<3	O
mm	O
Hg.	O

Success	O
in	O
fluctuation	O
reduction	O
was	O
defined	O
as	O
at	O
least	O
a	O
50%	O
reduction	O
in	O
these	O
fluctuations.	O

Fifty-eight	O
eyes	O
were	O
analyzed.	O

Overall,	O
eyes	B-Premise
in	I-Premise
the	I-Premise
SLT	I-Premise
and	I-Premise
the	I-Premise
travoprost	I-Premise
groups	I-Premise
achieved	I-Premise
a	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
IOP	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
baseline	I-Premise
IOP	I-Premise
values	I-Premise
(-3.7	I-Premise
mm	I-Premise
Hg	I-Premise
[P	I-Premise
=	I-Premise
0.002]	I-Premise
vs	I-Premise
-4.1	I-Premise
mm	I-Premise
Hg	I-Premise
[P	I-Premise
<	I-Premise
0.001],	I-Premise
respectively).	I-Premise

There	O
was	O
no	O
significant	O
difference	O
in	O
IOP	O
reduction	O
in	O
both	O
groups	O
according	O
to	O
type	O
of	O
glaucoma.	O

During	O
the	O
diurnal	O
period,	O
100%	O
of	O
POAG	O
eyes	O
in	O
the	O
travoprost	O
group	O
achieved	O
posttreatment	O
IOP	O
fluctuations	O
<3	O
mm	O
Hg,	O
and	O
87%	O
of	O
eyes	O
in	O
the	O
SLT	O
group	O
achieved	O
the	O
same	O
level	O
of	O
fluctuations	O
(P	O
<	O
0.001).	O

Ninety-six	B-Premise
percent	I-Premise
of	I-Premise
NTG	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
travoprost	I-Premise
group,	I-Premise
and	I-Premise
82%	I-Premise
of	I-Premise
eyes	I-Premise
in	I-Premise
the	I-Premise
SLT	I-Premise
group	I-Premise
had	I-Premise
IOP	I-Premise
fluctuations	I-Premise
<3	I-Premise
mm	I-Premise
Hg	I-Premise
(P	I-Premise
=	I-Premise
0.01).	I-Premise

Success	B-Premise
in	I-Premise
fluctuation	I-Premise
reduction	I-Premise
was	I-Premise
75%	I-Premise
and	I-Premise
92%	I-Premise
for	I-Premise
the	I-Premise
SLT	I-Premise
and	I-Premise
travoprost	I-Premise
groups,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.005).	I-Premise

The	B-Claim
effect	I-Claim
of	I-Claim
travoprost	I-Claim
on	I-Claim
IOP	I-Claim
reduction	I-Claim
in	I-Claim
POAG	I-Claim
and	I-Claim
NTG	I-Claim
patients	I-Claim
was	I-Claim
significant	I-Claim
both	I-Claim
during	I-Claim
the	I-Claim
daytime	I-Claim
and	I-Claim
the	I-Claim
nighttime,	I-Claim
while	O
the	B-Claim
SLT's	I-Claim
effect	I-Claim
was	I-Claim
significant	I-Claim
only	I-Claim
during	I-Claim
the	I-Claim
nighttime.	I-Claim

Both	B-Claim
travoprost	I-Claim
and	I-Claim
SLT	I-Claim
can	I-Claim
significantly	I-Claim
reduce	I-Claim
the	I-Claim
IOP	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
POAG	I-Claim
and	I-Claim
NTG.	I-Claim

Based	O
on	O
habitual	O
positions,	O
travoprost	B-Claim
better	I-Claim
controls	I-Claim
IOP	I-Claim
fluctuations	I-Claim
than	I-Claim
SLT,	I-Claim
especially	I-Claim
during	I-Claim
the	I-Claim
daytime.	I-Claim

The	O
Baerveldt	O
glaucoma	O
implant	O
is	O
a	O
large	O
equatorial	O
aqueous	O
shunting	O
device	O
that	O
is	O
installed	O
through	O
a	O
single-quadrant	O
conjunctival	O
incision.	O

The	O
intermediate-term	O
results	O
of	O
a	O
randomized	O
study	O
comparing	O
the	O
350-	O
and	O
500-mm2	O
Baerveldt	O
implants	O
are	O
reported.	O

Seventy-three	O
patients	O
with	O
medically	O
uncontrollable,	O
nonneovascular	O
glaucomas	O
associated	O
with	O
aphakia,	O
pseudophakia,	O
or	O
failed	O
filters	O
were	O
enrolled	O
in	O
a	O
randomized,	O
prospective	O
study	O
comparing	O
350-	O
and	O
500-mm2	O
Baerveldt	O
implants.	O

Surgical	O
success	O
was	O
defined	O
as	O
6	O
mmHg	O
<	O
or	O
=	O
final	O
intraocular	O
pressure	O
<	O
or	O
=	O
21	O
mmHg	O
without	O
glaucoma	O
reoperation	O
or	O
devastating	O
complication.	O

Of	B-Premise
patients	I-Premise
with	I-Premise
350-	I-Premise
and	I-Premise
500-mm2	I-Premise
implants,	I-Premise
93%	I-Premise
and	I-Premise
88%,	I-Premise
respectively,	I-Premise
achieved	I-Premise
surgical	I-Premise
success	I-Premise
(18-month	I-Premise
life-table	I-Premise
analysis,	I-Premise
P	I-Premise
=	I-Premise
0.93).	I-Premise

The	B-Premise
500-mm2	I-Premise
implants	I-Premise
afforded	I-Premise
intraocular	I-Premise
pressure	I-Premise
control	I-Premise
with	I-Premise
significantly	I-Premise
fewer	I-Premise
medications	I-Premise
(0.7	I-Premise
versus	I-Premise
1.3;	I-Premise
P	I-Premise
=	I-Premise
0.006).	I-Premise

The	B-Premise
postoperative	I-Premise
visual	I-Premise
acuities	I-Premise
remained	I-Premise
within	I-Premise
one	I-Premise
line	I-Premise
of	I-Premise
the	I-Premise
preoperative	I-Premise
visual	I-Premise
acuities	I-Premise
or	I-Premise
improved	I-Premise
in	I-Premise
62%	I-Premise
and	I-Premise
66%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
350-	I-Premise
and	I-Premise
500-mm2	I-Premise
groups,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.93).	I-Premise

Complication	B-Claim
rates	I-Claim
were	I-Claim
statistically	I-Claim
similar.	I-Claim

The	B-Premise
most	I-Premise
frequent	I-Premise
ones	I-Premise
in	I-Premise
the	I-Premise
350-	I-Premise
and	I-Premise
500-mm2	I-Premise
groups,	I-Premise
respectively,	I-Premise
were	I-Premise
serous	I-Premise
choroidal	I-Premise
effusion	I-Premise
(16%	I-Premise
and	I-Premise
32%),	I-Premise
strabismus	I-Premise
(16%	I-Premise
and	I-Premise
19%),	I-Premise
anterior	I-Premise
uveitis	I-Premise
(14%	I-Premise
and	I-Premise
11%),	I-Premise
and	I-Premise
corneal	I-Premise
or	I-Premise
corneal	I-Premise
graft	I-Premise
edema	I-Premise
(11%	I-Premise
each).	I-Premise

The	B-Claim
intermediate-term	I-Claim
results	I-Claim
of	I-Claim
the	I-Claim
350-	I-Claim
and	I-Claim
500-mm2	I-Claim
Baerveldt	I-Claim
implants	I-Claim
were	I-Claim
statistically	I-Claim
comparable	I-Claim
with	I-Claim
respect	I-Claim
to	I-Claim
surgical	I-Claim
and	I-Claim
visual	I-Claim
outcomes,	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
complications,	I-Claim
although	B-Claim
the	I-Claim
larger	I-Claim
implant	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
higher	I-Claim
rate	I-Claim
of	I-Claim
some	I-Claim
complications.	I-Claim

However,	O
the	B-Claim
500-mm2	I-Claim
Baerveldt	I-Claim
implant	I-Claim
afforded	I-Claim
intraocular	I-Claim
pressure	I-Claim
control	I-Claim
with	I-Claim
fewer	I-Claim
medications	I-Claim
than	I-Claim
the	I-Claim
350-mm2	I-Claim
implant.	I-Claim

To	O
compare	O
the	O
intraocular	O
pressure	O
(IOP)-reducing	O
effect	O
and	O
side	O
effects	O
of	O
0.005%	O
latanoprost	O
administered	O
once	O
daily	O
with	O
0.5%	O
timolol	O
administered	O
twice	O
daily	O
in	O
patients	O
with	O
open-angle	O
glaucoma	O
or	O
ocular	O
hypertension.	O

This	O
was	O
a	O
randomized,	O
double-masked	O
study	O
with	O
two	O
parallel	O
groups	O
and	O
a	O
treatment	O
period	O
of	O
6	O
months.	O

The	O
primary	O
objective	O
of	O
the	O
study	O
is	O
to	O
compare	O
the	O
IOP-reducing	O
effect	O
of	O
latanoprost	O
with	O
that	O
of	O
timolol	O
at	O
the	O
end	O
of	O
the	O
6-month	O
treatment	O
period.	O

A	O
total	O
of	O
294	O
patients	O
were	O
included:	O
149	O
were	O
in	O
the	O
latanoprost	O
group	O
and	O
145	O
were	O
in	O
timolol	O
group.	O

Latanoprost	O
was	O
administered	O
in	O
the	O
evening.	O

Diurnal	B-Premise
IOP	I-Premise
(9:00	I-Premise
am,	I-Premise
1:00	I-Premise
pm,	I-Premise
5:00	I-Premise
pm)	I-Premise
was	I-Premise
reduced	I-Premise
from	I-Premise
25.2	I-Premise
to	I-Premise
16.7	I-Premise
mmHg	I-Premise
(33.7%)	I-Premise
with	I-Premise
lantanoprost	I-Premise
and	I-Premise
from	I-Premise
25.4	I-Premise
to	I-Premise
17.1	I-Premise
mmHg	I-Premise
(32.7%)	I-Premise
with	I-Premise
timolol	I-Premise
as	I-Premise
determined	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
6-month	I-Premise
treatment	I-Premise
period.	I-Premise

No	O
upward	O
drift	O
in	O
IOP	O
occurred	O
with	O
either	O
drug	O
during	O
the	O
treatment	O
period.	O

Latanoprost	B-Premise
caused	I-Premise
a	I-Premise
somewhat	I-Premise
more	I-Premise
conjunctival	I-Premise
hyperemia	I-Premise
than	I-Premise
timolol	I-Premise
and	I-Premise
more	I-Premise
corneal	I-Premise
punctuate	I-Premise
epithelial	I-Premise
erosions.	I-Premise

However,	O
both	B-Premise
drugs	I-Premise
were	I-Premise
generally	I-Premise
well	I-Premise
tolerated.	I-Premise

The	B-Premise
most	I-Premise
significant	I-Premise
side	I-Premise
effect	I-Premise
of	I-Premise
latanoprost	I-Premise
was	I-Premise
increased	I-Premise
pigmentation	I-Premise
of	I-Premise
the	I-Premise
iris	I-Premise
which	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
15	I-Premise
patients	I-Premise
(10.1%).	I-Premise

Timolol	B-Claim
caused	I-Claim
more	I-Claim
systemic	I-Claim
side	I-Claim
effects	I-Claim
than	I-Claim
latanoprost.	I-Claim

Latanoprost	B-Claim
0.005%	I-Claim
administered	I-Claim
once	I-Claim
daily	I-Claim
in	I-Claim
the	I-Claim
evening	I-Claim
reduced	I-Claim
IOP	I-Claim
at	I-Claim
least	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
timolol	I-Claim
0.5%	I-Claim
administered	I-Claim
twice	I-Claim
daily.	I-Claim

Latanoprost	B-Claim
was	I-Claim
generally	I-Claim
well	I-Claim
tolerated	I-Claim
systemically	I-Claim
and	I-Claim
in	I-Claim
the	I-Claim
eye.	I-Claim

However,	O
the	O
drug	O
has	O
an	O
unusual	O
side	O
effect	O
of	O
increasing	O
the	O
pigmentation	O
of	O
the	O
iris,	O
particularly	O
in	O
individuals	O
with	O
green-brown	O
or	O
blue-brown	O
eyes.	O

Latanoprost,	O
a	O
new	O
prostaglandin	O
analogue,	O
was	O
compared	O
with	O
timolol	O
for	O
ocular	O
hypotensive	O
efficacy	O
and	O
side	O
effects.	O

In	O
a	O
multicenter,	O
randomized,	O
double-masked,	O
parallel	O
group	O
study,	O
268	O
patients	O
with	O
ocular	O
hypertension	O
or	O
early	O
primary	O
open-angle	O
glaucoma	O
received	O
either	O
0.005%	O
latanoprost	O
once	O
daily	O
or	O
0.5%	O
timolol	O
twice	O
daily	O
for	O
6	O
months.	O

All	O
except	O
ten	O
patients	O
from	O
each	O
group	O
successfully	O
completed	O
the	O
study.	O

Intraocular	B-Premise
pressure	I-Premise
(IOP)	I-Premise
was	I-Premise
significantly	I-Premise
(P<0.001)	I-Premise
reduced	I-Premise
and	I-Premise
maintained	I-Premise
by	I-Premise
both	I-Premise
medications	I-Premise
without	I-Premise
evidence	I-Premise
of	I-Premise
a	I-Premise
long-term	I-Premise
drift	I-Premise
over	I-Premise
6	I-Premise
months.	I-Premise

Comparing	B-Premise
6-month	I-Premise
with	I-Premise
baseline	I-Premise
diurnal	I-Premise
IOP	I-Premise
values,	I-Premise
the	I-Premise
IOP	I-Premise
reduction	I-Premise
(mean	I-Premise
+/-	I-Premise
standard	I-Premise
deviation)	I-Premise
achieved	I-Premise
with	I-Premise
latanoprost	I-Premise
(-6.7	I-Premise
+/-	I-Premise
3.4	I-Premise
mmHg)	I-Premise
was	I-Premise
significantly	I-Premise
(P<0.001)	I-Premise
greater	I-Premise
than	I-Premise
that	I-Premise
produced	I-Premise
with	I-Premise
timolol	I-Premise
(4.9	I-Premise
+/-	I-Premise
2.9	I-Premise
mmHg).	I-Premise

Four	O
patients	O
treated	O
with	O
timolol	O
and	O
none	O
treated	O
with	O
latanoprost	O
were	O
withdrawn	O
from	O
the	O
study	O
because	O
of	O
inadequate	O
IOP	O
control.	O

Pulse	B-Premise
rate	I-Premise
was	I-Premise
significantly	I-Premise
reduced	I-Premise
with	I-Premise
timolol,	I-Premise
but	I-Premise
not	I-Premise
with	I-Premise
latanoprost.	I-Premise

Slightly	B-Premise
more	I-Premise
conjunctival	I-Premise
hyperemia	I-Premise
appeared	I-Premise
in	I-Premise
latanoprost-treated	I-Premise
compared	I-Premise
with	I-Premise
timolol-treated	I-Premise
eyes.	I-Premise

Fewer	B-Claim
subjective	I-Claim
side	I-Claim
effects	I-Claim
occurred	I-Claim
in	I-Claim
latanoprost-treated	I-Claim
eyes.	I-Claim

Both	B-Premise
eyes	I-Premise
of	I-Premise
a	I-Premise
patient	I-Premise
with	I-Premise
a	I-Premise
characteristic,	I-Premise
concentric	I-Premise
iris	I-Premise
heterochromia	I-Premise
(darker	I-Premise
centrally)	I-Premise
at	I-Premise
baseline	I-Premise
showed	I-Premise
a	I-Premise
definite,	I-Premise
photographically	I-Premise
documented	I-Premise
increase	I-Premise
in	I-Premise
pigmentation	I-Premise
during	I-Premise
latanoprost	I-Premise
treatment,	I-Premise
making	I-Premise
the	I-Premise
irides	I-Premise
uniformly	I-Premise
darker.	I-Premise

Three	O
additional	O
patients	O
treated	O
with	O
latanoprost	O
were	O
suspects	O
for	O
this	O
color	O
change.	O

Otherwise,	O
no	B-Claim
significant	I-Claim
difference	I-Claim
between	I-Claim
treatment	I-Claim
groups	I-Claim
occurred	I-Claim
visual	I-Claim
acuity,	I-Claim
slit-lamp	I-Claim
examination,	I-Claim
blood	I-Claim
pressure,	I-Claim
and	I-Claim
laboratory	I-Claim
values.	I-Claim

Latanoprost	B-Claim
has	I-Claim
the	I-Claim
potential	I-Claim
for	I-Claim
becoming	I-Claim
a	I-Claim
new	I-Claim
first-line	I-Claim
treatment	I-Claim
for	I-Claim
glaucoma.	I-Claim

Latanoprost	O
is	O
a	O
PGF2	O
alpha	O
analogue	O
which	O
reduces	O
the	O
intraocular	O
pressure	O
(IOP)	O
by	O
increasing	O
the	O
uveoscleral	O
outflow.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
two	O
different	O
regimens	O
of	O
latanoprost	O
on	O
the	O
diurnal	O
IOP	O
and	O
also	O
the	O
effect	O
of	O
latanoprost	O
on	O
the	O
blood-aqueous	O
barrier	O
measured	O
with	O
a	O
laser	O
flare	O
cell	O
meter	O
(Kowa	O
FM-500).	O

Moreover,	O
the	O
safety	O
aspects	O
of	O
the	O
two	O
regimens	O
regarding	O
hyperemia	O
were	O
studied.	O

A	O
double-masked,	O
randomized	O
study	O
was	O
performed	O
in	O
30	O
patients	O
(9	O
males,	O
21	O
females;	O
mean	O
age	O
61.9	O
years)	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
pseudoexfoliation	O
glaucoma.	O

Twenty	O
patients	O
were	O
treated	O
with	O
latanoprost	O
0.0015%	O
twice	O
daily	O
or	O
0.005%	O
once	O
daily	O
for	O
3	O
weeks	O
in	O
a	O
cross-over	O
design.	O

Ten	O
patients	O
received	O
timolol	O
0.5%	O
twice	O
daily	O
as	O
control.	O

Latanoprost	B-Premise
0.005%	I-Premise
once	I-Premise
daily	I-Premise
reduced	I-Premise
IOP	I-Premise
(+/-	I-Premise
SEM)	I-Premise
more	I-Premise
effectively	I-Premise
than	I-Premise
latanoprost	I-Premise
0.0015%	I-Premise
twice	I-Premise
daily	I-Premise
(9.8	I-Premise
+/-	I-Premise
0.9	I-Premise
mm	I-Premise
Hg	I-Premise
and	I-Premise
6.7	I-Premise
+/-	I-Premise
0.9	I-Premise
mm	I-Premise
Hg,	I-Premise
respectively).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
increase	I-Premise
in	I-Premise
the	I-Premise
aqueous	I-Premise
humour	I-Premise
protein	I-Premise
concentration	I-Premise
within	I-Premise
the	I-Premise
timolol	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.004),	I-Premise
but	I-Premise
not	I-Premise
within	I-Premise
the	I-Premise
latanoprost	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.97).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
change	I-Premise
in	I-Premise
aqueous	I-Premise
humour	I-Premise
protein	I-Premise
concentration	I-Premise
from	I-Premise
baseline	I-Premise
between	I-Premise
latanoprost	I-Premise
and	I-Premise
timolol	I-Premise
groups	I-Premise
(P	I-Premise
=	I-Premise
0.08).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
conjunctival	I-Premise
hyperemia	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
latanoprost	I-Premise
regimens	I-Premise
was	I-Premise
found	I-Premise
(P	I-Premise
=	I-Premise
0.37).	I-Premise

Latanoprost	B-Premise
0.005%	I-Premise
once	I-Premise
daily	I-Premise
reduced	I-Premise
IOP	I-Premise
more	I-Premise
effectively	I-Premise
than	I-Premise
latanoprost	I-Premise
0.0015%	I-Premise
twice	I-Premise
daily	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

Latanoprost	B-Claim
had	I-Claim
no	I-Claim
statistically	I-Claim
or	I-Claim
clinically	I-Claim
significant	I-Claim
effect	I-Claim
on	I-Claim
the	I-Claim
blood-aqueous	I-Claim
barrier.	I-Claim

There	B-Claim
was	I-Claim
no	I-Claim
difference	I-Claim
in	I-Claim
hyperemia	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
regimens.	I-Claim

Both	B-Claim
concentrations	I-Claim
of	I-Claim
latanoprost	I-Claim
reduced	I-Claim
IOP	I-Claim
at	I-Claim
least	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
timolol	I-Claim
0.5%	I-Claim
eye	I-Claim
drops.	I-Claim

Brimonidin	O
tartrate	O
is	O
a	O
highly	O
selective	O
alpha	O
2-agonist.	O

This	O
study	O
investigates	O
the	O
safety	O
and	O
efficacy	O
of	O
0.2%	O
brimonidine	O
administered	O
twice	O
daily	O
for	O
1	O
year	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension.	O

The	O
study	O
design	O
was	O
a	O
multicenter,	O
double-masked,	O
randomized,	O
parallel-group,	O
active-controlled	O
comparison	O
clinical	O
trial.	O

Subjects	O
instilled	O
0.2%	O
brimonidine	O
or	O
0.5%	O
timolol	O
maleate	O
twice	O
daily	O
for	O
12	O
months.	O

Subjects	O
were	O
examined	O
at	O
baseline,	O
week	O
1,	O
and	O
months	O
1,	O
2,	O
3,	O
6,	O
9,	O
and	O
12.	O

A	O
subset	O
of	O
subjects	O
was	O
examined	O
at	O
week	O
2.	O

Of	O
443	O
subjects	O
enrolled	O
in	O
this	O
study,	O
374	O
met	O
the	O
entry	O
criteria;	O
186	O
received	O
brimonidine	O
and	O
188	O
received	O
timolol.	O

Brimonidine-treated	B-Premise
subjects	I-Premise
showed	I-Premise
an	I-Premise
overall	I-Premise
mean	I-Premise
peak	I-Premise
reduction	I-Premise
in	I-Premise
intraocular	I-Premise
pressure	I-Premise
(IOP)	I-Premise
of	I-Premise
6.5	I-Premise
mm	I-Premise
Hg;	I-Premise
timolol-treated	I-Premise
subjects	I-Premise
had	I-Premise
a	I-Premise
mean	I-Premise
peak	I-Premise
reduction	I-Premise
in	I-Premise
IOP	I-Premise
of	I-Premise
6.1	I-Premise
mm	I-Premise
Hg.	I-Premise

Brimonidine	B-Premise
lowered	I-Premise
mean	I-Premise
peak	I-Premise
IOP	I-Premise
significantly	I-Premise
more	I-Premise
than	I-Premise
timolol	I-Premise
at	I-Premise
week	I-Premise
2	I-Premise
and	I-Premise
month	I-Premise
3	I-Premise
(P	I-Premise
<	I-Premise
.03);	I-Premise
no	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
groups	O
for	O
this	O
variable	O
at	O
other	O
visits	O
throughout	O
the	O
1-year	O
course	O
of	O
the	O
study.	O

No	B-Premise
evidence	I-Premise
of	I-Premise
tachyphylaxis	I-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
either	I-Premise
group.	I-Premise

Allergy	B-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
9%	I-Premise
of	I-Premise
subjects	I-Premise
treated	I-Premise
with	I-Premise
brimonidine.	I-Premise

Dry	B-Premise
mouth	I-Premise
was	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
brimonidine-treated	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
timolol-treated	I-Premise
group	I-Premise
(33.0%	I-Premise
vs	I-Premise
19.4%),	I-Premise
but	O
complaints	B-Premise
of	I-Premise
burning	I-Premise
and	I-Premise
stinging	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
timolol-treated	I-Premise
group	I-Premise
(41.9%)	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
brimonidine-treated	I-Premise
patients	I-Premise
(28.1%).	I-Premise

Headache,	B-Premise
fatigue,	I-Premise
and	I-Premise
drowsiness	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
2	I-Premise
groups.	I-Premise

In	O
general,	O
the	O
tolerance	O
to	O
medication	O
was	O
acceptable.	O

Brimonidine	B-Claim
is	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
in	I-Claim
lowering	I-Claim
IOP	I-Claim
in	I-Claim
glaucomatous	I-Claim
eyes.	I-Claim

Brimonidine	B-Claim
provides	I-Claim
a	I-Claim
sustained	I-Claim
long-term	I-Claim
ocular	I-Claim
hypotensive	I-Claim
effect,	I-Claim
is	I-Claim
well	I-Claim
tolerated,	I-Claim
and	I-Claim
has	I-Claim
a	I-Claim
low	I-Claim
rate	I-Claim
of	I-Claim
allergic	I-Claim
response.	I-Claim

